| HEL |
IC50 |
= |
24.0 |
ug.mL-1 |
Antiviral activity was measured against Varicella-Zoster virus (VZV) 07/1 strain in human embryonic lung (HEL) cells |
CHEMBL1129905 |
| HEL |
IC50 |
= |
26.0 |
ug.mL-1 |
Antiviral activity was measured against Varicella-Zoster virus (VZV) YS/R strain in human embryonic lung (HEL) cells |
CHEMBL1129905 |
| HeLa |
CC50 |
= |
200.0 |
ug.mL-1 |
Cytotoxic activity was measured in human embryonic lung cells (HeLa) |
CHEMBL1129905 |
| Human herpesvirus 1 DNA polymerase |
MP |
= |
17.0 |
% |
Percentage of monophosphates (MP) formed in the first step of staggered assay compound was incubated with HSV-1 thymidine kinase for 4 hr |
CHEMBL1124020 |
| Human herpesvirus 1 DNA polymerase |
MP |
= |
3.0 |
% |
Percentage of monophosphates (MP) in the second step of staggered assay mixture from step 1 was incubated with GMP kinase and crude extract of HSV-1 infected HeLa cells over night |
CHEMBL1124020 |
| Human herpesvirus 1 DNA polymerase |
DP |
= |
9.0 |
% |
Percentage of diphosphates (DP) in the second step of staggered assay mixture from step 1 was incubated with GMP kinase and crude extract of HSV-1 infected HeLa cells over night |
CHEMBL1124020 |
| Human herpesvirus 1 DNA polymerase |
TP |
= |
60.0 |
% |
Percentage of triphosphates (TP) in the second step of staggered assay mixture from step 1 was incubated with GMP kinase and crude extract of HSV-1 infected HeLa cells over night |
CHEMBL1124020 |
| Human herpesvirus 1 DNA polymerase |
Inhibition |
= |
79.0 |
% |
Inhibition of DNA polymerase |
CHEMBL1124020 |
| Unchecked |
Inhibition |
= |
40.0 |
% |
Inhibition of DNA polymerase |
CHEMBL1124020 |
| NON-PROTEIN TARGET |
ED50 |
= |
3.0 |
ug ml-1 |
Antiviral activity against HSV-1 cell line (concentration required to prevent viral cytopathic effect in half of primary rabbit kidney cell cultures) |
CHEMBL1124020 |
| NON-PROTEIN TARGET |
ED50 |
= |
3.0 |
ug ml-1 |
Antiviral activity against HSV-2 cell line (concentration required to prevent viral cytopathic effect in half of primary rabbit kidney cell cultures) |
CHEMBL1124020 |
| Human herpesvirus 1 |
IC50 |
= |
4800.0 |
nM |
Compound was tested for its antiviral activity against HSV-1 (SC16) using plaque reduction assay. |
CHEMBL1125754 |
| Human herpesvirus 2 |
IC50 |
= |
1200.0 |
nM |
Compound was tested for its antiviral activity against HSV-2(MS) using plaque reduction assay. |
CHEMBL1125754 |
| Human herpesvirus 3 |
IC50 |
= |
15000.0 |
nM |
Compound was tested for its antiviral activity against VZV(Ellen) using plaque reduction assay. |
CHEMBL1125754 |
| Human herpesvirus 1 |
Inhibition |
= |
100.0 |
% |
In Vitro antiviral activity against HSV-1 at 0.05 ug/mL concentration |
CHEMBL1127461 |
| Human herpesvirus 1 |
Inhibition |
= |
100.0 |
% |
In Vitro antiviral activity against HSV-1 at 0.5 ug/mL concentration |
CHEMBL1127461 |
| Human herpesvirus 1 |
Inhibition |
= |
100.0 |
% |
In Vitro antiviral activity against HSV-1 at 5 ug/mL concentration |
CHEMBL1127461 |
| Human herpesvirus 1 |
Inhibition |
= |
100.0 |
% |
In Vitro antiviral activity against HSV-1 at 50 ug/mL concentration |
CHEMBL1127461 |
| Human herpesvirus 1 |
Inhibition |
= |
100.0 |
% |
In Vitro antiviral activity against HSV-1 at 500 ug/mL concentration |
CHEMBL1127461 |
| Human herpesvirus 1 |
Inhibition |
= |
0.0 |
% |
In Vitro cytotoxicity against HSV-1 at 5 ug/mL concentration |
CHEMBL1127461 |
| Human herpesvirus 1 |
Inhibition |
= |
0.0 |
% |
In Vitro cytotoxicity against HSV-1 at 50 ug/mL concentration |
CHEMBL1127461 |
| Human herpesvirus 1 |
Inhibition |
= |
0.0 |
% |
In Vitro cytotoxicity against HSV-1 at 500 ug/mL concentration |
CHEMBL1127461 |
| Human herpesvirus 3 |
MIC |
= |
0.82 |
ug.mL-1 |
Minimum Inhibition Concentration (MIC) for activity against Varicella-Zoster Virus(VZV) using OKA (TK+) strain |
CHEMBL1129240 |
| Human herpesvirus 3 |
MIC |
= |
0.95 |
ug.mL-1 |
Minimum Inhibition Concentration (MIC) for activity against Varicella-Zoster Virus(VZV) using YS(TK+) strain. |
CHEMBL1129240 |
| Human herpesvirus 3 |
MIC |
= |
25.0 |
ug.mL-1 |
Minimum Inhibition Concentration (MIC) for activity against Varicella-Zoster Virus(VZV) using 07/1 (TK-) strain. |
CHEMBL1129240 |
| Human herpesvirus 3 |
MIC |
= |
40.0 |
ug.mL-1 |
Minimum Inhibition Concentration (MIC) for activity against Varicella-Zoster Virus(VZV) using YS/R (TK-) strain. |
CHEMBL1129240 |
| HEL |
MCC |
> |
100.0 |
ug.mL-1 |
Minimum cytotoxic concentration to reduce the HEL cell proliferation by 50% |
CHEMBL1129240 |
| E6SM |
CC50 |
> |
400.0 |
ug.mL-1 |
Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of E6SM cells |
CHEMBL1129240 |
| Human herpesvirus 1 |
ID50 |
= |
0.4 |
uM |
In vitro antiviral and anticellular activity was evaluated against herpes simplex virus HSV-1 (F strain) in vero cells tissue culture |
CHEMBL1123033 |
| Human herpesvirus 2 |
ID50 |
= |
1.5 |
uM |
In vitro antiviral and anticellular activity was evaluated against herpes simplex virus HSV-2 (G strain) in vero cells. |
CHEMBL1123033 |
| Human herpesvirus 5 |
ID50 |
= |
100.0 |
uM |
In vitro antiviral and anticellular activity was evaluated against human cytomegalovirus (HCMV AD 169) in (HCMV AD 169) cells. |
CHEMBL1123033 |
| Vero |
ID50 |
= |
1100.0 |
uM |
In vitro antiviral and anticellular activity was evaluated against vero cells in tissue culture |
CHEMBL1123033 |
| E6SM |
MCC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology |
CHEMBL1134545 |
| E6SM |
MIC |
= |
0.077 |
ug.mL-1 |
Antiviral activity against herpes simplex virus-1 KOS (HSV-1) in E6SM cell cultures |
CHEMBL1134545 |
| E6SM |
MIC |
= |
0.077 |
ug.mL-1 |
Antiviral activity against herpes simplex virus-2 G (HSV-2) in E6SM cell cultures |
CHEMBL1134545 |
| E6SM |
MIC |
> |
400.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus in E6SM cell cultures |
CHEMBL1134545 |
| E6SM |
MIC |
> |
400.0 |
ug.mL-1 |
Antiviral activity against vesicular simplex virus-1 in E6SM cell cultures |
CHEMBL1134545 |
| E6SM |
MIC |
= |
48.0 |
ug.mL-1 |
Antiviral activity against herpes simplex virus-1 TK-KOS ACV (HSV-1) in E6SM cell cultures |
CHEMBL1134545 |
| E6SM |
MIC |
= |
0.384 |
ug.mL-1 |
Antiviral activity against herpes simplex virus-1 TK-VMW 1837 (HSV-1) in E6SM cell cultures |
CHEMBL1134545 |
| Oryctolagus cuniculus |
MIC |
= |
0.08 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-1 ((KOS) |
CHEMBL1122219 |
| Oryctolagus cuniculus |
MIC |
= |
0.1 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-1 (McIntyre) |
CHEMBL1122219 |
| Oryctolagus cuniculus |
MIC |
= |
0.09 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-1 (F) |
CHEMBL1122219 |
| Oryctolagus cuniculus |
MIC |
= |
0.04 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-2 (Lycons) |
CHEMBL1122219 |
| Oryctolagus cuniculus |
MIC |
= |
0.06 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-2 (G) |
CHEMBL1122219 |
| Oryctolagus cuniculus |
MIC |
= |
0.06 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-2 (196) |
CHEMBL1122219 |
| Oryctolagus cuniculus |
MIC |
= |
80.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against Vaccinia virus |
CHEMBL1122219 |
| Oryctolagus cuniculus |
MIC |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against Vesicular stomatitis virus |
CHEMBL1122219 |
| Human herpesvirus 1 |
Control |
= |
0.2 |
% |
Antiviral activity against HSV-1 kinase mutant resistant to SCS(parental) was determined at a conc of 50 uM |
CHEMBL1123554 |
| Human herpesvirus 1 |
Control |
= |
18.0 |
% |
Antiviral activity against HSV-1 kinase mutant resistant to S1(ACV) was determined at a conc of 50 uM |
CHEMBL1123554 |
| Human herpesvirus 1 |
Control |
= |
0.3 |
% |
Antiviral activity against HSV-1 kinase mutant resistant to B3(BVdU) was determined at a conc of 50 uM |
CHEMBL1123554 |
| Human herpesvirus 1 |
Control |
= |
10.0 |
% |
Antiviral activity against HSV-1 kinase mutant resistant to Tr7(ACV) was determined at a conc of 50 uM |
CHEMBL1123554 |
| Human herpesvirus 1 |
Control |
= |
3.0 |
% |
Antiviral activity against DNA polymerase mutant resistant to KOS(parental) was determined at a conc of 50 uM |
CHEMBL1123554 |
| Human herpesvirus 1 |
Control |
= |
37.0 |
% |
Antiviral activity against DNA polymerase mutant resistant to PFA 1a (PFA) was determined at a conc of 50 uM |
CHEMBL1123554 |
| Human herpesvirus 1 |
Control |
= |
63.0 |
% |
Antiviral activity against DNA polymerase mutant resistant to PFA 3b(PFA) was determined at a conc of 50 uM |
CHEMBL1123554 |
| Human herpesvirus 1 |
Control |
= |
21.0 |
% |
Antiviral activity against DNA polymerase mutant resistant to PFA 5a(PFA) was determined at a conc of 50 uM |
CHEMBL1123554 |
| Vero |
CC50 |
> |
400000.0 |
nM |
In vitro cytotoxic concentration in vero cells. |
CHEMBL1145894 |
| Human herpesvirus 1 |
ED50 |
= |
0.5 |
uM |
Inhibitory activity against HSV-1 in vero cells |
CHEMBL1145894 |
| Human herpesvirus 2 |
ED50 |
= |
2.5 |
uM |
Inhibitory activity against HSV-2 in vero cells |
CHEMBL1145894 |
| ADMET |
TI |
> |
800.0 |
|
Therapeutic index (vero CC50/ED50) against HSV-1 |
CHEMBL1145894 |
| ADMET |
TI |
> |
160.0 |
|
Therapeutic index (vero CC50/ED50) against HSV-2 |
CHEMBL1145894 |
| Duck hepatitis B virus |
Inhibition |
|
|
% |
Percent inhibition of viral DNA in the presence of 10 mg/mL compound compared to untreated infected controls in duck hepatocytes; ND means Not determined |
CHEMBL1133838 |
| Nucleic Acid |
EC50 |
|
|
ug.mL-1 |
Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls; ND means Not determined |
CHEMBL1133838 |
| Vero |
EC50 |
= |
40.0 |
ug.mL-1 |
Concentration required to inhibit plaque formation by HSV-1 strain KOSSB (TK-) in monolayers of vero cells |
CHEMBL1133838 |
| Vero |
EC50 |
= |
0.5 |
ug.mL-1 |
Concentration required to inhibit plaque formation by HSV-1 strain KOS (TK+) in monolayers of vero cells |
CHEMBL1133838 |
| Vero |
CC50 |
> |
100.0 |
ug.mL-1 |
Compound was evaluated for cytotoxicity against stationary Vero cells using MTT assay |
CHEMBL1133838 |
| Homo sapiens |
IC50 |
= |
|
ug.mL-1 |
Concentration required to reduce the proliferation of PHA stimulated human peripheral blood T lymphocytes |
CHEMBL1133838 |
| E6SM |
MCC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration (MCC) required to cause a microscopically detectable alteration of normal cell morphology against E6SM cells |
CHEMBL1125440 |
| E6SM |
MIC |
= |
0.07 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce KOS strain of HSV-1 induced cytopathogenicity by 50% in E6SM cells |
CHEMBL1125440 |
| E6SM |
MIC |
= |
0.04 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce F strain of HSV-1 induced cytopathogenicity by 50% in E6SM cells |
CHEMBL1125440 |
| E6SM |
MIC |
= |
0.02 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce McIntyre strain of HSV-1 induced cytopathogenicity by 50% in E6SM cells |
CHEMBL1125440 |
| E6SM |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce B2006 strain of TK-HSV-1 induced cytopathogenicity by 50% in E6SM cells |
CHEMBL1125440 |
| E6SM |
MIC |
= |
10.0 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce VMW 1837 strain of TK-HSV-1 induced cytopathogenicity by 50% in E6SM cells |
CHEMBL1125440 |
| E6SM |
MIC |
= |
0.04 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce G strain of HSV-2 induced cytopathogenicity by 50% in E6SM cells |
CHEMBL1125440 |
| E6SM |
MIC |
= |
0.015 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce 196 strain of HSV-2 induced cytopathogenicity by 50% in E6SM cells |
CHEMBL1125440 |
| E6SM |
MIC |
= |
0.02 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce Lyons strain of HSV-2 induced cytopathogenicity by 50% in E6SM cells |
CHEMBL1125440 |
| E6SM |
VV |
> |
400.0 |
|
Compounds was evaluated for its inhibitory effect on cytopathogenicity of vaccinia virus (VV) in E6SM cells |
CHEMBL1125440 |
| E6SM |
VSV |
> |
400.0 |
|
Compounds was evaluated for its inhibitory effect on cytopathogenicity of vesicular stomatitis virus (VSV) in E6SM cells |
CHEMBL1125440 |
| Human herpesvirus 1 |
IC50 |
> |
100.0 |
ug.mL-1 |
In vitro cytotoxicity against herpes simplex virus type-1 (HSV-1) HF strain in infected KB cells |
CHEMBL1124297 |
| Human herpesvirus 1 |
IC50 |
= |
2.6 |
ug.mL-1 |
Inhibitory activity against herpes simplex virus type-1 (HSV-1) replication in KB cells |
CHEMBL1124297 |
| Human herpesvirus 1 |
Therapeutic index |
> |
38.0 |
|
In vitro therapeutic index as ratio of cytotoxicity to inhibition of viral replication |
CHEMBL1124297 |
| HeLa |
IC50 |
|
|
ug.mL-1 |
In vitro inhibitory concentration for cytotoxic activity was tested against HeLa cells; No data |
CHEMBL1130504 |
| Human herpesvirus 1 |
MIC |
= |
1.5630000000000002 |
ug.mL-1 |
In vitro minimum inhibitory concentration for antiviral activity was tested against Herpes simplex virus type 1(HSV-1) |
CHEMBL1130504 |
| Vero |
IC50 |
= |
50.0 |
ug.mL-1 |
In vitro inhibitory concentration for antiviral activity was tested against vero cells |
CHEMBL1130504 |
| Human herpesvirus 3 |
MIC |
= |
6.25 |
ug.mL-1 |
In vitro minimum inhibitory concentration for antiviral activity was tested against Varicella-Zoster virus(VZV) |
CHEMBL1130504 |
| HEL |
IC50 |
> |
50.0 |
ug.mL-1 |
In vitro inhibitory concentration for antiviral activity was tested against HEL cells |
CHEMBL1130504 |
| Human herpesvirus 1 |
ED50 |
= |
0.14 |
ug ml-1 |
Antiviral activity against herpes simplex virus-1 VR-3 strain in HEL (human erythroleukemia) cells. |
CHEMBL1130421 |
| Human herpesvirus 2 |
ED50 |
= |
0.23 |
ug ml-1 |
Antiviral activity against herpes simplex virus-2 (HSV-2) Ms strain in HEL (human erythroleukemia) cells. |
CHEMBL1130421 |
| Human herpesvirus 3 |
ED50 |
= |
2.7 |
ug ml-1 |
Antiviral activity against varicella zoster virus (VZV) Oka strain in HEL (human erythroleukemia) cells. |
CHEMBL1130421 |
| Human herpesvirus 5 |
ED50 |
= |
6.9 |
ug ml-1 |
Antiviral activity against human cytomegalovirus (HCMV) AD 169 strain HEL (human erythroleukemia) cells. |
CHEMBL1130421 |
| CCRF-HSB-2 |
IC50 |
> |
100.0 |
ug.mL-1 |
Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells. |
CHEMBL1130421 |
| Human herpesvirus 1 |
ID50 |
= |
0.48 |
uM |
Ability to reduce plaque formation of herpes simplex virus type 1 (HSV-1) by 50% in human embryonic lung fibroblast (HELF) cell cultures |
CHEMBL1124232 |
| Human herpesvirus 2 |
ID50 |
= |
1.6 |
uM |
Ability to reduce plaque formation of herpes simplex virus type 2 (HSV-2) by 50% in human embryonic lung fibroblast (HELF) cell cultures |
CHEMBL1124232 |
| ADMET |
ID50 |
= |
360.0 |
uM |
Inhibitory dose for HELF cell proliferation during 3-day treatment period |
CHEMBL1124232 |
| Vero |
MNTD |
= |
40.0 |
ug ml-1 |
Maximum nontoxic dose that allow exponential cell growth for three cell cycles |
CHEMBL1124988 |
| Vero |
TD50 |
= |
240.0 |
ug ml-1 |
Toxic dose that reduced by 50% the number of cells with respect to untreated controls. |
CHEMBL1124988 |
| Human herpesvirus 1 |
ED50 |
= |
0.02 |
ug ml-1 |
Effective dose required for antiviral activity against HSV-1 virus |
CHEMBL1124988 |
| Vaccinia virus |
ED50 |
> |
110.0 |
ug ml-1 |
Effective dose required for antiviral activity against Vaccinia virus |
CHEMBL1124988 |
| African swine fever virus |
ED50 |
= |
40.0 |
ug ml-1 |
Effective dose required for antiviral activity against ASFV virus |
CHEMBL1124988 |
| Vesicular stomatitis virus |
ED50 |
> |
40.0 |
ug ml-1 |
Effective dose required for antiviral activity against VSV virus |
CHEMBL1124988 |
| Homo sapiens |
Reduction |
= |
100.0 |
% |
Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 1000 uM |
CHEMBL1123640 |
| Homo sapiens |
Reduction |
= |
100.0 |
% |
Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 320 uM |
CHEMBL1123640 |
| Homo sapiens |
Reduction |
= |
94.0 |
% |
Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 100 uM |
CHEMBL1123640 |
| Homo sapiens |
Reduction |
= |
79.0 |
% |
Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 32 uM |
CHEMBL1123640 |
| Homo sapiens |
Reduction |
= |
41.0 |
% |
Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 10 uM |
CHEMBL1123640 |
| Homo sapiens |
Reduction |
= |
32.0 |
% |
Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 3.2 uM |
CHEMBL1123640 |
| Homo sapiens |
Reduction |
= |
35.0 |
% |
Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 1 uM |
CHEMBL1123640 |
| Homo sapiens |
Cytotoxicity |
= |
0.0 |
|
Cytotoxicity was determined at 1000 uM |
CHEMBL1123640 |
| Homo sapiens |
Cytotoxicity |
= |
0.0 |
|
Cytotoxicity was determined at 320 uM |
CHEMBL1123640 |
| Homo sapiens |
Cytotoxicity |
= |
0.0 |
|
Cytotoxicity was determined at 100 uM |
CHEMBL1123640 |
| Homo sapiens |
Cytotoxicity |
= |
0.0 |
|
Cytotoxicity was determined at 32 uM |
CHEMBL1123640 |
| No relevant target |
LogP |
= |
1.6 |
|
Partition coefficient (logP) |
CHEMBL1135649 |
| Nucleic Acid |
EC50 |
= |
6750.0 |
nM |
Effective concentration for the inhibition of Epstein-Barr virus EBV-DNA synthesis in human lymphoblastoid P3HR-1 cells |
CHEMBL1135649 |
| P3HR-1 |
CC50 |
= |
392000.0 |
nM |
Cytotoxic concentration for the inhibition of P3HR-1 cell growth |
CHEMBL1135649 |
| Unchecked |
Selectivity |
= |
58.0 |
|
Selectivity as the ratio of CC50 value to that of EC50 value. |
CHEMBL1135649 |
| NON-PROTEIN TARGET |
MIC |
= |
0.02 |
ug.mL-1 |
The minimum inhibitory concentration was measured against Herpes simplex virus type 1 (KOS strain) on E6SM cells |
CHEMBL1127471 |
| Human herpesvirus 1 |
MIC |
= |
0.004 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 1 (F strain) |
CHEMBL1127471 |
| NON-PROTEIN TARGET |
MIC |
= |
0.07 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 1 (McIntyre strain) |
CHEMBL1127471 |
| NON-PROTEIN TARGET |
MIC |
= |
0.09 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (G strain) |
CHEMBL1127471 |
| NON-PROTEIN TARGET |
MIC |
= |
0.01 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (196 strain) |
CHEMBL1127471 |
| NON-PROTEIN TARGET |
MIC |
= |
0.009000000000000001 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (Lyons strain) |
CHEMBL1127471 |
| Human herpesvirus 1 |
MIC |
= |
5.0 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against TK+/TK-Herpes simplex virus type 1 (VMW1837 strain) |
CHEMBL1127471 |
| Human herpesvirus 1 |
MIC |
= |
70.0 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against TK-Herpes simplex virus type 1 (B2006 strain) |
CHEMBL1127471 |
| Human herpesvirus 3 |
MIC |
= |
0.38 |
ug.mL-1 |
The minimum inhibitory concentration was measured on HEL cells against Varicella zoster virus (YS strain) |
CHEMBL1127471 |
| Human herpesvirus 3 |
MIC |
= |
0.18 |
ug.mL-1 |
The minimum inhibitory concentration was measured on HEL cells against Varicella zoster virus (OKA strain) |
CHEMBL1127471 |
| Human herpesvirus 3 |
MIC |
= |
4.7 |
ug.mL-1 |
The minimum inhibitory concentration was measured on HEL cells against TK-Varicella zoster virus (YS-R strain) |
CHEMBL1127471 |
| Human herpesvirus 3 |
MIC |
= |
13.7 |
ug.mL-1 |
The minimum inhibitory concentration was measured on HEL cells against TK-Varicella zoster virus (07/1 strain) |
CHEMBL1127471 |
| Human herpesvirus 5 |
MIC |
= |
13.2 |
ug.mL-1 |
The minimum inhibitory concentration was measured on HEL cells against Cytomegalovirus virus (AD-169 strain) |
CHEMBL1127471 |
| Human herpesvirus 3 |
MIC |
> |
220.0 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against Vesicular stomatitis virus |
CHEMBL1127471 |
| Vaccinia virus |
MIC |
> |
180.0 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against Vaccinia virus |
CHEMBL1127471 |
| E6SM |
MIC |
= |
350.0 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells for morphological alteration |
CHEMBL1127471 |
| HEL |
MIC |
> |
200.0 |
ug.mL-1 |
The minimum inhibitory concentration was measured on HEL cells in cell growth |
CHEMBL1127471 |
| Human herpesvirus 1 |
ED50 |
= |
0.08 |
ug ml-1 |
In vitro antiviral activity against herpesvirus, HSV-1,E-377 strain by plaque reduction assay in human foreskin fibroblasts |
CHEMBL1124752 |
| Human herpesvirus 2 |
ED50 |
= |
0.09 |
ug ml-1 |
In vitro antiviral activity against herpesvirus, HSV-2, MS strain by plaque reduction assay in human foreskin fibroblasts |
CHEMBL1124752 |
| Human herpesvirus 2 |
ED50 |
= |
0.1 |
ug ml-1 |
In vitro antiviral activity against herpesvirus,HSV-2,X-79 strain by plaque reduction assay in human foreskin fibroblasts |
CHEMBL1124752 |
| Human herpesvirus 2 |
ED50 |
= |
0.07 |
ug ml-1 |
In vitro antiviral activity against herpesvirus, HSV-2, JEN strain by plaque reduction assay in human foreskin fibroblasts |
CHEMBL1124752 |
| Human herpesvirus 2 |
ED50 |
= |
0.06 |
ug ml-1 |
In vitro antiviral activity against herpesvirus,HSV-2,HEET strain by plaque reduction assay in human foreskin fibroblasts |
CHEMBL1124752 |
| Human herpesvirus 3 |
ED50 |
= |
2.3 |
ug ml-1 |
In vitro antiviral activity tested against herpesvirus, VZV, Ellen strain by plaque reduction assay in human foreskin fibroblasts. |
CHEMBL1124752 |
| Human herpesvirus 3 |
ED50 |
= |
3.7 |
ug ml-1 |
In vitro antiviral activity tested against herpesvirus, VZV, OKA strain by plaque reduction assay in human foreskin fibroblasts. |
CHEMBL1124752 |
| Raji |
ED50 |
= |
3.8 |
ug ml-1 |
Tested for the inhibition of diffuse early antigen production assayed by immunofluorescent monoclonal antibody. |
CHEMBL1124752 |
| Human herpesvirus 1 |
ID50 |
> |
100.0 |
ug ml-1 |
In vitro antiviral activity against herpesvirus, HSV-1, E-377 strain by plaque reduction assay in human foreskin fibroblasts. |
CHEMBL1124752 |
| Human herpesvirus 2 |
ID50 |
> |
100.0 |
ug ml-1 |
In vitro antiviral activity against herpesvirus, HSV-2, MS strain by plaque reduction assay in human foreskin fibroblasts. |
CHEMBL1124752 |
| Human herpesvirus 2 |
ID50 |
> |
100.0 |
ug ml-1 |
In vitro antiviral activity against herpesvirus, HSV-2, X-79 strain by plaque reduction assay in human foreskin fibroblasts. |
CHEMBL1124752 |
| NON-PROTEIN TARGET |
ID50 |
> |
100.0 |
ug ml-1 |
In vitro antiviral activity against herpesvirus, HSV-JEN strain by plaque reduction assay in human foreskin fibroblasts. |
CHEMBL1124752 |
| NON-PROTEIN TARGET |
ID50 |
> |
100.0 |
ug ml-1 |
In vitro antiviral activity against herpesvirus, HSV-HEET strain by plaque reduction assay in human foreskin fibroblasts. |
CHEMBL1124752 |
| Human herpesvirus 3 |
ID50 |
> |
100.0 |
ug ml-1 |
In vitro antiviral activity against herpesvirus, VZV, Ellen strain by plaque reduction assay in human foreskin fibroblasts. |
CHEMBL1124752 |
| Human herpesvirus 3 |
ID50 |
> |
100.0 |
ug ml-1 |
In vitro antiviral activity against herpesvirus, VZV, OKA strain by plaque reduction assay in human foreskin fibroblasts. |
CHEMBL1124752 |
| Raji |
ID50 |
> |
100.0 |
ug ml-1 |
Tested for the inhibition of diffuse early antigen production assayed by immunofluorescent monoclonal antibody. |
CHEMBL1124752 |
| Homo sapiens |
ID50 |
= |
165.0 |
ug ml-1 |
The drug concentration was determined to reduce proliferation of human foreskin fibroblasts to 50% of untreated controls in proliferation assay. |
CHEMBL1124752 |
| Human herpesvirus 1 |
MDD |
= |
12.3 |
|
Tested for mean day to death of nonsurvivors against HSV-1 infection in mice at 200 mg/kg per day |
CHEMBL1124752 |
| Human herpesvirus 1 |
MDD |
= |
8.0 |
|
Tested for mean day to death of nonsurvivors against HSV-1 infection in mice at 50 mg/kg per day |
CHEMBL1124752 |
| Human herpesvirus 1 |
MDD |
= |
7.8 |
|
Tested for mean day to death of nonsurvivors against HSV-1 infection in mice at 12.5 mg/kg per day |
CHEMBL1124752 |
| Human herpesvirus 1 |
Survivors / treated |
= |
4.0 |
|
Number of survivors per number of HSV-1 infected mice treated with 200 mg/kg per day; 4/10 |
CHEMBL1124752 |
| Human herpesvirus 1 |
Survivors / treated |
= |
0.0 |
|
Number of survivors per number of HSV-1 infected mice treated with 50 mg/kg per day; 0/10 |
CHEMBL1124752 |
| Human herpesvirus 1 |
Survivors / treated |
= |
2.0 |
|
Number of survivors per number of HSV-1 infected mice treated with 12.5 mg/kg per day; 2/10 |
CHEMBL1124752 |
| Human herpesvirus 1 |
ED50 |
= |
189.9 |
ug ml-1 |
Tested for the effective dose required to inhibit HSV-1 in infected mice |
CHEMBL1124752 |
| Thymidine kinase, cytosolic |
Km |
= |
1500.0 |
nM |
Michaelis rate constant is determined by the Lineweaver and Burk method against HSV thymidine kinase |
CHEMBL1134666 |
| Thymidine kinase, cytosolic |
Relative Vmax |
= |
39.2 |
|
Maximum velocity constant of the rate of phosphorylation was determined against HSV thymidine kinase |
CHEMBL1134666 |
| Thymidine kinase, cytosolic |
Km |
= |
2200.0 |
nM |
Michaelis rate constant is determined by the Lineweaver and Burk method against Vero cell thymidine kinase |
CHEMBL1134666 |
| Thymidine kinase, cytosolic |
Relative Vmax |
< |
3.0 |
|
Maximum velocity constant of the rate of phosphorylation was determined against Vero cell thymidine kinase |
CHEMBL1134666 |
| Unchecked |
Symptom initiation |
> |
21.0 |
% |
Inhibitory effects on HSV-1 induced mortality in NMRI mice upon (ip) administration at a dose of 250 mk/kg/day |
CHEMBL1134666 |
| Unchecked |
Symptom initiation |
= |
19.1 |
% |
Inhibitory effects on HSV-1 induced mortality in NMRI mice upon (ip) administration at a dose of 150 mk/kg/day |
CHEMBL1134666 |
| Unchecked |
Symptom initiation |
= |
15.6 |
% |
Inhibitory effects on HSV-1 induced mortality in NMRI mice upon (ip) administration at a dose of 100 mk/kg/day |
CHEMBL1134666 |
| Unchecked |
Animal death |
> |
21.0 |
% |
Inhibitory effects on HSV-1 induced mortality in NMRI mice upon (ip) administration at a dose of 250 mk/kg/day |
CHEMBL1134666 |
| Unchecked |
Animal death |
> |
21.0 |
% |
Inhibitory effects on HSV-1 induced mortality in NMRI mice upon (ip) administration at a dose of 150 mk/kg/day |
CHEMBL1134666 |
| Unchecked |
Animal death |
= |
18.9 |
% |
Inhibitory effects on HSV-1 induced mortality in NMRI mice upon (ip) administration at a dose of 100 mk/kg/day |
CHEMBL1134666 |
| ADMET |
MIC |
= |
0.07 |
ug.mL-1 |
Minimum inhibitory concentration required for antiviral activity to reduce HSV-1 (KOS) induced cytopathicity in human embryonic skin-muscle cells (ESM) |
CHEMBL1127647 |
| ADMET |
MIC |
= |
0.07 |
ug.mL-1 |
Minimum inhibitory concentration required for antiviral activity to reduce HSV-2 (G) induced cytopathicity in human embryonic skin-muscle cells (ESM) |
CHEMBL1127647 |
| Human herpesvirus 1 |
MIC |
= |
100.0 |
ug.mL-1 |
Minimum inhibitory concentration required for antiviral activity to reduce TK-HSV-1 (B2006) induced cytopathicity in human embryonic skin-muscle cells (ESM) |
CHEMBL1127647 |
| Vaccinia virus |
MIC |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory concentration required for antiviral activity to reduce Vaccinia virus (VV) induced cytopathicity in human embryonic skin-muscle cells (ESM) |
CHEMBL1127647 |
| Vesicular stomatitis virus |
MIC |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory concentration required for antiviral activity to reduce Vesicular stomatitis virus (VSV) induced cytopathicity in human embryonic skin-muscle cells (ESM) |
CHEMBL1127647 |
| HEL |
MIC |
= |
4.0 |
ug.mL-1 |
Minimum inhibitory concentration required for antiviral activity to reduce Varicella Zoster virus (VZV) (Oka) induced cytopathicity in human embryonic lung cells (HEL) |
CHEMBL1127647 |
| HEL |
MIC |
= |
80.0 |
ug.mL-1 |
Minimum inhibitory concentration required for antiviral activity to reduce TK Varicella Zoster virus (VZV) (07/1) induced cytopathicity in human embryonic lung cells (HEL) |
CHEMBL1127647 |
| HEL |
MIC |
= |
50.0 |
ug.mL-1 |
Minimum inhibitory concentration required for antiviral activity to reduce Cytomegalovirus (CMV) (Davis) induced cytopathicity in human embryonic lung cells (HEL) |
CHEMBL1127647 |
| HEL |
MIC |
= |
35.0 |
ug.mL-1 |
Minimum inhibitory concentration required for antiviral activity to reduce Cytomegalovirus (CMV) (AD-169) induced cytopathicity in human embryonic lung cells (HEL) |
CHEMBL1127647 |
| ESM |
MIC |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory concentration to reduce cytopathicity by 50% in morphology of human embryonic skin-muscle cells (ESM) |
CHEMBL1127647 |
| HEL |
MIC |
> |
200.0 |
ug.mL-1 |
Minimum inhibitory concentration to reduce cytopathicity by 50% in proliferation of human embryonic lung cells (HEL) |
CHEMBL1127647 |
| Human herpesvirus 1 |
MIC |
= |
0.004 |
ug.mL-1 |
Compound was tested for antiherpes activity against Herpes simplex virus-1(KOS) in E6SM cell cultures |
CHEMBL1129103 |
| Human herpesvirus 2 |
MIC |
= |
0.004 |
ug.mL-1 |
Compound was tested for antiherpes activity against Herpes simplex virus-2(G) in E6SM cell cultures |
CHEMBL1129103 |
| Human herpesvirus 3 |
MIC |
= |
0.5 |
ug.mL-1 |
Compound was tested for antiherpes activity against Varicella zoster virus(OKA) in HEL cells |
CHEMBL1129103 |
| Cytomegalovirus |
MIC |
|
|
ug.mL-1 |
Compound was tested for antiherpes activity against Cytomegalovirus virus(AD 169) in HEL cells; Not determined |
CHEMBL1129103 |
| Human herpesvirus 1 |
IC50 |
= |
0.01 |
ug.mL-1 |
Tested for antiviral activity against HSV-1 (KOS) |
CHEMBL1134101 |
| Human herpesvirus 1 |
IC50 |
= |
9.6 |
ug.mL-1 |
Tested for antiviral activity against HSV-1 (TK-KOS) |
CHEMBL1134101 |
| Human herpesvirus 2 |
IC50 |
= |
0.02 |
ug.mL-1 |
Tested for antiviral activity against HSV-2 (G) |
CHEMBL1134101 |
| Human herpesvirus 3 |
IC50 |
= |
1.1 |
ug.mL-1 |
Tested for antiviral activity against VZV (YS) |
CHEMBL1134101 |
| Human herpesvirus 3 |
IC50 |
= |
13.0 |
ug.mL-1 |
Tested for antiviral activity against VZV (TK-KOS) |
CHEMBL1134101 |
| Cytomegalovirus |
IC50 |
|
|
ug.mL-1 |
Tested for antiviral activity against HCMV (AD169); Not determined |
CHEMBL1134101 |
| Hepatitis B virus |
IC50 |
> |
50.0 |
ug.mL-1 |
Tested for antiviral activity against HBV (Hep AD79) |
CHEMBL1134101 |
| Cytomegalovirus |
EC50 |
= |
16.0 |
ug.mL-1 |
Effective concentration required against HCMV AD169 for antiviral activity |
CHEMBL1134101 |
| Cytomegalovirus |
EC50 |
= |
16.0 |
ug.mL-1 |
Effective concentration required against HCMV strain for antiviral activity |
CHEMBL1134101 |
| Cytomegalovirus |
EC50 |
|
|
ug.mL-1 |
Effective concentration required against HCMV strain for antiviral activity |
CHEMBL1134101 |
| Cytomegalovirus |
EC50 |
|
|
ug.mL-1 |
Effective concentration required against HCMV strain for antiviral activity; Not determined |
CHEMBL1134101 |
| Human herpesvirus 3 |
EC50 |
= |
2900.0 |
nM |
Compound was evaluated for the inhibition of VZV strains of OKA |
CHEMBL1132458 |
| Human herpesvirus 3 |
EC50 |
= |
1000.0 |
nM |
Compound was evaluated for the inhibition of VZV strains of YS |
CHEMBL1132458 |
| Human herpesvirus 3 |
EC50 |
= |
74000.0 |
nM |
Compound was evaluated for the inhibition of VZV (TK-) thymidine kinases Strain 07 |
CHEMBL1132458 |
| Human herpesvirus 3 |
EC50 |
= |
125000.0 |
nM |
Compound was evaluated for the inhibition of VZV (TK-) thymidine kinases Strain YS-R |
CHEMBL1132458 |
| HEL |
MCC |
> |
200000.0 |
nM |
Compound was evaluated for the cytotoxicity against HEL cells |
CHEMBL1132458 |
| HEL |
IC50 |
> |
200000.0 |
nM |
Compound was evaluated for the anti-viral activity against HEL cells |
CHEMBL1132458 |
| Human herpesvirus 1 |
EC50 |
= |
2220.0 |
nM |
Inhibitory concentration required to reduce HSV-1 induced cytopathogenic effect (CPE) in human skin fibroblast |
CHEMBL1144911 |
| Homo sapiens |
CC50 |
|
|
nM |
Cytotoxic concentration that produces 50% growth inhibition of human skin fibroblast in CPE assay; ND: No data |
CHEMBL1144911 |
| Unchecked |
SI |
|
|
|
Selectivity index calculated as CC50/EC50 in the study of cytopathogenic effect by HSV-1; ND: No data |
CHEMBL1144911 |
| Homo sapiens |
EC50 |
= |
10210.0 |
nM |
Inhibitory concentration required to reduce HSV-2 induced cytopathogenic effect in human skin fibroblast |
CHEMBL1144911 |
| Unchecked |
SI |
|
|
|
Selectivity index calculated as CC50/EC50 in the study of cytopathogenic effect by HSV-1; ND: No data |
CHEMBL1144911 |
| Homo sapiens |
EC50 |
= |
1100.0 |
nM |
Inhibitory concentration required to reduce HSV-1 induced virus plaque reduction (VPR) in human skin fibroblast |
CHEMBL1144911 |
| Homo sapiens |
CC50 |
|
|
nM |
Cytotoxic concentration that produces 50% growth inhibition of human skin fibroblast in VPR assay; ND: No data |
CHEMBL1144911 |
| Unchecked |
SI |
|
|
|
Selectivity index calculated as CC50/EC50 in the VPR assay of HSV-1; ND: No data |
CHEMBL1144911 |
| Homo sapiens |
EC50 |
= |
1680.0 |
nM |
Inhibitory concentration required to reduce HSV-2 induced virus plaque reduction (VPR) in human skin fibroblast |
CHEMBL1144911 |
| Unchecked |
SI |
|
|
|
Selectivity index calculated as CC50/EC50 in the VPR assay of HSV-2; ND: No data |
CHEMBL1144911 |
| Human immunodeficiency virus 1 |
EC50 |
|
|
ug.mL-1 |
Compound was evaluated for the antiviral activity against HIV-1; Not determined |
CHEMBL1130783 |
| Human herpesvirus 1 |
EC50 |
= |
1.054 |
ug.mL-1 |
Compound was evaluated for the antiviral activity against HSV-1 |
CHEMBL1130783 |
| Human herpesvirus 2 |
EC50 |
= |
5.12 |
ug.mL-1 |
Compound was evaluated for the antiviral activity against HSV-2 |
CHEMBL1130783 |
| Human herpesvirus 5 |
EC50 |
|
|
ug.mL-1 |
Compound was evaluated for the antiviral activity against HCMV; Not determined |
CHEMBL1130783 |
| NON-PROTEIN TARGET |
IC50 |
= |
250.0 |
ug.mL-1 |
Compound was evaluated for its cytotoxicity. |
CHEMBL1130783 |
| Human herpesvirus 1 |
ID50 |
= |
0.5 |
ug ml-1 |
Evaluated for the antiviral activity against Herpes simplex virus type 1 (HSV-1) strain BWS by the plaque reduction assay |
CHEMBL1124745 |
| Human herpesvirus 2 |
ID50 |
= |
2.4 |
ug ml-1 |
Evaluated for the antiviral activity against Herpes simplex virus type 2 (HSV-2) strain G by the plaque reduction assay |
CHEMBL1124745 |
| Human herpesvirus 5 |
ID50 |
= |
38.4 |
ug ml-1 |
Evaluated for the antiviral activity against Human cytomegalovirus (HCMV) strain AD-169 by the plaque reduction assay |
CHEMBL1124745 |
| Vero |
ID50 |
= |
100.0 |
ug ml-1 |
Evaluated for the antiviral activity against Vero cells by proliferation assays (in uninfected cells) |
CHEMBL1124745 |
| Human herpesvirus 3 |
EC50 |
= |
1500.0 |
nM |
Antiviral activity against Varicella-Zoster virus (YS) |
CHEMBL1146720 |
| Human herpesvirus 3 |
EC50 |
= |
1100.0 |
nM |
Antiviral activity against Varicella-Zoster virus (OKA) |
CHEMBL1146720 |
| Human herpesvirus 3 |
EC50 |
= |
40000.0 |
nM |
Antiviral activity against Varicella-Zoster virus (thymidine kinase deficient) TK-(07/1) |
CHEMBL1146720 |
| HeLa |
MCC |
> |
200000.0 |
nM |
Minimal cytotoxic concentration, required to alter microscopically detectable cell morphology |
CHEMBL1146720 |
| HeLa |
CC50 |
> |
400000.0 |
nM |
Cytotoxic concentration required to inhibit Hel cell growth |
CHEMBL1146720 |
| Cytomegalovirus |
IC50 |
= |
63000.0 |
nM |
Inhibitory activity against human cytomegalovirus determined by plaque reduction assay |
CHEMBL1124273 |
| Human herpesvirus 1 |
IC50 |
= |
2600.0 |
nM |
Antiviral activity against Herpes simplex virus type 1 determined by plaque reduction assay |
CHEMBL1124273 |
| HFF |
IC50 |
> |
100000.0 |
nM |
The compound was tested for cytotoxicity against human foreskin fibroblast cell |
CHEMBL1124273 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
The compound was tested for cytotoxicity against BSC1 cell |
CHEMBL1124273 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Average percent inhibition of DNA, RNA, and protein synthesis determined in KB cells |
CHEMBL1124273 |
| Human herpesvirus 1 |
MIC |
= |
0.02 |
ug.mL-1 |
Inhibitory concentration against HSV type 1 strain KOS in human embryonic skin muscle (ESM) fibroblast cell culture |
CHEMBL1126736 |
| Human herpesvirus 1 |
MIC |
= |
0.4 |
ug.mL-1 |
Inhibitory concentration against HSV type 1 strain F in human embryonic skin muscle (ESM) fibroblast cell culture |
CHEMBL1126736 |
| Human herpesvirus 1 |
MIC |
= |
0.7 |
ug.mL-1 |
Inhibitory concentration against HSV type 1 strain Mc Intyre in human embryonic skin muscle (ESM) fibroblast cell culture |
CHEMBL1126736 |
| Human herpesvirus 2 |
MIC |
= |
0.02 |
ug.mL-1 |
Inhibitory concentration against HSV type 2 strain G in human embryonic skin muscle (ESM) fibroblast cell culture |
CHEMBL1126736 |
| Human herpesvirus 2 |
MIC |
= |
2.0 |
ug.mL-1 |
Inhibitory concentration against HSV type 2 strain 196 in human embryonic skin muscle (ESM) fibroblast cell culture |
CHEMBL1126736 |
| Human herpesvirus 2 |
MIC |
= |
0.7 |
ug.mL-1 |
Inhibitory concentration against HSV type 2 strain Lyons in human embryonic skin muscle (ESM) fibroblast cell culture |
CHEMBL1126736 |
| Human herpesvirus 1 |
MIC |
= |
70.0 |
ug.mL-1 |
Inhibitory concentration against TK-HSV type 1 strain B2006 in human embryonic skin muscle (ESM) fibroblast cell culture |
CHEMBL1126736 |
| Human herpesvirus 3 |
MIC |
= |
0.15 |
ug.mL-1 |
Inhibitory concentration against VZV strain YS in human embryonic lung (HEL) cell culture |
CHEMBL1126736 |
| Human herpesvirus 3 |
MIC |
= |
0.04 |
ug.mL-1 |
Inhibitory concentration against VZV strain OKA in human embryonic lung (HEL) cell culture |
CHEMBL1126736 |
| Human herpesvirus 3 |
MIC |
= |
5.0 |
ug.mL-1 |
Inhibitory concentration against TK-VZV strain YS-R in human embryonic lung (HEL) cell culture |
CHEMBL1126736 |
| Human herpesvirus 3 |
MIC |
= |
3.0 |
ug.mL-1 |
Inhibitory concentration against TK-VZV strain 07-1 in human embryonic lung (HEL) cell culture |
CHEMBL1126736 |
| Vesicular stomatitis virus |
MIC |
> |
400.0 |
ug.mL-1 |
Inhibitory concentration against VSV in human embryonic skin muscle (ESM) fibroblast cell culture |
CHEMBL1126736 |
| Vaccinia virus |
MIC |
> |
400.0 |
ug.mL-1 |
Inhibitory concentration against VV in human embryonic skin muscle (ESM) fibroblast cell culture |
CHEMBL1126736 |
| HEL |
MIC |
> |
200.0 |
ug.mL-1 |
Inhibitory concentration required to inhibit cell growth by 50% in human embryonic lung (HEL) cell culture |
CHEMBL1126736 |
| Vero |
ED50 |
= |
0.5 |
uM |
Antiviral activity against HSV-1 (Herpes simplex virus) in vero cells |
CHEMBL1127499 |
| Vero |
ED50 |
= |
0.5 |
uM |
Antiviral activity against HSV-2 (Herpes simplex virus) in vero cells |
CHEMBL1127499 |
| Vero |
CD50 |
> |
50.0 |
uM |
Cytotoxic dose of compound required to reduce the viability of normal uninfected vero cells by 50%. |
CHEMBL1127499 |
| Unchecked |
Selectivity index |
> |
100.0 |
|
Selectivity index against HSV-1 was determined as CD50/ED50 ratio |
CHEMBL1127499 |
| Unchecked |
Selectivity index |
> |
100.0 |
|
Selectivity index against HSV-2 was determined as CD50/ED50 ratio |
CHEMBL1127499 |
| Thymidine kinase, cytosolic |
Activity |
= |
23.0 |
% |
Phosphorylation of compound by purified HSV-1 (F strain) thymidine kinase |
CHEMBL1123332 |
| Vero |
ID50 |
= |
0.5 |
uM |
Antiviral activity determined against herpes simplex type 1 (F strain) by plaque reduction in Vero cells |
CHEMBL1123332 |
| E6SM |
MIC |
= |
0.04 |
ug.mL-1 |
Minimum inhibitory conc. for 50% inhibition of HSV-1 (KOS) virus induced cytopathicity in E6SM cells |
CHEMBL1130007 |
| E6SM |
MIC |
= |
0.07 |
ug.mL-1 |
Minimum inhibitory conc. for 50% inhibition of HSV-2 (G) virus induced cytopathicity in E6SM cells |
CHEMBL1130007 |
| E6SM |
MIC |
> |
200.0 |
ug.mL-1 |
Minimum inhibitory conc. for 50% inhibition of vaccinia virus induced cytopathicity in E6SM cells |
CHEMBL1130007 |
| E6SM |
MIC |
> |
200.0 |
ug.mL-1 |
Minimum inhibitory conc. for 50% inhibition of vesicular stomatitis virus induced cytopathicity in E6SM cells |
CHEMBL1130007 |
| E6SM |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory conc. for 50% inhibition of TK HSV-1 (B2006) virus induced cytopathicity in E6SM cells |
CHEMBL1130007 |
| E6SM |
MIC |
= |
400.0 |
ug.mL-1 |
Minimum inhibitory conc. for 50% inhibition of alteration of morphology in E6SM cells |
CHEMBL1130007 |
| HEL |
MIC |
= |
0.1 |
ug.mL-1 |
Minimum inhibitory conc. for 50% inhibition of VZV (OKA) virus plaque formation in HEL cells |
CHEMBL1130007 |
| HEL |
MIC |
= |
0.1 |
ug.mL-1 |
Minimum inhibitory conc. for 50% inhibition of VZV (YS) virus plaque formation in HEL cells |
CHEMBL1130007 |
| HEL |
MIC |
= |
5.0 |
ug.mL-1 |
Minimum inhibitory conc. for 50% inhibition of TK VZV (07/1) virus plaque formation in HEL cells |
CHEMBL1130007 |
| HEL |
MIC |
= |
5.0 |
ug.mL-1 |
Minimum inhibitory conc. for 50% inhibition of TK-VZV (YS/R) virus plaque formation in HEL cells |
CHEMBL1130007 |
| HEL |
MIC |
> |
200.0 |
ug.mL-1 |
Minimum inhibitory conc. for 50% inhibition of growth in HEL cells |
CHEMBL1130007 |
| Human herpesvirus 3 |
EC50 |
= |
2000.0 |
nM |
Effective concentration to show 50% of activity was measured on varicella zoster virus(VZV) cell culture |
CHEMBL1133761 |
| Human herpesvirus 4 |
EC50 |
= |
19700.0 |
nM |
Effective concentration to show 50% of activity was measured on Epstein Barr virus(EBV) cell culture |
CHEMBL1133761 |
| ADMET |
EC50 |
= |
13600.0 |
nM |
Effective concentration to show 50% of activity was measured on herpes simplex virus-1 KOS strain cell culture. |
CHEMBL1133761 |
| CCRF-CEM |
ID50 |
> |
100.0 |
|
Dose that inhibited 50% cell growth of human T-lymphoid CEM cells compared with untreated control |
CHEMBL1133761 |
| CCRF-CEM |
ID50 |
> |
200.0 |
|
The mitochondrial toxicity was measured on human T-lymphoid CEM cells. |
CHEMBL1133761 |
| Vero |
IC50 |
= |
3800.0 |
nM |
Compound was tested for antiviral activity against Herpes Simplex virus Type-1(HFEM) in vero cells |
CHEMBL1123836 |
| Vero |
IC50 |
= |
2500.0 |
nM |
Compound was tested for antiviral activity against Herpes Simplex virus Type-2(MS) in vero cells |
CHEMBL1123836 |
| MRC5 |
IC90 |
= |
4800.0 |
nM |
Compound was tested for antiviral activity against Herpes Simplex virus Type-1(HFEM) in human lung fibroblasts (MRC-5) |
CHEMBL1123836 |
| MRC5 |
IC90 |
= |
700.0 |
nM |
Compound was tested for antiviral activity against Herpes Simplex virus Type-1(18189) in human lung fibroblasts (MRC-5) |
CHEMBL1123836 |
| MRC5 |
IC90 |
= |
1400.0 |
nM |
Compound was tested for antiviral activity against Herpes Simplex virus Type-1(19407) in human lung fibroblasts (MRC-5) |
CHEMBL1123836 |
| MRC5 |
IC90 |
= |
900.0 |
nM |
Compound was tested for antiviral activity against Herpes Simplex virus Type-1(20132) in human lung fibroblasts (MRC-5) |
CHEMBL1123836 |
| MRC5 |
IC90 |
= |
1200.0 |
nM |
Compound was tested for antiviral activity against Herpes Simplex virus Type-2(MS) in human lung fibroblasts (MRC-5) |
CHEMBL1123836 |
| MRC5 |
IC90 |
= |
700.0 |
nM |
Compound was tested for antiviral activity against Herpes Simplexin human lung fibroblasts (MRC-5)in vero cells |
CHEMBL1123836 |
| MRC5 |
IC90 |
= |
300.0 |
nM |
Compound was tested for antiviral activity against Herpes Simplex virus Type-2(20605) in human lung fibroblasts (MRC-5) |
CHEMBL1123836 |
| MRC5 |
IC90 |
= |
900.0 |
nM |
Compound was tested for antiviral activity against Herpes Simplex virus Type-2(21929) in human lung fibroblasts (MRC-5) |
CHEMBL1123836 |
| WI-38 |
ID50 |
= |
4.0 |
uM |
Anti viral activity against VZV(Ellen strain) in WI-38 cell monolayers. |
CHEMBL1126039 |
| WI-38 |
ID50 |
= |
2.0 |
uM |
Anti viral activity against VZV(Ito strain) in WI-38 cell monolayers. |
CHEMBL1126039 |
| WI-38 |
ID50 |
= |
4.0 |
uM |
Anti viral activity against VZV(Oka strain) in WI-38 cell monolayers. |
CHEMBL1126039 |
| WI-38 |
ID50 |
= |
4.0 |
uM |
Anti viral activity against VZV(9021 strain) in WI-38 cell monolayers. |
CHEMBL1126039 |
| WI-38 |
ID50 |
= |
4.0 |
uM |
Anti viral activity against VZV(pplla strain) in WI-38 cell monolayers. |
CHEMBL1126039 |
| WI-38 |
ID50 |
= |
220.0 |
uM |
Anti viral activity against VZV(40a2 (TK-) strain) in WI-38 cell monolayers. |
CHEMBL1126039 |
| WI-38 |
ID50 |
= |
110.0 |
uM |
Anti viral activity against VZV (Kanno-Kohmura(TK-) strain) in WI-38 cell monolayers. |
CHEMBL1126039 |
| WI-38 |
ID50 |
= |
0.2 |
uM |
Anti viral activity against HSV-1(Schooler) in WI-38 cell monolayers |
CHEMBL1126039 |
| WI-38 |
ID50 |
= |
0.8 |
uM |
Anti viral activity against HSV-2(186) in WI-38 cell monolayers |
CHEMBL1126039 |
| WI-38 |
ID50 |
= |
40.0 |
uM |
Anti viral activity against HCMV(AD169) in WI-38 cell monolayers |
CHEMBL1126039 |
| WI-38 |
ID50 |
> |
750.0 |
uM |
Growth inhibitory activity against WI-38 cells |
CHEMBL1126039 |
| Thymidine kinase, cytosolic |
Kinase activity |
= |
13.0 |
pM min-1*ml-1 |
Kinase activity against purified VZV Thymidine kinase (conversion of the nucleoside analogue to its monophosphate by VZV -TK ) |
CHEMBL1126039 |
| ADMET |
Therapeutic index |
> |
3.8 |
|
Therapeutic index of compound maesured as ratio of ID50 for WI-38 cell growth inhibition / ID50 anti-VZV (strain Ellen) |
CHEMBL1126039 |
| Vero |
Virus rating |
= |
6.2 |
|
In vitro antiviral activity against herpes simplex virus type 1 (E-377 strain) in Vero host cell cultures |
CHEMBL1125060 |
| Vero |
ID50 |
= |
0.9 |
ug ml-1 |
In vitro minimum drug concentration that inhibited herpes simplex virus type 1 (E-377 strain) virus-induced cytopathogenic effects by 50% in vero cells |
CHEMBL1125060 |
| Vero |
MTC |
> |
255.2 |
ug ml-1 |
Minimum concentration (ug/mL) for in vitro antiviral activity against herpes simplex virus type 1 (E-377 strain) in Vero host cell cultures |
CHEMBL1125060 |
| Vero |
Therapeutic index |
> |
240.3 |
|
In vitro antiviral activity against herpes simplex virus type 1 (E-377 strain) in Vero host cell cultures (MTC/ID50) |
CHEMBL1125060 |
| Human herpesvirus 1 |
ID50 |
= |
0.2 |
ug ml-1 |
Concentration required to inhibit HSV-1 strain KOS cytopathic effect by 50% was measured by plaque reduction assay |
CHEMBL1125642 |
| Human herpesvirus 2 |
ID50 |
= |
0.6 |
ug ml-1 |
Concentration required to inhibit HSV-2 strain 186 cytopathic effect by 50% was measured by plaque reduction assay |
CHEMBL1125642 |
| Vero |
ID50 |
> |
300.0 |
ug ml-1 |
Cytotoxicity was evaluated by measuring the inhibition of HSV replication in vero cells |
CHEMBL1125642 |
| Human herpesvirus 1 |
Survivors |
= |
8.0 |
|
In vivo efficacy of compound against HSV-1 strain A133 in the mouse system model was measured at 100 dose(mg/kg), activity expressed as Survivors counted on day 21; 8/10 |
CHEMBL1125642 |
| Human herpesvirus 2 |
Survivors |
= |
7.0 |
|
In vivo efficacy of compound against HSV-2 strain A133 in the mouse system model was measured at 100 dose(mg/kg), activity expressed as Survivors counted on day 21; 7/10 |
CHEMBL1125642 |
| Human herpesvirus 1 |
Survivors |
= |
1.0 |
|
In vivo efficacy of compound against HSV-1 strain A133 in the mouse system model was measured at 25 dose(mg/kg), activity expressed as Survivors counted on day 21; 1/10 |
CHEMBL1125642 |
| Human herpesvirus 1 |
ED50 |
= |
58.0 |
mg.kg-1 |
Compound was measured for the inhibition of HSV-1 strain A133 in the mouse system model at 25 dose(mg/kg) |
CHEMBL1125642 |
| Human herpesvirus 2 |
Survivors |
= |
2.0 |
|
In vivo efficacy of compound against HSV-2 strain A133 in the mouse system model was measured at 25 dose(mg/kg), activity expressed as Survivors counted on day 21; 2/10 |
CHEMBL1125642 |
| Human herpesvirus 2 |
ED50 |
= |
58.0 |
mg.kg-1 |
Compound was measured for the inhibition of HSV-2 strain A133 in the mouse system model at 25 dose(mg/kg) |
CHEMBL1125642 |
| Human herpesvirus 1 |
Survivors |
= |
0.0 |
|
In vivo efficacy of compound against HSV-1 strain A133 in the mouse system model was measured at 6.25 dose(mg/kg), activity expressed as Survivors counted on day 21; 0/10 |
CHEMBL1125642 |
| Human herpesvirus 2 |
Survivors |
= |
0.0 |
|
In vivo efficacy of compound against HSV-2 strain A133 in the mouse system model was measured at 6.25 dose(mg/kg), activity expressed as Survivors counted on day 21 |
CHEMBL1125642 |
| Human herpesvirus 1 |
Survivors |
= |
3.0 |
|
In vivo efficacy of compound against HSV-1 strain A133 in the mouse system model was measured at 100 dose(mg/kg), activity expressed as Survivors counted on day 21; 3/5 |
CHEMBL1125642 |
| Human herpesvirus 2 |
Survivors |
= |
2.0 |
|
In vivo efficacy of compound against HSV-2 strain A133 in the mouse system model was measured at 100dose(mg/kg), activity expressed as Survivors counted on day 21; 2/5 |
CHEMBL1125642 |
| Human herpesvirus 1 |
ED50 |
~ |
50.0 |
mg.kg-1 |
Compound was measured for the inhibition of HSV-1 strain A133 in the mouse system model at 25 dose(mg/kg) |
CHEMBL1125642 |
| Human herpesvirus 1 |
Survivors |
= |
2.0 |
|
In vivo efficacy of compound against HSV-1 strain A133 in the mouse system model was measured at 25 dose(mg/kg), activity expressed as Survivors counted on day 21; 2/5 |
CHEMBL1125642 |
| Human herpesvirus 2 |
Survivors |
= |
1.0 |
|
In vivo efficacy of compound against HSV-2 strain A133 in the mouse system model was measured at 50 dose(mg/kg), activity expressed as Survivors counted on day 21; 1/5 |
CHEMBL1125642 |
| Human herpesvirus 1 |
Survivors |
= |
0.0 |
|
In vivo efficacy of compound against HSV-1 strain A133 in the mouse system model was measured at 6.25 dose(mg/kg), activity expressed as Survivors counted on day 21; 0/5 |
CHEMBL1125642 |
| Human herpesvirus 2 |
Survivors |
= |
3.0 |
|
In vivo efficacy of compound against HSV-2 strain A133 in the mouse system model was measured at 25 dose(mg/kg), activity expressed as Survivors counted on day 21; 3/5 |
CHEMBL1125642 |
| HeLa |
IC50 |
= |
1900.0 |
nM |
Inhibition of HSV-1 DNA synthesis in virus-infected HeLa cells |
CHEMBL1128737 |
| HeLa |
IC50 |
> |
200000.0 |
nM |
Inhibition of [3H]thymidine incorporation into the DNA of uninfected HeLa cells |
CHEMBL1128737 |
| ADMET |
Permeability coefficient |
= |
6.21 |
|
Permeability coefficient reported (Expressed as Permeability coefficient x 10 e 4 cm/s) |
CHEMBL1129412 |
| Vero |
MIC50 |
= |
4.3 |
ug.mL-1 |
Inhibition of cytopathogenic effect was determined against Herpes simplex virus (HSV) -2 in vero cell monolayer culture |
CHEMBL1123751 |
| Human herpesvirus 2 |
Virus rating |
= |
5.1 |
|
Virus rating is measurement of degree of inhibition of virus-induced cytopathogenic effects and the degree of cytotoxicity produced by the test compound for Herpes simplex virus (HSV) -2 |
CHEMBL1123751 |
| Human herpesvirus 3 |
EC50 |
= |
1000.0 |
nM |
The compound was tested for its effective concentration required to reduce virus plaque formation by using Varicella-Zoster virus YS strain |
CHEMBL1132902 |
| Human herpesvirus 3 |
EC50 |
= |
2900.0 |
nM |
The compound was tested for its effective concentration required to reduce virus plaque formation by using Varicella-Zoster virus OKA strain |
CHEMBL1132902 |
| Human herpesvirus 3 |
EC50 |
= |
74000.0 |
nM |
The compound was tested for its effective concentration required to reduce virus plaque formation by using TK (thymidine kinase -deficient)-Varicella-Zoster virus 07/1 strain |
CHEMBL1132902 |
| Human herpesvirus 3 |
EC50 |
= |
125000.0 |
nM |
The compound was tested for its effective concentration required to reduce virus plaque formation by using TK (thymidine kinase -deficient) -Varicella-Zoster virus YS/R strain |
CHEMBL1132902 |
| NON-PROTEIN TARGET |
MCC |
> |
200000.0 |
nM |
The compound was tested for its minimal cytotoxic concentration required to alter microscopically detectable cell morphology |
CHEMBL1132902 |
| HEL |
CC50 |
> |
200000.0 |
nM |
The compound was tested for cytotoxic concentration required to inhibit Hel cell growth by 50% |
CHEMBL1132902 |
| Human herpesvirus 1 |
CPE50 |
= |
60.0 |
uM |
Concentration that protects by 50% the cytopathic effect induced by herpes simplex virus - 1. |
CHEMBL1122931 |
| HeLa |
Tox50 |
= |
10000.0 |
uM |
Concentration that induces 50% cell toxicity was determined using monolayers of uninfected HeLa cells |
CHEMBL1122931 |
| Vero |
MIC |
= |
1.3 |
ug.mL-1 |
In vitro anti-herpetic activity against HSV-2 plaque formation in vero cells. |
CHEMBL1128426 |
| Vero |
MTL |
> |
200.0 |
ug ml-1 |
The compound was tested in vitro for the highest concentration (maximum tolerated level) that showed no cellular toxicity by visualization of stained cells. |
CHEMBL1128426 |
| Mus musculus |
MED |
= |
12.0 |
mg kg-1 |
The compound was tested in vivo for the lowest dose(minimum effective dose) at which anti-herpetic activity was observed in terms of survival times of mice after po administration. |
CHEMBL1128426 |
| Mus musculus |
MTD |
> |
200.0 |
mg kg-1 |
The maximum tolerated dose (MTD) was defined as the highest dose of compound that did not show any signs of toxicity in mice after po administration. |
CHEMBL1128426 |
| Human herpesvirus 1 |
Inhibition |
= |
85.0 |
% |
Evaluated for DNA polymerase inhibition activity against herpes simplex virus-1 (HSV-1) |
CHEMBL1123083 |
| Human herpesvirus 2 |
Inhibition |
= |
34.0 |
% |
Evaluated for DNA polymerase inhibition activity against HeLa cells. |
CHEMBL1123083 |
| Human herpesvirus 1 |
ED50 |
= |
1.0 |
ug ml-1 |
In vitro anti viral activity tested against HSV-1(Schooler) virus on Rabbit kidney cell cultures; 1-3 |
CHEMBL1123083 |
| Human herpesvirus 2 |
ED50 |
= |
1.0 |
ug ml-1 |
In vitro anti viral activity tested against HSV-2(Curtis) virus on Rabbit kidney cell cultures; 1-3 |
CHEMBL1123083 |
| Human herpesvirus 5 |
ED50 |
= |
20.0 |
ug ml-1 |
In vitro anti viral activity tested against HCMV(AD169) virus on MRC-5 cell monolayers; 20-25 |
CHEMBL1123083 |
| Human herpesvirus 3 |
ED50 |
= |
1.0 |
ug ml-1 |
In vitro anti viral activity tested against VZV(KMcC) virus on MRC-5 cell monolayers; 1-2 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Survivors |
= |
2.0 |
|
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally; Total mice tested 10 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Average survival |
= |
8.7 |
day |
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally. |
CHEMBL1123083 |
| Human herpesvirus 1 |
Survivors |
= |
1.0 |
|
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally; Total mice tested 10 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Average survival |
= |
7.6 |
day |
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally. |
CHEMBL1123083 |
| Human herpesvirus 1 |
Survivors |
= |
0.0 |
|
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally; Total mice tested 10 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Average survival |
= |
6.5 |
day |
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally. |
CHEMBL1123083 |
| Human herpesvirus 1 |
Mice with lesions |
= |
6.0 |
|
Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Average lesion score |
= |
1.45 |
|
Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day. |
CHEMBL1123083 |
| Human herpesvirus 1 |
Mice with lesions |
= |
8.0 |
|
Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Average lesion score |
= |
2.95 |
|
Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day. |
CHEMBL1123083 |
| Human herpesvirus 1 |
Mice with lesions |
= |
10.0 |
|
Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Average lesion score |
= |
3.75 |
|
Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day. |
CHEMBL1123083 |
| Human herpesvirus 1 |
EC50 |
= |
23000.0 |
nM |
Concentration required to inhibit 50% of HSV-1 replication |
CHEMBL1132735 |
| Human herpesvirus 2 |
EC50 |
= |
35000.0 |
nM |
Concentration required to inhibit 50% of HSV-2 replication |
CHEMBL1132735 |
| Hepatitis B virus |
EC50 |
|
|
nM |
Concentration required to inhibit 50% of Hepatitis B virus replication; not determined |
CHEMBL1132735 |
| Human immunodeficiency virus 1 |
EC50 |
|
|
nM |
Concentration required to inhibit 50% of HIV-IIIB virus replication; not determined |
CHEMBL1132735 |
| Vero |
IC50 |
> |
50000.0 |
nM |
Concentration required to inhibit 50% of host cell replication in Vero cell used against HSV-1 and HSV-2 studies |
CHEMBL1132735 |
| HepG2 |
IC50 |
|
|
nM |
Concentration required to inhibit 50% of host cell replication in human hepatoma (2.2.15) cells used against HBV studies; not determined |
CHEMBL1132735 |
| MT2 |
IC50 |
|
|
nM |
Concentration required to inhibit 50% of host cell replication in MT-2 cells used against HIV studies; not determined |
CHEMBL1132735 |
| Human herpesvirus 5 |
IC50 |
= |
63000.0 |
nM |
Tested for antiviral activity against human cytomegalovirus (HCMV) by means of plaque reduction assay. |
CHEMBL1124845 |
| Human herpesvirus 1 |
IC50 |
= |
3900.0 |
nM |
Tested for antiviral activity against herpes simplex virus-1(HSV-1) by means of plaque reduction assay. |
CHEMBL1124845 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Tested for cytotoxic activity against human foreskin fibroblasts (HFF) cells. |
CHEMBL1124845 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Tested for cytotoxic activity against monkey kidney cells(BSC-1) cells. |
CHEMBL1124845 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Tested for cytotoxic activity against human neoplastic cell line(KB cells). |
CHEMBL1124845 |
| Human herpesvirus 5 |
IC50 |
= |
63000.0 |
nM |
Tested in vitro for antiviral activity against human cytomegalovirus (HCMV) in plaque reduction assay. |
CHEMBL1125150 |
| Human herpesvirus 5 |
IC90 |
= |
90000.0 |
nM |
Tested in vitro for antiviral activity against human cytomegalovirus (HCMV) in yield reduction assay. |
CHEMBL1125150 |
| Human herpesvirus 1 |
IC50 |
= |
4000.0 |
nM |
Tested in vitro for antiviral activity against HSV-1 in plaque reduction assay. |
CHEMBL1125150 |
| Human herpesvirus 1 |
IC90 |
= |
7000.0 |
nM |
Tested in vitro for antiviral activity against HSV-1 in yield reduction assay. |
CHEMBL1125150 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Tested in vitro for cytotoxicity against the normal human diploid cells (HFF cells). |
CHEMBL1125150 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Tested in vitro for cytotoxicity against the monkey kidney cells (BSC-1 cells). |
CHEMBL1125150 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Tested in vitro for cytotoxicity against the human neoplastic cell line (KB cells). |
CHEMBL1125150 |
| Human herpesvirus 1 |
MIC |
= |
0.2 |
ug.mL-1 |
In vitro minimum inhibitory concentration to inhibit HSV-1 (KOS)-induced cytopathogenicity in primary rabbit kidney cells by 50% |
CHEMBL1124149 |
| Human herpesvirus 1 |
MIC |
= |
0.1 |
ug.mL-1 |
In vitro minimum inhibitory concentration to inhibit HSV-1 (F)-induced cytopathogenicity in primary rabbit kidney cells by 50% |
CHEMBL1124149 |
| Human herpesvirus 1 |
MIC |
= |
0.2 |
ug.mL-1 |
In vitro minimum inhibitory concentration to inhibit HSV-1 (McIntyre)-induced cytopathogenicity in PRK cells by 50% |
CHEMBL1124149 |
| Human herpesvirus 2 |
MIC |
= |
0.07 |
ug.mL-1 |
In vitro minimum inhibitory concentration to inhibit HSV-2 (G)-induced cytopathogenicity in PRK cells by 50% |
CHEMBL1124149 |
| Human herpesvirus 2 |
MIC |
= |
0.2 |
ug.mL-1 |
In vitro minimum inhibitory concentration to inhibit HSV-2 (Lyons)-induced cytopathogenicity in PRK cells by 50% |
CHEMBL1124149 |
| Human herpesvirus 2 |
MIC |
= |
0.07 |
ug.mL-1 |
In vitro minimum inhibitory concentration to inhibit HSV-2 (196)-induced cytopathogenicity in PRK cells by 50% |
CHEMBL1124149 |
| Vaccinia virus |
MIC |
= |
150.0 |
ug.mL-1 |
In vitro minimum inhibitory concentration to inhibit VV-induced cytopathogenicity in PRK cells by 50% |
CHEMBL1124149 |
| Human herpesvirus 1 |
MIC |
= |
20.0 |
ug.mL-1 |
In vitro minimum inhibitory concentration to inhibit thymidine deficient HSV-1 (B2006)-induced cytopathogenicity in PRK cells by 50% |
CHEMBL1124149 |
| Human herpesvirus 1 |
MIC |
= |
20.0 |
ug.mL-1 |
In vitro minimum inhibitory concentration to inhibit thymidine deficient HSV-1 (VMV 1837)- induced cytopathogenicity in PRK cells by 50% |
CHEMBL1124149 |
| Human herpesvirus 3 |
MIC |
= |
0.3 |
ug.mL-1 |
In vitro minimum inhibitory concentration to inhibit VZV (YS)-induced cytopathogenicity in HEL cells by 50% |
CHEMBL1124149 |
| Human herpesvirus 3 |
MIC |
= |
0.6 |
ug.mL-1 |
In vitro minimum inhibitory concentration to inhibit VZV (Oka)-induced cytopathogenicity in HEL cells by 50% |
CHEMBL1124149 |
| Human herpesvirus 3 |
MIC |
= |
25.0 |
ug.mL-1 |
In vitro minimum inhibitory concentration to inhibit thymidine deficient VZV (YSR)-induced cytopathogenicity in HEL cells by 50% |
CHEMBL1124149 |
| Human herpesvirus 3 |
MIC |
= |
10.0 |
ug.mL-1 |
In vitro minimum inhibitory concentration to inhibit thymidine deficient VZV(7-1)-induced cytopathogenicity in PRK cells by 50% |
CHEMBL1124149 |
| Cytomegalovirus |
MIC |
= |
20.0 |
ug.mL-1 |
In vitro minimum inhibitory concentration to inhibit CMV (Davis)-induced cytopathogenicity in HEL cells by 50% |
CHEMBL1124149 |
| Cytomegalovirus |
MIC |
= |
25.0 |
ug.mL-1 |
In vitro minimum inhibitory concentration to inhibit CMV (AD-169)-induced cytopathogenicity in HEL cells by 50% |
CHEMBL1124149 |
| Suid herpesvirus 1 |
MIC |
= |
7.0 |
ug.mL-1 |
In vitro minimum inhibitory concentration to inhibit SHV-1-induced cytopathogenicity in PRK cells by 50% |
CHEMBL1124149 |
| Bovine herpesvirus 1 |
MIC |
= |
7.0 |
ug.mL-1 |
In vitro minimum inhibitory concentration to inhibit BHV-1-induced cytopathogenicity in PRK cells by 50% |
CHEMBL1124149 |
| Equid herpesvirus 1 |
MIC |
= |
0.2 |
ug.mL-1 |
In vitro minimum inhibitory concentration to inhibit EHV-1-induced cytopathogenicity in PRK cells by 50% |
CHEMBL1124149 |
| ADMET |
MIC |
= |
8.0 |
ug.mL-1 |
In vitro minimum inhibitory concentration to inhibit protein synthesis (incorporation of [methyl-3H]dThd) in PRK cells by 50% |
CHEMBL1124149 |
| L1210 |
MIC |
= |
55.0 |
ug.mL-1 |
Antitumor activity against murine leukemia L1210 cells |
CHEMBL1124149 |
| FM3A |
MIC |
= |
66.0 |
ug.mL-1 |
Antitumor activity against murine mammary carcinoma FM3A cells |
CHEMBL1124149 |
| Vero |
ED50 |
= |
0.04 |
uM |
Concentration of compound required to reduce by 50% the number of herpes simplex virus (HSV-1) plaques in vero cells |
CHEMBL1125397 |
| Vero |
ED50 |
> |
1300.0 |
uM |
Concentration of compound required to reduce by 50% the number of african swine fever virus (ASFV) plaques in vero cells |
CHEMBL1125397 |
| Vero |
EC50 |
= |
0.32 |
ug.mL-1 |
In vitro evaluation of antiviral activity against HSV-1 (Herpes simplex virus-1) induced cytopathic effect in vero cells by a plaque reduction assay |
CHEMBL1151604 |
| Vero |
EC50 |
= |
0.39 |
ug.mL-1 |
In vitro evaluation of antiviral activity against HSV-2 (Herpes simplex virus-2) induced cytopathic effect in vero cells by a plaque reduction assay |
CHEMBL1151604 |
| MT4 |
EC50 |
|
|
ug.mL-1 |
In vitro evaluation of antiviral activity against HSV-1 (Herpes simplex virus-1) induced cytopathic effect in MT-4 cells by indirect immunofluorescence assay; not determined |
CHEMBL1151604 |
| Human herpesvirus 1 |
VR |
= |
1.4 |
|
In vitro antiviral activity against herpes simplex virus/1(HSV/1) expressed as viral rating (VR) |
CHEMBL1121727 |
| Human herpesvirus 1 |
ID50 |
= |
0.5 |
ug ml-1 |
In vitro antiviral activity of the compound, determined by plaque-reduction assay against Herpes simplex virus (HSV) type 1, BW5 strain in Vero cells |
CHEMBL1124514 |
| Human herpesvirus 1 |
ID50 |
= |
4.3 |
ug ml-1 |
In vitro antiviral activity of the compound, determined by plaque-reduction assay against thymidine kinase deficient Herpes simplex virus type 1, Z826 strain in Vero cells |
CHEMBL1124514 |
| Human herpesvirus 2 |
ID50 |
= |
0.3 |
ug ml-1 |
In vitro antiviral activity determined by plaque-reduction assay against Herpes simplex virus type 2, G strain in Vero cells |
CHEMBL1124514 |
| Mus musculus |
Survival |
= |
75.0 |
% |
Percentage survival of mice after intraperitoneal administration of compound at 200 mg/kg per day in experiment 1; survival/ tested =3/4 |
CHEMBL1124514 |
| Mus musculus |
Survival |
= |
70.0 |
% |
Percentage survival of mice after intraperitoneal administration of compound at 100 mg/kg per day in experiment 1; survival/ tested =7/10 |
CHEMBL1124514 |
| Mus musculus |
Survival |
= |
50.0 |
% |
Percentage survival of mice after intraperitoneal administration of compound at 50 mg/kg per day in experiment 1; survival/ tested =5/10 |
CHEMBL1124514 |
| Mus musculus |
Survival |
= |
2.0 |
% |
Percentage survival of mice after intraperitoneal administration of compound at 10 mg/kg per day in experiment 1; survival/ tested =2/10 |
CHEMBL1124514 |
| Mus musculus |
Survival |
= |
78.0 |
% |
Percentage survival of mice after intraperitoneal administration of compound at 200 mg/kg per day in experiment 2; survival/ tested =7/9 |
CHEMBL1124514 |
| Cavia porcellus |
Total score |
= |
14.0 |
|
Total score of lesion formation in HSV-1 cutaneous infection in guinea pig at 5% ACV |
CHEMBL1124514 |
| Cavia porcellus |
Duration time |
= |
5.4 |
|
Duration of time of lesion formation in HSV-1 cutaneous infection in guinea pig at 5%ACV |
CHEMBL1124514 |
| Cavia porcellus |
Total score |
= |
60.4 |
|
Total score of healing period in HSV-1 cutaneous infection in guinea pig at 5% ACV |
CHEMBL1124514 |
| Cavia porcellus |
Duration time |
= |
4.2 |
|
Duration of time of healing period in HSV-1 cutaneous infection in guinea pig at 5%ACV |
CHEMBL1124514 |
| Cavia porcellus |
Severity mean |
= |
2.4 |
|
Mean of severity score obtained from five different individuals at 5% ACV |
CHEMBL1124514 |
| Vero |
EC50 |
= |
6000.0 |
nM |
Anti-herpes virus activity was evaluated against Herpes simplex virus type 1 (HSV-1,strain HF) grown in Vero cells |
CHEMBL1128166 |
| Vero |
EC50 |
= |
3000.0 |
nM |
Anti-herpes virus activity was evaluated against Herpes simplex virus type 2 (HSV-2,strain G) grown in Vero cells |
CHEMBL1128166 |
| MRC5 |
EC50 |
= |
18000.0 |
nM |
Anti-herpes virus activity was evaluated against human cytomegalovirus (HCMV, strain AD-169) grown in MRC-5 cells |
CHEMBL1128166 |
| Vero |
CC50 |
> |
100000.0 |
nM |
The lowest concentration of compound producing overt cytotoxicity in virus-free vero cell cultures |
CHEMBL1128166 |
| MRC5 |
CC50 |
>= |
100000.0 |
nM |
The lowest concentration of compound producing overt cytotoxicity in virus-free MRC-5 cell cultures |
CHEMBL1128166 |
| Human herpesvirus 1 |
Virus rating |
= |
6.7 |
|
Degree of inhibition of virus-induced cytopathogenic effect and the degree of cytotoxicity produced by compound against herpes simplex type-1 virus E-377(TK+ ) |
CHEMBL1124192 |
| Human herpesvirus 1 |
ID50 |
= |
0.7 |
ug ml-1 |
Dose of compound required to inhibit the herpes simplex type-1 virusE-377(TK+ ) induced cytopathogenic effects |
CHEMBL1124192 |
| Human herpesvirus 2 |
Virus rating |
= |
4.5 |
|
Degree of inhibition of virus-induced cytopathogenic effect and the degree of cytotoxicity produced by compound against herpes simplex type-2 MS virus |
CHEMBL1124192 |
| Human herpesvirus 2 |
ID50 |
= |
5.3 |
ug ml-1 |
Dose of compound required to inhibit the herpes simplex type-2 MS virus induced cytopathogenic effects |
CHEMBL1124192 |
| Vero |
Zone of inhibition |
= |
11.0 |
mM |
Zone of inhibition of plaque formation in vero cells inoculated with HSV-1 virus along with disks containing 50 ug of compound; 11-50 mm zone of inhibition |
CHEMBL1122925 |
| Vero |
IC50 |
= |
100.0 |
nM |
The concentration required to inhibit the growth of viral plaques by 50% of control in plaque reduction assay |
CHEMBL1122925 |
| Thymidine kinase, cytosolic |
Inhibition |
= |
69.0 |
% |
Ability (300 uM) to compete with 150 uM of [14C]ACV for binding sites on viral enzyme, Mac strain (HSV-1 TK) |
CHEMBL1122925 |
| Thymidine kinase, cytosolic |
Relative substrate velocity |
= |
36.0 |
% |
Relative substrate velocity was evaluated against Mac strain by using HSV-1 TK assay |
CHEMBL1122925 |
| HEL |
MIC |
> |
150000.0 |
nM |
Minimum inhibitory concentration required to elicit microscopically visible cell morphology in HEL cell lines |
CHEMBL1134563 |
| HEL |
EC50 |
= |
4530.0 |
nM |
Effective concentration required to inhibit Tyrosine kinase (TK+) Varicella-Zoster virus-induced cytopathicity by 50% in OKA strain HEL cell lines |
CHEMBL1134563 |
| HEL |
EC50 |
= |
4090.0 |
nM |
Effective concentration required to inhibit Tyrosine kinase (TK+) Varicella-Zoster virus-induced cytopathicity by 50% in YS strain HEL cell lines |
CHEMBL1134563 |
| HEL |
EC50 |
= |
41000.0 |
nM |
Effective concentration required to inhibit Tyrosine kinase deficient (TK-) Varicella-Zoster virus-induced cytopathicity by 50% in 07/01 strain HEL cell lines |
CHEMBL1134563 |
| HEL |
EC50 |
= |
63000.0 |
nM |
Effective concentration required to inhibit Tyrosine kinase deficient (TK-) Varicella-Zoster virus-induced cytopathicity by 50% in YS/R strain HEL cell lines |
CHEMBL1134563 |
| Vero |
ID50 |
= |
0.2 |
ug ml-1 |
Tested for the concentration required to inhibit HSV-1 strain KOS cytopathic effect by 50% in vero cells |
CHEMBL1150003 |
| Vero |
ID50 |
= |
0.6 |
ug ml-1 |
Tested for the concentration required to inhibit HSV-2 strain 186 cytopathic effect by 50% in vero cells |
CHEMBL1150003 |
| Vero |
ID50 |
> |
300.0 |
ug ml-1 |
Tested for the cytotoxic effect in vero cell monolayers after incubation for 48 hr at 37 degree Centigrade |
CHEMBL1150003 |
| ESM |
MIC |
= |
0.02 |
ug.mL-1 |
Concentration required to inhibit HSV-1 (KOS) induced cytopathogenicity in ESM cells by 50% |
CHEMBL1125932 |
| ESM |
MIC |
= |
0.006999999999999999 |
ug.mL-1 |
Concentration required to inhibit HSV-1 (F) induced cytopathogenicity in ESM cells by 50% |
CHEMBL1125932 |
| ESM |
MIC |
= |
0.006999999999999999 |
ug.mL-1 |
Concentration required to inhibit HSV-1 (McIntyre) induced cytopathogenicity in ESM cells by 50% |
CHEMBL1125932 |
| ESM |
MIC |
= |
0.02 |
ug.mL-1 |
Concentration required to inhibit HSV-2(G) induced cytopathogenicity in ESM cells by 50% |
CHEMBL1125932 |
| ESM |
MIC |
= |
0.01 |
ug.mL-1 |
Concentration required to inhibit HSV-2(lyons) induced cytopathogenicity in ESM cells by 50% |
CHEMBL1125932 |
| ESM |
MIC |
= |
0.07 |
ug.mL-1 |
Concentration required to inhibit HSV-2(196) induced cytopathogenicity in ESM cells by 50% |
CHEMBL1125932 |
| ESM |
MIC |
> |
200.0 |
ug.mL-1 |
Concentration required to inhibit VV induced cytopathogenicity in ESM cells by 50%. |
CHEMBL1125932 |
| ESM |
MIC |
= |
100.0 |
ug.mL-1 |
Concentration required to inhibit TK-HSV-1 (B2006) induced cytopathogenicity in ESM cells by 50% |
CHEMBL1125932 |
| ESM |
MIC |
= |
40.0 |
ug.mL-1 |
Concentration required to inhibit TK-HSV-1 (VMW2837) induced cytopathogenicity in ESM cells by 50% |
CHEMBL1125932 |
| HEL |
MIC |
= |
0.3 |
ug.mL-1 |
Concentration required to inhibit VZV (YS) induced cytopathogenicity in HEL cells by 50% |
CHEMBL1125932 |
| HEL |
MIC |
= |
0.2 |
ug.mL-1 |
Concentration required to inhibit VZV (oka) induced cytopathogenicity in HEL cells by 50% |
CHEMBL1125932 |
| HEL |
MIC |
= |
10.0 |
ug.mL-1 |
Concentration required to inhibit TK-VZV (YSR) induced cytopathogenicity in HEL cells by 50% |
CHEMBL1125932 |
| HEL |
MIC |
= |
5.0 |
ug.mL-1 |
Concentration required to inhibit TK-VZV (07-1) induced cytopathogenicity in HEL cells by 50% |
CHEMBL1125932 |
| HEL |
MIC |
= |
15.0 |
ug.mL-1 |
Concentration required to inhibit CMV (Davis) induced cytopathogenicity in HEL cells by 50% |
CHEMBL1125932 |
| HEL |
MIC |
= |
15.0 |
ug.mL-1 |
Concentration required to inhibit CMV (AD-169) induced cytopathogenicity in HEL cells by 50% |
CHEMBL1125932 |
| ESM |
MIC |
= |
400.0 |
ug.mL-1 |
Concentration required to cause a microscopically detectable alteration of normal cell morphology in ESM cells |
CHEMBL1125932 |
| ESM |
MIC |
> |
200.0 |
ug.mL-1 |
Concentration required to cause 50% reduction in cellular DNA synthesis in ESM cells |
CHEMBL1125932 |
| HEL |
MIC |
= |
200.0 |
ug.mL-1 |
Concentration required to cause 50% reduction in HEL cell growth. |
CHEMBL1125932 |
| Vero |
IC50 |
= |
1200.0 |
nM |
In vitro antiherpesvirus activity against vero cells infected with HSV-2(G strain)[plaque reduction assay] |
CHEMBL1125512 |
| Oryctolagus cuniculus |
MTC |
= |
440.0 |
uM |
Minimum cytotoxic concentration causing toxic effects on uninfected cells in rabbit |
CHEMBL1124209 |
| Human herpesvirus 1 |
MIC |
= |
10.0 |
nM |
Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus-1 (Brand) in vero cells |
CHEMBL1124209 |
| Human herpesvirus 1 |
MIC |
= |
4400.0 |
nM |
Minimum inhibitory concentration causing 25% inhibition cytopathic effect induced by Herpes simplex virus-1 (Brand) in HEp-2 cells |
CHEMBL1124209 |
| Human herpesvirus 1 |
MIC |
= |
1300.0 |
nM |
Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by herpes simplex virus (HSV)-1 (K979) in vero cells. |
CHEMBL1124209 |
| Human herpesvirus 1 |
MIC |
= |
13200.0 |
nM |
Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus-1 (K979) in HEp-2 cells |
CHEMBL1124209 |
| Human herpesvirus 1 |
MIC |
= |
44000.0 |
nM |
Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus(HSV) -1 (thymidine kinase deficient) in vero cells |
CHEMBL1124209 |
| Human herpesvirus 1 |
MIC |
= |
440000.0 |
nM |
Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus(HSV) -1 (thymidine kinase deficient) in HEp-2 cells |
CHEMBL1124209 |
| Human herpesvirus 2 |
MIC |
= |
132000.0 |
nM |
Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus(HSV) -2 (thymidine kinase deficient) in vero cells |
CHEMBL1124209 |
| Human herpesvirus 2 |
MIC |
= |
440000.0 |
nM |
Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus(HSV) -2 (thymidine kinase deficient) in HEp-2 cells |
CHEMBL1124209 |
| Mus musculus |
CMP |
= |
10.0 |
|
Cumulative mortality in percent of HSV-1 infected mice, after peroral administration of 100 mg/kg of compound |
CHEMBL1124209 |
| Mus musculus |
MST |
= |
18.9 |
day |
Mean survival time in HSV-1 infected mice, after peroral administration of 100 mg/kg |
CHEMBL1124209 |
| Mus musculus |
CMP |
= |
15.0 |
|
Cumulative mortality in percent of HSV-1 infected mice, after intraperitoneal administration of 25 mg/kg |
CHEMBL1124209 |
| Mus musculus |
MST |
= |
18.6 |
day |
Mean survival time in HSV-1 infected mice, after intraperitoneal administration of 25 mg/kg |
CHEMBL1124209 |
| Human herpesvirus 1 |
VR |
= |
5.7 |
|
Antiviral activity is expressed as virus rating (VR) against the HSV-1 377 strain |
CHEMBL1123762 |
| Human herpesvirus 1 |
VR |
= |
0.0 |
|
Antiviral activity is expressed as virus rating (VR) against the HSV-1 HF strain |
CHEMBL1123762 |
| Human herpesvirus 1 |
MIC50 |
= |
3.0 |
ug.mL-1 |
Antiviral activity against the HSV-1 377 strain from monolayers of vero cells |
CHEMBL1123762 |
| Unchecked |
Ratio |
= |
0.33 |
|
Ratio measured as the VR of C-3''-deoxyribofuranoside to the VR at a MIC of 3 ug/mL |
CHEMBL1123762 |
| Human herpesvirus 3 |
IC50 |
= |
0.73 |
ug.mL-1 |
The concentration required to reduce virus plaque formation by 50% was measured on OKA strain of VZV expressing viral thymidine kinase(TK+) |
CHEMBL1132117 |
| Human herpesvirus 3 |
IC50 |
= |
0.78 |
ug.mL-1 |
The concentration required to reduce virus plaque formation by 50% was measured on YS strain of VZV expressing viral thymidine kinase(TK+) |
CHEMBL1132117 |
| Human herpesvirus 3 |
IC50 |
= |
24.0 |
ug.mL-1 |
The concentration required to reduce virus plaque formation by 50% was measured on 07/1 strain of VZV expressing viral thymidine kinase(TK-) |
CHEMBL1132117 |
| Human herpesvirus 3 |
IC50 |
= |
26.0 |
ug.mL-1 |
The concentration required to reduce virus plaque formation by 50% was measured on YS/Rstrain of VZV expressing viral thymidine kinase(TK-) |
CHEMBL1132117 |
| HEL |
CC50 |
> |
200.0 |
ug.mL-1 |
The concentration required to reduce cell growth by 50% was measured on Human Embryonic Lung (HEL) cells |
CHEMBL1132117 |
| HEL |
MCC |
> |
50.0 |
ug.mL-1 |
The minimum cytotoxic concentration was measured on Human Embryonic Lung (HEL) cells |
CHEMBL1132117 |
| Cavia porcellus |
Log geometric mean |
= |
4.3 |
pfu mg-1 |
Effect on the growth of Herpes simplex Type 1 on the skin of Guinea pigs infected intradermally on day 1 at 5% concentration |
CHEMBL1122659 |
| Cavia porcellus |
Log geometric mean |
= |
4.09 |
pfu mg-1 |
Effect on the growth of Herpes simplex Type 1 on the skin of Guinea pigs infected intradermally on day 2 at 5 % concentration |
CHEMBL1122659 |
| Cavia porcellus |
Log geometric mean |
= |
3.31 |
pfu mg-1 |
Effect on the growth of Herpes simplex Type 1 on the skin of Guinea pigs infected intradermally on day 3 at 5 % concentration |
CHEMBL1122659 |
| Cavia porcellus |
Log geometric mean |
= |
2.13 |
pfu mg-1 |
Effect on the growth of Herpes simplex Type 1 on the skin of Guinea pigs infected intradermally on day 4 at 5 % concentration |
CHEMBL1122659 |
| Cavia porcellus |
Mean vesicle score |
= |
0.58 |
|
Effect on the development of Herpetic vesicles in Guinea pigs infected intradermally with Herpes virus Hominis, Type 1,AA strain on day 1 at 5% concentration |
CHEMBL1122659 |
| Cavia porcellus |
Mean vesicle score |
= |
0.83 |
|
Effect on the development of Herpetic vesicles in Guinea pigs infected intradermally with Herpes virus Hominis, Type 1,AA strain on day 2 at 5 % concentration |
CHEMBL1122659 |
| Cavia porcellus |
Mean vesicle score |
= |
1.16 |
|
Effect on the development of Herpetic vesicles in Guinea pigs infected intradermally with Herpes virus Hominis, Type 1,AA strain on day 3 at 5 % concentration |
CHEMBL1122659 |
| Cavia porcellus |
Mean vesicle score |
= |
1.0 |
|
Effect on the development of Herpetic vesicles in Guinea pigs infected intradermally with Herpes virus Hominis, Type 1,AA strain on day 4 at 5 % concentration |
CHEMBL1122659 |
| Human herpesvirus 1 |
EC50 |
= |
0.06 |
ug.mL-1 |
The compound was tested for the cytopathic effect inhibition against herpes simplex virus 1; Effective concentration required to inhibit 50% virus proliferation |
CHEMBL1130360 |
| Human herpesvirus 1 |
EC50 |
= |
0.3 |
ug.mL-1 |
The compound was tested for the cytopathic effect inhibition against herpes simplex virus 1; Effective concentration required to inhibit 50% virus proliferation |
CHEMBL1130360 |
| Human herpesvirus 2 |
EC50 |
= |
0.2 |
ug.mL-1 |
The compound was tested for the cytopathic effect inhibition against herpes simplex virus 2; Effective concentration required to inhibit 50% virus proliferation |
CHEMBL1130360 |
| Human herpesvirus 2 |
EC50 |
= |
1.1 |
ug.mL-1 |
The compound was tested for the viral plaque reduction against herpes simplex virus 2; Effective concentration required to inhibit 50% virus proliferation |
CHEMBL1130360 |
| Human herpesvirus 3 |
EC50 |
= |
0.6 |
ug.mL-1 |
The compound was tested for the cytopathic effect inhibition against herpes simplex virus 2; Effective concentration required to inhibit 50% virus proliferation |
CHEMBL1130360 |
| Human herpesvirus 1 |
ID50 |
= |
0.05 |
ug ml-1 |
Concentration required to reduce cytopathogenicity of Herpes simplex virus type 1 (strain KOS) by 50% in primary rabbit kidney (PRK) cells |
CHEMBL1122521 |
| Human herpesvirus 2 |
ID50 |
= |
0.04 |
ug ml-1 |
Concentration required to reduce cytopathogenicity of Herpes simplex virus type 2 (strain G) by 50% in primary rabbit kidney (PRK) cells |
CHEMBL1122521 |
| Vaccinia virus |
ID50 |
= |
50.0 |
ug ml-1 |
Concentration required to reduce cytopathogenicity of vaccinia virus by 50% in primary rabbit kidney (PRK) cells |
CHEMBL1122521 |
| Vesicular stomatitis virus |
ID50 |
> |
400.0 |
ug ml-1 |
Concentration required to reduce cytopathogenicity of Vesicular stomatitis virus by 50% in primary rabbit kidney (PRK) cells |
CHEMBL1122521 |
| ADMET |
ID50 |
= |
12.0 |
ug ml-1 |
Inhibitory concentration required to reduce incorporation of 2-deoxythymidine (dThd) into DNA of Primary Rabbit kidney (PRK) cell cultures |
CHEMBL1122521 |
| ADMET |
ID50 |
= |
13.0 |
ug ml-1 |
Inhibitory concentration required to reduce 2-deoxyuridine ([3H-1'2']dUrd) incorporation into DNA of Primary Rabbit kidney (PRK) cell cultures |
CHEMBL1122521 |
| Unchecked |
Antiviral index |
= |
300.0 |
|
Ratio of ID50 for dThd or dUrd incorporation to ID50 for HSV-1, HSV-2 or VV(whatever was lowest) |
CHEMBL1122521 |
| L1210 |
ID50 |
= |
13.0 |
ug ml-1 |
Inhibitory concentration required to reduce cell growth of Murine Leukemia L1210 cells |
CHEMBL1122521 |
| L1210 |
ID50 |
= |
367.0 |
ug ml-1 |
Inhibitory concentration required to reduce [3H-methyl]-dThd C incorporation into cellular DNA by 50% in Murine Leukemia L1210 cells |
CHEMBL1122521 |
| L1210 |
ID50 |
= |
50.0 |
ug ml-1 |
Inhibitory concentration required to reduce [3H1',2']dUrd incorporation into cellular DNA by 50% in Murine Leukemia L1210 cells |
CHEMBL1122521 |
| Human herpesvirus 1 |
EC50 |
= |
3080.0 |
nM |
In vitro antiviral activity against Herpes simplex virus (HSV-1) was determined |
CHEMBL1135020 |
| Human herpesvirus 2 |
EC50 |
= |
6160.0 |
nM |
In vitro antiviral activity against Herpes simplex virus (HSV-2) was determined |
CHEMBL1135020 |
| Human herpesvirus 5 |
EC50 |
|
|
nM |
In vitro antiviral activity against Human cytomegalovirus (HCMV) was determined; ND= Not determined |
CHEMBL1135020 |
| Human herpesvirus 4 |
EC50 |
= |
3960.0 |
nM |
In vitro antiviral activity against Epstein Barr virus (EBV) was determined |
CHEMBL1135020 |
| Human herpesvirus 3 |
EC50 |
= |
8810.0 |
nM |
In vitro antiviral activity against Varicella zoster virus (VZV) was determined |
CHEMBL1135020 |
| CCRF-CEM |
IC50 |
> |
440000.0 |
nM |
In vitro anti-HIV screen using HIV-1 infected CD4 lymphocytes (CEM cell line), determines cytotoxicity |
CHEMBL1135020 |
| CCRF-CEM |
IC50 |
|
|
nM |
Inhibitory concentration for spectrum antiviral activity against herpes viruses; ND= Not determined |
CHEMBL1135020 |
| Human herpesvirus 3 |
EC50 |
= |
2900.0 |
nM |
Effective concentration required for reduction of plaque formation of Varicella-Zoster Virus (OKA strain) |
CHEMBL1134172 |
| Human herpesvirus 3 |
EC50 |
= |
1000.0 |
nM |
Effective concentration required for reduction of plaque formation of Varicella-Zoster Virus, (YS strain) |
CHEMBL1134172 |
| Human herpesvirus 3 |
EC50 |
> |
4000.0 |
nM |
Effective concentration required for reduction of plaque formation of thymidine kinase deficient Varicella-Zoster Virus (071 strain) |
CHEMBL1134172 |
| Human herpesvirus 3 |
EC50 |
= |
125000.0 |
nM |
Effective concentration required for reduction of plaque formation of thymidine kinase deficient Varicella-Zoster Virus (YSR strain) |
CHEMBL1134172 |
| HEL |
MCC |
> |
200000.0 |
nM |
Minimum cytotoxic concentration required to alter microscopically detectable HEL cell morphology |
CHEMBL1134172 |
| HEL |
CC50 |
> |
200000.0 |
nM |
Cytotoxic concentration required to inhibit HEL cell growth by 50 % |
CHEMBL1134172 |
| Human herpesvirus 5 |
IC50 |
= |
63000.0 |
nM |
Inhibition of human cytomegalovirus (HCMV) in plaque reduction assay |
CHEMBL1124846 |
| Human herpesvirus 5 |
IC50 |
= |
90000.0 |
nM |
Inhibition of human cytomegalovirus (HCMV) in plaque reduction assay |
CHEMBL1124846 |
| Human herpesvirus 1 |
IC50 |
= |
4000.0 |
nM |
Inhibition of herpes simplex virus (HSV-1) in plaque reduction assay |
CHEMBL1124846 |
| Human herpesvirus 1 |
IC50 |
= |
7000.0 |
nM |
Inhibition of herpes simplex virus (HSV-1) in yield reduction assay |
CHEMBL1124846 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Cytotoxic activity against HFF cells. |
CHEMBL1124846 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Cytotoxic activity against BSC cells |
CHEMBL1124846 |
| Neoplastic cell line |
IC50 |
> |
100000.0 |
nM |
Cytotoxic activity against KB cells. |
CHEMBL1124846 |
| Human herpesvirus 1 |
ID50 |
= |
1.3 |
uM |
Concentration required to reduce the number of viral plaques in vivo cell monolayers of herpes simplex virus type 1. |
CHEMBL1124390 |
| Human herpesvirus 2 |
ID50 |
= |
2.2 |
uM |
Concentration required to reduce the number of viral plaques in vivo cell monolayers of herpes simplex virus type 2. |
CHEMBL1124390 |
| E6SM |
MCC |
> |
400.0 |
ug.mL-1 |
Inhibition of virus-induced cytopathicity in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| ADMET |
EC50 |
= |
0.077 |
ug.mL-1 |
Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| Human herpesvirus 1 |
EC50 |
= |
0.077 |
ug.mL-1 |
Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| Human herpesvirus 1 |
EC50 |
= |
0.077 |
ug.mL-1 |
Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| ADMET |
EC50 |
= |
0.384 |
ug.mL-1 |
Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| Unchecked |
EC50 |
= |
0.384 |
ug.mL-1 |
Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| Unchecked |
EC50 |
= |
0.384 |
ug.mL-1 |
Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| Vaccinia virus |
EC50 |
> |
400.0 |
ug.mL-1 |
Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| Vesicular stomatitis virus |
EC50 |
> |
400.0 |
ug.mL-1 |
Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| ADMET |
EC50 |
= |
48.0 |
ug.mL-1 |
Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| NON-PROTEIN TARGET |
MCC |
= |
1776000.0 |
nM |
Minimum cytotoxic concentration in E6SM fibroblast cells |
CHEMBL1135643 |
| NON-PROTEIN TARGET |
MIC |
= |
341.0 |
nM |
Minimum inhibitory concentration against Herpes simplex Virus-1(KOS) |
CHEMBL1135643 |
| NON-PROTEIN TARGET |
MIC |
= |
341.0 |
nM |
Minimum inhibitory concentration against Herpes simplex Virus-1(F) |
CHEMBL1135643 |
| NON-PROTEIN TARGET |
MIC |
= |
341.0 |
nM |
Minimum inhibitory concentration against Herpes simplex Virus-1 (McIntyre) |
CHEMBL1135643 |
| NON-PROTEIN TARGET |
MIC |
= |
242.0 |
nM |
Minimum inhibitory concentration against Herpes simplex Virus-2(G) |
CHEMBL1135643 |
| NON-PROTEIN TARGET |
MIC |
= |
1000.0 |
nM |
Minimum inhibitory concentration against Herpes simplex Virus-2(196) |
CHEMBL1135643 |
| NON-PROTEIN TARGET |
MIC |
= |
1000.0 |
nM |
Minimum inhibitory concentration against Herpes simplex Virus-2(Lyons) |
CHEMBL1135643 |
| NON-PROTEIN TARGET |
MIC |
= |
249000.0 |
nM |
Minimum inhibitory concentration against Herpes simplex Virus-1 (KOS) (ACV) |
CHEMBL1135643 |
| Vero |
IC50 |
= |
0.1 |
ug.mL-1 |
Inhibitory activity against Herpes Simplex virus type 1 (KOS strain) in a Plaque reduction Assay in vero cells |
CHEMBL1151552 |
| Vero |
IC50 |
= |
0.5 |
ug.mL-1 |
Inhibitory activity against Herpes Simplex virus type 1 (186 strain) in a Plaque reduction Assay in vero cells |
CHEMBL1151552 |
| Vero |
CC50 |
> |
10.0 |
ug.mL-1 |
Cytotoxicity in Vero cell line |
CHEMBL1151552 |
| F2002 cell line |
IC50 |
|
|
ug.mL-1 |
Inhibitory activity against human cytomegalo virus (WFI strain) in a plaque reduction assay in flow 2002 human fibroblast cells; Not determined |
CHEMBL1151552 |
| ADMET |
CC50 |
|
|
ug.mL-1 |
Cytotoxicity in Flow 2002 cell line;Not determined |
CHEMBL1151552 |
| Vero |
ID50 |
= |
0.01 |
ug ml-1 |
Dose to inhibit plaque formation in vero cells infected with herpes simplex virus type 1 (HSV-1,strainJLJ) was determined |
CHEMBL1124828 |
| E6SM |
MIC |
= |
0.08 |
ug.mL-1 |
Tested for antiviral activity against herpes simplex virus type 1(KOS) in E6SM cell line(human embryonic skin-muscle fibroblasts) |
CHEMBL1135216 |
| E6SM |
MIC |
= |
48.0 |
ug.mL-1 |
The compound was tested for antiviral activity against thymidine kinase-deficient (TK-HSV-1)virus in E6SM cell line(human embryonic skin-muscle fibroblasts) |
CHEMBL1135216 |
| E6SM |
MIC |
= |
0.08 |
ug.mL-1 |
Tested for antiviral activity against thymidine kinase-deficient (TK-HSV-2G) virus in E6SM cell line(human embryonic skin-muscle fibroblasts) |
CHEMBL1135216 |
| HEL |
MIC |
= |
1.1 |
ug.mL-1 |
Tested for antiviral activity against thymidine kinase wild type Varicella zoster virus in human embryonic lung fibroblast |
CHEMBL1135216 |
| HeLa |
MIC |
= |
12.3 |
ug.mL-1 |
Tested for antiviral activity against thymidine kinase deficient Varicella zoster virus in human embryonic lung fibroblasts |
CHEMBL1135216 |
| E6SM |
MIC |
> |
400.0 |
ug.mL-1 |
Tested for antiviral activity against vaccinia virus in human embryonic skin muscle fibroblast |
CHEMBL1135216 |
| E6SM |
MIC |
= |
48.0 |
ug.mL-1 |
Tested for antiviral activity against VSV-virus in human embryonic skin muscle fibroblasts |
CHEMBL1135216 |
| E6SM |
MCC |
> |
400.0 |
ug.mL-1 |
Tested for cytotoxic activity in human embryonic skin muscle fibroblast (E6SM) |
CHEMBL1135216 |
| HEL |
MCC |
> |
50.0 |
ug.mL-1 |
Tested for cytotoxic activity in human embryonic lung fibroblast (HEL) |
CHEMBL1135216 |
| Vero |
ID50 |
= |
0.5 |
ug ml-1 |
Antiviral activity determined by plaque reduction assay of HSV-1 (BWS) in vero cells |
CHEMBL1125595 |
| Vero |
ID50 |
= |
2.4 |
ug ml-1 |
Antiviral activity determined by plaque reduction assay of HSV-2 (G) in vero cells |
CHEMBL1125595 |
| MRC5 |
ID50 |
= |
38.4 |
ug ml-1 |
Antiviral activity determined by plaque reduction assay of HCMV (AD-169) in MRC-5 cells |
CHEMBL1125595 |
| Vero |
ID50 |
> |
100.0 |
ug ml-1 |
Anticellular activity was determined by plaque reduction assay in vero cells. |
CHEMBL1125595 |
| Mus musculus |
Survival |
= |
86.0 |
% |
Antiviral activity in terms of percentage survival at a dose of 300 mg/kg after intraperitoneal inoculation of HSV-1(BWS) in mice (6/7) |
CHEMBL1125595 |
| Mus musculus |
Survival |
= |
70.0 |
% |
Antiviral activity in terms of percentage survival at a dose of 100 mg/kg after intraperitoneal inoculation of HSV-1(BWS) in mice (7/10) |
CHEMBL1125595 |
| Mus musculus |
MST |
= |
20.0 |
day |
Compound tested for its effect on mean survival time in mice against HSV-1(BWS) at a dose of 300 mg/kg. |
CHEMBL1125595 |
| Mus musculus |
MST |
= |
18.4 |
day |
Compound tested for its effect on mean survival time in mice against HSV-1(BWS) at a dose of 100 mg/kg. |
CHEMBL1125595 |
| HEL |
IC50 |
|
|
ug.mL-1 |
The compound was tested for anti CMV (Cytomegalovirus- virus) activity against AD-169 strain in HEL cells;d ='not determined' |
CHEMBL1131427 |
| HEL |
IC50 |
|
|
ug.mL-1 |
The compound was tested for anti CMV (Cytomegalovirus- virus) activity against Davis strain in HEL cells;d ='not determined' |
CHEMBL1131427 |
| Human herpesvirus 3 |
IC50 |
= |
0.82 |
ug.mL-1 |
Anti-VZV activity against OKA strain TK+ in HEL cells |
CHEMBL1131427 |
| Human herpesvirus 3 |
IC50 |
= |
0.95 |
ug.mL-1 |
Anti-VZV activity against YS TK+ in HEL cells |
CHEMBL1131427 |
| Human herpesvirus 3 |
IC50 |
> |
25.0 |
ug.mL-1 |
Anti-VZV activity against 07/1 TK- in HEL cells |
CHEMBL1131427 |
| Human herpesvirus 3 |
IC50 |
> |
40.0 |
ug.mL-1 |
Anti-VZV activity against YS/R TK- in HEL cells |
CHEMBL1131427 |
| HEL |
CC |
> |
100.0 |
ug ml-1 |
Inhibition of cell proliferation expressed as CC50 |
CHEMBL1131427 |
| NON-PROTEIN TARGET |
Selectivity index |
|
|
|
Ratio of Cytotoxicity concentration to that of virus-inhibitory concentration;d ='not determined' |
CHEMBL1131427 |
| Human immunodeficiency virus 1 |
Inhibition |
|
|
% |
Antiviral activity against HIV-1 was determined; No inhibition |
CHEMBL1124905 |
| Human herpesvirus 5 |
Inhibition |
|
|
% |
Antiviral activity against HCMV was determined; No inhibition |
CHEMBL1124905 |
| Homo sapiens |
% absorbed |
= |
20.0 |
% |
% absorbed in human GI-tract |
CHEMBL1134374 |
| ADMET |
Log Pe |
= |
-4.8 |
cm s-1 |
Effective permeability (Pe) across a hexadecane membrane (pH 6.8) |
CHEMBL1134374 |
| ADMET |
Log Pe |
= |
-4.8 |
cm s-1 |
Highest effective permeability across hexadecane membrane (pH 4-8) |
CHEMBL1134374 |
| No relevant target |
LogD |
= |
-2.0 |
|
Partition coefficient (logD6.8) |
CHEMBL1134374 |
| Human herpesvirus 5 |
IC50 |
= |
63000.0 |
nM |
Inhibitory concentration against human cytomegalovirus (HCMV) in plaque reduction assay |
CHEMBL1123999 |
| Human herpesvirus 1 |
IC50 |
= |
2600.0 |
nM |
Inhibitory concentration against HCMV in plaque reduction assay |
CHEMBL1123999 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against uninfected human foreskin fibroblast(HFF cells) |
CHEMBL1123999 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against uninfected monkey kidney cells (BSC-1) |
CHEMBL1123999 |
| ADMET |
Inhibition |
> |
100.0 |
% |
Cytotoxicity against human neoplastic cell line(KB cells) |
CHEMBL1123999 |
| MT4 |
Activity |
|
|
|
Compound was tested for antiviral activity indicative of 50% cytopathic concentration in virus (HIV-1) infected MT-4 cells; ND is not determined |
CHEMBL1134898 |
| Human herpesvirus 1 |
EC50 |
= |
0.13 |
ug.mL-1 |
Compound was tested for antiviral activity against HSV-1 |
CHEMBL1134898 |
| Human herpesvirus 2 |
EC50 |
= |
0.88 |
ug.mL-1 |
Compound was tested for antiviral activity against HSV-2 |
CHEMBL1134898 |
| MT4 |
CC50 |
> |
76.6 |
ug.mL-1 |
Cytotoxicity indicative of 50% survival concentration in HSV-1-uninfected MT-4 cells. |
CHEMBL1134898 |
| MT4 |
CC50 |
> |
11.4 |
ug.mL-1 |
Cytotoxicity indicative of 50% survival concentration in HSV-2-uninfected MT-4 cells. |
CHEMBL1134898 |
| Human herpesvirus 3 |
EC50 |
= |
2900.0 |
nM |
Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV OKA Plaque formation after 5 days in HEL cell cultures compared to untreated controls. |
CHEMBL1132955 |
| Human herpesvirus 3 |
EC50 |
= |
1000.0 |
nM |
Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV TS plaque formation after 5 days in HEL cell cultures compared to untreated controls. |
CHEMBL1132955 |
| Human herpesvirus 3 |
EC50 |
= |
74000.0 |
nM |
Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-07 ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls. |
CHEMBL1132955 |
| Human herpesvirus 3 |
EC50 |
= |
125000.0 |
nM |
Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-YS-R ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls. |
CHEMBL1132955 |
| Human herpesvirus 3 |
MCC |
> |
200000.0 |
nM |
Minimal cytotoxic concentration, the concentration required to cause a microscopically visible alteration of normal cell morphology. |
CHEMBL1132955 |
| Human herpesvirus 3 |
CC50 |
> |
200000.0 |
nM |
cytostatic concentration required to reduce the HEL cell number by 50%. after 5 days in the absence of virus |
CHEMBL1132955 |
| Vero |
IC50 |
= |
7540.0 |
nM |
Comparative Potency (IC50s) at HSV-1 passage 10 in vero cells |
CHEMBL1131049 |
| Vero |
IC50 |
= |
37800.0 |
nM |
Comparative Potency (IC50s) at HSV-1 passage 2 in vero cells |
CHEMBL1131049 |
| Vero |
IC50 |
> |
88800.0 |
nM |
Comparative Potency (IC50s) at HSV-1 passage 3 in vero cells |
CHEMBL1131049 |
| Vero |
IC50 |
= |
138400.0 |
nM |
Comparative Potency (IC50s) at HSV-1 passage 4 in vero cells |
CHEMBL1131049 |
| Vero |
IC50 |
= |
111000.0 |
nM |
Comparative Potency (IC50s) at HSV-1 passage 5 in vero cells |
CHEMBL1131049 |
| Vero |
IC50 |
= |
130700.0 |
nM |
Comparative Potency (IC50s) at HSV-1 passage 6 in vero cells |
CHEMBL1131049 |
| Vero |
IC50 |
= |
189800.0 |
nM |
Comparative Potency (IC50s) at HSV-1 passage 7 in vero cells |
CHEMBL1131049 |
| Vero |
IC50 |
= |
444000.0 |
nM |
Comparative Potency (IC50s) at HSV-1 passage 8 in vero cells |
CHEMBL1131049 |
| Vero |
IC50 |
= |
378800.0 |
nM |
Comparative Potency (IC50s) at HSV-1 passage 9 in vero cells |
CHEMBL1131049 |
| Vero |
IC50 |
= |
444000.0 |
nM |
Comparative Potency (IC50s) at HSV-1 passage 10 in vero cells |
CHEMBL1131049 |
| Vero |
IC50 |
= |
6660.0 |
nM |
Comparative Potency (IC50s) at HSV-2 passage 1 in vero cells |
CHEMBL1131049 |
| Vero |
IC50 |
> |
44400.0 |
nM |
Comparative Potency (IC50s) at HSV-2 passage 2 in vero cells |
CHEMBL1131049 |
| Vero |
IC50 |
= |
62800.0 |
nM |
Comparative Potency (IC50s) at HSV-2 passage 3 in vero cells |
CHEMBL1131049 |
| Vero |
IC50 |
> |
88800.0 |
nM |
Comparative Potency (IC50s) at HSV-2 passage 4 in vero cells |
CHEMBL1131049 |
| Unchecked |
Selectivity index |
= |
589.0 |
|
Ralative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 1 in vero cells |
CHEMBL1131049 |
| Unchecked |
Selectivity index |
= |
117.0 |
|
Ralative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 2 in vero cells |
CHEMBL1131049 |
| Unchecked |
Selectivity index |
= |
50.0 |
|
Ralative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 3 in vero cells |
CHEMBL1131049 |
| Unchecked |
Selectivity index |
= |
32.0 |
|
Ralative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 4 in vero cells |
CHEMBL1131049 |
| Unchecked |
Selectivity index |
= |
40.0 |
|
Ralative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 5 in vero cells |
CHEMBL1131049 |
| Unchecked |
Selectivity index |
= |
34.0 |
|
Ralative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 6 in vero cells |
CHEMBL1131049 |
| Unchecked |
Selectivity index |
= |
23.0 |
|
Ralative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 7 in vero cells |
CHEMBL1131049 |
| Unchecked |
Selectivity index |
= |
23.0 |
|
Ralative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 8 in vero cells |
CHEMBL1131049 |
| Unchecked |
Selectivity index |
= |
11.0 |
|
Ralative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 9 in vero cells |
CHEMBL1131049 |
| Unchecked |
Selectivity index |
= |
10.0 |
|
Ralative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 10 in vero cells |
CHEMBL1131049 |
| Unchecked |
Selectivity index |
= |
667.0 |
|
Ralative safety was expressed as Selective index (TC50/IC50) at HSV-2 passage 1 in vero cells |
CHEMBL1131049 |
| Unchecked |
Selectivity index |
= |
100.0 |
|
Ralative safety was expressed as Selective index (TC50/IC50) at HSV-2 passage 2 in vero cells |
CHEMBL1131049 |
| Unchecked |
Selectivity index |
= |
70.0 |
|
Ralative safety was expressed as Selective index (TC50/IC50) at HSV-2 passage 3 in vero cells |
CHEMBL1131049 |
| Unchecked |
Selectivity index |
= |
50.0 |
|
Ralative safety was expressed as Selective index (TC50/IC50) at HSV-2 passage 4 in vero cells |
CHEMBL1131049 |
| HEL |
EC50 |
= |
1500.0 |
nM |
Antiviral activity was measured as effective concentration required to reduce Varicella Zoster virus (YS)-induced plaque formation in human embryonic lung cells |
CHEMBL1133962 |
| HEL |
EC50 |
= |
1100.0 |
nM |
Antiviral activity was measured as effective concentration required to reduce Varicella Zoster virus (OKA)-induced plaque formation in human embryonic lung cells |
CHEMBL1133962 |
| HEL |
EC50 |
= |
40000.0 |
nM |
Antiviral activity was measured as effective concentration required to reduce thymidine kinase-deficient. Varicella Zoster virus (07/1)-induced plaque formation in human embryonic lung cells |
CHEMBL1133962 |
| HEL |
EC50 |
= |
44000.0 |
nM |
Antiviral activity was measured as effective concentration required to reduce thymidine kinase-deficient. Varicella Zoster virus (YS/R)-induced plaque formation in human embryonic lung cells |
CHEMBL1133962 |
| HEL |
MCC |
> |
200000.0 |
nM |
Minimal cytotoxic concentration required to alter microscopically detectable cell (of human embryonic lung cells (HEL)) morphology |
CHEMBL1133962 |
| HEL |
CC50 |
> |
400000.0 |
nM |
Cytotoxic concentration required to inhibit growth of human embryonic lung cells (HEL) |
CHEMBL1133962 |
| MRC5 |
EC50 |
= |
50000.0 |
nM |
Compound was tested for inhibition against human cytomegalovirus (HCMV) in MRC-5 cells |
CHEMBL1133316 |
| Vero |
EC50 |
= |
3000.0 |
nM |
Compound was tested for inhibition against herpes simplex virus (HSV-2) infected vero cells |
CHEMBL1133316 |
| MRC5 |
EC50 |
= |
5000.0 |
nM |
Compound was tested for inhibition against varicella zoster virus(VZV) infected MRC5 cells |
CHEMBL1133316 |
| Vero |
CC50 |
> |
5000.0 |
nM |
Compound was tested for cytotoxic activity uninfected vero cells |
CHEMBL1133316 |
| FM3A |
Concentration |
>= |
400.0 |
ug ml-1 |
Concentration required to cause a microscopically detectable alteration of normal cell morphology |
CHEMBL1124895 |
| ADMET |
MIC |
= |
0.2 |
ug.mL-1 |
Antiviral Activity against herpes simplex virus-1 (KOS) in rabbit kidney cell |
CHEMBL1124895 |
| ADMET |
MIC |
= |
0.1 |
ug.mL-1 |
Antiviral Activity against herpes simplex virus-1 (F) in rabbit kidney cell |
CHEMBL1124895 |
| ADMET |
MIC |
= |
0.2 |
ug.mL-1 |
Antiviral Activity against herpes simplex virus-1 (McIntyre) in rabbit kidney cell |
CHEMBL1124895 |
| ADMET |
MIC |
= |
0.02 |
ug.mL-1 |
Antiviral Activity against herpes simplex virus-2 (G) in rabbit kidney cell |
CHEMBL1124895 |
| ADMET |
MIC |
= |
0.07 |
ug.mL-1 |
Antiviral Activity against herpes simplex virus-2 (196) in rabbit kidney cell |
CHEMBL1124895 |
| ADMET |
MIC |
= |
0.1 |
ug.mL-1 |
Antiviral Activity against herpes simplex virus-2 (Lyons) in rabbit kidney cell |
CHEMBL1124895 |
| ADMET |
MIC |
= |
150.0 |
ug.mL-1 |
Antiviral Activity against vaccinia virus in rabbit kidney cell |
CHEMBL1124895 |
| ADMET |
MIC |
> |
400.0 |
ug.mL-1 |
Antiviral Activity against vesicular stomatitis virus in rabbit kidney cell |
CHEMBL1124895 |
| ADMET |
MIC |
= |
20.0 |
ug.mL-1 |
Antiviral Activity against herpes simplex virus-1 TK- B2006 in rabbit kidney cell |
CHEMBL1124895 |
| ADMET |
MIC |
= |
10.0 |
ug.mL-1 |
Antiviral Activity against herpes simplex virus-1 TK- VMW 1837 in rabbit kidney cell |
CHEMBL1124895 |
| L1210 |
ID50 |
= |
41.0 |
ug ml-1 |
Inhibitory activity against L1210 cell line |
CHEMBL1124895 |
| FM3A |
ID50 |
= |
17.0 |
ug ml-1 |
Inhibitory activity against FM3A/0 cell line |
CHEMBL1124895 |
| FM3A |
ID50 |
= |
0.62 |
ug ml-1 |
Inhibitory activity against FM3A TK- cell line |
CHEMBL1124895 |
| FM3A |
ID50 |
= |
0.0009 |
ug ml-1 |
Inhibitory activity against FMBA TK-/HSV-2 TK+ cell line |
CHEMBL1124895 |
| Raji |
ID50 |
> |
100.0 |
ug ml-1 |
Inhibitory activity against Raji cell line |
CHEMBL1124895 |
| MOLT-4F |
ID50 |
> |
100.0 |
ug ml-1 |
Inhibitory activity against Molt/4F cell line |
CHEMBL1124895 |
| Mus musculus |
Activity |
= |
17.2 |
|
Tested for the appearance of skin lesions or paralysis of the legs after 39 days when administered intraperitoneally at 100 mg/kg per day |
CHEMBL1124895 |
| Mus musculus |
Mean survival time |
= |
30.4 |
day |
Compound was evaluated in nu/nu mice infected with TK- HSV-1 (VMW-1837) to increase the mean survival time when administered intraperitoneally at 100 mg/kg per day after 39 days |
CHEMBL1124895 |
| Mus musculus |
Activity |
= |
40.8 |
|
Tested for the appearance of skin lesions or paralysis of the legs after 52 days when applied topically at 10% after 52 days |
CHEMBL1124895 |
| Mus musculus |
Mean survival time |
= |
46.2 |
day |
Compound was evaluated in nu/nu mice infected with TK- HSV-1 (VMW-1837) to increase the mean survival time when applied topically at 10% after 52 days |
CHEMBL1124895 |
| Human herpesvirus 1 |
EC50 |
= |
2220.0 |
nM |
Inhibitory concentration required to reduce HSV-1 induced cytopathogenic effect (CPE) by 50 % in HFF cells |
CHEMBL1144911 |
| Human herpesvirus 2 |
EC50 |
= |
10210.0 |
nM |
Inhibitory concentration required to reduce HSV-2 induced cytopathogenic effect (CPE) by 50 % in HFF cells |
CHEMBL1144911 |
| HFF |
EC50 |
= |
1100.0 |
nM |
Concentration for HSV-1 plaque reduction (VPR) by 50% in HFF cells |
CHEMBL1144911 |
| HFF |
EC50 |
= |
1680.0 |
nM |
Concentration for HSV-2 plaque reduction (VPR) by 50% in HFF cells |
CHEMBL1144911 |
| Human herpesvirus 3 |
EC50 |
= |
2400.0 |
nM |
Effective concentration against TK+ Varicella-Zoster Virus (VZV)YS strain |
CHEMBL1144911 |
| Human herpesvirus 3 |
EC50 |
= |
2400.0 |
nM |
Effective concentration against TK+ Varicella-Zoster Virus (VZV) OKA strain |
CHEMBL1144911 |
| Human herpesvirus 3 |
EC50 |
= |
30000.0 |
nM |
Effective concentration against TK- Varicella-Zoster Virus (VZV) 07/1 strain |
CHEMBL1144911 |
| Human herpesvirus 3 |
EC50 |
= |
19000.0 |
nM |
Effective concentration against TK- Varicella-Zoster Virus (VZV) YS/R strain |
CHEMBL1144911 |
| Human herpesvirus 3 |
MCC |
> |
200000.0 |
nM |
Minimum cytotoxic concentration that causes alterations of VZV infected Osteosarcoma cell morphology |
CHEMBL1144911 |
| Human herpesvirus 3 |
CC50 |
= |
488000.0 |
nM |
Cytotoxic concentration that causes growth inhibition of VZV infected Osteosarcoma cells |
CHEMBL1144911 |
| Thymidine kinase, cytosolic |
k cat |
= |
0.1 |
s-1 |
Catalytic turnover constant against HSV-1 thymidine kinase |
CHEMBL1144911 |
| Mus musculus |
No. of dead mice |
= |
0.0 |
|
Toxicity of compound against mice was determined at a concentration of 100 mg/kg |
CHEMBL1123394 |
| Mus musculus |
No. of dead mice |
= |
0.0 |
|
Toxicity of compound against mice was determined at a concentration of 250 mg/kg |
CHEMBL1123394 |
| Mus musculus |
No. of dead mice |
= |
1.0 |
|
Toxicity of compound against mice was determined at a concentration of 750 mg/kg |
CHEMBL1123394 |
| Mus musculus |
No. of dead mice |
= |
7.0 |
|
Toxicity of compound against mice was determined at a concentration of 1200 mg/kg |
CHEMBL1123394 |
| Mus musculus |
No. of dead mice |
= |
7.0 |
|
Toxicity of compound against mice was determined at a concentration of 2000 mg/kg |
CHEMBL1123394 |
| ADMET |
LD50 |
= |
1250.0 |
mg.kg-1 |
Number of living cells on the proliferation of mouse myeloma cells SP2 was measured at concentration 1 ug/mL at 96 h. |
CHEMBL1123394 |
| Mus musculus |
Efficacy |
= |
0.0 |
mg kg-1 |
Efficacy expressed as number of surviving mice infected with herpetic encephalitis at dose of 0 mg/kg |
CHEMBL1123394 |
| Mus musculus |
Efficacy |
|
|
|
Efficacy expressed as number of surviving mice infected with herpetic encephalitis at dose of 75 mg/kg; Not determined |
CHEMBL1123394 |
| Mus musculus |
Efficacy |
|
|
|
Efficacy expressed as number of surviving mice infected with herpetic encephalitis at dose of 150 mg/kg; Not determined |
CHEMBL1123394 |
| HEL |
MIC |
= |
0.001 |
ug.mL-1 |
Concentration required to reduce varicella zoster virus(VZV)OKA plaque formation by 50% at 20 plaque forming units(PFU) in human embryonic lung (HEL) cell cultures. |
CHEMBL1126074 |
| HEL |
MIC |
= |
0.0007 |
ug.mL-1 |
Concentration required to reduce varicella zoster virus (VZV)YS-TK-PFU plaque formation by 50% in human embryonic lung (HEL) cell cultures. |
CHEMBL1126074 |
| HEL |
MIC |
> |
10.0 |
ug.mL-1 |
Concentration required to reduce VZV-07/1-TK- plaque formation by 50% in human embryonic lung (HEL) cell cultures. |
CHEMBL1126074 |
| HEL |
MIC |
> |
10.0 |
ug.mL-1 |
Concentration required to reduce VZV-YS/R-TK- plaque formation by 50% in human embryonic lung (HEL) cell cultures. |
CHEMBL1126074 |
| Human herpesvirus 5 |
IC50 |
= |
63000.0 |
nM |
Antiviral activity against Human cytomegalovirus in a plaque-reduction assay |
CHEMBL1124509 |
| Human herpesvirus 1 |
IC50 |
= |
3900.0 |
nM |
Antiviral activity was determined against Herpes simplex virus type 1 by Plaque-reduction assay |
CHEMBL1124509 |
| Homo sapiens |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against Normal human diploid cells (human foreskin fibroblasts cells) |
CHEMBL1124509 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against Monkey kidney cells(BSC-1 cells) |
CHEMBL1124509 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against human neoplastic cell line (KB) |
CHEMBL1124509 |
| Unchecked |
Inhibition |
|
|
% |
Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process |
CHEMBL1130487 |
| Human herpesvirus 1 |
IC50 |
= |
1800.0 |
nM |
Inhibitory activity against herpes simplex virus type 1 (HSV-1) strain SC16 in Vero cells. |
CHEMBL1129482 |
| ADMET |
IC50 |
= |
1700.0 |
nM |
Inhibitory activity against herpes simplex virus type 2 (HSV 2) strain 186 in Vero cells. |
CHEMBL1129482 |
| Human herpesvirus 3 |
IC50 |
= |
46800.0 |
nM |
Inhibitory activity against varicella zoster virus (VZV) strain G31 in MRC-5 cells. |
CHEMBL1129482 |
| Human herpesvirus 5 |
IC50 |
> |
85000.0 |
nM |
Inhibitory activity against human cytomegalovirus (HCMV) strain AD169 in MRC-5 cells. |
CHEMBL1129482 |
| Vero |
CCID50 |
> |
500.0 |
uM |
Inhibitory dose required to reduce the growth of vero cells by 50% over a 4 day period. |
CHEMBL1129482 |
| Human herpesvirus 1 |
VR |
= |
6.3 |
|
Compound was evaluated for antiviral activity against HSV-1 reported as virus rating |
CHEMBL1123936 |
| Human herpesvirus 1 |
ED50 |
= |
12.3 |
ug ml-1 |
Compound was evaluated for antiviral activity against HSV-1 reported as ED50 value |
CHEMBL1123936 |
| Human herpesvirus 2 |
VR |
= |
4.8 |
|
Compound was evaluated for antiviral activity against HSV-2 reported as virus rating |
CHEMBL1123936 |
| Human herpesvirus 2 |
ED50 |
= |
4.8 |
ug ml-1 |
Compound was evaluated for antiviral activity against HSV-2 reported as ED50 value |
CHEMBL1123936 |
| Vero |
ID50 |
= |
0.01 |
ug ml-1 |
In vitro antiviral activity against herpes simplex virus type-1 in vero cells |
CHEMBL1124466 |
| Human herpesvirus 1 |
ED50 |
= |
0.2 |
uM |
Effective dose required to inhibit cell growth against HSV-1 (schooler); Value ranges from 0.2-0.4 |
CHEMBL1152115 |
| Human herpesvirus 2 |
ED50 |
= |
0.4 |
uM |
Effective dose required to inhibit cell growth against HSV-2 (186); Value ranges from 0.4-0.8 |
CHEMBL1152115 |
| Human herpesvirus 3 |
ED50 |
= |
2.0 |
uM |
Effective dose required to inhibit cell growth against VZV (Ellen); Value ranges from 2-4 |
CHEMBL1152115 |
| Human herpesvirus 5 |
ED50 |
= |
20.0 |
uM |
Effective dose required to inhibit cell growth against HCMV (AD169); Value ranges from 20-40 |
CHEMBL1152115 |
| Human herpesvirus 5 |
IC50 |
= |
63000.0 |
nM |
Antiviral activity of the compound was evaluated against the Human cytomegalo virus (HCMV) |
CHEMBL1124393 |
| ADMET |
IC50 |
= |
2600.0 |
nM |
Antiviral activity of the compound was evaluated against the Herpes simplex virus type-1 in BSC-1 cells |
CHEMBL1124393 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity was evaluated against the Human diploid cells (HFF) |
CHEMBL1124393 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity was evaluated against the Monkey kidney cells (BSC) |
CHEMBL1124393 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity was evaluated in Human neoplastic cell line (KB) |
CHEMBL1124393 |
| Human herpesvirus 1 |
Control |
= |
6.5 |
% |
Antiherpes activity was tested as percent of control of plaque-formation against HSV-1 (KOS) virus by 5 uM of the compound |
CHEMBL1122901 |
| Human herpesvirus 1 |
Control |
= |
4.0 |
% |
Antiherpes activity was tested as percent of control of plaque-formation against HSV-1 (CL101) virus by 5 uM of the compound |
CHEMBL1122901 |
| Human herpesvirus 1 |
Control |
= |
100.0 |
% |
Antiherpes activity was tested as percent of control of plaque-formation against ACG (S1) virus by 5 uM of the compound |
CHEMBL1122901 |
| Human herpesvirus 1 |
Control |
= |
85.0 |
% |
Antiherpes activity was tested as percent of control of plaque-formation against ACG (Tr7) virus by 5 uM of the compound |
CHEMBL1122901 |
| Human herpesvirus 1 |
Control |
= |
0.7 |
% |
Antiherpes activity was tested as percent of control of plaque-formation against BVdUr virus by 5 uM of the compound |
CHEMBL1122901 |
| NON-PROTEIN TARGET |
Control |
= |
100.0 |
% |
Antiherpes activity was tested as percent of control of plaque-formation against PFAr virus by 5 uM of the compound |
CHEMBL1122901 |
| HeLa |
IC50 |
= |
0.1 |
ug.mL-1 |
Inhibition of cytopathogenicity of herpes simplex type 1 virus (HSV-1)(KOS) in Hela cell culture. |
CHEMBL1128665 |
| HeLa |
IC50 |
= |
0.23 |
ug.mL-1 |
Inhibition of cytopathogenicity of herpes simplex type 2 virus(HSV-12(G) in Hela cell culture |
CHEMBL1128665 |
| HeLa |
IC50 |
= |
20.0 |
ug.mL-1 |
Inhibition of cytopathogenicity of Varicella-Zoster virus(VZV)(YS) in Hela cell culture. |
CHEMBL1128665 |
| HeLa |
IC50 |
= |
250.0 |
ug.mL-1 |
Concentration required to cause microscopically visible change or disruption in about 50% of Hela cell sheet. |
CHEMBL1128665 |
| HeLa |
IC50 |
= |
110.0 |
nM |
Ability to inhibit cytopathogenicity of herpes simplex type 1 virus (KOS) in HeLa cell culture |
CHEMBL1134486 |
| HeLa |
IC50 |
= |
190.0 |
nM |
Ability to inhibit cytopathogenicity of herpes simplex type 1 virus (G) in HeLa cell culture |
CHEMBL1134486 |
| HeLa |
IC50 |
= |
8710.0 |
nM |
Ability to inhibit cytopathogenicity of thymidine kinase-positive(TK+) strain of Varicella zoster virus (YS) in HeLa cell culture |
CHEMBL1134486 |
| HeLa |
IC50 |
= |
26430.0 |
nM |
Ability to inhibit cytopathogenicity of thymidine kinase-deficient (TK-) strain of Varicella zoster virus (YS/R) in HeLa cell culture |
CHEMBL1134486 |
| HeLa |
IC50 |
= |
253640.0 |
nM |
Concentration required to cause microscopically visible change or disruption in about 50% of cell sheet of HeLa cells |
CHEMBL1134486 |
| Human herpesvirus 1 |
ID50 |
= |
0.9 |
uM |
Antiviral activity against Herpes simplex virus-1 (Schooler strain) |
CHEMBL1126655 |
| ADMET |
ID50 |
= |
2.0 |
uM |
Antiviral activity against Herpes simplex virus-1 (KOS strain) |
CHEMBL1126655 |
| Human herpesvirus 1 |
ID50 |
> |
440.0 |
uM |
Antiviral activity against Herpes simplex virus-1 (thymidine kinase deficient strains isolated as BVaraU resistant mutants of HSV-1 (KOS)) |
CHEMBL1126655 |
| ADMET |
ID50 |
= |
0.9 |
uM |
Antiviral activity against Herpes simplex virus-2 (186 strain) |
CHEMBL1126655 |
| Human herpesvirus 2 |
ID50 |
> |
440.0 |
uM |
Antiviral activity against Herpes simplex virus-2 (thymidine kinase deficient strains isolated as BVaraU resistant mutants of HSV-1 (KOS)) |
CHEMBL1126655 |
| Human herpesvirus 3 |
ID50 |
= |
4.0 |
uM |
Antiviral activity against Varicella zoster virus (Ellen strain) |
CHEMBL1126655 |
| Human herpesvirus 5 |
ID50 |
= |
40.0 |
uM |
Antiviral activity against Human cytomegalovirus (AD169 strain) |
CHEMBL1126655 |
| Vaccinia virus |
ID50 |
> |
440.0 |
uM |
Antiviral activity against vaccinia virus (CL strain) |
CHEMBL1126655 |
| WI-38 |
ID50 |
> |
800.0 |
uM |
Tested for growth inhibition against WI-38 cells |
CHEMBL1126655 |
| Mus musculus |
PD50 |
> |
200.0 |
mg kg-1 day-1 |
Protective dose against Herpes simplex virus type type -1 infection in mice at 200 mg/kg |
CHEMBL1126655 |
| Mus musculus |
Survivors |
= |
2.0 |
|
Number of survivors against Herpes simplex virus type-1 infection in mice at 200 mg/kg/day |
CHEMBL1126655 |
| Mus musculus |
Mean day of death |
= |
14.0 |
|
Day of death in lethal test against herpes simplex virus type-1 at 200 mg/kg/day (mean day of death +/-SD) |
CHEMBL1126655 |
| Mus musculus |
Survivors |
= |
2.0 |
|
Number of survivors against Herpes simplex virus type-1 infection in mice at 150 mg/kg/day |
CHEMBL1126655 |
| Mus musculus |
Mean day of death |
= |
11.8 |
|
Day of death in lethal test against herpes simplex virus type-1 at 150 mg/kg/day (mean day of death +/-SD) |
CHEMBL1126655 |
| Mus musculus |
Survivors |
= |
2.0 |
|
Number of survivors against Herpes simplex virus type-1 infection in mice at 100 mg/kg/day |
CHEMBL1126655 |
| Mus musculus |
Mean day of death |
= |
9.3 |
|
Day of death in lethal test against herpes simplex virus type-1 at 100 mg/kg/day (mean day of death +/-SD) |
CHEMBL1126655 |
| Mus musculus |
Survivors |
= |
1.0 |
|
Number of survivors against Herpes simplex virus type-1 infection in mice at 50 mg/kg/day |
CHEMBL1126655 |
| Mus musculus |
Mean day of death |
= |
9.0 |
|
Day of death in lethal test against herpes simplex virus type-1 at 50 mg/kg/day (mean day of death +/-SD) |
CHEMBL1126655 |
| Mus musculus |
Survivors |
= |
3.0 |
|
Number of survivors against Herpes simplex virus type-1 infection in mice at 25 mg/kg/day |
CHEMBL1126655 |
| Mus musculus |
Mean day of death |
= |
7.8 |
|
Day of death in lethal test against herpes simplex virus type-1 at 25 mg/kg/day (mean day of death +/-SD) |
CHEMBL1126655 |
| Mus musculus |
Survivors |
= |
0.0 |
|
Number of survivors against Herpes simplex virus type-1 infection in mice at 12.5 mg/kg/day |
CHEMBL1126655 |
| Mus musculus |
Mean day of death |
= |
8.3 |
|
Day of death in lethal test against herpes simplex virus type-1 at 12.5 mg/kg/day (mean day of death +/-SD) |
CHEMBL1126655 |
| Mus musculus |
PD50 |
> |
200.0 |
mg kg-1 day-1 |
Protective dose against Herpes simplex virus type type -2 infection in mice at 200 mg/kg |
CHEMBL1126655 |
| Mus musculus |
Survivors |
= |
5.0 |
|
Number of survivors against Herpes simplex virus type-2 infection in mice at 200 mg/kg/day |
CHEMBL1126655 |
| Mus musculus |
Mean day of death |
= |
13.0 |
|
Day of death in lethal test against herpes simplex virus type-2 at 200 mg/kg/day (mean day of death +/-SD) |
CHEMBL1126655 |
| Mus musculus |
Survivors |
= |
4.0 |
|
Number of survivors against Herpes simplex virus type-2 infection in mice at 150 mg/kg/day |
CHEMBL1126655 |
| Mus musculus |
Mean day of death |
= |
13.0 |
|
Day of death in lethal test against herpes simplex virus type-2 at 150 mg/kg/day (mean day of death +/-SD) |
CHEMBL1126655 |
| Mus musculus |
Survivors |
= |
2.0 |
|
Number of survivors against Herpes simplex virus type-2 infection in mice at 100 mg/kg/day |
CHEMBL1126655 |
| Mus musculus |
Mean day of death |
= |
13.5 |
|
Day of death in lethal test against herpes simplex virus type-2 at 100 mg/kg/day (mean day of death +/-SD) |
CHEMBL1126655 |
| Mus musculus |
Survivors |
= |
1.0 |
|
Number of survivors against Herpes simplex virus type-2 infection in mice at 50 mg/kg/day |
CHEMBL1126655 |
| Mus musculus |
Mean day of death |
= |
11.7 |
|
Day of death in lethal test against herpes simplex virus type-2 at 50 mg/kg/day (mean day of death +/-SD) |
CHEMBL1126655 |
| Mus musculus |
Survivors |
= |
0.0 |
|
Number of survivors against Herpes simplex virus type-2 infection in mice at 25 mg/kg/day |
CHEMBL1126655 |
| Mus musculus |
Mean day of death |
= |
11.6 |
|
Day of death in lethal test against herpes simplex virus type-2 at 25 mg/kg/day (mean day of death +/-SD) |
CHEMBL1126655 |
| Mus musculus |
Survivors |
= |
0.0 |
|
Number of survivors against Herpes simplex virus type-2 infection in mice at 12.5 mg/kg/day |
CHEMBL1126655 |
| Mus musculus |
Mean day of death |
= |
10.0 |
|
Day of death in lethal test against herpes simplex virus type-2 at 12.5 mg/kg/day (mean day of death +/-SD) |
CHEMBL1126655 |
| Human herpesvirus 3 |
ID50 |
= |
2.0 |
uM |
Antiviral activity against Varicella zoster virus (9021 strain) |
CHEMBL1126655 |
| Human herpesvirus 3 |
ID50 |
= |
4.0 |
uM |
Antiviral activity against Varicella zoster virus (ppIIa strain) |
CHEMBL1126655 |
| Human herpesvirus 3 |
ID50 |
= |
4.0 |
uM |
Antiviral activity against Varicella zoster virus (Oka strain) |
CHEMBL1126655 |
| Human herpesvirus 3 |
ID50 |
= |
2.0 |
uM |
Antiviral activity against Varicella zoster virus (Ito strain) |
CHEMBL1126655 |
| Human herpesvirus 3 |
ID50 |
= |
100.0 |
uM |
Antiviral activity against Varicella zoster virus (Kanno-Kohmura thymidine kinase deficient strain) |
CHEMBL1126655 |
| Cercopithecine herpesvirus 9 |
ID50 |
= |
100.0 |
uM |
Antiviral activity against Simina varicella virus (G815 strain) |
CHEMBL1126655 |
| NC-37 |
EC50 |
= |
0.17 |
ug.mL-1 |
Concentration required to reduce HSV-1 (KOS strain) induced cytopathogenicity in NC-37 cells |
CHEMBL1152064 |
| NC-37 |
CC50 |
> |
100.0 |
ug.mL-1 |
Cytotoxic concentration required to inhibit NC-37 cells by 50% |
CHEMBL1152064 |
| HEL |
CC50 |
> |
200.0 |
ug.mL-1 |
Tested for the cytotoxic concentration, required to reduce cell growth by 50% in human embryonic lung (HEL) cells. |
CHEMBL1128256 |
| HEL |
IC50 |
= |
0.04 |
ug.mL-1 |
Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%. |
CHEMBL1128256 |
| HEL |
IC50 |
= |
0.15 |
ug.mL-1 |
Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50% |
CHEMBL1128256 |
| HEL |
IC50 |
= |
3.0 |
ug.mL-1 |
Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%. |
CHEMBL1128256 |
| HEL |
IC50 |
= |
5.0 |
ug.mL-1 |
Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%. |
CHEMBL1128256 |
| HEL |
IC50 |
= |
20.0 |
ug.mL-1 |
Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%. |
CHEMBL1128256 |
| HEL |
IC50 |
= |
15.0 |
ug.mL-1 |
Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%. |
CHEMBL1128256 |
| Purine nucleoside phosphorylase |
Ki |
= |
180000.0 |
nM |
PNP activity in human RBC |
CHEMBL1126636 |
| Vero |
IC50 |
= |
1.5 |
ug.mL-1 |
Concentration required for 50% inhibition of herpes simplex virus 2(HSV-2) using standard plaque reduction assay in vero cells |
CHEMBL1127281 |
| NON-PROTEIN TARGET |
IC50 |
= |
0.015 |
ug.mL-1 |
Antiviral activity against herpes simplex virus-1 KOS in E6SM cell culture |
CHEMBL1129435 |
| ADMET |
IC50 |
= |
0.02 |
ug.mL-1 |
Antiviral activity in herpes simplex virus-2 (HSV-2) G strain in E6SM cell culture |
CHEMBL1129435 |
| Human herpesvirus 5 |
IC50 |
= |
13.0 |
ug.mL-1 |
Antiviral activity against cytomegalovirus (CMV) AD169 strain in HEL cell culture |
CHEMBL1129435 |
| Human herpesvirus 3 |
IC50 |
= |
0.18 |
ug.mL-1 |
Antiviral activity in TK+ varicella zoster virus (VZV) OKA strain in HEL cell culture |
CHEMBL1129435 |
| Human herpesvirus 3 |
IC50 |
= |
0.35 |
ug.mL-1 |
Antiviral activity in TK+ varicella zoster virus (VZV) YS strain in HEL cell culture |
CHEMBL1129435 |
| Human herpesvirus 3 |
IC50 |
= |
11.0 |
ug.mL-1 |
Antiviral activity in TK+ varicella zoster virus (VZV) 07/1 strain in HEL cell culture |
CHEMBL1129435 |
| Human herpesvirus 3 |
IC50 |
= |
22.0 |
ug.mL-1 |
Antiviral activity in TK+ varicella zoster virus (VZV) YS/R strain in HEL cell culture |
CHEMBL1129435 |
| NON-PROTEIN TARGET |
IC50 |
= |
0.81 |
ug.mL-1 |
Tested for inhibitory activity against Herpes simplex virus type-1(HSV-1), activity is expressed as IC50. |
CHEMBL1133668 |
| Vero |
CC50 |
= |
820.0 |
ug.mL-1 |
Tested for cytotoxicity in vero cells, activity is expressed as CC50. |
CHEMBL1133668 |
| HEL |
IC50 |
= |
3.4 |
ug.mL-1 |
Tested for inhibitory activity against Varicella zoster virus(VZV) by plaque reduction assay using HEL cells |
CHEMBL1133668 |
| MRC5 |
IC50 |
= |
0.29 |
ug.mL-1 |
Tested for Antiherpetic activity against HSV-1 from Tomioka strain in MRC-5 cell lines. |
CHEMBL1133668 |
| MRC5 |
IC50 |
= |
0.25 |
ug.mL-1 |
Tested for Antiherpetic activity against HSV-2 from 186 strain in MRC-5 cell lines. |
CHEMBL1133668 |
| HEL |
IC50 |
= |
3.4 |
ug.mL-1 |
Tested for Antiherpetic activity against VZV from Kawaguchi strain in HEL cell lines. |
CHEMBL1133668 |
| MRC5 |
IC50 |
= |
1.3 |
ug.mL-1 |
Tested for Antiherpetic activity against VZV from clinical isolates of MRC-5 cell lines.(average of six isolates) |
CHEMBL1133668 |
| HEL |
IC50 |
= |
5.4 |
ug.mL-1 |
Tested for Antiherpetic activity against VZV from clinical isolates of HEL cell lines.(average of 11 isolates) |
CHEMBL1133668 |
| BHK-21 |
EC50 |
= |
2000.0 |
nM |
Effective concentration was evaluated against HSV-1 by using serum starved baby hamster kidney cells in a colorimetric viral yield assay. |
CHEMBL1129444 |
| BHK-21 |
EC50 |
= |
2000.0 |
nM |
Effective concentration was evaluated against HSV-2 by using serum starved baby hamster kidney cells in a colorimetric viral yield assay. |
CHEMBL1129444 |
| HEp-2 |
MTC |
= |
330.0 |
ug ml-1 |
Minimum toxic effect against HEp-2 cells. |
CHEMBL1122848 |
| Human herpesvirus 1 |
MIC |
= |
0.3 |
ug.mL-1 |
Minimum inhibitory concentration against HSV-1. |
CHEMBL1122848 |
| Human herpesvirus 2 |
MIC |
= |
3.0 |
ug.mL-1 |
Minimum inhibitory concentration against HSV-2. |
CHEMBL1122848 |
| Mus musculus |
Survivors |
= |
91.0 |
% |
In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 100 mg/kg per day |
CHEMBL1122848 |
| Mus musculus |
Survivors |
= |
100.0 |
% |
In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 50 mg/kg per day |
CHEMBL1122848 |
| Mus musculus |
Survivors |
= |
100.0 |
% |
In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through at a dose 25 mg/kg per day |
CHEMBL1122848 |
| Mus musculus |
Survivors |
= |
83.0 |
% |
In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 10 mg/kg per day |
CHEMBL1122848 |
| Mus musculus |
Survivors |
= |
75.0 |
% |
In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 5 mg/kg per day |
CHEMBL1122848 |
| Mus musculus |
Survivors |
|
|
|
In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 2.5 mg/kg per day; NT=Not tested |
CHEMBL1122848 |
| Mus musculus |
Survivors |
= |
54.0 |
% |
In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 1 mg/kg per day |
CHEMBL1122848 |
| Mus musculus |
Survivors |
|
|
|
In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 100 mg/kg per day; NT=Not tested |
CHEMBL1122848 |
| Mus musculus |
Survivors |
= |
92.0 |
% |
In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 50 mg/kg per day |
CHEMBL1122848 |
| Mus musculus |
Survivors |
= |
55.0 |
% |
In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 25 mg/kg per day |
CHEMBL1122848 |
| Mus musculus |
Survivors |
|
|
|
In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 10 mg/kg per day; NT=Not tested |
CHEMBL1122848 |
| Mus musculus |
Survivors |
= |
9.0 |
% |
In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 5 mg/kg per day |
CHEMBL1122848 |
| Mus musculus |
Survivors |
= |
0.0 |
% |
In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 2.5 mg/kg per day |
CHEMBL1122848 |
| Vero |
IC50 |
= |
0.81 |
ug.mL-1 |
Inhibition of Tomioka strain of herpes simplex virus( Tomioka strain of HSV-1) by quantitative CPE reduction assay in vero cells |
CHEMBL1131329 |
| Vero |
CC50 |
= |
820.0 |
ug.mL-1 |
Cytotoxic concentration to uninfected vero cells |
CHEMBL1131329 |
| HFF |
IC50 |
= |
2.7 |
ug.mL-1 |
Inhibitory activity against DM625 strain of zoster virus(VZV) by plaque reduction assay in HFF cells |
CHEMBL1131329 |
| HFF |
MTC |
> |
320.0 |
|
Minimum cytotoxic concentration against uninfected HFF cells |
CHEMBL1131329 |
| HFF |
SI |
> |
83.0 |
|
Selectivity index is the ratio between IC50 (Anti-VZV Activity (DM625 in HFF Cells)) and minimum cytotoxic concentration (against HFF cells) values of the compound |
CHEMBL1131329 |
| Human herpesvirus 2 |
MIC |
= |
1.3 |
ug.mL-1 |
In vitro minimum inhibitory concentration against herpes simplex virus-2 (HSV-2) by plaque-reduction assay in vero cells |
CHEMBL1127020 |
| Human herpesvirus 2 |
MTL |
> |
200.0 |
ug ml-1 |
In vitro maximum tolerated level against herpes simplex virus-2 (HSV-2) by plaque-reduction assay in vero cells |
CHEMBL1127020 |
| Human herpesvirus 2 |
MED |
= |
12.0 |
mg kg-1 |
Minimum effective dose against herpes simplex virus-2 (HSV-2) by oral administration in female mice. |
CHEMBL1127020 |
| Human herpesvirus 2 |
MTD |
> |
200.0 |
mg kg-1 |
In vivo maximum tolerated dose against herpes simplex virus-2 (HSV-2) by oral administration in female mice |
CHEMBL1127020 |
| Vero |
MIC |
= |
1.3 |
ug.mL-1 |
Tested in vitro for minimum inhibitory concentration against herpes simplex virus-2 (HSV-2) curtis strain by plaque-reduction assay in vero cells |
CHEMBL1127020 |
| Vero |
MIC |
= |
0.29 |
ug.mL-1 |
Tested in vitro for minimum inhibitory concentration against herpes simplex virus-1 (HSV-1) F strain by plaque-reduction assay in vero cells |
CHEMBL1127020 |
| Vero |
MIC |
= |
0.14 |
ug.mL-1 |
Tested in vitro for minimum inhibitory concentration against herpes simplex virus-1 (HSV-1) KOS strain by plaque-reduction assay in vero cells |
CHEMBL1127020 |
| Vero |
MIC |
= |
43.0 |
ug.mL-1 |
Tested in vitro for minimum inhibitory concentration against herpes simplex virus-1 (HSV-1) KOS, ACG strain by plaque-reduction assay in vero cells |
CHEMBL1127020 |
| Vero |
MIC |
= |
7.8 |
ug.mL-1 |
Tested in vitro for minimum inhibitory concentration against herpes simplex virus-1 (HSV-1) 1142 strain by plaque-reduction assay in vero cells |
CHEMBL1127020 |
| Vero |
MIC |
= |
11.0 |
ug.mL-1 |
Tested in vitro for minimum inhibitory concentration against herpes simplex virus-1 (HSV-1) 2992 strain by plaque-reduction assay in vero cells |
CHEMBL1127020 |
| Vero |
MIC |
= |
43.0 |
ug.mL-1 |
Tested in vitro for minimum inhibitory concentration against herpes simplex virus-2 (HSV-2) 2011 strain by plaque-reduction assay in vero cells |
CHEMBL1127020 |
| Vero |
MIC |
= |
77.0 |
ug.mL-1 |
Tested in vitro for minimum inhibitory concentration against herpes simplex virus-2 (HSV-2) 2115 strain by plaque-reduction assay in vero cells |
CHEMBL1127020 |
| Human herpesvirus 5 |
IC50 |
> |
100000.0 |
nM |
Antiviral activity against human cytomegalovirus by plaque reduction assay |
CHEMBL1129622 |
| Human herpesvirus 1 |
IC50 |
= |
3400.0 |
nM |
Antiviral activity against herpes simplex virus using ELISA |
CHEMBL1129622 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity produced in human foreskin fibroblasts (HFF) cells estimated by visual scoring of cells unaffected by virus infection. |
CHEMBL1129622 |
| KB |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity (growth inhibition) against human epidermoid oral carcinoma KB cell line. |
CHEMBL1129622 |
| Human herpesvirus 1 |
IC50 |
= |
400.0 |
nM |
In vitro antiviral activity was evaluated against HSV-1 using viral plaque reduction assay |
CHEMBL1126501 |
| Human herpesvirus 2 |
IC50 |
= |
400.0 |
nM |
In vitro antiviral activity was evaluated against HSV-2 using viral plaque reduction assay |
CHEMBL1126501 |
| Human herpesvirus 3 |
IC50 |
= |
2000.0 |
nM |
In vitro antiviral activity was evaluated against VZV using viral plaque reduction assay; Value ranges from 2-4 |
CHEMBL1126501 |
| Human herpesvirus 5 |
IC50 |
= |
20000.0 |
nM |
In vitro antiviral activity was evaluated against HCMV using viral plaque reduction assay; Value ranges from 20-40 |
CHEMBL1126501 |
| Human herpesvirus 1 |
ID50 |
= |
0.8 |
ug ml-1 |
Antiviral activity against various strains of Herpes Simplex virus type I |
CHEMBL1121969 |
| Vero |
IC50 |
= |
6700.0 |
nM |
Antiviral activity in plaque reduction assay was determined against herpes simplex virus type 1 (HSV-1) in Vero cells. |
CHEMBL1124932 |
| MRC5 |
IC50 |
= |
2500.0 |
nM |
Antiviral activity in plaque reduction assay was determined against herpes simplex virus type 2 (HSV-2) in MRC-5 cells. |
CHEMBL1124932 |
| MRC5 |
IC50 |
= |
20000.0 |
nM |
Antiviral activity in plaque reduction assay was determined against varicella zoster virus (VZV) in MRC-5 cells. |
CHEMBL1124932 |
| Homo sapiens |
IC50 |
> |
440000.0 |
nM |
Concentration of the drug required to reduce the uptake of neural red stain by uninfected cell monolayers (HFF) |
CHEMBL1126774 |
| Homo sapiens |
EC50 |
= |
40.0 |
nM |
Inhibitory concentration of the drug against the cytopathic effect for E-377 strain of herpes simplex virus-1 (HSV-1) in human HFF cells |
CHEMBL1126774 |
| Homo sapiens |
EC50 |
= |
90.0 |
nM |
Inhibitory concentration of the drug against the cytopathic effect for MS strain of herpes simplex virus-2 (HSV-2) in human HFF cells |
CHEMBL1126774 |
| Homo sapiens |
EC50 |
= |
7100.0 |
nM |
Inhibitory concentration of the drug against the cytopathic effect for ellen strain of varicella zoster virus-2 (VZV-2) in human HFF cells |
CHEMBL1126774 |
| Raji |
EC50 |
= |
2900.0 |
nM |
Inhibitory concentration of the drug against the antigen production against P3HR-1 strain of epstein barr virus-2 (EBV) in Raji cells |
CHEMBL1126774 |
| Homo sapiens |
EC50 |
|
|
nM |
Inhibitory concentration of the drug against the cytopathic effect for AD169 strain of epstein barr virus-2 (HCMV) in human HFF cells; ND is Not Determined |
CHEMBL1126774 |
| Homo sapiens |
IC50 |
> |
440000.0 |
nM |
Concentration of the drug required to reduce the proliferation of human foreskin fibroblast cells |
CHEMBL1126774 |
| ADMET |
Virus yield |
= |
2.0 |
log pfu ml-1 |
Inhibitory effect on KOS strain of Herper simplex virus-1 yield, in primary rabbit kidney cell culture at 4 ug/mL concentration after 24 hours |
CHEMBL1123770 |
| ADMET |
Virus yield |
= |
3.6 |
log pfu ml-1 |
Inhibitory effect on KOS strain of Herper simplex virus-1 yield, in primary rabbit kidney cell culture at 1 ug/mL concentration after 24 hours |
CHEMBL1123770 |
| ADMET |
Virus yield |
= |
4.1 |
log pfu ml-1 |
Inhibitory effect on KOS strain of Herper simplex virus-1 yield, in primary rabbit kidney cell culture at 0.4 ug/mL concentration after 24 hours |
CHEMBL1123770 |
| ADMET |
Virus yield |
= |
5.2 |
log pfu ml-1 |
Inhibitory effect on KOS strain of Herper simplex virus-1 yield, in primary rabbit kidney cell culture at 0.1 ug/mL concentration after 24 hours |
CHEMBL1123770 |
| ADMET |
Virus yield |
= |
5.6 |
log pfu ml-1 |
Inhibitory effect on KOS strain of Herper simplex virus-1 yield, in primary rabbit kidney cell culture at 0.04 ug/mL concentration after 24 hours |
CHEMBL1123770 |
| ADMET |
Virus yield |
< |
2.0 |
log pfu ml-1 |
Inhibitory effect on 196 strain of Herper simplex virus-2 yield, in primary rabbit kidney cell culture 4 ug/mL concentration after 24 hours. |
CHEMBL1123770 |
| ADMET |
Virus yield |
= |
3.1 |
log pfu ml-1 |
Inhibitory effect on 196 strain of Herper simplex virus-2 yield, in primary rabbit kidney cell culture 1 ug/mL concentration after 24 hours. |
CHEMBL1123770 |
| ADMET |
Virus yield |
= |
4.1 |
log pfu ml-1 |
Inhibitory effect on 196 strain of Herper simplex virus-2 yield, in primary rabbit kidney cell culture 0.4 ug/mL concentration after 24 hours. |
CHEMBL1123770 |
| ADMET |
Virus yield |
= |
4.8 |
log pfu ml-1 |
Inhibitory effect on 196 strain of Herper simplex virus-2 yield, in primary rabbit kidney cell culture 0.1 ug/mL concentration after 24 hours. |
CHEMBL1123770 |
| ADMET |
Virus yield |
= |
5.8 |
log pfu ml-1 |
Inhibitory effect on 196 strain of Herper simplex virus-2 yield, in primary rabbit kidney cell culture 0.04 ug/mL concentration after 24 hours. |
CHEMBL1123770 |
| ADMET |
Virus yield |
= |
3.3 |
log pfu ml-1 |
Inhibitory effect on KOS strain of Herper simplex virus-1 yield, in primary rabbit kidney cell culture 4 ug/mL concentration after 48 hours. |
CHEMBL1123770 |
| ADMET |
Virus yield |
= |
5.3 |
log pfu ml-1 |
Inhibitory effect on KOS strain of Herper simplex virus-1 yield, in primary rabbit kidney cell culture 1 ug/mL concentration after 48 hours. |
CHEMBL1123770 |
| ADMET |
Virus yield |
= |
5.0 |
log pfu ml-1 |
Inhibitory effect on KOS strain of Herper simplex virus-1 yield, in primary rabbit kidney cell culture 0.4 ug/mL concentration after 48 hours. |
CHEMBL1123770 |
| ADMET |
Virus yield |
= |
5.6 |
log pfu ml-1 |
Inhibitory effect on KOS strain of Herper simplex virus-1 yield, in primary rabbit kidney cell culture 0.1 ug/mL concentration after 48 hours. |
CHEMBL1123770 |
| ADMET |
Virus yield |
= |
5.9 |
log pfu ml-1 |
Inhibitory effect on KOS strain of Herper simplex virus-1 yield, in primary rabbit kidney cell culture 0.04 ug/mL concentration after 48 hours. |
CHEMBL1123770 |
| ADMET |
Virus yield |
= |
3.8 |
log pfu ml-1 |
Inhibitory effect on 196 strain of Herper simplex virus-2 yield, in primary rabbit kidney cell culture 4 ug/mL concentration after 48 hours. |
CHEMBL1123770 |
| ADMET |
Virus yield |
= |
5.3 |
log pfu ml-1 |
Inhibitory effect on 196 strain of Herper simplex virus-2 yield, in primary rabbit kidney cell culture 1 ug/mL concentration after 48 hours. |
CHEMBL1123770 |
| ADMET |
Virus yield |
= |
5.0 |
log pfu ml-1 |
Inhibitory effect on 196 strain of Herper simplex virus-2 yield, in primary rabbit kidney cell culture 0.4 ug/mL concentration after 48 hours. |
CHEMBL1123770 |
| ADMET |
Virus yield |
= |
5.6 |
log pfu ml-1 |
Inhibitory effect on 196 strain of Herper simplex virus-2 yield, in primary rabbit kidney cell culture 0.1 ug/mL concentration after 48 hours. |
CHEMBL1123770 |
| ADMET |
Virus yield |
= |
5.7 |
log pfu ml-1 |
Inhibitory effect on 196 strain of Herper simplex virus-2 yield, in primary rabbit kidney cell culture 0.04 ug/mL concentration after 48 hours. |
CHEMBL1123770 |
| Mus musculus |
No. of mice |
= |
10.0 |
|
Number of mice normal, without lesion after HSV-1 infection observed from day 0 to day 3 |
CHEMBL1123770 |
| Mus musculus |
No. of mice |
= |
10.0 |
|
Number of mice normal, without lesion after HSV-1 infection observed from day 12 to day 20 |
CHEMBL1123770 |
| Mus musculus |
Survival rate |
= |
10.0 |
|
Survival rate at 20th day expressed as number of mice survived infected with HSV-1; out of 10 |
CHEMBL1123770 |
| Mus musculus |
No. of mice |
= |
10.0 |
|
Number of mice normal, without lesion after HSV-2 infection observed from day 0 to day 3 |
CHEMBL1123770 |
| Mus musculus |
No. of mice |
= |
5.0 |
|
Number of mice normal, without lesion after HSV-2 infection observed from day 12 to day 20 |
CHEMBL1123770 |
| Mus musculus |
Survival rate |
= |
5.0 |
|
Survival rate at 20th day expressed as number of mice survived infected with HSV-2; out of 10 |
CHEMBL1123770 |
| Mus musculus |
No. of mice |
= |
5.0 |
|
Number of dead, after HSV-2 infection observed from day 12 to day 20 |
CHEMBL1123770 |
| Human herpesvirus 1 |
MIC |
= |
0.13 |
ug.mL-1 |
Minimal inhibitory concentration to reduce virus-induced cytopathicity against KOS strain of human Herpes Simplex Virus -1 |
CHEMBL1134637 |
| Human herpesvirus 1 |
MIC |
= |
0.08 |
ug.mL-1 |
Minimal inhibitory concentration to reduce virus-induced cytopathicity against F strain of human Herpes Simplex Virus-1 (HSV-1) |
CHEMBL1134637 |
| Human herpesvirus 1 |
MIC |
= |
0.13 |
ug.mL-1 |
Minimal inhibitory concentration to reduce virus-induced cytopathicity against McIntyre strain of human Herpes Simplex Virus-1 |
CHEMBL1134637 |
| Human herpesvirus 2 |
MIC |
= |
0.19 |
ug.mL-1 |
Minimal inhibitory concentration to reduce virus-induced cytopathicity against G strain of human Herpes Simplex Virus-2 |
CHEMBL1134637 |
| Human herpesvirus 2 |
MIC |
= |
0.07 |
ug.mL-1 |
Minimal inhibitory concentration to reduce virus-induced cytopathicity against 196 strain of human Herpes Simplex Virus-2 |
CHEMBL1134637 |
| Human herpesvirus 2 |
MIC |
= |
0.28 |
ug.mL-1 |
Minimal inhibitory concentration to reduce virus-induced cytopathicity against Lyons strain of human Herpes Simplex Virus-2 |
CHEMBL1134637 |
| Vaccinia virus |
MIC |
> |
80.0 |
ug.mL-1 |
Minimal inhibitory concentration to reduce virus-induced cytopathicity against VV |
CHEMBL1134637 |
| Vesicular stomatitis virus |
MIC |
> |
80.0 |
ug.mL-1 |
Minimal inhibitory concentration to reduce virus-induced cytopathicity against VSV |
CHEMBL1134637 |
| Human herpesvirus 1 |
MIC |
= |
19.0 |
ug.mL-1 |
Minimal inhibitory concentration to reduce virus-induced cytopathicity against Thymidine kinase deficient(TK-) HSV-1 (Acyclovir) |
CHEMBL1134637 |
| Human herpesvirus 1 |
MIC |
= |
7.1 |
ug.mL-1 |
Minimal inhibitory concentration to reduce virus-induced cytopathicity against TK-/TK+ HSV-1 (VMW 837) |
CHEMBL1134637 |
| NON-PROTEIN TARGET |
MCC |
> |
400.0 |
ug.mL-1 |
Minimal cytotoxic concentration (MCC) to cause a microscopically detectable change in normal cell morphology |
CHEMBL1134637 |
| NON-PROTEIN TARGET |
MIC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology |
CHEMBL1129698 |
| Human herpesvirus 1 |
MIC |
= |
0.02 |
ug.mL-1 |
Compound was tested for the antiviral activity against herpes simplex virus-1 (HSV-1) KOS strain |
CHEMBL1129698 |
| Human herpesvirus 2 |
MIC |
= |
0.03 |
ug.mL-1 |
Compound was tested for the antiviral activity against herpes simplex virus-2 (HSV-2) G strain |
CHEMBL1129698 |
| Human herpesvirus 1 |
MIC |
= |
80.0 |
ug.mL-1 |
Compound was tested for the antiviral activity against herpes simplex virus-1 thymidine kinase deficient (HSV-1 TK-) B2006 strain |
CHEMBL1129698 |
| Human herpesvirus 1 |
MIC |
= |
4.0 |
ug.mL-1 |
Compound was tested for the antiviral activity against herpes simplex virus-1 thymidine kinase deficient (HSV-1 TK-) VMW 1837 strain |
CHEMBL1129698 |
| Human herpesvirus 5 |
IC50 |
= |
86000.0 |
nM |
Activity against human cytomegalovirus (HCMV) using plaque reduction assay |
CHEMBL1127453 |
| Human herpesvirus 5 |
IC90 |
= |
85000.0 |
nM |
Tested for the activity against human cytomegalovirus (HCMV) using yield reduction assay |
CHEMBL1127453 |
| Human herpesvirus 1 |
IC50 |
= |
1700.0 |
nM |
Tested for anti-viral activity against Herpes simplex virus type-1 using ELISA. |
CHEMBL1127453 |
| Human herpesvirus 5 |
IC50 |
> |
100000.0 |
nM |
Tested for the visual cytotoxicity on HFF cells at the time of human cytomegalovirus (HCMV) plaque enumeration |
CHEMBL1127453 |
| KB |
IC50 |
> |
100000.0 |
nM |
The inhibition of KB cell growth was determined |
CHEMBL1127453 |
| MRC5 |
MIC50 |
= |
1300.0 |
nM |
Minimum inhibitory concentration required to reduce cytopathogenicity of Herpes Virus-1 (HSV-1) in MRC -5 cells by 50%. |
CHEMBL1125203 |
| Vero |
MIC50 |
= |
1800.0 |
nM |
Minimum inhibitory concentration required to reduce cytopathogenicity of Herpes Virus-2 (HSV-2) in vero cells by 50%. |
CHEMBL1125203 |
| MRC5 |
MIC50 |
= |
14500.0 |
nM |
Minimum inhibitory concentration required to reduce cytopathogenicity of Varicella Zoster Virus (VZV) in MRC-5 cells by 50%. |
CHEMBL1125203 |
| MRC5 |
MIC50 |
= |
100000.0 |
nM |
Minimum inhibitory concentration required to reduce cytopathogenicity of Cytomegalovirus Virus (CMV) in MRC-5 cells by 50%. |
CHEMBL1125203 |
| Vero |
ID50 |
> |
500.0 |
|
Inhibitory dose required to reduce the viability of vero cells by 50% |
CHEMBL1125203 |
| Human herpesvirus 5 |
IC50 |
= |
63000.0 |
nM |
Concentration required to decrease the growth rate to 50% of control was evaluated against HCMV by using plaque reduction assay. |
CHEMBL1126319 |
| Human herpesvirus 5 |
IC90 |
= |
90000.0 |
nM |
Concentration required to decrease the growth rate to 50% of control was evaluated against HCMV by using yield reduction assay. |
CHEMBL1126319 |
| Human herpesvirus 1 |
IC50 |
= |
3400.0 |
nM |
Concentration required to decrease the growth rate to 50% of control was evaluated against HSV-1 by using plaque reduction assay. |
CHEMBL1126319 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity of compound was determined visually in human diploid fibroblasts (HFF). |
CHEMBL1126319 |
| KB |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity of compound was determined by assaying cell growth in human neoplastic cell line(KB). |
CHEMBL1126319 |
| E6SM |
MCC |
> |
200.0 |
ug.mL-1 |
Compound was evaluated for the minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology. |
CHEMBL1131160 |
| E6SM |
MIC |
= |
0.075 |
ug.mL-1 |
Compound was evaluated for the minimum inhibition concentration required to reduce virus-induced cytopathogenicity by 50%, determined against KOS,F,McIntyre strains of HSV-1 virus. |
CHEMBL1131160 |
| E6SM |
MIC |
= |
0.38 |
ug.mL-1 |
Compound was evaluated for the minimum inhibition concentration required to reduce virus-induced cytopathogenicity by 50%, determined against HSV-2 virus as means of G, 196, and Lyons strains |
CHEMBL1131160 |
| E6SM |
MIC |
= |
1.92 |
ug.mL-1 |
Compound was evaluated for the minimum inhibition concentration required to reduce virus-induced cytopathogenicity by 50%, determined against HSV-1 (TK-B2006) virus |
CHEMBL1131160 |
| E6SM |
MIC |
= |
0.1 |
ug.mL-1 |
Compound was evaluated for the minimum inhibition concentration required to reduce virus-induced cytopathogenicity by 50%, determined against Varicella-Zoster virus (YS) |
CHEMBL1131160 |
| Vero |
EC50 |
= |
6000.0 |
nM |
Compound was evaluated for inhibition of HSV-1 induced plaques in vero cells (African green monkey kidney cells) |
CHEMBL1133288 |
| Human herpesvirus 3 |
EC50 |
= |
2600.0 |
nM |
In vitro antiviral activity against Varicella zoster virus |
CHEMBL1134840 |
| HEL |
IC50 |
= |
780.0 |
nM |
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+YS strain |
CHEMBL1132303 |
| HEL |
IC50 |
= |
160.0 |
nM |
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+OKA strain |
CHEMBL1132303 |
| HEL |
IC50 |
= |
17000.0 |
nM |
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) 07/1 strain |
CHEMBL1132303 |
| HEL |
IC50 |
= |
12000.0 |
nM |
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) YS/R strain |
CHEMBL1132303 |
| HEL |
IC50 |
|
|
nM |
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus AD-169 strain; Not determined |
CHEMBL1132303 |
| HEL |
IC50 |
|
|
nM |
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus Davis strain; Not determined |
CHEMBL1132303 |
| HEL |
IC50 |
> |
50000.0 |
nM |
Minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology in human embryonic lung cells |
CHEMBL1132303 |
| HEL |
IC50 |
> |
100000.0 |
nM |
The compound was tested for cytotoxic concentration required to reduce human embryonic lung cell growth by 50% |
CHEMBL1132303 |
| HEL |
IC50 |
= |
0.1 |
ug.mL-1 |
Tested for inhibitory effect on DNA virus VZV (Oka) in HEL cell line |
CHEMBL1127059 |
| HEL |
IC50 |
= |
0.1 |
ug.mL-1 |
Tested for inhibitory effect on DNA virus VZV (YS) in HEL cell line |
CHEMBL1127059 |
| HEL |
IC50 |
= |
4.0 |
ug.mL-1 |
Tested for inhibitory effect on DNA virus TK-VZV (07/1) in HEL cell line |
CHEMBL1127059 |
| HEL |
IC50 |
= |
5.0 |
ug.mL-1 |
Tested for inhibitory effect on DNA virus TK-VZV (YS/R) in HEL cell line |
CHEMBL1127059 |
| HEL |
IC50 |
= |
26.0 |
ug.mL-1 |
Tested for inhibitory effect on DNA virus CMV (AD-169) in HEL cell line |
CHEMBL1127059 |
| HEL |
IC50 |
= |
22.0 |
ug.mL-1 |
Tested for inhibitory effect on DNA virus CMV (Davis) in HEL cell line |
CHEMBL1127059 |
| HEL |
IC50 |
> |
200.0 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus cell growth in HEL cell line |
CHEMBL1127059 |
| MT4 |
IC50 |
> |
100.0 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus cell growth in MT-4 cell line |
CHEMBL1127059 |
| CCRF-CEM |
EC50 |
> |
200000.0 |
nM |
Compound was tested for anti-viral activity against HIV-1 in CEM cells |
CHEMBL1136483 |
| CCRF-CEM |
EC50 |
> |
200000.0 |
nM |
Compound was tested for anti-viral activity against HIV-2 in CEM cells |
CHEMBL1136483 |
| CCRF-CEM |
CC50 |
> |
200000.0 |
nM |
Compound concentration required to reduce viability of CEM cells |
CHEMBL1136483 |
| HEL |
EC50 |
= |
320.0 |
nM |
Compound was tested for anti-viral activity against HSV-1(KOS) in HEL cells |
CHEMBL1136483 |
| HEL |
EC50 |
= |
1300.0 |
nM |
Compound was tested for anti-viral activity against HSV-1(G) in HEL cells |
CHEMBL1136483 |
| HEL |
EC50 |
= |
88000.0 |
nM |
Compound was tested for anti-viral activity against HSV-1TK neg in HEL cells |
CHEMBL1136483 |
| HEL |
CC50 |
> |
1700000.0 |
nM |
Compound concentration required to reduce viability of HEL cells |
CHEMBL1136483 |
| Human herpesvirus 1 |
EC50 |
= |
117600.0 |
nM |
Inhibition of plaque formation in monolayers of HSV-1 KOSSB(TK-) Vero cells by 50% |
CHEMBL1134633 |
| Human herpesvirus 1 |
EC50 |
= |
2200.0 |
nM |
Inhibition of plaque formation in monolayers of HSV-1 KOS Vero cells by 50% |
CHEMBL1134633 |
| Human herpesvirus 1 |
EC50 |
= |
4400.0 |
nM |
Inhibition of plaque formation in monolayers of HSV-1 E-377 Vero cells by 50% |
CHEMBL1134633 |
| Human herpesvirus 2 |
EC50 |
= |
6200.0 |
nM |
Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell monolayers of HSV-2 MS Vero cells by 50% |
CHEMBL1134633 |
| Human herpesvirus 3 |
EC50 |
= |
2600.0 |
nM |
Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of VZV Ellen Vero cells by 50% |
CHEMBL1134633 |
| Human herpesvirus 1 |
Inhibition |
= |
86.0 |
% |
Compound was tested for the inhibition of HSV-1 polymerase |
CHEMBL1123186 |
| DNA polymerase alpha subunit |
Inhibition |
= |
37.0 |
% |
Compound was tested for the inhibition of HeLa DNA polymerase |
CHEMBL1123186 |
| Human herpesvirus 1 |
EC50 |
= |
160.0 |
nM |
Antiviral activity against HSV-1 (herpes simplex virus) |
CHEMBL1132504 |
| Human herpesvirus 1 |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against HSV-1 (herpes simplex virus) |
CHEMBL1132504 |
| Human immunodeficiency virus 1 |
EC50 |
|
|
nM |
Antiviral activity against HIV-1 (human immunodeficiency virus type 1); Not determined |
CHEMBL1132504 |
| Human immunodeficiency virus 1 |
CC50 |
|
|
nM |
Cytotoxicity against HIV-1 (human immunodeficiency virus type 1); Not determined |
CHEMBL1132504 |
| Human herpesvirus 1 |
EC50 |
= |
360.0 |
nM |
Antiviral activity against Herpes simplex virus type-1 (HSV-1). |
CHEMBL1132321 |
| Human herpesvirus 1 |
IC50 |
> |
350000.0 |
nM |
Antiviral activity against Herpes simplex virus type-1 (HSV-1). |
CHEMBL1132321 |
| Human herpesvirus 2 |
EC50 |
= |
1100.0 |
nM |
Antiviral activity against Herpes simplex virus type-2 (HSV-2). |
CHEMBL1132321 |
| Human herpesvirus 2 |
IC50 |
> |
350000.0 |
nM |
Antiviral activity against Herpes simplex virus type-2 (HSV-2). |
CHEMBL1132321 |
| Human herpesvirus 1 |
IC50 |
= |
200.0 |
nM |
Antiviral activity against herpes simplex virus-1. |
CHEMBL1159161 |
| Human herpesvirus 2 |
IC50 |
= |
2100.0 |
nM |
Antiviral activity against herpes simplex virus-2. |
CHEMBL1159161 |
| HEL |
IC50 |
= |
0.23 |
ug.mL-1 |
Antiviral activity against thymidine kinase-positive (TK+) OKA strain of Varicella zoster virus to reduce plaque formation in human embryonic lung (HEL) cells |
CHEMBL1153258 |
| HEL |
IC50 |
= |
0.32 |
ug.mL-1 |
Antiviral activity against thymidine kinase-positive (TK+) YS strain of Varicella zoster virus to reduce plaque formation in human embryonic lung (HEL) cells |
CHEMBL1153258 |
| HEL |
IC50 |
= |
22.0 |
ug.mL-1 |
Antiviral activity against thymidine kinase-negative (TK-) O7/1 strain of Varicella zoster virus to reduce plaque formation in human embryonic lung (HEL) cells |
CHEMBL1153258 |
| HEL |
IC50 |
= |
9.0 |
ug.mL-1 |
Antiviral activity against thymidine kinase-negative (TK-) YS/R strain of Varicella zoster virus to reduce plaque formation in human embryonic lung (HEL) cells |
CHEMBL1153258 |
| HEL |
MCC |
> |
40.0 |
ug.mL-1 |
Cytotoxicity (to alter cell morphology) against Varicella-Zoster virus in human embryonic lung (HEL) cells |
CHEMBL1153258 |
| HEL |
CC50 |
> |
50.0 |
ug.mL-1 |
Cytotoxicity (to reduce cell growth) against Varicella-Zoster virus in human embryonic lung (HEL) cells |
CHEMBL1153258 |
| Human herpesvirus 5 |
IC50 |
|
|
ug.mL-1 |
Antiviral activity against human cytomegalovirus AD-169 which reduces virus plaque formation by 50%; ND denotes no data |
CHEMBL1135344 |
| Human herpesvirus 5 |
IC50 |
|
|
ug.mL-1 |
Antiviral activity against human cytomegalovirus Davis which reduces virus plaque formation by 50%; ND denotes no data |
CHEMBL1135344 |
| Human herpesvirus 3 |
IC50 |
= |
0.38 |
ug.mL-1 |
Antiviral activity was tested against TK+ Varicella-Zoster virus YS which reduces virus plaque formation by 50% |
CHEMBL1135344 |
| Human herpesvirus 3 |
IC50 |
= |
0.35 |
ug.mL-1 |
Antiviral activity was tested against TK+ Varicella-Zoster virus OKA which reduces virus plaque formation by 50% |
CHEMBL1135344 |
| Human herpesvirus 3 |
IC50 |
= |
6.5 |
ug.mL-1 |
Antiviral activity was tested against TK- Varicella-Zoster virus 07/1 which reduces virus plaque formation by 50% |
CHEMBL1135344 |
| Human herpesvirus 3 |
IC50 |
= |
3.1 |
ug.mL-1 |
Antiviral activity was tested against TK- Varicella-Zoster virus YS/R which reduces virus plaque formation by 50% |
CHEMBL1135344 |
| HEL |
IC50 |
|
|
ug.mL-1 |
Minimum cytotoxic concentration against HEL cell morphology; ND denotes no data |
CHEMBL1135344 |
| HEL |
MCC |
> |
50.0 |
ug.mL-1 |
Minimum cytotoxic concentration against HEL cell morphology. |
CHEMBL1135344 |
| HEL |
CC50 |
|
|
ug.mL-1 |
Cytotoxic concentration to reduce HEL cell growth by 50%; ND denotes no data |
CHEMBL1135344 |
| HEL |
CC50 |
> |
200.0 |
ug.mL-1 |
Cytotoxic concentration reducing HEL cell growth by 50%. |
CHEMBL1135344 |
| Human herpesvirus 1 |
IC50 |
= |
3900.0 |
nM |
Compound was evaluated for anti-herpesvirus activity against Herpes simplex virus-1 (SC16) strain. |
CHEMBL1126681 |
| Human herpesvirus 2 |
IC50 |
= |
4300.0 |
nM |
Compound was evaluated for anti-herpesvirus activity against Herpes simplex virus-2 (MS) strain. |
CHEMBL1126681 |
| Human herpesvirus 3 |
IC50 |
= |
21000.0 |
nM |
Compound was evaluated for anti-herpesvirus activity against Varicella Zoster virus (Ellen) strain. |
CHEMBL1126681 |
| Cytomegalovirus |
IC50 |
= |
93000.0 |
nM |
Compound was evaluated for anti-herpesvirus activity against Cytomegalovirus (AD169) strain plaques in infected human fibroblast (MRC-5) cells. |
CHEMBL1126681 |
| MRC5 |
CD50 |
= |
355.0 |
uM |
Compound was evaluated for the inhibition of cell replication of human fibroblast (MRC-5) cells. |
CHEMBL1126681 |
| ADMET |
MIC |
= |
0.01 |
ug.mL-1 |
Minimum inhibitory concentration was determined against HSV-1 (KOS) in E6SM cell culture |
CHEMBL1133586 |
| Human herpesvirus 1 |
MIC |
= |
0.003 |
ug.mL-1 |
Minimum inhibitory concentration was determined against HSV-1 (F) in E6SM cell culture |
CHEMBL1133586 |
| ADMET |
MIC |
= |
0.005 |
ug.mL-1 |
Minimum inhibitory concentration was determined against HSV-1 (McIntyre) in E6SM cell culture |
CHEMBL1133586 |
| Human herpesvirus 1 |
MIC |
= |
0.02 |
ug.mL-1 |
Minimum inhibitory concentration was determined against HSV-2 (G) in E6SM cell culture |
CHEMBL1133586 |
| ADMET |
MIC |
= |
0.02 |
ug.mL-1 |
Minimum inhibitory concentration was determined against HSV-2 (196) in E6SM cell culture |
CHEMBL1133586 |
| NON-PROTEIN TARGET |
MIC |
= |
0.02 |
ug.mL-1 |
Minimum inhibitory concentration was determined against HSV-2 (Lyons) in E6SM cell culture |
CHEMBL1133586 |
| NON-PROTEIN TARGET |
MIC |
= |
9.6 |
ug.mL-1 |
Minimum inhibitory concentration was determined against HSV-1 (TK-KOS ACV) in E6SM cell culture |
CHEMBL1133586 |
| NON-PROTEIN TARGET |
MIC |
= |
0.07 |
ug.mL-1 |
Minimum inhibitory concentration was determined against HSV-1 (TK-/TK+VMW1837) in E6SM cell culture |
CHEMBL1133586 |
| NON-PROTEIN TARGET |
MIC |
= |
1.1 |
ug.mL-1 |
Minimum inhibitory concentration was determined against VZV (YS) in HEL cells |
CHEMBL1133586 |
| Human herpesvirus 3 |
MIC |
= |
0.8 |
ug.mL-1 |
Minimum inhibitory concentration was determined against VZV (OKA) in HEL cells |
CHEMBL1133586 |
| Human herpesvirus 3 |
MIC |
= |
13.0 |
ug.mL-1 |
Minimum inhibitory concentration was determined against VZV (TK-07/1) in HEL cells |
CHEMBL1133586 |
| Human herpesvirus 3 |
MIC |
= |
28.0 |
ug.mL-1 |
Minimum inhibitory concentration was determined against VZV (TK-YS/R) in HEL cells |
CHEMBL1133586 |
| Vero |
Cytotoxicity |
> |
400.0 |
|
Cytotoxicity concentration required to microscopically detectable alteration of cell morphology in Vero |
CHEMBL1133586 |
| E6SM |
Cytotoxicity |
> |
50.0 |
|
Cytotoxicity concentration required to microscopically detectable alteration of cell morphology in E6SM |
CHEMBL1133586 |
| HEL |
Cytotoxicity |
> |
200.0 |
|
Cytotoxicity concentration required to microscopically detectable alteration of cell morphology HEL |
CHEMBL1133586 |
| Vero |
ID50 |
= |
0.5 |
uM |
Antiviral activity was determined in plaque reduction assay in vero cells against HSV-1 F strain |
CHEMBL1122960 |
| HEL |
EC50 |
|
|
|
concentration required to reduce virus HCMV (AD-169)plaque formation by 50%; ND=No Data |
CHEMBL1133628 |
| HEL |
EC50 |
|
|
|
concentration required to reduce virus HHuman Cytomegalovirus (Davis)plaque formation by 50%; ND=No Data |
CHEMBL1133628 |
| Human herpesvirus 3 |
IC50 |
= |
4530.0 |
nM |
In vitro inhibition of Thymidine Kinase-Varicella-Zoster Virus(OKA) plaque formation. |
CHEMBL1133628 |
| Human herpesvirus 3 |
IC50 |
= |
4090.0 |
nM |
In vitro inhibition of Thymidine Kinase-Varicella Zoster Virus(YS) plaque formation. |
CHEMBL1133628 |
| Human herpesvirus 3 |
IC50 |
= |
41000.0 |
nM |
In vitro inhibition of Thymidine Kinase deficient Varicella Zoster Virus (07/1) plaque formation. |
CHEMBL1133628 |
| Human herpesvirus 3 |
IC50 |
= |
63000.0 |
nM |
In vitro inhibition of Thymidine Kinase deficient Varicella Zoster Virus (YS/R) plaque formation. |
CHEMBL1133628 |
| HEL |
CC50 |
> |
400000.0 |
nM |
Inhibition of cell growth in HEL cells. |
CHEMBL1133628 |
| HEL |
MCC |
> |
150000.0 |
nM |
In vitro alteration in cell morphology in HEL cells. |
CHEMBL1133628 |
| Human herpesvirus 1 |
Plaque inhibition result |
|
|
|
The compound was tested for plaque inhibition in HSV-1 in cell culture; +=active at 50 ug per disk |
CHEMBL1121912 |
| Human herpesvirus 1 |
IC50 |
= |
100.0 |
nM |
The compound was tested for plaque inhibition in HSV-1 in cell culture, activity is determined by plaque reduction assay |
CHEMBL1121912 |
| ADMET |
Papp |
= |
0.38 |
cm/s * 10E6 |
Permeability Coefficient in Caco-2 cell culture model |
CHEMBL1145178 |
| ADMET |
Papp |
= |
8.2 |
cm/s * 10E6 |
Permeability Coefficient in 2/4/A1 cell model |
CHEMBL1145178 |
| Unchecked |
Papp |
= |
0.034 |
cm/s * 10E6 |
Permeability Coefficient in hexadecane membranes model |
CHEMBL1145178 |
| ADMET |
Papp |
= |
93.0 |
cm/s * 10E6 |
Percentage of mass balance in hexadecane membranes model |
CHEMBL1145178 |
| ADMET |
FA |
= |
19.0 |
% |
Fraction absorbed in human intestine after oral administration compound was measured |
CHEMBL1145178 |
| Hepatitis B virus |
EC50 |
= |
20.0 |
nM |
Effective concentration to inhibit 50% of hepatitis B virus replication in a cell culture model |
CHEMBL1141180 |
| Hepatitis C virus |
EC50 |
|
|
nM |
Effective concentration to inhibit 50 % of hepatitis C virus replication in a cell culture model;ND=Not determined |
CHEMBL1141180 |
| Human herpesvirus 1 |
EC50 |
= |
8000.0 |
nM |
Effective concentration to inhibit 50 % of Herpes simplex virus type 1 replication in a cell culture model |
CHEMBL1141180 |
| Oryctolagus cuniculus |
EC50 |
= |
51000.0 |
nM |
Effective concentration to inhibit 50 % of herpes simplex virus type 2 replication in a cell culture model;ND=Not determined |
CHEMBL1141180 |
| Human herpesvirus 4 |
EC50 |
|
|
nM |
Effective concentration to inhibit 50 % of epstein Barr virus replication in a cell culture model;ND=Not determined |
CHEMBL1141180 |
| Unchecked |
EC50 |
|
|
nM |
Effective concentration to inhibit 50% of cytomegalovirus (CMV) replication in a cell culture model;ND=Not determined |
CHEMBL1141180 |
| Human immunodeficiency virus |
EC50 |
|
|
nM |
Effective concentration to inhibit 50 % of Human immunodeficiency virus replication in a cell culture model;ND=Not determined |
CHEMBL1141180 |
| MT2 |
ID50 |
|
|
|
Cytotoxicity against MT-2 cell lines of human |
CHEMBL1141180 |
| CCRF-CEM |
ID50 |
|
|
|
Cytotoxicity against CEM cell lines of human |
CHEMBL1141180 |
| Cytomegalovirus |
EC50 |
|
|
ug.mL-1 |
Effective concentration of compound required to reduce plaque formation by AD-169 strain of CMV virus in Human embryonic lung cells; ND=Not determined |
CHEMBL1141177 |
| Human herpesvirus 3 |
EC50 |
= |
9.4 |
ug.mL-1 |
Effective concentration to reduce plaque formation of thymidine kinase deficient Varicella zoster virus TK- VZV 07/1 strain in human embryonic lung cell cultures |
CHEMBL1141177 |
| HEL |
MCC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration of compound that causes alteration of cell morphology in human embryonic lung cells |
CHEMBL1141177 |
| HEL |
CC50 |
= |
200.0 |
ug.mL-1 |
Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells |
CHEMBL1141177 |
| Cytomegalovirus |
EC50 |
|
|
ug.mL-1 |
Effective concentration of compound required to reduce plaque formation by Davis strain of CMV virus in Human embryonic lung cells; ND=Not determined |
CHEMBL1141177 |
| Human herpesvirus 3 |
EC50 |
= |
0.6 |
ug.mL-1 |
Effective concentration of compound required to reduce plaque formation by OKA strain of thymidine kinase positive VZ virus TK+ in human embryonic lung cells |
CHEMBL1141177 |
| Human herpesvirus 3 |
EC50 |
= |
9.4 |
ug.mL-1 |
Reduction of plaque formation by VZV07/1 strain of thymidine kinase(TK-) deficient VZ virus in human embryonic lung cells |
CHEMBL1141177 |
| HEL |
MCC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration of compound that causes alteration of cell morphology in human embryonic lung cells |
CHEMBL1141177 |
| HEL |
CC50 |
= |
200.0 |
ug.mL-1 |
Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells |
CHEMBL1141177 |
| Cytomegalovirus |
EC50 |
|
|
ug.mL-1 |
Effective concentration to reduce plaque formation of Cytomegalovirus AD-169 strain in human embryonic lung cell cultures;ND=Not determined |
CHEMBL1141177 |
| Cytomegalovirus |
EC50 |
|
|
ug.mL-1 |
Effective concentration to reduce plaque formation of Cytomegalovirus Davis strain in human embryonic lung cell cultures; ND=Not determined |
CHEMBL1141177 |
| Human herpesvirus 3 |
EC50 |
= |
0.6 |
ug.mL-1 |
Effective concentration to reduce plaque formation of thymidine kinase positive Varicella zoster virus TK+ VZ OKA strain in human embryonic lung cell cultures |
CHEMBL1141177 |
| Molecular identity unknown |
EC50 |
= |
1500.0 |
nM |
Effective concentration required to reduce Varicella Zoster virus OKA plaque formation by using DMSO as solvent |
CHEMBL1142787 |
| Molecular identity unknown |
EC50 |
= |
3100.0 |
nM |
Effective concentration required to reduce Varicella Zoster virus YS plaque formation by using DMSO as solvent |
CHEMBL1142787 |
| Molecular identity unknown |
EC50 |
= |
40000.0 |
nM |
Effective concentration required to reduce thymidine kinase-Varicella Zoster virus VZV 07/1 plaque formation by using DMSO as solvent |
CHEMBL1142787 |
| Molecular identity unknown |
EC50 |
= |
53000.0 |
nM |
Effective concentration required to reduce thymidine kinase-Varicella Zoster virus YS/R plaque formation by using DMSO as solvent |
CHEMBL1142787 |
| NON-PROTEIN TARGET |
MCC |
> |
200000.0 |
nM |
Minimal cytotoxic concentration required to alter microscopically detectable cell morphology |
CHEMBL1142787 |
| HeLa |
CC50 |
> |
400000.0 |
nM |
Cytotoxic concentration required to inhibit Hel cell growth by using DMSO as solvent |
CHEMBL1142787 |
| E6SM |
EC50 |
= |
0.07 |
ug.mL-1 |
Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture |
CHEMBL1138797 |
| HEL |
EC50 |
> |
200000.0 |
nM |
Effective concentration required to reduce CMV AD169 strain virus plaque formation by 50% in HEL cell culture |
CHEMBL1138797 |
| HEL |
EC50 |
> |
400000.0 |
nM |
Effective concentration required to reduce CMV davis strain virus plaque formation by 50% in HEL cell culture |
CHEMBL1138797 |
| E6SM |
EC50 |
= |
0.07 |
ug.mL-1 |
Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture |
CHEMBL1138797 |
| E6SM |
EC50 |
= |
48.0 |
ug.mL-1 |
Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture |
CHEMBL1138797 |
| E6SM |
EC50 |
= |
0.38 |
ug.mL-1 |
Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture |
CHEMBL1138797 |
| E6SM |
MCC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration that caused a microscopically detectable alteration of cell morphology in E6SM Cell Culture |
CHEMBL1138797 |
| HEL |
EC50 |
= |
1300.0 |
nM |
Effective concentration required to reduce TK+ (thymidine kinase presence) VZV strain YS virus plaque formation by 50% in HEL cell culture |
CHEMBL1138797 |
| HEL |
EC50 |
= |
900.0 |
nM |
Effective concentration required to reduce TK+ (thymidine kinase presence) VZV strain OKA virus plaque formation by 50% in HEL cell culture |
CHEMBL1138797 |
| HEL |
EC50 |
= |
24000.0 |
nM |
Effective concentration required to reduce TK+ (thymidine kinase deficient) VZV strain 07/1 virus plaque formation by 50% in HEL cell culture |
CHEMBL1138797 |
| HEL |
EC50 |
= |
27000.0 |
nM |
Effective concentration required to reduce TK+ (thymidine kinase deficient) VZV strain YS/R virus plaque formation by 50% in HEL cell culture |
CHEMBL1138797 |
| HEL |
EC50 |
= |
17000.0 |
nM |
Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection |
CHEMBL1143578 |
| HEL |
EC50 |
= |
20000.0 |
nM |
Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection |
CHEMBL1143578 |
| HEL |
EC50 |
= |
7100.0 |
nM |
Effective concentration required to reduce Varicella-Zoster virus OKA(TK) plaque formation after 5 days in HEL fibroblast cell line |
CHEMBL1143578 |
| HEL |
EC50 |
= |
111000.0 |
nM |
Effective concentration required to reduce Varicella-Zoster virus 07/1(TK-) plaque formation after 5 days in HEL fibroblast cell line |
CHEMBL1143578 |
| HEL |
MCC |
> |
1200000.0 |
nM |
Minimum cytotoxic concentration required to cause a microscopically visible alteration of HEL fibroblast cell morphology |
CHEMBL1143578 |
| HEL |
CC50 |
= |
511000.0 |
nM |
Cytotoxic concentration required to reduce HEL cell growth |
CHEMBL1143578 |
| Mus musculus |
Activity |
= |
10.0 |
|
Effect on ocular HSV-2 reactivation in mice following intraperitoneal dosage at 200 mg/kg; expressed as HSV-2 positive cultures/15 mice |
CHEMBL1139534 |
| Mus musculus |
Activity |
= |
7.0 |
|
Effect on HSV-1 encephalitis in mice following intraperitoneal dosage at 100 mg/kg; expressed as number of survivors/10 |
CHEMBL1139534 |
| Mus musculus |
Activity |
= |
13.0 |
|
Effect on HSV-1 encephalitis in mice following intraperitoneal dosage at 100 mg/kg; expressed as mean day of death |
CHEMBL1139534 |
| Mus musculus |
Activity |
= |
6.0 |
|
Effect on HSV-2 encephalitis in mice following intraperitoneal dosage at 100 mg/kg; expressed as number of survivors/10 |
CHEMBL1139534 |
| Mus musculus |
Activity |
= |
17.2 |
|
Effect on HSV-2 encephalitis in mice following intraperitoneal dosage at 100 mg/kg; expressed as mean day of death |
CHEMBL1139534 |
| Mus musculus |
Activity |
= |
1.0 |
|
Effect on HSV-1 encephalitis in mice following intraperitoneal dosage at 25 mg/kg; expressed as number of survivors/10 |
CHEMBL1139534 |
| Mus musculus |
Activity |
= |
10.0 |
|
Effect on HSV-1 encephalitis in mice following intraperitoneal dosage at 25 mg/kg; expressed as mean day of death |
CHEMBL1139534 |
| Mus musculus |
Activity |
= |
0.0 |
|
Effect on HSV-2 encephalitis in mice following intraperitoneal dosage at 25 mg/kg; expressed as number of survivors/10 |
CHEMBL1139534 |
| Mus musculus |
Activity |
= |
14.2 |
|
Effect on HSV-2 encephalitis in mice following intraperitoneal dosage at 25 mg/kg; expressed as mean day of death |
CHEMBL1139534 |
| Mus musculus |
Activity |
= |
3.0 |
|
Effect on HSV-1 encephalitis in mice following intraperitoneal dosage at 50 mg/kg; expressed as number of survivors/10 |
CHEMBL1139534 |
| Mus musculus |
Activity |
= |
11.0 |
|
Effect on HSV-1 encephalitis in mice following intraperitoneal dosage at 50 mg/kg; expressed as mean day of death |
CHEMBL1139534 |
| Mus musculus |
Activity |
= |
2.0 |
|
Effect on HSV-2 encephalitis in mice following intraperitoneal dosage at 50 mg/kg; expressed as number of survivors/10 |
CHEMBL1139534 |
| Mus musculus |
Activity |
= |
15.0 |
|
Effect on HSV-2 encephalitis in mice following intraperitoneal dosage at 50 mg/kg; expressed as mean day of death |
CHEMBL1139534 |
| Human herpesvirus 4 |
EC50 |
= |
1100.0 |
nM |
Effective concentration required to inhibit Epstein-barr virus replication in daudi cells in viral capsid immunofluorescence ELISA |
CHEMBL1139499 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxic concentration required to inhibit herpes simplex virus 1 infected BSC-1 cells |
CHEMBL1139499 |
| HFF |
CC50 |
> |
444000.0 |
nM |
Cytotoxic concentration to inhibit Herpes simplex virus 1 infected HFF cells |
CHEMBL1139499 |
| Vero |
CC50 |
> |
200000.0 |
nM |
Cytotoxic concentration required to inhibit herpes simplex virus 1 infected vero cells |
CHEMBL1139499 |
| HFF |
CC50 |
> |
444000.0 |
nM |
Cytotoxic concentration to inhibit Herpes simplex virus 2 infected HFF cells |
CHEMBL1139499 |
| Vero |
CC50 |
> |
200000.0 |
nM |
Cytotoxic concentration required to inhibit herpes simplex virus 2 infected vero cells |
CHEMBL1139499 |
| Daudi |
CC50 |
> |
222000.0 |
nM |
Cytotoxic concentration to inhibit replication in daudi cells |
CHEMBL1139499 |
| Molecular identity unknown |
EC50 |
= |
1600.0 |
nM |
Effective concentration required to inhibit varicella zoster virus replication in HFF cells |
CHEMBL1139499 |
| HFF |
CC50 |
> |
444000.0 |
nM |
Cytotoxic concentration to inhibit replication in HFF cells in cytopathic effect inhibition assay |
CHEMBL1139499 |
| Human herpesvirus 1 |
EC50 |
= |
1500.0 |
nM |
Effective concentration required to inhibit herpes simplex virus 1 in BSC-1 cells in ELISA |
CHEMBL1139499 |
| Human herpesvirus 1 |
EC50 |
= |
900.0 |
nM |
Effective concentration required to inhibit herpes simplex virus 1 in HFF cells in cytopathic effect (CPE) assay |
CHEMBL1139499 |
| Human herpesvirus 1 |
EC50 |
= |
13500.0 |
nM |
Effective concentration required to inhibit herpes simplex virus 1 in vero cells in plaque reduction assay |
CHEMBL1139499 |
| Human herpesvirus 2 |
EC50 |
= |
6700.0 |
nM |
Effective concentration required to inhibit herpes simplex virus 2 in HFF cells in cytopathic effect (CPE) assay |
CHEMBL1139499 |
| Human herpesvirus 2 |
EC50 |
= |
32300.0 |
nM |
Effective concentration required to inhibit herpes simplex virus 2 in vero cells in plaque reduction assay |
CHEMBL1139499 |
| Coxsackievirus |
EC50 |
|
|
nM |
Effective concentration required to inhibit Coxsackie B3 virus induced cytopathicity in vero cells; not determined |
CHEMBL1141175 |
| Human herpesvirus 1 |
EC50 |
= |
320.0 |
nM |
Effective concentration required to inhibit herpes simplex virus type 1 Kos strain induced cytopathicity in Hel cells |
CHEMBL1141175 |
| HFF |
IC50 |
> |
20000.0 |
nM |
Antiviral activity against human cytomegalovirus (Davis strain) grown on human foreskin fibroblast cells determined by reduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO |
CHEMBL1141075 |
| Vero |
IC50 |
> |
10000.0 |
nM |
Antiviral activity against herpes simplex virus type 1 KOS (PFAr2) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO |
CHEMBL1141075 |
| Vero |
IC50 |
= |
5400.0 |
nM |
Antiviral activity against herpes simplex virus type 1 Patton (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO |
CHEMBL1141075 |
| Vero |
IC50 |
> |
10000.0 |
nM |
Antiviral activity against herpes simplex virus type 1 Patton (BWr) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO |
CHEMBL1141075 |
| Vero |
IC50 |
= |
2400.0 |
nM |
Antiviral activity against herpes simplex virus type 2 (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO |
CHEMBL1141075 |
| Vero |
IC50 |
= |
2800.0 |
nM |
Antiviral activity against herpes simplex virus type 2 (V826A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO |
CHEMBL1141075 |
| HFF |
IC50 |
= |
8100.0 |
nM |
Antiviral activity against Varicella-Zoster virus (Webster strain) grown on human foreskin fibroblast cells determined by vedduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO until plaque were formed [nd = not determined] |
CHEMBL1141075 |
| Vero |
IC50 |
= |
2100.0 |
nM |
Antiviral activity against herpes simplex virus type 1 (KOS strain) grown on human foreskin fibroblast cells determined by vedduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO until plaque were formed [nd = not determined] |
CHEMBL1141075 |
| HFF |
CC50 |
> |
100000.0 |
nM |
Toxicity on uninfected human foreskin fibroblast cells determined in microscopic evaluation and quantitative neutral red dye uptake assay |
CHEMBL1141075 |
| Vero |
CC50 |
> |
100000.0 |
nM |
Toxicity on uninfected African green monkey kidney cells determined in microscopic evaluation and quantitative neutral red dye uptake assay |
CHEMBL1141075 |
| Vero |
IC50 |
= |
3500.0 |
nM |
Antiviral activity against herpes simplex virus type 1 KOS (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO |
CHEMBL1141075 |
| Vero |
IC50 |
= |
4400.0 |
nM |
Antiviral activity against herpes simplex virus type 1 KOS (V823A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO |
CHEMBL1141075 |
| Vero |
IC50 |
> |
10000.0 |
nM |
Antiviral activity against herpes simplex virus type 1 KOS (AraAr13) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO |
CHEMBL1141075 |
| Vero |
IC50 |
> |
10000.0 |
nM |
Antiviral activity against herpes simplex virus type 1 KOS (PAAr5) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO |
CHEMBL1141075 |
| Human herpesvirus 3 |
EC50 |
= |
36000.0 |
nM |
Antiviral activity against Varicella-Zoster virus 07/1 strain |
CHEMBL1148578 |
| Human herpesvirus 3 |
EC50 |
= |
1400.0 |
nM |
Antiviral activity against Varicella-Zoster virus YS strain |
CHEMBL1148578 |
| Human herpesvirus 1 |
EC50 |
= |
1120.0 |
nM |
Antiviral activity against HSV1 KOS in HEL cells |
CHEMBL1148592 |
| Human herpesvirus 1 |
EC50 |
= |
86600.0 |
nM |
Antiviral activity against HSV1 TK- in HEL cells |
CHEMBL1148592 |
| Human herpesvirus 2 |
EC50 |
= |
1760.0 |
nM |
Antiviral activity against HSV2 G in HEL cells |
CHEMBL1148592 |
| HEL |
MTC |
> |
1700.0 |
uM |
Minimum toxic concentration in HEL cells |
CHEMBL1148592 |
| Human immunodeficiency virus 1 |
EC50 |
> |
50000.0 |
nM |
Antiviral activity against HIV1 IIIB in CEM cells |
CHEMBL1148592 |
| Human immunodeficiency virus 2 |
EC50 |
> |
50000.0 |
nM |
Antiviral activity against HIV2 ROD in CEM cells |
CHEMBL1148592 |
| Human herpesvirus 3 |
EC50 |
= |
24000.0 |
nM |
Antiviral activity against Varicella-Zoster virus YS/R strain |
CHEMBL1148578 |
| Human herpesvirus 5 |
EC50 |
|
|
|
Antiviral activity against human cytomegalovirus AD169 strain |
CHEMBL1148578 |
| Human herpesvirus 5 |
EC50 |
|
|
|
Antiviral activity against human cytomegalovirus Davis strain |
CHEMBL1148578 |
| HEL |
CC50 |
> |
889000.0 |
nM |
Cytotoxic activity against cultured human embryonic lung (HEL) cells |
CHEMBL1148578 |
| HEL |
MCC |
> |
222000.0 |
nM |
Cytotoxic activity against cultured human embryonic lung (HEL) cells |
CHEMBL1148578 |
| HEL |
MCC |
> |
400.0 |
ug.mL-1 |
Antiviral activity against HEL cells |
CHEMBL1147740 |
| Vero |
MCC |
|
|
|
Antiviral activity against vero cells |
CHEMBL1147740 |
| HeLa |
MCC |
|
|
|
Antiviral activity against HeLa cells |
CHEMBL1147740 |
| Human herpesvirus 1 |
MIC50 |
= |
0.384 |
ug.mL-1 |
Antiviral activity against Herpes simplex virus 1 KOS strain in HEL cells |
CHEMBL1147740 |
| Human herpesvirus 2 |
MIC50 |
= |
0.384 |
ug.mL-1 |
Antiviral activity against Herpes simplex virus 2 G strain in HEL cells |
CHEMBL1147740 |
| Vaccinia virus |
MIC50 |
> |
400.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus in HEL cells |
CHEMBL1147740 |
| Vesicular stomatitis virus |
MIC50 |
> |
400.0 |
ug.mL-1 |
Antiviral activity against Vesicular stomatitis virus in HEL cells |
CHEMBL1147740 |
| Human herpesvirus 1 |
MIC50 |
= |
48.0 |
ug.mL-1 |
Antiviral activity against herpes simplex virus 1 TK- KOS ACVr strain in HEL cells |
CHEMBL1147740 |
| Human parainfluenza virus 3 |
MIC50 |
|
|
|
Antiviral activity against Parainfluenza-3 virus in vero cells |
CHEMBL1147740 |
| Mammalian orthoreovirus 1 |
MIC50 |
|
|
|
Antiviral activity against Reovirus 1 in vero cells |
CHEMBL1147740 |
| Sindbis virus |
MIC50 |
|
|
|
Antiviral activity against Sindbis virus in vero cells |
CHEMBL1147740 |
| Human coxsackievirus B4 |
MIC50 |
|
|
|
Antiviral activity against Coxsackie virus B4 in vero cells |
CHEMBL1147740 |
| Punta Toro virus |
MIC50 |
|
|
|
Antiviral activity against Punta Toro virus in vero cells |
CHEMBL1147740 |
| Respiratory syncytial virus |
MIC50 |
|
|
|
Antiviral activity against Respiratory syncytial virus in HeLa cells |
CHEMBL1147740 |
| Human coxsackievirus B4 |
MIC50 |
|
|
|
Antiviral activity against Coxsackie virus B4 in HeLa cells |
CHEMBL1147740 |
| Vesicular stomatitis virus |
MIC50 |
|
|
|
Antiviral activity against Vesicular stomatitis virus in HeLa cells |
CHEMBL1147740 |
| Human herpesvirus 3 |
EC50 |
= |
0.22 |
ug.mL-1 |
Antiviral activity against TK+ VZV OKA in human embryonic lung cells |
CHEMBL1149435 |
| Human herpesvirus 3 |
EC50 |
= |
14.0 |
ug.mL-1 |
Antiviral activity against TK- VZV 07/10 in human embryonic lung cells |
CHEMBL1149435 |
| HEL |
MCC |
> |
400.0 |
ug.mL-1 |
Cytotoxicity as determined by alteration in the cell morphology of HEL cells |
CHEMBL1149435 |
| HEL |
CC50 |
= |
118.0 |
ug.mL-1 |
Cytotoxicity against HEL cells |
CHEMBL1149435 |
| Human herpesvirus 1 |
Inhibition |
= |
96.0 |
% |
Antiviral activity against HSV1 at 10 uM |
CHEMBL1138118 |
| Human herpesvirus 1 |
EC50 |
= |
1090.0 |
nM |
Antiviral activity against HSV1 in vero cells |
CHEMBL1138118 |
| Vero |
CC50 |
= |
960000.0 |
nM |
Cytotoxicity against Vero cells by MTT assay |
CHEMBL1138118 |
| Vero |
Selectivity index |
= |
880.0 |
|
Selectivity index (CC50/EC50) in Vero cells |
CHEMBL1138118 |
| Human herpesvirus 1 |
EC50 |
= |
3500.0 |
nM |
Inhibition of HSV1 replication in BSC1 cells by ELISA |
CHEMBL1137379 |
| KB |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against KB cells |
CHEMBL1137379 |
| Human herpesvirus 4 |
EC50 |
= |
330.0 |
nM |
Inhibition of EBV replication in Daudi cells by viral capsid antigen-ELISA |
CHEMBL1137379 |
| Daudi |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against Daudi cells |
CHEMBL1137379 |
| Human herpesvirus 3 |
EC50 |
= |
30.0 |
nM |
Inhibition of VZV replication in HFF cells by cytopathic effect assay |
CHEMBL1137379 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
480.0 |
nM |
Antiviral activity against HSV1 KOS in HEL cells |
CHEMBL1138863 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
12000.0 |
nM |
Antiviral activity against HSV1 KOS in HEL cells |
CHEMBL1138863 |
| Human herpesvirus 2 |
EC50 |
= |
480.0 |
nM |
Antiviral activity against HSV2 in HEL cells |
CHEMBL1138863 |
| Vaccinia virus |
EC50 |
= |
300000.0 |
nM |
Antiviral activity against vaccinia virus in HEL cells |
CHEMBL1138863 |
| Vesicular stomatitis virus |
EC50 |
> |
500000.0 |
nM |
Antiviral activity against vesicular somatitis virus in HEL cells |
CHEMBL1138863 |
| HEL |
CC50 |
> |
500000.0 |
nM |
Cytotoxicity against HEL cells |
CHEMBL1138863 |
| E6SM |
MIC |
> |
500000.0 |
nM |
Cytotoxicity against E6SM cells |
CHEMBL1141413 |
| Vaccinia virus |
MIC |
> |
500000.0 |
nM |
Antiviral activity against vaccinia virus |
CHEMBL1141413 |
| Vesicular stomatitis virus |
MIC |
> |
500000.0 |
nM |
Antiviral activity against VSV |
CHEMBL1141413 |
| Human herpesvirus 1 strain KOS |
MIC |
= |
480.0 |
nM |
Antiviral activity against HSV1 KOS |
CHEMBL1141413 |
| Human herpesvirus 2 |
MIC |
= |
480.0 |
nM |
Antiviral activity against HSV2 G |
CHEMBL1141413 |
| Human herpesvirus 1 |
MIC |
= |
60000.0 |
nM |
Antiviral activity against HSV1 TK KOS ACVr |
CHEMBL1141413 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
0.015 |
ug.mL-1 |
Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1142867 |
| Human herpesvirus 1 strain KOS |
EC50 |
> |
20.0 |
ug.mL-1 |
Antiviral activity against ACV-resistant TK- HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1142867 |
| Human herpesvirus 2 |
EC50 |
= |
0.018000000000000002 |
ug.mL-1 |
Antiviral activity against HSV2 Lyons in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1142867 |
| Human herpesvirus 2 |
EC50 |
= |
0.048 |
ug.mL-1 |
Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1142867 |
| Human herpesvirus 3 |
EC50 |
= |
0.75 |
ug.mL-1 |
Antiviral activity against VZV OKA in HEL cells assessed as inhibition of plaque formation |
CHEMBL1142867 |
| Human herpesvirus 3 |
EC50 |
>= |
25.1 |
ug.mL-1 |
Antiviral activity against TK- VZV 07-1 in HEL cells assessed as inhibition of plaque formation |
CHEMBL1142867 |
| HEL |
Activity |
> |
100.0 |
ug ml-1 |
Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days |
CHEMBL1142867 |
| HEL |
Activity |
= |
173.5 |
ug ml-1 |
Cytotoxicity against HEL cells assessed as inhibition of cell growth after 3 days |
CHEMBL1142867 |
| ADMET |
IC50 |
= |
57730.0 |
nM |
Cytotoxicity against mouse L1210/0 cells after 48 hrs |
CHEMBL1142978 |
| Human herpesvirus 3 |
EC50 |
= |
1600.0 |
nM |
Inhibition of VZV replication in HFF cells by CPE assay |
CHEMBL1149318 |
| HFF |
CC50 |
> |
444000.0 |
nM |
Cytotoxicity against HFF cells |
CHEMBL1149318 |
| Human herpesvirus 4 |
EC50 |
= |
1100.0 |
nM |
Inhibition of EBV replication in Daudi cells by VCA ELISA |
CHEMBL1149318 |
| Human herpesvirus 4 |
EC50 |
= |
5300.0 |
nM |
Inhibition of EBV replication in Daudi cells by DNA hybridization assay |
CHEMBL1149318 |
| Daudi |
CC50 |
> |
222000.0 |
nM |
Cytotoxicity against Daudi cells |
CHEMBL1149318 |
| Human herpesvirus 1 |
EC50 |
= |
10000.0 |
nM |
Inhibition of HSV1 replication in BSC1 cells by ELISA |
CHEMBL1149318 |
| ADMET |
CC50 |
> |
10000.0 |
nM |
Cytotoxicity against BSC1 cells |
CHEMBL1149318 |
| Human herpesvirus 1 strain KOS |
MIC |
= |
480.0 |
nM |
Antiviral activity against HSV1 KOS-induced cytopathogenicity in E6SM cells |
CHEMBL1144557 |
| Human herpesvirus 2 |
MIC |
= |
800.0 |
nM |
Antiviral activity against HSV2 G-induced cytopathogenicity in E6SM cells |
CHEMBL1144557 |
| Vaccinia virus |
MIC |
= |
300000.0 |
nM |
Antiviral activity against Vaccinia virus-induced cytopathogenicity in E6SM cells |
CHEMBL1144557 |
| Vesicular stomatitis virus |
MIC |
> |
500000.0 |
nM |
Antiviral activity against in Vesicular stomatitis virus-induced cytopathogenicity in E6SM cells |
CHEMBL1144557 |
| Human herpesvirus 1 strain KOS |
MIC |
= |
60000.0 |
nM |
Antiviral activity against HSV1 TK- KOS ACV-induced cytopathogenicity in E6SM cells |
CHEMBL1144557 |
| E6SM |
MIC |
> |
500000.0 |
nM |
Cytotoxicity against E6SM cells |
CHEMBL1144557 |
| Human herpesvirus 8 |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay |
CHEMBL1147135 |
| Human herpesvirus 8 |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC2 cells after 120 hrs by MTT assay |
CHEMBL1147135 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against DG75 cells after 120 hrs by MTT assay |
CHEMBL1147135 |
| E6SM |
MCC |
> |
400.0 |
ug.mL-1 |
Cytotoxicity against E6SM cells assessed as alteration in cell morphology |
CHEMBL1143708 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
0.02 |
ug.mL-1 |
Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1143708 |
| Human herpesvirus 2 |
EC50 |
= |
0.07 |
ug.mL-1 |
Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1143708 |
| Vaccinia virus |
EC50 |
> |
400.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1143708 |
| Human herpesvirus 1 |
EC50 |
= |
40.0 |
ug.mL-1 |
Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1143708 |
| Human herpesvirus 1 |
EC50 |
= |
7.0 |
ug.mL-1 |
Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1143708 |
| Human herpesvirus 1 |
IC50 |
= |
390.0 |
nM |
Antiviral activity against HSV1 SC16 in Vero cells by capture hybrid method |
CHEMBL1144639 |
| Vero |
CC50 |
> |
200000.0 |
nM |
Cytotoxicity against Vero cells |
CHEMBL1144639 |
| Human herpesvirus 3 |
EC50 |
= |
1000.0 |
nM |
Antiviral activity against thymidine kinase expressing Varicella-Zoster virus OKA assessed as reduction of plaque formation |
CHEMBL1145384 |
| Human herpesvirus 3 |
EC50 |
= |
32000.0 |
nM |
Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07/1 assessed as reduction of plaque formation |
CHEMBL1145384 |
| HEL |
MCC |
> |
1778000.0 |
nM |
Cytotoxicity against HEL cells assessed as cell morphology after 7 days |
CHEMBL1145384 |
| HEL |
CC50 |
= |
649000.0 |
nM |
Cytotoxicity against HEL cells assessed as cell growth after 7 days |
CHEMBL1145384 |
| Human herpesvirus 3 |
EC50 |
= |
1400.0 |
nM |
Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days |
CHEMBL1148703 |
| Human herpesvirus 3 |
EC50 |
= |
4000.0 |
nM |
Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation after 5 days |
CHEMBL1148703 |
| Human herpesvirus 3 |
EC50 |
= |
36000.0 |
nM |
Antiviral activity against thymidine kinase deficient VZV 07/1 in HEL cells assessed as reduction of virus plaque formation after 5 days |
CHEMBL1148703 |
| Human herpesvirus 3 |
EC50 |
= |
24000.0 |
nM |
Antiviral activity against thymidine kinase deficient VZV YS/R in HEL cells assessed as reduction of virus plaque formation after 5 days |
CHEMBL1148703 |
| Human herpesvirus 5 |
EC50 |
|
|
|
Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days |
CHEMBL1148703 |
| Human herpesvirus 5 |
EC50 |
|
|
|
Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days |
CHEMBL1148703 |
| HEL |
MCC |
> |
220000.0 |
nM |
Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days |
CHEMBL1148703 |
| HEL |
CC50 |
> |
890000.0 |
nM |
Cytotoxicity against HEL cells after 3 days |
CHEMBL1148703 |
| Human herpesvirus 3 |
EC50 |
= |
1000.0 |
nM |
Antiviral activity against thymidine kinase-positive VZV OKA in human HEL cells after 7 days |
CHEMBL1148744 |
| Human herpesvirus 3 |
EC50 |
= |
32000.0 |
nM |
Antiviral activity against thymidine kinase deficient VZV 07/1 in human HEL cells after 7 days |
CHEMBL1148744 |
| HEL |
MCC |
> |
1778000.0 |
nM |
Cytotoxicity against human HEL cells assessed as alteration in cell morphology |
CHEMBL1148744 |
| HEL |
CC50 |
= |
545000.0 |
nM |
Cytotoxicity against human HEL cells assessed as reduction of cell growth |
CHEMBL1148744 |
| Human herpesvirus 1 strain KOS |
MIC |
= |
400.0 |
nM |
Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1148744 |
| Human herpesvirus 2 |
MIC |
= |
400.0 |
nM |
Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1148744 |
| Vaccinia virus |
MIC |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1148744 |
| Human herpesvirus 5 |
IC50 |
> |
20000.0 |
nM |
Antiviral activity against HCMV in human foreskin fibroblast assessed as inhibition of virus plaque formation |
CHEMBL1149529 |
| Human herpesvirus 1 |
IC50 |
= |
2100.0 |
nM |
Antiviral activity against HSV1 in human foreskin fibroblast assessed as inhibition of virus plaque formation |
CHEMBL1149529 |
| Human herpesvirus 3 |
IC50 |
= |
8100.0 |
nM |
Antiviral activity against VZV in human foreskin fibroblast assessed as inhibition of virus plaque formation |
CHEMBL1149529 |
| HEL |
EC50 |
= |
0.03 |
ug.mL-1 |
Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1138246 |
| HEL |
EC50 |
>= |
25.2 |
ug.mL-1 |
Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1138246 |
| Human herpesvirus 2 |
EC50 |
= |
0.02 |
ug.mL-1 |
Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1138246 |
| Human herpesvirus 2 |
EC50 |
= |
0.05 |
ug.mL-1 |
Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1138246 |
| Human herpesvirus 3 |
EC50 |
= |
0.23 |
ug.mL-1 |
Antiviral activity against VZV OKA in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1138246 |
| Human herpesvirus 3 |
EC50 |
= |
10.2 |
ug.mL-1 |
Antiviral activity against VZV 07-1 TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1138246 |
| HEL |
MCC |
> |
100.0 |
ug.mL-1 |
Cytotoxicity against HEL cells assessed as alteration in morphology after 3 days |
CHEMBL1138246 |
| HEL |
CC50 |
= |
212.0 |
ug.mL-1 |
Cytotoxicity against HEL cells assessed as cell growth after 3 days |
CHEMBL1138246 |
| ADMET |
permeability |
= |
0.01 |
10^6cm/s |
Permeability across artificial membrane by PAMPA |
CHEMBL1138295 |
| ADMET |
permeability |
= |
0.01 |
10^6cm/s |
Permeability across artificial membrane by PAMPA model |
CHEMBL1138310 |
| Human herpesvirus 3 |
EC50 |
= |
2900.0 |
nM |
Antiviral activity against TK+ VZV OKA in HEL cells after 5 days |
CHEMBL1138364 |
| Human herpesvirus 3 |
EC50 |
= |
1000.0 |
nM |
Antiviral activity against TK+ VZV YS in HEL cells after 5 days |
CHEMBL1138364 |
| Human herpesvirus 3 |
EC50 |
= |
74000.0 |
nM |
Antiviral activity against TK- VZV 07 in HEL cells after 5 days |
CHEMBL1138364 |
| Human herpesvirus 3 |
EC50 |
= |
125000.0 |
nM |
Antiviral activity against TK- VZV YS in HEL cells after 5 days |
CHEMBL1138364 |
| HEL |
MCC |
> |
200000.0 |
nM |
Cytotoxicity against HEL cells assessed as alteration in cell morphology |
CHEMBL1138364 |
| HEL |
CC50 |
> |
200000.0 |
nM |
Cytotoxicity against HEL cells |
CHEMBL1138364 |
| Unchecked |
IC50 |
> |
100000.0 |
nM |
Inhibition of VZV-TK catalyzed dThd phosphorylation |
CHEMBL1138364 |
| Human herpesvirus 5 |
IC50 |
> |
20000.0 |
nM |
Antiviral activity against HCMV Davis in HFF cells by plaque reduction assay |
CHEMBL1139940 |
| Human herpesvirus 1 |
IC50 |
= |
2100.0 |
nM |
Antiviral activity against HSV1 KOS in Vero cells by plaque reduction assay |
CHEMBL1139940 |
| Human herpesvirus 3 |
IC50 |
= |
8100.0 |
nM |
Antiviral activity against VZV Webster in HFF cells by plaque reduction assay |
CHEMBL1139940 |
| HFF |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against HFF cells after 3 days |
CHEMBL1139940 |
| Human herpesvirus 4 |
IC50 |
= |
6900.0 |
nM |
Antiviral activity against EBV in GG68 cells after 72 hrs |
CHEMBL1139940 |
| Human herpesvirus 3 |
EC50 |
= |
0.7 |
ug.mL-1 |
Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation |
CHEMBL1140488 |
| Human herpesvirus 3 |
EC50 |
= |
28.0 |
ug.mL-1 |
Antiviral activity against TK- VZV 07/1 in HEL cells assessed as reduction of virus plaque formation |
CHEMBL1140488 |
| Human herpesvirus 5 strain AD169 |
EC50 |
|
|
|
Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 5 days |
CHEMBL1140488 |
| Human herpesvirus 5 |
EC50 |
|
|
|
Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 5 days |
CHEMBL1140488 |
| HEL |
MCC |
> |
400.0 |
ug.mL-1 |
Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days |
CHEMBL1140488 |
| HEL |
CC50 |
> |
200.0 |
ug.mL-1 |
Cytotoxicity against HEL cells assessed as reduction of cell growth after 3 days |
CHEMBL1140488 |
| Vero |
CC50 |
= |
126000.0 |
nM |
Cytotoxicity against african green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay |
CHEMBL1140766 |
| Human herpesvirus 1 |
IC50 |
= |
390.0 |
nM |
Antiviral activity against HSV1 SC16 in african green monkey Vero cells |
CHEMBL1140823 |
| Vero |
CC50 |
> |
200000.0 |
nM |
Cytotoxicity against african green monkey Vero cells |
CHEMBL1140823 |
| Human herpesvirus 1 |
EC50 |
= |
6000.0 |
nM |
Antiviral activity against HSV1 KOS in african green monkey Vero cells by plaque reduction assay |
CHEMBL1143232 |
| Vero |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against african green monkey Vero cells after 69 hrs by Alamar blue assay |
CHEMBL1143232 |
| Human herpesvirus 1 |
EC50 |
> |
444000.0 |
nM |
Antiviral activity against TK- HSV1 DM2.1 in HFF cells after 72 hrs by plaque reduction assay |
CHEMBL1145474 |
| Human herpesvirus 1 |
EC50 |
= |
1300.0 |
nM |
Antiviral activity against TK+ HSV1 E377 in HFF cells after 72 hrs by plaque reduction assay |
CHEMBL1145474 |
| Human herpesvirus 2 |
EC50 |
= |
3100.0 |
nM |
Antiviral activity against TK- HSV2 MS in HFF cells after 72 hrs by plaque reduction assay |
CHEMBL1145474 |
| Human herpesvirus 2 |
EC50 |
> |
444000.0 |
nM |
Antiviral activity against TK- HSV2 AG3 in HFF cells after 72 hrs by plaque reduction assay |
CHEMBL1145474 |
| Human herpesvirus 3 |
EC50 |
= |
8500.0 |
nM |
Antiviral activity against Varicella-Zoster virus Ellen in HFF cells after 10 days by plaque reduction assay |
CHEMBL1145474 |
| Thymidine kinase |
IC50 |
= |
1000000.0 |
nM |
Inhibition of Herpes B virus recombinant thymidine kinase-mediated [3H]TdR phosphorylation |
CHEMBL1145504 |
| Thymidine kinase |
Activity |
|
|
|
Activity of Herpes B virus recombinant thymidine kinase at 100 uM |
CHEMBL1145504 |
| Thymidine kinase |
Activity |
|
|
|
Activity of Herpes B virus recombinant thymidine kinase at 1 mM |
CHEMBL1145504 |
| Macacine herpesvirus 1 |
EC50 |
= |
112000.0 |
nM |
Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs |
CHEMBL1145504 |
| Macacine herpesvirus 1 |
EC50 |
= |
118000.0 |
nM |
Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs |
CHEMBL1145504 |
| Macacine herpesvirus 1 |
EC50 |
= |
47500.0 |
nM |
Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs |
CHEMBL1145504 |
| Human herpesvirus 1 |
EC50 |
= |
1400.0 |
nM |
Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs |
CHEMBL1145504 |
| Vero |
CC50 |
> |
890000.0 |
nM |
Cytotoxicity against african green monkey Vero cells after 2 days |
CHEMBL1145504 |
| Thymidine kinase |
IC50 |
= |
122000.0 |
nM |
Inhibition of Herpes simplex virus 1 recombinant thymidine kinase |
CHEMBL1145504 |
| Thymidine kinase |
IC50 |
= |
200000.0 |
nM |
Inhibition of Herpes simplex virus 2 recombinant thymidine kinase |
CHEMBL1145504 |
| Human herpesvirus 4 |
EC50 |
= |
1700.0 |
nM |
Antiviral activity against Epstein-Barr virus infected in human akata cells |
CHEMBL1144038 |
| Vero |
CC50 |
= |
122000.0 |
ug.mL-1 |
Cytotoxicity against african green monkey Vero cells by MTT assay |
CHEMBL1156361 |
| Human herpesvirus 2 |
IC50 |
= |
4.21 |
ug.mL-1 |
Antiviral activity against Herpes simplex virus 2 infected in african green monkey Vero cells assessed inhibition of virus-induced effect after 48 hrs by MTT assay |
CHEMBL1156361 |
| Human herpesvirus 2 |
Activity |
= |
6.0 |
ug ml-1 |
Antiviral activity against Herpes simplex virus 2 infected in african green monkey Vero cells assessed as maximal nontoxic dose that showed the highest viral reduction factor after 48 hrs by end-point titration technique |
CHEMBL1156361 |
| Human herpesvirus 2 |
Ratio |
= |
100000.0 |
|
Antiviral activity against Herpes simplex virus 2 infected in african green monkey Vero cells assessed as ratio of the viral titers in absence to presence of drug after 48 hrs by end-point titration technique |
CHEMBL1156361 |
| Vero |
CC100 |
> |
600.0 |
ug ml-1 |
Cytotoxicity against african green monkey Vero cells by end-point titration technique |
CHEMBL1156361 |
| Human herpesvirus 1 |
IC50 |
= |
2.0 |
ug.mL-1 |
Antiviral activity against HSV1 infected in african green monkey Vero cells after 72 hrs by SRB assay |
CHEMBL1150578 |
| Human herpesvirus 1 |
EC50 |
= |
0.8 |
ug.mL-1 |
Antiviral activity against HSV1 F infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay |
CHEMBL1150133 |
| Human herpesvirus 2 |
EC50 |
= |
2.4 |
ug.mL-1 |
Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay |
CHEMBL1150133 |
| Human herpesvirus 1 |
IC50 |
= |
10200.0 |
nM |
Antiviral activity against HSV1 by colorimetric method |
CHEMBL1149907 |
| E6SM |
MCC |
> |
400.0 |
ug.mL-1 |
Cytotoxicity against human E6SM cells |
CHEMBL1149790 |
| HEL |
MCC |
> |
400.0 |
ug.mL-1 |
Cytotoxicity against human HEL cells assessed as alteration of cell morphology |
CHEMBL1149790 |
| Human herpesvirus 1 |
MIC |
= |
0.384 |
ug.mL-1 |
Antiviral activity against HSV1 KOS in human E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Human herpesvirus 1 |
MIC |
= |
0.384 |
ug.mL-1 |
Antiviral activity against HSV1 KOS in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Human herpesvirus 2 |
MIC |
= |
0.384 |
ug.mL-1 |
Antiviral activity against HSV2 G in human E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Human herpesvirus 2 |
MIC |
= |
0.384 |
ug.mL-1 |
Antiviral activity against HSV2 G in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Vaccinia virus |
MIC |
> |
400.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus in human E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Vaccinia virus |
MIC |
> |
400.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Vesicular stomatitis virus |
MIC |
> |
400.0 |
ug.mL-1 |
Antiviral activity against in Vesicular stomatitis virus in human E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Vesicular stomatitis virus |
MIC |
> |
400.0 |
ug.mL-1 |
Antiviral activity against in Vesicular stomatitis virus in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Human herpesvirus 1 |
MIC |
= |
48.0 |
ug.mL-1 |
Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Human herpesvirus 1 |
MIC |
= |
48.0 |
ug.mL-1 |
Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Human herpesvirus 3 |
EC50 |
= |
0.17 |
ug.mL-1 |
Antiviral activity against TK+ VZV OKA infected HEL cells assessed as reduction in virus plaque formation |
CHEMBL1149790 |
| Human herpesvirus 3 |
EC50 |
= |
16.0 |
ug.mL-1 |
Antiviral activity against TK- VZV 07/1 infected HEL cells assessed as reduction in virus plaque formation |
CHEMBL1149790 |
| HEL |
CC50 |
= |
200.0 |
ug.mL-1 |
Cytotoxicity against human HEL cells assessed as reduction of cell growth |
CHEMBL1149790 |
| Human herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against HSV1 assessed as reduction in plaque formation at 100 ug |
CHEMBL1137795 |
| Human herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against HSV1 assessed as reduction in plaque formation at 10 ug |
CHEMBL1137795 |
| Human herpesvirus 2 |
EC50 |
= |
2.3 |
ug.mL-1 |
Antiviral activity against herpes simplex virus type 2 assessed as effect on virus-induced cytopathic effect |
CHEMBL1158236 |
| Human herpesvirus 2 |
EC50 |
= |
1.5 |
ug.mL-1 |
Antiviral activity against HSV2 MS in african green monkey Vero cells by viral cytopathic effect assay |
CHEMBL1145712 |
| Vero |
IC50 |
> |
100.0 |
ug.mL-1 |
Cytotoxicity against african green monkey Vero cells by MTT assay |
CHEMBL1145712 |
| Unchecked |
Ratio IC50/EC50 |
> |
60.0 |
|
Selectivity index, ratio of IC50 for african green monkey Vero cells to EC50 for HSV2 MS |
CHEMBL1145712 |
| Influenza A virus |
IC50 |
|
|
|
Antiviral activity against influenza A virus infected in MDCK cells |
CHEMBL1151276 |
| Human herpesvirus 1 |
IC50 |
= |
0.1 |
ug.mL-1 |
Antiviral activity against herpes simplex virus 1 infected in MDCK cells |
CHEMBL1151276 |
| Human herpesvirus 1 |
EC50 |
= |
1100.0 |
nM |
Antiviral activity against HSV1 |
CHEMBL1151179 |
| Human herpesvirus 2 |
EC50 |
= |
1000.0 |
nM |
Antiviral activity against HSV2 |
CHEMBL1151179 |
| Human immunodeficiency virus 1 |
EC50 |
|
|
|
Antiviral activity against HIV1 |
CHEMBL1151179 |
| Human herpesvirus 1 |
EC50 |
= |
0.26 |
ug.mL-1 |
Antiviral activity against HSV1 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days |
CHEMBL1150874 |
| ADMET |
IC50 |
> |
67.0 |
ug.mL-1 |
Cytotoxicity against HSV1 infected human Hep2 cells after 3 days |
CHEMBL1150874 |
| Unchecked |
Ratio IC50/EC50 |
> |
250.0 |
|
Selectivity index, ratio of EC50 for HSV1 by cytopathic effect over IC50 for human Hep2 cells |
CHEMBL1150874 |
| Human herpesvirus 2 |
EC50 |
= |
2.3 |
ug.mL-1 |
Antiviral activity against HSV2 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days |
CHEMBL1150874 |
| ADMET |
IC50 |
> |
10.0 |
ug.mL-1 |
Cytotoxicity against HSV2 infected human Hep2 cells after 3 days |
CHEMBL1150874 |
| Unchecked |
Ratio IC50/EC50 |
> |
4.3 |
|
Selectivity index, ratio of EC50 for HSV2 by cytopathic effect over IC50 for human Hep2 cells |
CHEMBL1150874 |
| Solute carrier family 22 member 1 |
Inhibition |
= |
-3.9 |
% |
Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy |
CHEMBL1140113 |
| Human herpesvirus 5 |
EC50 |
= |
12.0 |
ug.mL-1 |
Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1140035 |
| Human herpesvirus 5 |
EC50 |
= |
7.9 |
ug.mL-1 |
Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1140035 |
| Human herpesvirus 5 |
EC50 |
= |
173.0 |
ug.mL-1 |
Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1140035 |
| Human herpesvirus 5 |
EC50 |
= |
130.0 |
ug.mL-1 |
Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1140035 |
| Human herpesvirus 5 |
EC50 |
= |
4.8 |
ug.mL-1 |
Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1140035 |
| Human herpesvirus 5 |
EC50 |
= |
91.0 |
ug.mL-1 |
Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1140035 |
| Human herpesvirus 5 |
EC50 |
= |
7.7 |
ug.mL-1 |
Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1140035 |
| Human herpesvirus 5 |
EC50 |
= |
22.0 |
ug.mL-1 |
Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1140035 |
| Human herpesvirus 1 |
EC50 |
= |
950.0 |
nM |
Antiviral activity against HSV1 |
CHEMBL1148918 |
| Human herpesvirus 2 |
EC50 |
= |
950.0 |
nM |
Antiviral activity against HSV2 |
CHEMBL1148918 |
| Vero |
CC100 |
> |
600.0 |
ug ml-1 |
Cytotoxicity against african green monkey Vero cells by EPTT method |
CHEMBL1159320 |
| Human herpesvirus 2 |
Activity |
= |
6.0 |
ug ml-1 |
Antiviral activity against HSV2 infected in human HeP2 ells |
CHEMBL1159320 |
| Human herpesvirus 1 |
Activity |
= |
3.25 |
|
Antiviral activity against HSV1 H29S in african green monkey Vero cells assessed as log reduction in viral titers after 0.001 multiple round of replication at 50 ug/ml after 72 hrs |
CHEMBL1149068 |
| Human herpesvirus 1 |
Activity |
= |
3.0 |
|
Antiviral activity against HSV1 H29S in african green monkey Vero cells assessed as log reduction in viral titers after 0.001 multiple round of replication at 25 ug/ml after 72 hrs |
CHEMBL1149068 |
| Human herpesvirus 1 |
Activity |
= |
3.0 |
|
Antiviral activity against HSV1 H29S in african green monkey Vero cells assessed as log reduction in viral titers after 0.001 multiple round of replication at 12.5 ug/ml after 72 hrs |
CHEMBL1149068 |
| Human herpesvirus 1 |
Activity |
= |
2.0 |
|
Antiviral activity against HSV1 H29S in african green monkey Vero cells assessed as log reduction in viral titers after 0.001 multiple round of replication at 6.25 ug/ml after 72 hrs |
CHEMBL1149068 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against HEL cells assessed as alteration in cell morphology by MTS assay |
CHEMBL1144203 |
| Human herpesvirus 3 |
EC50 |
= |
0.24 |
ug.mL-1 |
Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka in HEL cells assessed as inhibition of viral cytopathicity |
CHEMBL1142504 |
| Human herpesvirus 3 |
EC50 |
= |
13.0 |
ug.mL-1 |
Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07/1 in HEL cells assessed as inhibition of viral cytopathicity |
CHEMBL1142504 |
| HEL |
MCC |
> |
400.0 |
ug.mL-1 |
Cytotoxicity against HEL cells assessed as morphological alteration after 3 days |
CHEMBL1142504 |
| HEL |
CC50 |
= |
137.0 |
ug.mL-1 |
Cytotoxicity against HEL cells assessed as reduction of growth after 3 days |
CHEMBL1142504 |
| Human herpesvirus 5 strain AD169 |
EC50 |
|
|
|
Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as inhibition of viral cytopathicity |
CHEMBL1142504 |
| Human herpesvirus 5 |
EC50 |
|
|
|
Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as inhibition of viral cytopathicity |
CHEMBL1142504 |
| Human herpesvirus 4 |
EC50 |
= |
3300.0 |
nM |
Antiviral activity against Epstein-Barr virus infected in human Akata cells by DNA hybridization assay |
CHEMBL1138503 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human Akata cells |
CHEMBL1138503 |
| Hepatitis B virus |
Activity |
|
|
|
Antiviral activity against Hepatitis B virus |
CHEMBL1138503 |
| Hepatitis C virus |
Activity |
|
|
|
Antiviral activity against Hepatitis C virus |
CHEMBL1138503 |
| Vero |
CC50 |
> |
10.0 |
ug.mL-1 |
Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay |
CHEMBL1150133 |
| Human herpesvirus 1 |
IC50 |
= |
0.5 |
ug.mL-1 |
Antiviral activity against HSV1 ATCC VR260 by colorimetry |
CHEMBL1158078 |
| Unchecked |
Ratio CC50/IC50 |
|
|
|
Selectivity index, CC50 for human Hep2 cells to IC50 for Cox B3 virus |
CHEMBL1157953 |
| Human coxsackievirus B3 |
IC50 |
= |
25.0 |
ug.mL-1 |
Antiviral activity against Cox B3 virus in human Hep2 cells assessed as reduction of virus induced cytopathic effect |
CHEMBL1157953 |
| Unchecked |
Ratio CC50/IC50 |
|
|
|
Selectivity index, CC50 for MDCK cells to IC50 for influenza A virus H1N1 A/NWS/33 |
CHEMBL1157953 |
| Influenza A virus |
IC50 |
= |
15.7 |
ug.mL-1 |
Antiviral activity against influenza A virus H1N1 A/NWS/33 in human MDCK cells assessed as reduction of virus induced cytopathic effect |
CHEMBL1157953 |
| MDCK |
CC50 |
|
|
|
Cytotoxicity against MDCK cells after 3 days by MTT reduction assay |
CHEMBL1157953 |
| MDCK |
MNCC |
|
|
|
Cytotoxicity against MDCK cells after 3 days by MTT reduction assay |
CHEMBL1157953 |
| Unchecked |
Ratio CC50/IC50 |
> |
2000.0 |
|
Selectivity index, CC50 for african green monkey Vero cells to IC50 for HSV1 15577 |
CHEMBL1157953 |
| Human herpesvirus 1 |
IC50 |
= |
0.25 |
ug.mL-1 |
Antiviral activity against HSV1 15577 in african green monkey Vero cells assessed as reduction of virus induced cytopathic effect |
CHEMBL1157953 |
| Vero |
CC50 |
> |
500.0 |
ug.mL-1 |
Cytotoxicity against african green monkey Vero cells after 3 days by MTT reduction assay |
CHEMBL1157953 |
| Vero |
MNCC |
|
|
|
Cytotoxicity against african green monkey Vero cells after 3 days by MTT reduction assay |
CHEMBL1157953 |
| Unchecked |
Ratio CC50/IC50 |
|
|
|
Selectivity index, CC50 for human Hep2 cells to IC50 for RSV Long |
CHEMBL1157953 |
| Respiratory syncytial virus |
IC50 |
|
|
|
Antiviral activity against RSV Long in human Hep2 cells assessed as reduction of virus induced cytopathic effect |
CHEMBL1157953 |
| ADMET |
CC50 |
|
|
|
Cytotoxicity against human Hep2 cells after 3 days by MTT reduction assay |
CHEMBL1157953 |
| ADMET |
MNCC |
|
|
|
Cytotoxicity against human Hep2 cells after 3 days by MTT reduction assay |
CHEMBL1157953 |
| Human herpesvirus 1 |
EC50 |
= |
0.24 |
ug.mL-1 |
Antiviral activity against HSV1 |
CHEMBL1158662 |
| Human herpesvirus 2 |
EC50 |
= |
0.22 |
ug.mL-1 |
Antiviral activity against HSV2 |
CHEMBL1158662 |
| Human herpesvirus 1 |
IC50 |
= |
1.1 |
ug.mL-1 |
Antiviral activity against HSV1 |
CHEMBL1157224 |
| Human herpesvirus 1 |
EC50 |
= |
400.0 |
nM |
Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus induced cytopathicity within 48 hrs |
CHEMBL1155837 |
| Human herpesvirus 2 |
EC50 |
= |
200.0 |
nM |
Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus induced cytopathicity within 48 hrs |
CHEMBL1155837 |
| Human herpesvirus 1 |
EC50 |
= |
50000.0 |
nM |
Antiviral activity against acyclovir-resistant and thymidine kinase deficient HSV1 KOS in HEL cells assessed as inhibition of virus induced cytopathicity within 48 hrs |
CHEMBL1155837 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against HEL cells assessed as alteration of cell morphology |
CHEMBL1155837 |
| Human herpesvirus 3 |
EC50 |
= |
2500.0 |
nM |
Antiviral activity against TK+ VZV OKA infected HEL cells assessed as reduction in virus plaque formation after 5 days |
CHEMBL1155837 |
| Human herpesvirus 3 |
EC50 |
= |
2900.0 |
nM |
Antiviral activity against TK+ VZV YS infected HEL cells assessed as reduction in virus plaque formation after 5 days |
CHEMBL1155837 |
| Human herpesvirus 3 |
EC50 |
= |
61000.0 |
nM |
Antiviral activity against thymidine kinase deficient VZV 07/1 infected HEL cells assessed as reduction in virus plaque formation after 5 days |
CHEMBL1155837 |
| HEL |
CC50 |
= |
1350000.0 |
nM |
Cytotoxicity against HEL cells assessed as inhibition of cell proliferation |
CHEMBL1155837 |
| Human herpesvirus 2 |
EC50 |
= |
6000.0 |
nM |
Antiviral activity against acyclovir-sensitive HSV2 HG32 in african green monkey Vero cells assessed as inhibition of virus plaque formation |
CHEMBL1155837 |
| Human herpesvirus 2 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against acyclovir-resistant HSV2 ACR in african green monkey Vero cells assessed as inhibition of virus plaque formation |
CHEMBL1155837 |
| Human herpesvirus 3 |
EC50 |
= |
43000.0 |
nM |
Antiviral activity against thymidine kinase deficient VZV YS/R infected HEL cells assessed as reduction in virus plaque formation after 5 days |
CHEMBL1155837 |
| Human herpesvirus 4 |
IC50 |
= |
6900.0 |
nM |
Antiviral activity against EBV lytic replication in GG68 cells after 72 hrs by Southern blot analysis |
CHEMBL1155120 |
| HFF |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay |
CHEMBL1155120 |
| Human herpesvirus 3 |
IC50 |
= |
8100.0 |
nM |
Antiviral activity against VZV Webster by plaque reduction assay |
CHEMBL1155120 |
| Human herpesvirus 1 |
IC50 |
= |
2100.0 |
nM |
Antiviral activity against HSV1 KOS by plaque reduction assay |
CHEMBL1155120 |
| Human herpesvirus 5 |
IC50 |
> |
20000.0 |
nM |
Antiviral activity against HCMV Davis by plaque reduction assay |
CHEMBL1155120 |
| Monoamine oxidase A |
Activity |
|
|
|
Inhibition of mouse brain MAOA |
CHEMBL1152129 |
| Monoamine oxidase B |
Activity |
|
|
|
Inhibition of mouse brain MAOB |
CHEMBL1152129 |
| Human herpesvirus 1 |
IC50 |
= |
3040.0 |
nM |
Antiviral activity against acyclovir-sensitive HSV1 KOS isolate replication in african green monkey Vero cells by plaque reduction assay |
CHEMBL1139254 |
| Human herpesvirus 1 |
IC50 |
= |
31200.0 |
nM |
Antiviral activity against acyclovir-resistant HSV1 KOS-M isolate replication in african green monkey Vero cells by plaque reduction assay |
CHEMBL1139254 |
| Human herpesvirus 1 |
IC50 |
= |
580.0 |
nM |
Antiviral activity against acyclovir-sensitive HSV1 K161 isolate replication in african green monkey Vero cells by plaque reduction assay |
CHEMBL1139254 |
| Human herpesvirus 1 |
IC50 |
= |
75070.0 |
nM |
Antiviral activity against acyclovir-resistant HSV1 K143 isolate replication in african green monkey Vero cells by plaque reduction assay |
CHEMBL1139254 |
| Human herpesvirus 1 |
IC50 |
= |
320.0 |
nM |
Antiviral activity against acyclovir-sensitive HSV1 L177 isolate replication in african green monkey Vero cells by plaque reduction assay |
CHEMBL1139254 |
| Human herpesvirus 1 |
IC50 |
= |
9510.0 |
nM |
Antiviral activity against acyclovir-resistant HSV1 L182 isolate replication in african green monkey Vero cells by plaque reduction assay |
CHEMBL1139254 |
| Human herpesvirus 5 |
IC50 |
|
|
|
Antiviral activity against ganciclovir-sensitive HCMV1 isolate replication in HFF cells by plaque reduction assay |
CHEMBL1139254 |
| Human herpesvirus 5 |
IC50 |
|
|
|
Antiviral activity against ganciclovir-resistant HCMV3 isolate replication in HFF cells by plaque reduction assay |
CHEMBL1139254 |
| Human herpesvirus 5 |
IC50 |
|
|
|
Antiviral activity against ganciclovir-resistant HCMV U405 isolate replication in HFF cells by plaque reduction assay |
CHEMBL1139254 |
| Vaccinia virus |
IC50 |
= |
384.0 |
nM |
Antiviral activity against Vaccinia virus |
CHEMBL1136837 |
| Human herpesvirus 1 |
EC50 |
= |
0.18 |
ug.mL-1 |
Antiviral activity against HSV1 assessed as inhibition of virus-induced cytopathicity |
CHEMBL1136856 |
| Human herpesvirus 2 |
EC50 |
= |
0.36 |
ug.mL-1 |
Antiviral activity against HSV2 assessed as inhibition of virus-induced cytopathicity |
CHEMBL1136856 |
| Human herpesvirus 3 |
EC50 |
= |
1100.0 |
nM |
Antiviral activity against thymidine kinase expressing Varicella zoster virus Oka infected in human HEL cells assessed reduction in viral plaque formation |
CHEMBL1152768 |
| Human herpesvirus 3 |
EC50 |
= |
72000.0 |
nM |
Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed reduction in viral plaque formation |
CHEMBL1152768 |
| HEL |
MCC |
> |
200000.0 |
nM |
Cytotoxicity against human HEL cells assessed as morphological alteration after 3 days |
CHEMBL1152768 |
| HEL |
CC50 |
= |
733000.0 |
nM |
Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days |
CHEMBL1152768 |
| Human herpesvirus 5 |
EC50 |
= |
7500.0 |
nM |
Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1152768 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
15000.0 |
nM |
Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1152768 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
4300.0 |
nM |
Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1152768 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
176000.0 |
nM |
Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1152768 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
7600.0 |
nM |
Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1152768 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
125000.0 |
nM |
Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1152768 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
1000.0 |
nM |
Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1152768 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
200000.0 |
nM |
Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1152768 |
| HeLa |
CC100 |
> |
600.0 |
ug ml-1 |
Cytotoxicity against human HeLa cells |
CHEMBL1158392 |
| Human herpesvirus 1 |
Activity |
= |
10.0 |
|
Antiviral activity against HSV1 infected in human HeLa cells assessed as viral reduction factor preincubated for 0.5 hrs before infection measured after 36 hrs by end point titration technique relative to control |
CHEMBL1158392 |
| Human herpesvirus 1 |
Activity |
= |
6.0 |
ug ml-1 |
Antiviral activity against HSV1 infected in human HeLa cells assessed as maximum dose required for highest viral reduction factor preincubated for 0.5 hrs before infection measured after 36 hrs by end point titration technique |
CHEMBL1158392 |
| Human herpesvirus 1 |
EC50 |
= |
300.0 |
nM |
Antiviral activity against Herpes simplex virus type 1 in african green monkey BSC1 cells by plaque reduction assay |
CHEMBL1158417 |
| Human herpesvirus 1 |
EC50 |
= |
1300.0 |
nM |
Antiviral activity against Herpes simplex virus type 1 in HFF assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1158417 |
| HFF |
CC50 |
> |
300000.0 |
nM |
Cytotoxicity against HFF by neutral red uptake assay |
CHEMBL1158417 |
| Human herpesvirus 2 |
EC50 |
= |
1200.0 |
nM |
Antiviral activity against Herpes simplex virus type 2 in HFF assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1158417 |
| Human herpesvirus 3 |
EC50 |
= |
4400.0 |
nM |
Antiviral activity against Varicella zoster virus in HFF by plaque reduction assay |
CHEMBL1158417 |
| Equus caballus |
Cmax |
= |
47511.21 |
nM |
Total Cmax in horse at 10 mg/kg, iv after 1 hr by two-compartmental study |
CHEMBL1151420 |
| Equus caballus |
fCmax |
= |
10.5 |
ug ml-1 |
fCmax in horse at 10 mg/kg, iv after 1 hr by three-compartmental study |
CHEMBL1151420 |
| Equus caballus |
T1/2 |
= |
0.23 |
hr |
Total primary phase half life in horse at distribution phase at 10 mg/kg, iv after 1 hr by two-compartmental study |
CHEMBL1151420 |
| Equus caballus |
T1/2 |
= |
5.05 |
hr |
Total terminal half life in horse at elimination phase at 10 mg/kg, iv after 1 hr by two-compartmental study |
CHEMBL1151420 |
| Equus caballus |
Activity |
|
|
|
Renal toxicity in horse assessed as changes in urea level |
CHEMBL1151420 |
| Equus caballus |
Activity |
|
|
|
Renal toxicity in horse assessed as changes in creatinine level |
CHEMBL1151420 |
| Equus caballus |
T1/2 |
= |
0.1 |
hr |
Free primary phase half life in horse at rapid distribution phase at 10 mg/kg, iv after 1 hr by three-compartmental study |
CHEMBL1151420 |
| Equus caballus |
T1/2 |
= |
1.23 |
hr |
Free terminal half life in horse at slow distribution phase at 10 mg/kg, iv after 1 hr by three-compartmental study |
CHEMBL1151420 |
| Equus caballus |
T1/2 |
= |
11.9 |
hr |
Free redistribution half life in horse at elimination phase at 10 mg/kg, iv after 1 hr by three-compartmental study |
CHEMBL1151420 |
| Equus caballus |
CL |
= |
9.833 |
mL.min-1.kg-1 |
Total clearance in horse at 10 mg/kg, iv after 1 hr by two-compartmental study |
CHEMBL1151420 |
| Equus caballus |
CL |
= |
6.8329999999999975 |
mL.min-1.kg-1 |
Free clearance in horse at 10 mg/kg, iv after 1 hr by three-compartmental study |
CHEMBL1151420 |
| Equus caballus |
Vd |
= |
0.36 |
L.kg-1 |
Total volume of distribution in central compartment in horse at 10 mg/kg, iv after 1 hr by two-compartmental study |
CHEMBL1151420 |
| Equus caballus |
Vd |
= |
0.27 |
L.kg-1 |
Free volume of distribution in central compartment in horse at 10 mg/kg, iv after 1 hr by three-compartmental study |
CHEMBL1151420 |
| Equus caballus |
Vdss |
= |
2.96 |
L.kg-1 |
Total apparent volume of distribution in horse at 10 mg/kg, iv after 1 hr by two-compartmental study |
CHEMBL1151420 |
| Equus caballus |
AUC |
= |
18000.0 |
ng.hr.mL-1 |
Total AUC in horse at 10 mg/kg, iv after 1 hr by two-compartmental study |
CHEMBL1151420 |
| Equus caballus |
fAUC |
= |
24600.0 |
ng.hr.mL-1 |
fAUC in horse at 10 mg/kg, iv after 1 hr by three-compartmental study |
CHEMBL1151420 |
| Equus caballus |
MRT |
= |
5.38 |
hr |
Total mean residence time in horse at 10 mg/kg, iv after 1 hr by two-compartmental study |
CHEMBL1151420 |
| Equus caballus |
MRT |
= |
23.1 |
hr |
Free mean residence time in horse at 10 mg/kg, iv after 1 hr by three-compartmental study |
CHEMBL1151420 |
| Equus caballus |
Cmax |
= |
1465.3 |
nM |
Total Cmax in horse at 20 mg/kg, po administered as single dose |
CHEMBL1151420 |
| Equus caballus |
fCmax |
= |
0.4 |
ug ml-1 |
fCmax in horse at 20 mg/kg, po administered as single dose |
CHEMBL1151420 |
| Equus caballus |
Tmax |
= |
1.04 |
hr |
Total Tmax in horse at 20 mg/kg, po administered as single dose |
CHEMBL1151420 |
| Equus caballus |
Tmax |
= |
1.06 |
hr |
fTmax in horse at 20 mg/kg, po administered as single dose |
CHEMBL1151420 |
| Equus caballus |
T1/2 |
= |
1.56 |
hr |
Total elimination half life in horse at 20 mg/kg, po administered as single dose |
CHEMBL1151420 |
| Equus caballus |
T1/2 |
= |
13.5 |
hr |
Free elimination half life in horse at 20 mg/kg, po administered as single dose |
CHEMBL1151420 |
| Equus caballus |
AUC |
= |
1160.0 |
ng.hr.mL-1 |
Total AUC in horse at 20 mg/kg, po administered as single dose |
CHEMBL1151420 |
| Equus caballus |
fAUC |
= |
3530.0 |
ng.hr.mL-1 |
fAUC in horse at 20 mg/kg, po administered as single dose |
CHEMBL1151420 |
| Equus caballus |
F |
= |
3.13 |
% |
Total oral bioavailability in horse at 20 mg/kg administered as single dose |
CHEMBL1151420 |
| Equus caballus |
F |
= |
7.52 |
% |
Free oral bioavailability in horse at 20 mg/kg administered as single dose |
CHEMBL1151420 |
| Equid herpesvirus 1 |
EC50 |
= |
1.7 |
ug.mL-1 |
Antiviral activity against EHV1 assessed as inhibition of plaque formation |
CHEMBL1151420 |
| Homo sapiens |
F |
= |
54.0 |
% |
Oral bioavailability in human |
CHEMBL1151420 |
| Equus caballus |
Cp |
= |
50.0 |
ng/ml |
Plasma concentration in horse at 20 mg/kg, po administered as single dose after 5 hrs |
CHEMBL1151420 |
| Equus caballus |
Cmax |
= |
205141.87 |
nM |
Cmax in horse at 10 mg/kg, iv after 15 mins |
CHEMBL1151420 |
| Equus caballus |
AUC |
= |
37300.0 |
ng.hr.mL-1 |
AUC in horse at 10 mg/kg, iv |
CHEMBL1151420 |
| Equus caballus |
CL |
= |
0.3 |
L/hr |
Total body clearance in horse at 10 mg/kg, iv |
CHEMBL1151420 |
| Equus caballus |
Vdss |
= |
3.54 |
L.kg-1 |
Apparent volume of distribution at steady state in horse at 10 mg/kg, iv |
CHEMBL1151420 |
| Equus caballus |
F |
= |
2.8 |
% |
Oral bioavailability in horse at 20 mg/kg administered as single dose |
CHEMBL1151420 |
| No relevant target |
Solubility |
= |
1000.0 |
ug.mL-1 |
Solubility at pH 2.3 to 9.2 |
CHEMBL1151420 |
| No relevant target |
LogP |
= |
-1.59 |
|
Distribution coefficient, log P of the compound |
CHEMBL1151420 |
| ADMET |
PPB |
= |
10.0 |
% |
Protein binding in horse pooled plasma at 0.5 to 15 ug/ml |
CHEMBL1151420 |
| ADMET |
Fu |
= |
0.8 |
ug ml-1 |
Fraction unbound in horse plasma |
CHEMBL1151420 |
| Equus caballus |
Cmax |
= |
46179.12 |
nM |
Cmax in iv dosed adult horse |
CHEMBL1151420 |
| Equus caballus |
AUC |
= |
19200.0 |
ng.hr.mL-1 |
AUC in iv dosed adult horse |
CHEMBL1151420 |
| Equus caballus |
T1/2 |
= |
9.6 |
hr |
Elimination half life in iv dosed adult horse |
CHEMBL1151420 |
| Equus caballus |
MRT |
= |
7.09 |
hr |
Mean residence time in iv dosed adult horse |
CHEMBL1151420 |
| Equus caballus |
Vdss |
= |
9.81 |
L.kg-1 |
Free apparent volume of distribution in horse at 10 mg/kg, iv after 1 hr by three-compartmental study |
CHEMBL1151420 |
| Homo sapiens |
CL |
= |
4.7 |
mL.min-1.kg-1 |
Total body clearance in human |
CHEMBL1151930 |
| Homo sapiens |
CL_renal |
= |
3.57 |
mL.min-1.kg-1 |
Renal clearance in human |
CHEMBL1151930 |
| Human herpesvirus 1 |
IC50 |
= |
4300.0 |
nM |
Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days |
CHEMBL1152922 |
| Vero |
MNCC |
= |
1.11 |
mM |
Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay |
CHEMBL1152922 |
| Human herpesvirus 1 |
IC50 |
= |
6.86 |
ug.mL-1 |
Antiviral activity against HSV1 by green fluorescent protein microplate assay |
CHEMBL1152941 |
| CCRF-CEM |
IC50 |
> |
250000.0 |
nM |
Cytotoxicity against human CEM cells assessed as decrease in cell viability |
CHEMBL1153518 |
| Human immunodeficiency virus 1 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against HIV1 3B/Lai infected in human MT4 cells assessed as suppression of p24 production after 3 days |
CHEMBL1153518 |
| Human immunodeficiency virus 2 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days |
CHEMBL1153518 |
| Human immunodeficiency virus 1 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against HIV1 3B/Lai infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days |
CHEMBL1153518 |
| HEL |
IC50 |
|
|
|
Cytotoxicity against HEL cells assessed as inhibition of cell proliferation |
CHEMBL1153518 |
| HEL |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against HEL cells assessed as concentration required to cause alteration in cell alteration by microscopically |
CHEMBL1153518 |
| Human herpesvirus 1 |
EC50 |
= |
50000.0 |
nM |
Antiviral activity against acyclovir 5-monophosphate-resistant thymidine kinase-deficient HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1153518 |
| Human herpesvirus 2 |
EC50 |
= |
200.0 |
nM |
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1153518 |
| Human herpesvirus 1 |
EC50 |
= |
400.0 |
nM |
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1153518 |
| MT4 |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against human MT4 cells assessed as inhibition of cell proliferation |
CHEMBL1153518 |
| MT4 |
IC50 |
> |
250000.0 |
nM |
Cytotoxicity against human MT4 cells assessed as decrease in cell viability |
CHEMBL1153518 |
| Human herpesvirus 1 |
Activity |
= |
12.0 |
% |
Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as reduction in virus plaque formation at 10 ug per 10'5 cells by plaque infectivity assay |
CHEMBL1152999 |
| Human herpesvirus 1 |
Activity |
= |
28.0 |
% |
Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as reduction in virus plaque formation at 20 ug per 10'5 cells by plaque infectivity assay |
CHEMBL1152999 |
| Human herpesvirus 3 |
EC50 |
= |
2000.0 |
nM |
Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days |
CHEMBL1153001 |
| Human herpesvirus 3 |
EC50 |
= |
1800.0 |
nM |
Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days |
CHEMBL1153001 |
| Human herpesvirus 3 |
EC50 |
= |
62200.0 |
nM |
Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days |
CHEMBL1153001 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
178000.0 |
nM |
Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection |
CHEMBL1153001 |
| Human herpesvirus 5 |
EC50 |
= |
45000.0 |
nM |
Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection |
CHEMBL1153001 |
| HEL |
MCC |
> |
1778000.0 |
nM |
Cytotoxicity against human HEL cells assessed as microscopically detectable morphological alterations after 3 days |
CHEMBL1153001 |
| HEL |
CC50 |
= |
782000.0 |
nM |
Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days |
CHEMBL1153001 |
| Human herpesvirus 1 |
MIC50 |
= |
0.4 |
ug.mL-1 |
Antiviral activity against HSV1 KOS infected in HEL cells assessed as protection against virus-induced cytopathogenicity |
CHEMBL1153581 |
| Human herpesvirus 2 |
MIC50 |
= |
0.4 |
ug.mL-1 |
Antiviral activity against Herpes simplex virus 2 infected in HEL cells assessed as protection against in virus-induced cytopathogenicity |
CHEMBL1153581 |
| Vaccinia virus |
MIC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity |
CHEMBL1153581 |
| Vesicular stomatitis virus |
MIC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against sVesicular stomatitis virus infected in HEL cells assessed as protection against virus-induced cytopathogenicity |
CHEMBL1153581 |
| Human herpesvirus 1 |
MIC50 |
= |
50.0 |
ug.mL-1 |
Antiviral activity against acyclovir-resistant thymidine kinase-deficient HSV1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity |
CHEMBL1153581 |
| HEL |
MCC |
> |
250.0 |
ug.mL-1 |
Cytotoxicity against HEL cells assessed as change in cell morphology |
CHEMBL1153581 |
| Human herpesvirus 1 |
EC50 |
= |
3000.0 |
nM |
Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay |
CHEMBL1154067 |
| MT4 |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human MT4 cells after 96 hrs by MTT assay |
CHEMBL1154067 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDBK cells after 48 to 96 hrs by MTT assay |
CHEMBL1154067 |
| Bovine viral diarrhea virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Bovine viral diarrhea virus infected in MDBK cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay |
CHEMBL1154067 |
| Yellow fever virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay |
CHEMBL1154067 |
| Mammalian orthoreovirus 1 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay |
CHEMBL1154067 |
| Vero |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining |
CHEMBL1154067 |
| Human coxsackievirus B2 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay |
CHEMBL1154067 |
| Respiratory syncytial virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay |
CHEMBL1154067 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay |
CHEMBL1154067 |
| NON-PROTEIN TARGET |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Human poliovirus 1 strain Sabin after 2 days by plaque reduction assay |
CHEMBL1154067 |
| Homo sapiens |
Fg |
= |
1.05 |
|
Fraction escaping gut-wall elimination in human |
CHEMBL1156824 |
| Homo sapiens |
CL |
= |
1.1 |
mL.min-1.kg-1 |
Hepatic clearance in human |
CHEMBL1156824 |
| Homo sapiens |
CL_renal |
= |
3.6 |
mL.min-1.kg-1 |
Renal clearance in human |
CHEMBL1156824 |
| Homo sapiens |
CL |
= |
4.7 |
mL.min-1.kg-1 |
Total clearance in human |
CHEMBL1156824 |
| ADMET |
permeability |
= |
0.8 |
10'-6 cm/s |
Permeability at pH 6.5 by PAMPA method |
CHEMBL1156784 |
| Homo sapiens |
F |
= |
21.0 |
% |
Oral bioavailability in human |
CHEMBL1156784 |
| Homo sapiens |
F_fraction |
= |
0.23 |
|
Oral bioavailability in human |
CHEMBL1156824 |
| Homo sapiens |
Fa |
= |
0.23 |
|
Fraction absorbed in human |
CHEMBL1156824 |
| Homo sapiens |
Vdss |
= |
0.71 |
L.kg-1 |
Volume of distribution at steady state in human |
CHEMBL1156824 |
| Plasma |
Fu |
= |
0.85 |
|
Fraction unbound in human plasma |
CHEMBL1156824 |
| Homo sapiens |
Fh |
= |
0.95 |
|
Fraction escaping hepatic elimination in human |
CHEMBL1156824 |
| NON-PROTEIN TARGET |
IC50 |
= |
390.0 |
nM |
Antiviral activity against HSV1 SC16 infected in african green monkey Vero cells by hybrid capture method |
CHEMBL1156004 |
| Vero |
CC50 |
> |
200000.0 |
nM |
Cytotoxicity against african green monkey Vero cells |
CHEMBL1156004 |
| Caco-2 |
logPapp |
= |
-6.15 |
|
Permeability across human Caco-2 cells |
CHEMBL1152590 |
| Human herpesvirus 3 |
EC50 |
= |
840.0 |
nM |
Antiviral activity against thymidine kinase expressing Varicella Zoster Virus OKA infected in HEL cells assessed as reduction of viral plaque formation |
CHEMBL1156851 |
| Human herpesvirus 3 |
EC50 |
= |
26700.0 |
nM |
Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in HEL cells assessed as reduction of viral plaque formation |
CHEMBL1156851 |
| HEL |
MCC |
> |
1778000.0 |
nM |
Cytotoxicity against HEL cells assessed as microscopically detectable alteration of cell morphology |
CHEMBL1156851 |
| HEL |
CC50 |
= |
1778000.0 |
nM |
Cytotoxicity against HEL cells assessed as reduction of cell growth |
CHEMBL1156851 |
| Human herpesvirus 5 |
IC50 |
= |
20000.0 |
nM |
Antiviral activity against Human cytomegalovirus infected in HFF cells by plaque reduction assay |
CHEMBL1155400 |
| Human herpesvirus 3 |
IC50 |
= |
8100.0 |
nM |
Antiviral activity against Varicella zoster virus infected in HFF cells by plaque reduction assay |
CHEMBL1155400 |
| Human herpesvirus 1 |
IC50 |
= |
13000.0 |
nM |
Antiviral activity against Herpes simplex virus type 1 |
CHEMBL1154864 |
| Vero |
CC100 |
> |
600.0 |
ug ml-1 |
Cytotoxicity against african green monkey Vero cells assessed as minimal toxic dosed detached 100% of the cell monolayer |
CHEMBL1153719 |
| Human herpesvirus 1 |
Ratio |
= |
1000.0 |
|
Antiviral activity against Human herpesvirus 1 infected in african green monkey Vero cells assessed as ratio of viral titer in absence of drug over viral titer in presence of drug after 36 hrs by end point titration method |
CHEMBL1153719 |
| Human herpesvirus 1 |
Activity |
= |
6.0 |
ug ml-1 |
Antiviral activity against Human herpesvirus 1 infected in african green monkey Vero cells assessed as maximal nontoxic dose caused highest viral reduction factor after 36 hrs by end point titration method |
CHEMBL1153719 |
| Plasma |
logFu |
= |
0.85 |
|
Fraction unbound in human plasma |
CHEMBL1153781 |
| Homo sapiens |
Vdss |
= |
0.69 |
L.kg-1 |
Volume of distribution at steady state in human |
CHEMBL1153781 |
| Human herpesvirus 1 |
INH |
= |
0.0043 |
mM |
Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by crystal violet staining |
CHEMBL1154307 |
| Vero |
MNCC |
= |
1.11 |
mM |
Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay |
CHEMBL1154307 |
| Human poliovirus 1 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay |
CHEMBL1156237 |
| Human coxsackievirus B2 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay |
CHEMBL1156237 |
| Yellow fever virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Yellow fever virus 17D infected in BHK cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method |
CHEMBL1156237 |
| Bovine viral diarrhea virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Bovine viral diarrhea virus NADL infected in MDBK cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method |
CHEMBL1156237 |
| Vero |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against african green monkey Vero cells |
CHEMBL1156237 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against BHK cells after 48 to 96 hrs by MTT assay |
CHEMBL1156237 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDBK cells after 48 to 96 hrs by MTT assay |
CHEMBL1156237 |
| MT4 |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human MT4 cells after 96 hrs by MTT assay |
CHEMBL1156237 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus Elstree-Lister infected in african green monkey Vero cells after 3 days by plaque reduction assay |
CHEMBL1156237 |
| Respiratory syncytial virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay |
CHEMBL1156237 |
| Human herpesvirus 1 |
EC50 |
= |
3000.0 |
nM |
Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay |
CHEMBL1156237 |
| Homo sapiens |
Activity |
= |
0.23 |
% |
Human intestinal absorption in po dosed human |
CHEMBL1157012 |
| MDCK |
logPapp |
= |
-5.87 |
|
Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells |
CHEMBL1158536 |
| Unchecked |
IC50 |
> |
20000.0 |
nM |
Inhibition of HCMV DNA polymerase infected in HFF cells |
CHEMBL1157125 |
| Human herpesvirus 1 |
IC50 |
= |
2100.0 |
nM |
Antiviral activity against HSV1 KOS infected in african green monkey Vero cells assessed as reduction in plaque formation |
CHEMBL1157125 |
| Human herpesvirus 3 |
IC50 |
= |
8100.0 |
nM |
Antiviral activity against VZV Webster infected in HFF cells assessed as reduction in plaque formation |
CHEMBL1157125 |
| HFF |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay |
CHEMBL1157125 |
| Purine nucleoside phosphorylase |
Kd |
= |
12589.25 |
nM |
Binding affinity to Mycobacterium tuberculosis purine nucleoside phosphorylase by spectrophotometric analysis |
CHEMBL1177645 |
| Macacine herpesvirus 1 |
Activity |
= |
33.0 |
% |
Antiviral activity against Macacine herpesvirus 1 infected in rabbits assessed as survival after 5 months |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Human herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Human herpesvirus 2 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Vero |
MNCC |
= |
1.11 |
mM |
Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay |
CHEMBL1221229 |
| Human herpesvirus 1 |
IC50 |
= |
4300.0 |
nM |
Antiviral activity against HSV1 infected african green monkey Vero cells assessed as reduction of plaque formation after 3 days by using crystal violet stain |
CHEMBL1221229 |
| ADMET |
MNTD |
= |
1.6 |
ug ml-1 |
Cytotoxicity against MDBK cells after 48 hrs |
CHEMBL1240443 |
| Human herpesvirus 1 |
TCID50 |
= |
0.012 |
ug ml-1 |
Antiviral activity against HSV1 infected in MDCK cells assessed as reduction of virus-induced cytopathic effect |
CHEMBL1240443 |
| Human parainfluenza virus 3 |
TCID50 |
= |
0.012 |
ug ml-1 |
Antiviral activity against parainfluenza-3 virus infected in Vero cells assessed as reduction of virus-induced cytopathic effect |
CHEMBL1240443 |
| Unchecked |
Inhibition |
|
|
% |
Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay |
CHEMBL1255231 |
| Homo sapiens |
Cmax |
= |
42000.0 |
nM |
Cmax in human systemic circulation with normal renal function at 2000 mg, po every 6 hrs measured after fifth dose by radioimmunoassay |
CHEMBL1255392 |
| Homo sapiens |
Cmax |
= |
7800.0 |
nM |
Cmax in human CSF with normal renal function at 2000 mg, po every 6 hrs measured after fifth dose by radioimmunoassay |
CHEMBL1255392 |
| Homo sapiens |
Cmax |
= |
82000.0 |
nM |
Cmax in human systemic circulation with chronic kidney disease at 1500 mg, po every 12 hrs measured after fifth dose by radioimmunoassay |
CHEMBL1255392 |
| Homo sapiens |
Cmax |
= |
16000.0 |
nM |
Cmax in human CSF with chronic kidney disease at 1500 mg, po every 12 hrs measured after fifth dose by radioimmunoassay |
CHEMBL1255392 |
| Homo sapiens |
Tmax |
= |
2.1 |
hr |
Tmax in human systemic circulation with normal renal function at 2000 mg, po every 6 hrs measured after fifth dose by radioimmunoassay |
CHEMBL1255392 |
| Homo sapiens |
Tmax |
= |
2.3 |
hr |
Tmax in human CSF with normal renal function at 2000 mg, po every 6 hrs measured after fifth dose by radioimmunoassay |
CHEMBL1255392 |
| Homo sapiens |
Tmax |
= |
2.0 |
hr |
Tmax in human systemic circulation with chronic kidney disease at 1500 mg, po every 12 hrs measured after fifth dose by radioimmunoassay |
CHEMBL1255392 |
| Homo sapiens |
Tmax |
= |
5.3 |
hr |
Tmax in human CSF with chronic kidney disease at 1500 mg, po every 12 hrs measured after fifth dose by radioimmunoassay |
CHEMBL1255392 |
| Homo sapiens |
AUC |
= |
30853.77 |
ng.hr.mL-1 |
AUC (0 to 6 hrs) in human systemic circulation with normal renal function at 2000 mg, po every 6 hrs measured after fifth dose by radioimmunoassay |
CHEMBL1255392 |
| Homo sapiens |
AUC |
= |
8332.77 |
ng.hr.mL-1 |
AUC (0 to 6 hrs) in human CSF with normal renal function at 2000 mg, po every 6 hrs measured after fifth dose by radioimmunoassay |
CHEMBL1255392 |
| Homo sapiens |
AUC |
= |
129946.17 |
ng.hr.mL-1 |
AUC (0 to 12 hrs) in human systemic circulation with chronic kidney disease at 1500 mg, po every 12 hrs measured after fifth dose by radioimmunoassay |
CHEMBL1255392 |
| Homo sapiens |
AUC |
= |
35808.39 |
ng.hr.mL-1 |
AUC (0 to 12 hrs) in human CSF with chronic kidney disease at 1500 mg, po every 12 hrs measured after fifth dose by radioimmunoassay |
CHEMBL1255392 |
| Homo sapiens |
CL/F |
= |
759.0 |
ml/min |
Apparent oral clearance in human systemic circulation with normal renal function at 2000 mg, po every 6 hrs measured after fifth dose by radioimmunoassay |
CHEMBL1255392 |
| Homo sapiens |
CL/F |
= |
145.0 |
ml/min |
Apparent oral clearance in human systemic circulation with chronic kidney disease at 1500 mg, po every 12 hrs measured after fifth dose by radioimmunoassay |
CHEMBL1255392 |
| Homo sapiens |
Drug uptake |
= |
23.0 |
uM |
Drug level in human plasma with normal renal function at 2000 mg, po every 6 hrs measured after fifth dose by radioimmunoassay |
CHEMBL1255392 |
| Homo sapiens |
Drug uptake |
= |
48.0 |
uM |
Drug level in human plasma with chronic kidney disease at 1500 mg, po every 12 hrs measured after fifth dose by radioimmunoassay |
CHEMBL1255392 |
| Homo sapiens |
Drug uptake |
= |
6.25 |
uM |
Drug level in human CSF with normal renal function at 2000 mg, po every 6 hrs measured after fifth dose by radioimmunoassay |
CHEMBL1255392 |
| Homo sapiens |
Drug uptake |
= |
13.3 |
uM |
Drug level in human CSF with chronic kidney disease at 1500 mg, po every 12 hrs measured after fifth dose by radioimmunoassay |
CHEMBL1255392 |
| Homo sapiens |
Ratio |
= |
0.19 |
|
Ratio of Cmax in human CSF to Cmax in human plasma with normal renal function at 2000 mg, po every 6 hrs measured after fifth dose by radioimmunoassay |
CHEMBL1255392 |
| Homo sapiens |
Ratio |
= |
0.2 |
|
Ratio of Cmax in human CSF to Cmax in human plasma with chronic kidney disease at 1500 mg, po every 12 hrs measured after fifth dose by radioimmunoassay |
CHEMBL1255392 |
| HEL |
MCC |
> |
444000.0 |
nM |
Cytotoxicity against HEL assessed as change in cell morphology |
CHEMBL1255569 |
| HEL |
MCC |
= |
1576000.0 |
nM |
Cytotoxicity against HEL |
CHEMBL1255569 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
160.0 |
nM |
Antiviral activity against HSV1 KOS infected in HEL assessed as reduction in virus-induce cytopathicity |
CHEMBL1255569 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
125000.0 |
nM |
Antiviral activity against acyclovir-resistant HSV1 KOS infected in HEL assessed as reduction in virus-induce cytopathicity |
CHEMBL1255569 |
| Human herpesvirus 2 strain G |
EC50 |
= |
300.0 |
nM |
Antiviral activity against acyclovir-resistant HSV2 strain G infected in HEL assessed as reduction in virus-induce cytopathicity |
CHEMBL1255569 |
| Human herpesvirus 5 |
EC50 |
= |
3690.0 |
nM |
Antiviral activity against acyclovir-resistant VZV OKA infected in HEL assessed as reduction in virus-induce cytopathicity |
CHEMBL1255569 |
| Human herpesvirus 5 |
EC50 |
= |
60400.0 |
nM |
Antiviral activity against acyclovir-resistant VZV 07/1 infected in HEL assessed as reduction in virus-induce cytopathicity |
CHEMBL1255569 |
| Prelamin-A/C |
Potency |
= |
0.9 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Potency |
= |
12589.3 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Compounds that Induce Erasure of Genomic Imprints. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Thyroid stimulating hormone receptor |
Potency |
= |
15848.9 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor. (Class of assay: confirmatory) |
CHEMBL1201862 |
| NON-PROTEIN TARGET |
Potency |
= |
5623.4 |
nM |
PUBCHEM_BIOASSAY: qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2. (Class of assay: confirmatory) [Related PubChem assays: 1815 (Assay for Plasmodium falciparum line 7G8), 1877 (Assay for Plasmodium falciparum line D10), 1816 (Assay for Plasmodium falciparum line GB4), 1876 (Assay for Plasmodium falciparum line 7D3), 1828 (Summary assay)] |
CHEMBL1201862 |
| 4'-phosphopantetheinyl transferase ffp |
Potency |
= |
70794.6 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase). (Class of assay: confirmatory) |
CHEMBL1201862 |
| Ferritin light chain |
Potency |
= |
0.08913 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] |
CHEMBL1201862 |
| Hemoglobin beta chain |
Potency |
= |
12589.3 |
nM |
PUBCHEM_BIOASSAY: Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Ubiquitin carboxyl-terminal hydrolase 2 |
Potency |
= |
12589.3 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Thyroid stimulating hormone receptor |
Potency |
= |
15848.9 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Bloom syndrome protein |
Potency |
= |
501.2 |
nM |
PUBCHEM_BIOASSAY: qHTS Validation Assay for Inhibitors of Bloom's syndrome helicase (BLM). (Class of assay: confirmatory) [Related pubchem assays: 593 (Fluorescein region spectral profiling screen), 594 (Rhodamine region spectral profiling screen)] |
CHEMBL1201862 |
| Endoplasmic reticulum-associated amyloid beta-peptide-binding protein |
Potency |
= |
15848.9 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II). (Class of assay: confirmatory) |
CHEMBL1201862 |
| Bloom syndrome protein |
Potency |
= |
501.2 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM). (Class of assay: confirmatory) [Related pubchem assays: 593 (Fluorescein region spectral profiling screen), 2386 (Probe Development Summary for Inhibitors of Bloom's syndrome helicase (BLM)), 594 (Rhodamine region spectral profiling screen), 2364 (qHTS Validation Assay for Inhibitors of Bloom's syndrome helicase (BLM))] |
CHEMBL1201862 |
| ATP-dependent DNA helicase Q1 |
Potency |
= |
794.3 |
nM |
PUBCHEM_BIOASSAY: Confirmation qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1). (Class of assay: confirmatory) [Related pubchem assays: 593 (Fluorescein region spectral profiling screen), 594 (Rhodamine region spectral profiling screen), 2367 (Probe Development Summary for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1)), 2353 (qHTS Validation Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1)), 2549 (qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1))] |
CHEMBL1201862 |
| ADMET |
Vdss |
= |
0.61 |
L.kg-1 |
Volume of distribution at steady state in monkey after iv administration |
CHEMBL1614629 |
| ADMET |
Vdss |
= |
0.69 |
L.kg-1 |
Volume of distribution at steady state in human after iv administration |
CHEMBL1614629 |
| ADMET |
Vdss |
= |
0.7 |
mL/min/kg |
Volume of distribution at steady state in rat after iv administration |
CHEMBL1614629 |
| ADMET |
Vdss |
= |
0.71 |
L.kg-1 |
Volume of distribution at steady state in human after iv administration |
CHEMBL1614632 |
| NON-PROTEIN TARGET |
Fu |
= |
0.85 |
|
Fraction unbound in human after iv administration |
CHEMBL1614632 |
| ADMET |
Vdss |
= |
1.2 |
L.kg-1 |
Volume of distribution at steady state in dog after iv administration |
CHEMBL1614629 |
| ADMET |
MRT |
= |
2.5 |
hr |
Mean residence time in human after iv administration |
CHEMBL1614632 |
| ADMET |
T1/2 |
= |
2.5 |
hr |
Half life in human after iv administration |
CHEMBL1614632 |
| ADMET |
CL |
= |
3.4 |
mL.min-1.kg-1 |
Clearance in human after iv administration |
CHEMBL1614629 |
| ADMET |
CL |
= |
4.7 |
mL.min-1.kg-1 |
Clearance in human after iv administration |
CHEMBL1614632 |
| ADMET |
CL |
= |
5.8 |
mL.min-1.kg-1 |
Clearance in dog after iv administration |
CHEMBL1614629 |
| ADMET |
CL |
= |
6.7 |
mL.min-1.kg-1 |
Clearance in rat after iv administration |
CHEMBL1614629 |
| ADMET |
CL |
= |
8.4 |
mL.min-1.kg-1 |
Clearance in monkey after iv administration |
CHEMBL1614629 |
| Human herpesvirus 3 |
EC50 |
= |
3300.0 |
nM |
Antiviral activity against VZV OKA expressing thymidine kinase infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days |
CHEMBL1649078 |
| Human herpesvirus 3 |
EC50 |
= |
62000.0 |
nM |
Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days |
CHEMBL1649078 |
| Homo sapiens |
CL_renal |
= |
3.8 |
L/hr |
Renal clearance in children and young patient with malignancy assessed per m'2 at 5 mg/kg, iv administered every 8 hrs |
CHEMBL1649513 |
| Homo sapiens |
CL_renal |
= |
3.9 |
L/hr |
Renal clearance in children and young patient with malignancy assessed per m'2 at 10 mg/kg, po administered every 12 hrs |
CHEMBL1649513 |
| Homo sapiens |
CL |
= |
0.2 |
L/hr |
Clearance in children and young patient with malignancy at 5 mg/kg, iv administered every 8 hrs |
CHEMBL1649513 |
| Homo sapiens |
CL |
= |
0.2 |
L/hr |
Clearance in children and young patient with malignancy at 10 mg/kg, po administered every 12 hrs |
CHEMBL1649513 |
| Homo sapiens |
Vd |
= |
0.4 |
L.kg-1 |
Volume of distribution in children and young patient with malignancy at 5 mg/kg, iv administered every 8 hrs |
CHEMBL1649513 |
| Homo sapiens |
Vd |
= |
0.4 |
L.kg-1 |
Volume of distribution in children and young patient with malignancy at 10 mg/kg, po administered every 12 hrs |
CHEMBL1649513 |
| Homo sapiens |
T1/2 |
= |
1.5 |
hr |
Half life in children and young patient with malignancy at 5 mg/kg, iv administered every 8 hrs |
CHEMBL1649513 |
| Homo sapiens |
T1/2 |
= |
1.4 |
hr |
Half life in children and young patient with malignancy at 10 mg/kg, po administered every 12 hrs |
CHEMBL1649513 |
| Homo sapiens |
F |
= |
60.0 |
% |
Bioavailability in children and young patient with malignancy |
CHEMBL1649513 |
| Homo sapiens |
CL_renal |
= |
8.4 |
L/hr |
Renal clearance in immunocompromized children assessed per m'2 at 250 mg/kg, po administered every 12 hrs |
CHEMBL1649513 |
| Homo sapiens |
CL |
= |
0.5 |
L/hr |
Clearance in immunocompromized children at 10.5 mg/kg, iv |
CHEMBL1649513 |
| Homo sapiens |
CL |
= |
0.5 |
L/hr |
Clearance in immunocompromized children at 250 mg/kg, po administered every 12 hrs |
CHEMBL1649513 |
| Homo sapiens |
Vd |
= |
1.2 |
L.kg-1 |
Volume of distribution in immunocompromized children at 10.5 mg/kg, iv |
CHEMBL1649513 |
| Homo sapiens |
Vd |
= |
1.3 |
L.kg-1 |
Volume of distribution in immunocompromized children at 250 mg/kg, po administered every 12 hrs |
CHEMBL1649513 |
| Homo sapiens |
T1/2 |
= |
1.9 |
hr |
Half life in immunocompromized children at 10.5 mg/kg, iv |
CHEMBL1649513 |
| Homo sapiens |
T1/2 |
= |
2.1 |
hr |
Half life in immunocompromized children at 250 mg/kg, po administered every 12 hrs |
CHEMBL1649513 |
| Homo sapiens |
F |
= |
48.0 |
% |
Bioavailability in immunocompromized children at 250 mg/kg, po administered every 12 hrs |
CHEMBL1649513 |
| Homo sapiens |
CL_renal |
= |
3.6 |
L/hr |
Renal clearance in patient with Epstein-Barr virus infection assessed per m'2 at 500 mg/kg, po administered every 8 hrs |
CHEMBL1649513 |
| Homo sapiens |
CL |
= |
1.2 |
L/hr |
Clearance in patient with Epstein-Barr virus infection at 500 mg/kg, po administered every 8 hrs |
CHEMBL1649513 |
| Homo sapiens |
Vd |
= |
3.0 |
L.kg-1 |
Volume of distribution in patient with Epstein-Barr virus infection at 500 mg/kg, po administered every 8 hrs |
CHEMBL1649513 |
| Homo sapiens |
T1/2 |
= |
1.7 |
hr |
Half life in patient with Epstein-Barr virus infection at 500 mg/kg, po administered every 8 hrs |
CHEMBL1649513 |
| Human herpesvirus 2 |
EC50 |
= |
3000.0 |
nM |
Antiviral activity against HSV2 MS infected in HFF after 3 days by plaque reduction assay |
CHEMBL1649277 |
| HFF |
CC50 |
> |
444000.0 |
nM |
Cytotoxicity against HFF after 3 days by MTS assay |
CHEMBL1649277 |
| Unchecked |
Ratio CC50/EC50 |
> |
150.0 |
|
Selectivity index, ratio of CC50 for HFF to EC50 for HSV2 MS infected in HFF |
CHEMBL1649277 |
| HFF |
IC50 |
> |
444000.0 |
nM |
Antiproliferative activity against HFF after 3 days by Coulter counting analysis |
CHEMBL1649277 |
| Human herpesvirus 1 |
EC50 |
= |
80.0 |
nM |
Antiviral activity against HSV1 E377 infected in HFF after 3 days by plaque reduction assay |
CHEMBL1649277 |
| Human herpesvirus 1 |
EC50 |
= |
12000.0 |
nM |
Antiviral activity against HSV1 DM2.1 harboring frameshift mutation in TK infected in HFF after 3 days by plaque reduction assay |
CHEMBL1649277 |
| Human herpesvirus 1 |
EC50 |
= |
600.0 |
nM |
Antiviral activity against HSV1 SC16-S1 harboring TK A265T/C336Y mutant gene infected in HFF after 3 days by plaque reduction assay |
CHEMBL1649277 |
| Human herpesvirus 1 |
EC50 |
= |
11.0 |
nM |
Antiviral activity against HSV1 PAA5 harboring polymerase R842S mutant gene infected in HFF after 3 days by plaque reduction assay |
CHEMBL1649277 |
| Human herpesvirus 1 |
EC50 |
= |
4400.0 |
nM |
Antiviral activity against HSV1 B-2006 harboring frameshift mutation at Q185 in TK infected in HFF after 3 days by plaque reduction assay |
CHEMBL1649277 |
| Human herpesvirus 2 |
EC50 |
= |
4700.0 |
nM |
Antiviral activity against HSV2 AG-3 harboring TK Q105P mutant gene infected in HFF after 3 days by plaque reduction assay |
CHEMBL1649277 |
| Human herpesvirus 2 |
EC50 |
= |
9600.0 |
nM |
Antiviral activity against HSV2 12247 harboring TK C337Y mutant gene infected in HFF after 3 days by plaque reduction assay |
CHEMBL1649277 |
| Human herpesvirus 2 |
EC50 |
= |
4900.0 |
nM |
Antiviral activity against HSV2 13077 harboring TK R223H mutant gene infected in HFF after 3 days by plaque reduction assay |
CHEMBL1649277 |
| Human herpesvirus 2 |
EC50 |
= |
6600.0 |
nM |
Antiviral activity against HSV2 11680 harboring TK R223H mutant gene infected in HFF after 3 days by plaque reduction assay |
CHEMBL1649277 |
| Human herpesvirus 2 |
EC50 |
> |
440000.0 |
nM |
Antiviral activity against 4'-thioIDU-resistant HSV2 infected in HFF after 3 days by plaque reduction assay |
CHEMBL1649277 |
| Human herpesvirus 2 |
Ratio EC50 |
> |
100.0 |
|
Selectivity ratio of EC50 for 4'-thioIDU-resistant HSV2 infected in HFF to EC50 for HSV2 MS infected in HFF |
CHEMBL1649277 |
| Human herpesvirus 2 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against HSV2 harboring frameshift mutation in TK infected in HFF after 3 days by plaque reduction assay |
CHEMBL1649277 |
| Human herpesvirus 2 strain G |
EC50 |
= |
200.0 |
nM |
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1667805 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
400.0 |
nM |
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1667805 |
| NON-PROTEIN TARGET |
EC50 |
= |
1000.0 |
nM |
Antiviral activity against VZV OKA expressing thymidine kinase infected in HEL cells assessed as inhibition of plaque formation |
CHEMBL1667805 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
10000.0 |
nM |
Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1667805 |
| Human herpesvirus 3 |
EC50 |
= |
16500.0 |
nM |
Antiviral activity against VZV 07-1 infected in HEL cells assessed as inhibition of plaque formation |
CHEMBL1667805 |
| HEL |
CC50 |
> |
130000.0 |
nM |
Cytotoxicity against HEL cells after 3 days by coulter counter analysis |
CHEMBL1667805 |
| Vaccinia virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1667805 |
| HEL |
MCC |
> |
50000.0 |
nM |
Cytotoxicity against HEL cells after 3 days by coulter counter analysis |
CHEMBL1667805 |
| Human herpesvirus 1 |
EC50 |
> |
50000.0 |
nM |
Antiviral activity against Herpes simplex virus 1 isolate 1 harboring C6G N23S K36E L42P G240E A265T and A207P mutations in thymidine kinase and S33G, A330R, N425T, V905M mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 1 |
EC50 |
= |
11000.0 |
nM |
Antiviral activity against Herpes simplex virus 1 isolate 2 harboring C6G, N23S, K36E, R41H, A192V, A265T, L170P mutations in thymidine kinase and S33G, A330R, N425T, V905M, T1208A mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 1 |
EC50 |
= |
35000.0 |
nM |
Antiviral activity against Herpes simplex virus 1 isolate 3 harboring N23S, K36E, R89Q, A265T, Y53D mutations in thymidine kinase and S33G, A330R, V905M, E1005K mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 1 |
EC50 |
= |
16000.0 |
nM |
Antiviral activity against Herpes simplex virus 1 isolate 4 harboring N23S, K36E -1C 553 = frameshift mutations in thymidine kinase and S33G, A330R, A899V, L1188F mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 1 |
EC50 |
= |
16000.0 |
nM |
Antiviral activity against Herpes simplex virus 1 isolate 5 harboring N23S, K36E, A192V, G251C, A265T, V267L, P268T, -1G 856 = frameshift mutations in thymidine kinase and A330R, V905M, T1208A, H98Y mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 1 |
EC50 |
= |
26000.0 |
nM |
Antiviral activity against Herpes simplex virus 1 isolate 6 harboring N23S, K36E, R89Q, +1G 437-438 = Stop 225 mutations in thymidine kinase and S33G, A330R, A646T, S1123L, P1124H, T1208A, R1229I mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 1 |
EC50 |
= |
31000.0 |
nM |
Antiviral activity against Herpes simplex virus 1 isolate 7 harboring N23S, K36E, R89Q, +1C 464-465 = Stop 228 mutations in thymidine kinase and S33G, A330R, P1124H, T1208A, A870G mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 1 |
EC50 |
= |
10000.0 |
nM |
Antiviral activity against Herpes simplex virus 1 isolate 8 harboring N23S, K36E, R89Q, +1G 437-438 = Stop 228 mutations in thymidine kinase and A330R, P875S, V905M, P1124H, T1208A mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 1 |
EC50 |
> |
50000.0 |
nM |
Antiviral activity against Herpes simplex virus 1 isolate 9 harboring N23S, K36E, R89Q, +1G 437-438 = Stop 228 mutations in thymidine kinase and S33G, A330R, V905M, A1203T, T1208A mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 1 |
EC50 |
= |
22000.0 |
nM |
Antiviral activity against Herpes simplex virus 1 isolate 10 harboring N23S, K36E, R89Q, A265T C336Y mutations in thymidine kinase and S33G, A330R, V905M mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 1 |
EC50 |
> |
50000.0 |
nM |
Antiviral activity against Herpes simplex virus 1 isolate 11 harboring N23S, K36E, G251C, A265T, P268T, R176W mutations in thymidine kinase and S33G, A330R, P1124H, T1208A, S724N, V117L, L267M mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 2 |
EC50 |
= |
43000.0 |
nM |
Antiviral activity against Herpes simplex virus 2 isolate 12 harboring G39E, N78D, L140F, S66P, A72S mutations in thymidine kinase and A9T, P15S, L60P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 2 |
EC50 |
= |
33000.0 |
nM |
Antiviral activity against Herpes simplex virus 2 isolate 13 harboring, M183I mutations in thymidine kinase and A9T, P15S, R41H, L60P, E139K, A232T mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 2 |
EC50 |
= |
24000.0 |
nM |
Antiviral activity against Herpes simplex virus 2 isolate 14 harboring G39E, N78D, M70R mutations in thymidine kinase and A724V mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 2 |
EC50 |
= |
11000.0 |
nM |
Antiviral activity against Herpes simplex virus 2 isolate 15 harboring R221H mutations in thymidine kinase and A9T, P15S, L60P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 2 |
EC50 |
> |
50000.0 |
nM |
Antiviral activity against Herpes simplex virus 2 isolate 16 harboring D137Stop mutations in thymidine kinase and A9T, P15S, L60P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 2 |
EC50 |
> |
50000.0 |
nM |
Antiviral activity against Herpes simplex virus 2 isolate 17 harboring G39E, N78D Q222Stop mutations in thymidine kinase and A9T, P15S, L60P, T801P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 2 |
EC50 |
= |
18000.0 |
nM |
Antiviral activity against Herpes simplex virus 2 isolate 18 harboring A27T, G39E, N78D, -1C 556 = Stop 263, S29A mutations in thymidine kinase and A9T, P15S, L60P, E678G, del, DD676-677 mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 2 |
EC50 |
> |
50000.0 |
nM |
Antiviral activity against Herpes simplex virus 2 isolate 19 harboring G39E, +2G 439-440 = Stop 184 mutations in thymidine kinase and A9T, P15S, L60P, del, DGDE683-686 mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 2 |
EC50 |
> |
50000.0 |
nM |
Antiviral activity against Herpes simplex virus 2 isolate 20 harboring G39E, -1C 467 = Stop 183 mutations in thymidine kinase and A9T, P15S, L60P, E139K, T801P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 2 |
EC50 |
> |
50000.0 |
nM |
Antiviral activity against Herpes simplex virus 2 isolate 21 harboring G39E, N78D, L140F, -1C 452 = Stop 183 mutations in thymidine kinase and P15S, L60P, E678G mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 2 |
EC50 |
> |
50000.0 |
nM |
Antiviral activity against Herpes simplex virus 2 isolate 22 harboring G39E, N78D, L140F, +1G 439-440 = Stop 229 mutations in thymidine kinase and A9T, P15S, L60P, E678G, Y823C mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 2 |
EC50 |
> |
50000.0 |
nM |
Antiviral activity against Herpes simplex virus 2 isolate 23 harboring G39E, N78D, L140F, +1G 439-440 = Stop 229 mutations in thymidine kinase and A9T, P15S, L60P, I291V mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 2 |
EC50 |
> |
50000.0 |
nM |
Antiviral activity against Herpes simplex virus 2 isolate 24 harboring G39E, -1G 440 = Stop 229 mutations in thymidine kinase and A9T, P15S, L60P, E139K, H837R mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| Human herpesvirus 2 |
EC50 |
= |
42000.0 |
nM |
Antiviral activity against Herpes simplex virus 2 isolate 25 harboring I101S mutations in thymidine kinase and D785N, V544A mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1671752 |
| NON-PROTEIN TARGET |
IC50 |
= |
5800.0 |
nM |
Antiviral activity against Thymidine kinase-positive Varicella-zoster virus Oka infected in HELF assessed as virus-induced cytopathogenicity after 5 days by microscopy |
CHEMBL1671794 |
| Human herpesvirus 3 |
IC50 |
= |
58700.0 |
nM |
Antiviral activity against Thymidine kinase-deficient Varicella-zoster virus 07-1 infected in HELF assessed as virus-induced cytopathogenicity after 5 days by microscopy |
CHEMBL1671794 |
| ADMET |
MCC |
> |
1778000.0 |
nM |
Cytotoxicity against HELF cells assessed as after 3 days by Coulter counting analysis |
CHEMBL1671794 |
| ADMET |
CC50 |
> |
1778000.0 |
nM |
Cytotoxicity against HELF cells assessed as after 3 days by Coulter counting analysis |
CHEMBL1671794 |
| Human herpesvirus 1 |
Inhibition |
= |
95.0 |
% |
Antiviral activity against Herpes simplex viruses 1 infected in vero cells assessed as inhibition of viral replication at 50 uM after 72 hrs by XTT assay |
CHEMBL1681787 |
| Vero |
CC50 |
= |
860000.0 |
nM |
Cytotoxicity against african green monkey Vero cells after 72 hrs by XTT assay |
CHEMBL1681787 |
| Human herpesvirus 1 |
IC50 |
= |
990.0 |
nM |
Antiviral activity against 5 MOI Herpes simplex viruses 1 infected in vero cells after 24 hrs by viral plaque number reduction assay |
CHEMBL1681787 |
| Unchecked |
Ratio CC50/IC50 |
= |
869.0 |
|
Selectivity index, ratio of CC50 for african green monkey vero cells to IC50 for Herpes simplex viruses 1 |
CHEMBL1681787 |
| Vero |
CC50 |
> |
200000.0 |
nM |
Cytotoxicity against african green monkey Vero cells by MTT assay |
CHEMBL1681758 |
| Human herpesvirus 1 |
EC50 |
= |
1160.0 |
nM |
Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as inhibition of viral replication by plaque reduction assay |
CHEMBL1681758 |
| Human herpesvirus 2 |
EC50 |
= |
1720.0 |
nM |
Antiviral activity against HSV2 infected in african green monkey Vero cells assessed as inhibition of viral replication by plaque reduction assay |
CHEMBL1681758 |
| ADMET |
TI |
> |
172.42 |
|
Therapeutic index, ratio of CC50 for african green monkey Vero cells to EC50 for HSV1 |
CHEMBL1681758 |
| ADMET |
TI |
> |
116.27 |
|
Therapeutic index, ratio of CC50 for african green monkey Vero cells to EC50 for HSV2 |
CHEMBL1681758 |
| Human herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as reduction of UL54 expression at 1 uM after up to 24 hrs by RT-PCR analysis |
CHEMBL1681758 |
| Human herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as reduction of UL52 expression at 1 uM after up to 24 hrs by RT-PCR analysis |
CHEMBL1681758 |
| Human herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as reduction of UL27 expression at 1 uM after up to 24 hrs by RT-PCR analysis |
CHEMBL1681758 |
| Hepatotoxicity |
Hepatotoxicity |
|
|
|
Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans |
CHEMBL1697731 |
| Hepatotoxicity |
Hepatotoxicity |
|
|
|
Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents |
CHEMBL1697731 |
| Hepatotoxicity |
Hepatotoxicity |
|
|
|
Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents |
CHEMBL1697731 |
| Hepatotoxicity |
Composite Activity - Score |
|
|
|
FDA HLAED, liver enzyme composite activity |
CHEMBL1697781 |
| Hepatotoxicity |
Composite Activity - Active |
= |
0.0 |
|
FDA HLAED, liver enzyme composite activity |
CHEMBL1697781 |
| Hepatotoxicity |
Composite Activity - Marginal |
= |
0.0 |
|
FDA HLAED, liver enzyme composite activity |
CHEMBL1697781 |
| Hepatotoxicity |
Alkaline Phosphatase Increase - Activity Score |
|
|
|
FDA HLAED, alkaline phosphatase increase |
CHEMBL1697781 |
| Hepatotoxicity |
Alkaline Phosphatase Increase - Index Value |
= |
0.9 |
|
FDA HLAED, alkaline phosphatase increase |
CHEMBL1697781 |
| Hepatotoxicity |
Alkaline Phosphatase Increase - Number of Reports |
>= |
4.0 |
|
FDA HLAED, alkaline phosphatase increase |
CHEMBL1697781 |
| Hepatotoxicity |
SGOT Increase - Activity Score |
|
|
|
FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
SGOT Increase - Index Value |
= |
0.9 |
|
FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
SGOT Increase - Number of Reports |
>= |
4.0 |
|
FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
SGPT Increase - Activity Score |
|
|
|
FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
SGPT Increase - Index Value |
= |
0.1 |
|
FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
SGPT Increase - Number of Reports |
< |
4.0 |
|
FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
LDH Increase - Activity Score |
|
|
|
FDA HLAED, lactate dehydrogenase (LDH) increase |
CHEMBL1697781 |
| Hepatotoxicity |
LDH Increase - Index Value |
= |
0.1 |
|
FDA HLAED, lactate dehydrogenase (LDH) increase |
CHEMBL1697781 |
| Hepatotoxicity |
LDH Increase - Number of Reports |
< |
4.0 |
|
FDA HLAED, lactate dehydrogenase (LDH) increase |
CHEMBL1697781 |
| Hepatotoxicity |
GGT Increase - Activity Score |
|
|
|
FDA HLAED, gamma-glutamyl transferase (GGT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
GGT Increase - Index Value |
= |
0.0 |
|
FDA HLAED, gamma-glutamyl transferase (GGT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
GGT Increase - Number of Reports |
< |
4.0 |
|
FDA HLAED, gamma-glutamyl transferase (GGT) increase |
CHEMBL1697781 |
| Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 |
Potency |
|
25.1 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] |
CHEMBL1201862 |
| Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 |
Potency |
|
39810.7 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] |
CHEMBL1201862 |
| Thioredoxin reductase 1, cytoplasmic |
Potency |
|
2993.5 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488771, AID488773, AID587] |
CHEMBL1201862 |
| Runt-related transcription factor 1/Core-binding factor subunit beta |
Potency |
|
31622.8 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1484, AID504370, AID504374, AID504375] |
CHEMBL1201862 |
| Homo sapiens |
F |
= |
21.0 |
% |
Absolute bioavailability in human |
CHEMBL1158536 |
| Cytochrome P450 2C9 |
AC50 |
|
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Cytochrome P450 2C9 |
AC50 |
|
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Cytochrome P450 3A4 |
AC50 |
|
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp3a4 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Cytochrome P450 2C19 |
AC50 |
|
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c19 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Cytochrome P450 2D6 |
AC50 |
|
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2d6 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Cytochrome P450 1A2 |
AC50 |
|
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp1a2 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Cytochrome P450 3A4 |
AC50 |
|
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp3a4 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Cytochrome P450 2C19 |
AC50 |
|
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c19 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Cytochrome P450 2D6 |
AC50 |
|
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2d6 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Cytochrome P450 1A2 |
AC50 |
|
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp1a2 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Solute carrier family 22 member 6 |
Activity |
|
|
|
Substrates of transporters of clinical importance in the absorption and disposition of drugs, OAT1 |
CHEMBL1743141 |
| Cytochrome P450 1A2 |
Activity |
|
|
|
Clinically relevant inhibitors of human liver microsomal P450 enzymes, isoform CYP1A2 |
CHEMBL1743201 |
| Human herpesvirus 1 |
IC50 |
= |
300.0 |
nM |
Antiviral activity against HSV1 by plaque reduction assay |
CHEMBL1759988 |
| Human herpesvirus 2 |
IC50 |
= |
1270.0 |
nM |
Antiviral activity against HSV2 by plaque reduction assay |
CHEMBL1759988 |
| RD |
CC50 |
> |
25000.0 |
nM |
Cytotoxicity against human RD cells |
CHEMBL1759988 |
| Caco-2 |
logPapp |
= |
-6.15 |
|
Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis |
CHEMBL1764994 |
| Human herpesvirus 3 |
EC90 |
|
|
|
Antiviral activity against Varicella-zoster virus Ellen infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay |
CHEMBL1773001 |
| Human herpesvirus 5 strain AD169 |
EC50 |
|
|
|
Antiviral activity against Human cytomegalovirus (strain AD169) infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay |
CHEMBL1773001 |
| Human herpesvirus 5 strain AD169 |
EC90 |
|
|
|
Antiviral activity against Human cytomegalovirus (strain AD169) infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay |
CHEMBL1773001 |
| HFF |
CC50 |
|
|
|
Cytotoxicity against human HFF cells infected with Human cytomegalovirus AD169 assessed as viable cells by neutral red uptake assay |
CHEMBL1773001 |
| Unchecked |
Selectivity Index |
|
|
|
Selectivity index, ratio of CC50 for human HFF cells infected with Hepatitis C virus to EC50 for Human cytomegalovirus AD169 |
CHEMBL1773001 |
| NON-PROTEIN TARGET |
EC50 |
|
|
|
Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay |
CHEMBL1773001 |
| Vaccinia virus Copenhagen |
EC50 |
|
|
|
Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay |
CHEMBL1773001 |
| NON-PROTEIN TARGET |
EC90 |
|
|
|
Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay |
CHEMBL1773001 |
| Vaccinia virus Copenhagen |
EC90 |
|
|
|
Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay |
CHEMBL1773001 |
| HFF |
CC50 |
|
|
|
Cytotoxicity against human HFF cells infected with Cowpox virus (Brighton Red) assessed as viable cells by neutral red uptake assay |
CHEMBL1773001 |
| Unchecked |
Selectivity Index |
|
|
|
Selectivity index, ratio of CC50 for human HFF cells infected with Cowpox virus (Brighton Red) to EC50 for Cowpox virus (Brighton Red) |
CHEMBL1773001 |
| Unchecked |
Selectivity Index |
> |
90.9 |
|
Selectivity index, ratio of CC50 for human HFF cells infected with Hepatitis C virus to EC50 for Varicella-zoster virus Ellen |
CHEMBL1773001 |
| HFF |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human HFF cells infected with Varicella-zoster virus Ellen assessed as viable cells by neutral red uptake assay |
CHEMBL1773001 |
| Human herpesvirus 3 |
EC50 |
= |
1100.0 |
nM |
Antiviral activity against Varicella-zoster virus Ellen infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay |
CHEMBL1773001 |
| Human herpesvirus 1 |
IC50 |
= |
17000.0 |
nM |
Antiviral activity against HSV-1 by green fluorescent protein microplate assay |
CHEMBL1772945 |
| Human herpesvirus 3 |
EC50 |
= |
3640.0 |
nM |
Antiviral activity against Varicella-zoster virus YS expressing thymidine kinase assessed as reduction of virus induced cytopathicity by cell based assay |
CHEMBL1806434 |
| NON-PROTEIN TARGET |
EC50 |
= |
1560.0 |
nM |
Antiviral activity against Varicella-zoster virus strain OKA expressing thymidine kinase assessed as reduction of virus induced cytopathicity by cell based assay |
CHEMBL1806434 |
| Human herpesvirus 3 |
EC50 |
= |
71600.0 |
nM |
Antiviral activity against thymidine kinase-deficient Varicella-zoster virus 07/1 assessed as reduction of virus induced cytopathicity by cell based assay |
CHEMBL1806434 |
| Human herpesvirus 3 |
EC50 |
= |
76900.0 |
nM |
Antiviral activity against thymidine kinase-deficient Varicella-zoster virus YS/R assessed as reduction of virus induced cytopathicity by cell based assay |
CHEMBL1806434 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
300.0 |
nM |
Antiviral activity against Herpes simplex virus 1 strain KOS assessed as reduction of virus induced cytopathicity by cell based assay |
CHEMBL1806434 |
| Human herpesvirus 2 strain G |
EC50 |
= |
230.0 |
nM |
Antiviral activity against Herpes simplex virus 2 strain G assessed as reduction of virus induced cytopathicity by cell based assay |
CHEMBL1806434 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
7300.0 |
nM |
Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 strain KOS assessed as reduction of virus induced cytopathicity by cell based assay |
CHEMBL1806434 |
| Human herpesvirus 5 strain AD169 |
EC50 |
|
|
|
Antiviral activity against Human cytomegalovirus strain AD169 assessed as reduction of virus induced cytopathicity by cell based assay |
CHEMBL1806434 |
| Human herpesvirus 5 |
EC50 |
|
|
|
Antiviral activity against Human cytomegalovirus Davis assessed as reduction of virus induced cytopathicity by cell based assay |
CHEMBL1806434 |
| Vaccinia virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus Lederle assessed as reduction of virus induced cytopathicity by cell based assay |
CHEMBL1806434 |
| HEL |
MCC |
> |
444000.0 |
nM |
Cytotoxicity against human HEL cells assessed as alteration of cell morphology after 3 days by microscopic analysis |
CHEMBL1806434 |
| HEL |
CC50 |
= |
1338000.0 |
nM |
Cytotoxicity against human HEL cells after 3 days by coulter counter |
CHEMBL1806434 |
| HEL |
CC50 |
> |
400000.0 |
nM |
Cytotoxicity against human HEL cells by colorimetric formazan-based MTS assay |
CHEMBL1806488 |
| Human herpesvirus 3 |
EC50 |
= |
111000.0 |
nM |
Antiviral activity against thymidine kinase-deficient Varicella-zoster virus YS/R infected in human HEL cells assessed as reduction in the virus plaque formation |
CHEMBL1806488 |
| Human herpesvirus 3 |
EC50 |
= |
43000.0 |
nM |
Antiviral activity against thymidine kinase-deficient Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction in the virus plaque formation |
CHEMBL1806488 |
| NON-PROTEIN TARGET |
EC50 |
= |
1400.0 |
nM |
Antiviral activity against Varicella-zoster virus OKA expressing thymidine kinase infected in human HEL cells assessed as reduction in the virus plaque formation |
CHEMBL1806488 |
| Human herpesvirus 3 |
EC50 |
= |
4900.0 |
nM |
Antiviral activity against Varicella-zoster virus YS expressing thymidine kinase infected in human HEL cells assessed as reduction in the virus plaque formation |
CHEMBL1806488 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against cat CRFK cells by colorimetric formazan-based MTS assay |
CHEMBL1806488 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HEL cells assessed as alteration of normal cell morphology by microscopic analysis |
CHEMBL1806488 |
| Vaccinia virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis |
CHEMBL1806488 |
| Human herpesvirus 2 strain G |
EC50 |
= |
400.0 |
nM |
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis |
CHEMBL1806488 |
| Felid herpesvirus 1 |
EC50 |
= |
1000.0 |
nM |
Antiviral activity against Feline herpesvirus infected in cat CRFK cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis |
CHEMBL1806488 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
50000.0 |
nM |
Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis |
CHEMBL1806488 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
400.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis |
CHEMBL1806488 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
270.0 |
nM |
Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
27100.0 |
nM |
Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Human herpesvirus 2 strain G |
EC50 |
= |
230.0 |
nM |
Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| NON-PROTEIN TARGET |
EC50 |
= |
3000.0 |
nM |
Antiviral activity against VZV OKA infected in HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Human herpesvirus 3 |
EC50 |
= |
69300.0 |
nM |
Antiviral activity against VZV 07/1 infected in HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Human herpesvirus 5 strain AD169 |
EC50 |
|
|
|
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Human herpesvirus 5 |
EC50 |
|
|
|
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Felid herpesvirus 1 |
EC50 |
|
|
|
Antiviral activity against Feline herpesvirus infected in CRFK cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Vaccinia virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| HEL |
MCC |
> |
222000.0 |
nM |
Cytotoxicity against human HEL cells assessed as alteration of cell morphology after 3 days by microscopy |
CHEMBL1811861 |
| HEL |
CC50 |
= |
1421000.0 |
nM |
Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter |
CHEMBL1811861 |
| ADMET |
CC50 |
|
|
|
Cytotoxicity against cat CRFK cells assessed as growth inhibition after 3 days by coulter counter |
CHEMBL1811861 |
| HepG2 |
Potency |
|
891.3 |
nM |
PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] |
CHEMBL1201862 |
| Mothers against decapentaplegic homolog 3 |
Potency |
|
3981.1 |
nM |
PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] |
CHEMBL1201862 |
| HEK293 |
Potency |
|
2908.1 |
nM |
PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] |
CHEMBL1201862 |
| Acetylcholinesterase |
IC50 |
|
|
|
DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine) |
CHEMBL1909046 |
| Acetylcholinesterase |
Ki |
|
|
|
DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine) |
CHEMBL1909046 |
| Adenosine A1 receptor |
IC50 |
|
|
|
DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX) |
CHEMBL1909046 |
| Adenosine A1 receptor |
Ki |
|
|
|
DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX) |
CHEMBL1909046 |
| Adenosine A2a receptor |
IC50 |
|
|
|
DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA) |
CHEMBL1909046 |
| Adenosine A2a receptor |
Ki |
|
|
|
DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA) |
CHEMBL1909046 |
| Adenosine A3 receptor |
IC50 |
|
|
|
DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA) |
CHEMBL1909046 |
| Adenosine A3 receptor |
Ki |
|
|
|
DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine) |
CHEMBL1909046 |
| Alpha-1a adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin) |
CHEMBL1909046 |
| Alpha-1a adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin) |
CHEMBL1909046 |
| Alpha-1b adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin) |
CHEMBL1909046 |
| Alpha-1b adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin) |
CHEMBL1909046 |
| Alpha-1d adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin) |
CHEMBL1909046 |
| Alpha-1d adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin) |
CHEMBL1909046 |
| Alpha-2a adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) |
CHEMBL1909046 |
| Alpha-2a adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) |
CHEMBL1909046 |
| Alpha-2b adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine) |
CHEMBL1909046 |
| Alpha-2b adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine) |
CHEMBL1909046 |
| Alpha-2c adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912) |
CHEMBL1909046 |
| Alpha-2c adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912) |
CHEMBL1909046 |
| Beta-1 adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol) |
CHEMBL1909046 |
| Beta-1 adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol) |
CHEMBL1909046 |
| Beta-2 adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177) |
CHEMBL1909046 |
| Beta-2 adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177) |
CHEMBL1909046 |
| Beta-3 adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol) |
CHEMBL1909046 |
| Beta-3 adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol) |
CHEMBL1909046 |
| Norepinephrine transporter |
IC50 |
|
|
|
DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55) |
CHEMBL1909046 |
| Norepinephrine transporter |
Ki |
|
|
|
DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55) |
CHEMBL1909046 |
| Aldose reductase |
IC50 |
|
|
|
DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde) |
CHEMBL1909046 |
| Aldose reductase |
Ki |
|
|
|
DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde) |
CHEMBL1909046 |
| Angiotensin II type 2 (AT-2) receptor |
IC50 |
|
|
|
DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A) |
CHEMBL1909046 |
| Angiotensin II type 2 (AT-2) receptor |
Ki |
|
|
|
DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin) |
CHEMBL1909046 |
| Bradykinin B2 receptor |
IC50 |
|
|
|
DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin) |
CHEMBL1909046 |
| Bradykinin B2 receptor |
Ki |
|
|
|
DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin) |
CHEMBL1909046 |
| Calcitonin receptor |
IC50 |
|
|
|
DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)) |
CHEMBL1909046 |
| Calcitonin receptor |
Ki |
|
|
|
DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888)) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888)) |
CHEMBL1909046 |
| Cannabinoid CB1 receptor |
IC50 |
|
|
|
DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A) |
CHEMBL1909046 |
| Cannabinoid CB1 receptor |
Ki |
|
|
|
DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A) |
CHEMBL1909046 |
| Carbonic anhydrase II |
IC50 |
|
|
|
DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)) |
CHEMBL1909046 |
| Carbonic anhydrase II |
Ki |
|
|
|
DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)) |
CHEMBL1909046 |
| C-C chemokine receptor type 2 |
IC50 |
|
|
|
DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1) |
CHEMBL1909046 |
| C-C chemokine receptor type 2 |
Ki |
|
|
|
DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1) |
CHEMBL1909046 |
| C-C chemokine receptor type 4 |
IC50 |
|
|
|
DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC) |
CHEMBL1909046 |
| C-C chemokine receptor type 4 |
Ki |
|
|
|
DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC) |
CHEMBL1909046 |
| C-C chemokine receptor type 5 |
IC50 |
|
|
|
DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha) |
CHEMBL1909046 |
| C-C chemokine receptor type 5 |
Ki |
|
|
|
DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha) |
CHEMBL1909046 |
| Interleukin-8 receptor A |
IC50 |
|
|
|
DRUGMATRIX: Chemokine CXCR1 (IL-8A) |
CHEMBL1909046 |
| Interleukin-8 receptor A |
Ki |
|
|
|
DRUGMATRIX: Chemokine CXCR1 (IL-8A) |
CHEMBL1909046 |
| Interleukin-8 receptor B |
IC50 |
|
|
|
DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8) |
CHEMBL1909046 |
| Interleukin-8 receptor B |
Ki |
|
|
|
DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8) |
CHEMBL1909046 |
| Cholecystokinin A receptor |
IC50 |
|
|
|
DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718) |
CHEMBL1909046 |
| Cholecystokinin A receptor |
Ki |
|
|
|
DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718) |
CHEMBL1909046 |
| Cyclooxygenase-1 |
IC50 |
|
|
|
DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid) |
CHEMBL1909046 |
| Cyclooxygenase-1 |
Ki |
|
|
|
DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid) |
CHEMBL1909046 |
| Cyclooxygenase-2 |
IC50 |
|
|
|
DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid) |
CHEMBL1909046 |
| Cyclooxygenase-2 |
Ki |
|
|
|
DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid) |
CHEMBL1909046 |
| Cytochrome P450 1A2 |
IC50 |
|
|
|
DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 1A2 |
Ki |
|
|
|
DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2A6 |
IC50 |
|
|
|
DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2A6 |
Ki |
|
|
|
DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2C19 |
IC50 |
|
|
|
DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2C19 |
Ki |
|
|
|
DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2C9 |
IC50 |
|
|
|
DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2C9 |
Ki |
|
|
|
DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2D6 |
IC50 |
|
|
|
DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2D6 |
Ki |
|
|
|
DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2E1 |
IC50 |
|
|
|
DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2E1 |
Ki |
|
|
|
DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 3A4 |
IC50 |
|
|
|
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin) |
CHEMBL1909046 |
| Cytochrome P450 3A4 |
Ki |
|
|
|
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin) |
CHEMBL1909046 |
| Dopamine D1 receptor |
IC50 |
|
|
|
DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390) |
CHEMBL1909046 |
| Dopamine D1 receptor |
Ki |
|
|
|
DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390) |
CHEMBL1909046 |
| Dopamine D2 receptor |
IC50 |
|
|
|
DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) |
CHEMBL1909046 |
| Dopamine D2 receptor |
Ki |
|
|
|
DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) |
CHEMBL1909046 |
| Dopamine D3 receptor |
IC50 |
|
|
|
DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) |
CHEMBL1909046 |
| Dopamine D3 receptor |
Ki |
|
|
|
DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) |
CHEMBL1909046 |
| Dopamine D4 receptor |
IC50 |
|
|
|
DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone) |
CHEMBL1909046 |
| Dopamine D4 receptor |
Ki |
|
|
|
DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone) |
CHEMBL1909046 |
| Dopamine transporter |
IC50 |
|
|
|
DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) |
CHEMBL1909046 |
| Dopamine transporter |
Ki |
|
|
|
DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) |
CHEMBL1909046 |
| Endothelin receptor ET-A |
IC50 |
|
|
|
DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1) |
CHEMBL1909046 |
| Endothelin receptor ET-A |
Ki |
|
|
|
DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1) |
CHEMBL1909046 |
| Estrogen receptor alpha |
IC50 |
|
|
|
DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol) |
CHEMBL1909046 |
| Estrogen receptor alpha |
Ki |
|
|
|
DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol) |
CHEMBL1909046 |
| Estrogen receptor beta |
IC50 |
|
|
|
DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol) |
CHEMBL1909046 |
| Estrogen receptor beta |
Ki |
|
|
|
DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB) |
CHEMBL1909046 |
| Glucocorticoid receptor |
IC50 |
|
|
|
DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone) |
CHEMBL1909046 |
| Glucocorticoid receptor |
Ki |
|
|
|
DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP) |
CHEMBL1909046 |
| Glycine receptor |
IC50 |
|
|
|
DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine) |
CHEMBL1909046 |
| Glycine receptor |
Ki |
|
|
|
DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine) |
CHEMBL1909046 |
| Histamine H1 receptor |
IC50 |
|
|
|
DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine) |
CHEMBL1909046 |
| Histamine H1 receptor |
Ki |
|
|
|
DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine) |
CHEMBL1909046 |
| Histamine H2 receptor |
IC50 |
|
|
|
DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine) |
CHEMBL1909046 |
| Histamine H2 receptor |
Ki |
|
|
|
DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine) |
CHEMBL1909046 |
| HMG-CoA reductase |
IC50 |
|
|
|
DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA) |
CHEMBL1909046 |
| HMG-CoA reductase |
Ki |
|
|
|
DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan) |
CHEMBL1909046 |
| Insulin receptor |
IC50 |
|
|
|
DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin) |
CHEMBL1909046 |
| Insulin receptor |
Ki |
|
|
|
DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4) |
CHEMBL1909046 |
| Leukotriene C4 synthase |
IC50 |
|
|
|
DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4) |
CHEMBL1909046 |
| Leukotriene C4 synthase |
Ki |
|
|
|
DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4) |
CHEMBL1909046 |
| Cysteinyl leukotriene receptor 1 |
IC50 |
|
|
|
DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4) |
CHEMBL1909046 |
| Cysteinyl leukotriene receptor 1 |
Ki |
|
|
|
DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4) |
CHEMBL1909046 |
| Arachidonate 15-lipoxygenase |
IC50 |
|
|
|
DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid) |
CHEMBL1909046 |
| Arachidonate 15-lipoxygenase |
Ki |
|
|
|
DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid) |
CHEMBL1909046 |
| Melanocortin receptor 3 |
IC50 |
|
|
|
DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH) |
CHEMBL1909046 |
| Melanocortin receptor 3 |
Ki |
|
|
|
DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH) |
CHEMBL1909046 |
| Melanocortin receptor 4 |
IC50 |
|
|
|
DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH) |
CHEMBL1909046 |
| Melanocortin receptor 4 |
Ki |
|
|
|
DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH) |
CHEMBL1909046 |
| Melanocortin receptor 5 |
IC50 |
|
|
|
DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH) |
CHEMBL1909046 |
| Melanocortin receptor 5 |
Ki |
|
|
|
DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH) |
CHEMBL1909046 |
| Monoamine oxidase A |
IC50 |
|
|
|
DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine) |
CHEMBL1909046 |
| Monoamine oxidase A |
Ki |
|
|
|
DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M1 |
IC50 |
|
|
|
DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M1 |
Ki |
|
|
|
DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M2 |
IC50 |
|
|
|
DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M2 |
Ki |
|
|
|
DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M3 |
IC50 |
|
|
|
DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M3 |
Ki |
|
|
|
DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M4 |
IC50 |
|
|
|
DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M4 |
Ki |
|
|
|
DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M5 |
IC50 |
|
|
|
DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M5 |
Ki |
|
|
|
DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Neuropeptide Y receptor type 1 |
IC50 |
|
|
|
DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY) |
CHEMBL1909046 |
| Neuropeptide Y receptor type 1 |
Ki |
|
|
|
DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY) |
CHEMBL1909046 |
| Neuropeptide Y receptor type 2 |
IC50 |
|
|
|
DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY) |
CHEMBL1909046 |
| Neuropeptide Y receptor type 2 |
Ki |
|
|
|
DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine) |
CHEMBL1909046 |
| Nitric-oxide synthase, brain |
IC50 |
|
|
|
DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine) |
CHEMBL1909046 |
| Nitric-oxide synthase, brain |
Ki |
|
|
|
DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine) |
CHEMBL1909046 |
| Nitric oxide synthase, inducible |
IC50 |
|
|
|
DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine) |
CHEMBL1909046 |
| Nitric oxide synthase, inducible |
Ki |
|
|
|
DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine) |
CHEMBL1909046 |
| Delta opioid receptor |
IC50 |
|
|
|
DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole) |
CHEMBL1909046 |
| Delta opioid receptor |
Ki |
|
|
|
DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole) |
CHEMBL1909046 |
| Kappa opioid receptor |
IC50 |
|
|
|
DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine) |
CHEMBL1909046 |
| Kappa opioid receptor |
Ki |
|
|
|
DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine) |
CHEMBL1909046 |
| Mu opioid receptor |
IC50 |
|
|
|
DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine) |
CHEMBL1909046 |
| Mu opioid receptor |
Ki |
|
|
|
DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP) |
CHEMBL1909046 |
| Phosphodiesterase 5A |
IC50 |
|
|
|
DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP) |
CHEMBL1909046 |
| Phosphodiesterase 5A |
Ki |
|
|
|
DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP) |
CHEMBL1909046 |
| Platelet activating factor receptor |
IC50 |
|
|
|
DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF) |
CHEMBL1909046 |
| Platelet activating factor receptor |
Ki |
|
|
|
DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide) |
CHEMBL1909046 |
| HERG |
IC50 |
|
|
|
DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole) |
CHEMBL1909046 |
| HERG |
Ki |
|
|
|
DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole) |
CHEMBL1909046 |
| Progesterone receptor |
IC50 |
|
|
|
DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020) |
CHEMBL1909046 |
| Progesterone receptor |
Ki |
|
|
|
DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020) |
CHEMBL1909046 |
| Angiotensin-converting enzyme |
IC50 |
|
|
|
DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG) |
CHEMBL1909046 |
| Angiotensin-converting enzyme |
Ki |
|
|
|
DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG) |
CHEMBL1909046 |
| Caspase-1 |
IC50 |
|
|
|
DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC) |
CHEMBL1909046 |
| Caspase-1 |
Ki |
|
|
|
DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC) |
CHEMBL1909046 |
| Cathepsin G |
IC50 |
|
|
|
DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC) |
CHEMBL1909046 |
| Cathepsin G |
Ki |
|
|
|
DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC) |
CHEMBL1909046 |
| Leukocyte elastase |
IC50 |
|
|
|
DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA) |
CHEMBL1909046 |
| Leukocyte elastase |
Ki |
|
|
|
DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA) |
CHEMBL1909046 |
| Matrix metalloproteinase-1 |
IC50 |
|
|
|
DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) |
CHEMBL1909046 |
| Matrix metalloproteinase-1 |
Ki |
|
|
|
DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) |
CHEMBL1909046 |
| Matrix metalloproteinase 9 |
IC50 |
|
|
|
DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) |
CHEMBL1909046 |
| Matrix metalloproteinase 9 |
Ki |
|
|
|
DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) |
CHEMBL1909046 |
| Protein kinase C alpha |
IC50 |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone) |
CHEMBL1909046 |
| Protein kinase C alpha |
Ki |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone) |
CHEMBL1909046 |
| MAP kinase ERK1 |
IC50 |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein) |
CHEMBL1909046 |
| MAP kinase ERK1 |
Ki |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein) |
CHEMBL1909046 |
| MAP kinase ERK2 |
IC50 |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein) |
CHEMBL1909046 |
| MAP kinase ERK2 |
Ki |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein) |
CHEMBL1909046 |
| MAP kinase p38 alpha |
IC50 |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein) |
CHEMBL1909046 |
| MAP kinase p38 alpha |
Ki |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein) |
CHEMBL1909046 |
| Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform |
IC50 |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP) |
CHEMBL1909046 |
| Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform |
Ki |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP) |
CHEMBL1909046 |
| Epidermal growth factor receptor erbB1 |
IC50 |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Epidermal growth factor receptor erbB1 |
Ki |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Tyrosine-protein kinase FYN |
IC50 |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Tyrosine-protein kinase FYN |
Ki |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Receptor protein-tyrosine kinase erbB-2 |
IC50 |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Receptor protein-tyrosine kinase erbB-2 |
Ki |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Tyrosine-protein kinase LCK |
IC50 |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Tyrosine-protein kinase LCK |
Ki |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Leukocyte common antigen |
IC50 |
|
|
|
DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP) |
CHEMBL1909046 |
| Leukocyte common antigen |
Ki |
|
|
|
DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP) |
CHEMBL1909046 |
| Serotonin 1a (5-HT1a) receptor |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) |
CHEMBL1909046 |
| Serotonin 1a (5-HT1a) receptor |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) |
CHEMBL1909046 |
| Serotonin 1b (5-HT1b) receptor |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol) |
CHEMBL1909046 |
| Serotonin 1b (5-HT1b) receptor |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol) |
CHEMBL1909046 |
| Serotonin 2a (5-HT2a) receptor |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin) |
CHEMBL1909046 |
| Serotonin 2a (5-HT2a) receptor |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin) |
CHEMBL1909046 |
| Serotonin 2b (5-HT2b) receptor |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide) |
CHEMBL1909046 |
| Serotonin 2b (5-HT2b) receptor |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide) |
CHEMBL1909046 |
| Serotonin 2c (5-HT2c) receptor |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine) |
CHEMBL1909046 |
| Serotonin 2c (5-HT2c) receptor |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630) |
CHEMBL1909046 |
| Serotonin 4 (5-HT4) receptor |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808) |
CHEMBL1909046 |
| Serotonin 4 (5-HT4) receptor |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808) |
CHEMBL1909046 |
| Serotonin 6 (5-HT6) receptor |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide) |
CHEMBL1909046 |
| Serotonin 6 (5-HT6) receptor |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide) |
CHEMBL1909046 |
| Serotonin transporter |
IC50 |
|
|
|
DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) |
CHEMBL1909046 |
| Serotonin transporter |
Ki |
|
|
|
DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) |
CHEMBL1909046 |
| Sigma opioid receptor |
IC50 |
|
|
|
DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol) |
CHEMBL1909046 |
| Sigma opioid receptor |
Ki |
|
|
|
DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin) |
CHEMBL1909046 |
| Neurokinin 1 receptor |
IC50 |
|
|
|
DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P) |
CHEMBL1909046 |
| Neurokinin 1 receptor |
Ki |
|
|
|
DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P) |
CHEMBL1909046 |
| Neurokinin 2 receptor |
IC50 |
|
|
|
DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968) |
CHEMBL1909046 |
| Neurokinin 2 receptor |
Ki |
|
|
|
DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968) |
CHEMBL1909046 |
| Androgen Receptor |
IC50 |
|
|
|
DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone) |
CHEMBL1909046 |
| Androgen Receptor |
Ki |
|
|
|
DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone) |
CHEMBL1909046 |
| Thromboxane-A synthase |
IC50 |
|
|
|
DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2) |
CHEMBL1909046 |
| Thromboxane-A synthase |
Ki |
|
|
|
DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha) |
CHEMBL1909046 |
| Vascular endothelial growth factor receptor 1 |
IC50 |
|
|
|
DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF) |
CHEMBL1909046 |
| Vascular endothelial growth factor receptor 1 |
Ki |
|
|
|
DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF) |
CHEMBL1909046 |
| Vasoactive intestinal polypeptide receptor 1 |
IC50 |
|
|
|
DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP) |
CHEMBL1909046 |
| Vasoactive intestinal polypeptide receptor 1 |
Ki |
|
|
|
DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP) |
CHEMBL1909046 |
| Vasopressin V1a receptor |
IC50 |
|
|
|
DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr) |
CHEMBL1909046 |
| Vasopressin V1a receptor |
Ki |
|
|
|
DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr) |
CHEMBL1909046 |
| Hepatotoxicity |
LTKB_BD DILI severity score |
= |
5.0 |
|
FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI |
CHEMBL1909281 |
| Hepatotoxicity |
HepSE_bilirubinemia |
= |
1.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_cholecystitis |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_cholelithiasis |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_cirrhosis |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_elevated liver function tests |
= |
1.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_hepatic failure |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_hepatic necrosis |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_hepatitis |
= |
1.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_hepatomegaly |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_jaundice |
= |
1.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_liver disease |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_liver fatty |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_liver function tests abnormal |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_Combined Scores |
= |
4.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score |
CHEMBL1909294 |
| Human herpesvirus 1 strain KOS |
Activity |
|
|
|
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human herpesvirus 2 strain G |
Activity |
|
|
|
Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human herpesvirus 1 strain KOS |
Activity |
|
|
|
Antiviral activity against thymidine kinase-deficient acv-resistant Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Vaccinia virus |
Activity |
|
|
|
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Vesicular stomatitis virus |
Activity |
|
|
|
Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human herpesvirus 5 strain AD169 |
Activity |
|
|
|
Antiviral activity against Human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human herpesvirus 5 |
Activity |
|
|
|
Antiviral activity against Human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| NON-PROTEIN TARGET |
Activity |
|
|
|
Antiviral activity against thymidine kinase-positive Varicella Zoster virus Oka infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human herpesvirus 3 |
Activity |
|
|
|
Antiviral activity against thymidine kinase-deficient Varicella Zoster virus 07/1 infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human parainfluenza virus 3 |
Activity |
|
|
|
Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Mammalian orthoreovirus 1 |
Activity |
|
|
|
Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Sindbis virus |
Activity |
|
|
|
Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human coxsackievirus B4 |
Activity |
|
|
|
Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Punta Toro virus |
Activity |
|
|
|
Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Vesicular stomatitis virus |
Activity |
|
|
|
Antiviral activity against Vesicular stomatitis virus infected in human Hela cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human coxsackievirus B4 |
Activity |
|
|
|
Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Respiratory syncytial virus |
Activity |
|
|
|
Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Influenza A virus |
Activity |
|
|
|
Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Influenza A virus |
Activity |
|
|
|
Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Influenza B virus |
Activity |
|
|
|
Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Felid herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against Felid herpesvirus 1 infected in CrFK cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Feline coronavirus |
Activity |
|
|
|
Antiviral activity against Feline coronavirus infected in CrFK cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human immunodeficiency virus 1 |
Activity |
|
|
|
Antiviral activity against Human immunodeficiency virus 1 infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis |
CHEMBL1926651 |
| Human immunodeficiency virus 2 |
Activity |
|
|
|
Antiviral activity against Human immunodeficiency virus 2 infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis |
CHEMBL1926651 |
| NON-PROTEIN TARGET |
IC50 |
|
|
|
Antiviral activity against Cowpox virus Brighton infected in HFF cells incubated for 3 days by plaque reduction assay |
CHEMBL1926544 |
| Vaccinia virus Copenhagen |
IC50 |
|
|
|
Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells incubated for 3 days by plaque reduction assay |
CHEMBL1926544 |
| Human herpesvirus 1 strain KOS |
IC50 |
= |
600.0 |
nM |
Antiviral activity against HSV1 KOS infected in HFF cells incubated for 3 days by plaque reduction assay |
CHEMBL1926544 |
| Human herpesvirus 5 |
IC50 |
|
|
|
Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay |
CHEMBL1926544 |
| KB |
IC50 |
|
|
|
Cytotoxicity against human KB cells after 48 hrs by crystal violet staining based spectrophotometric analysis |
CHEMBL1926544 |
| Vero |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by crystal violet staining |
CHEMBL1938334 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
3000.0 |
nM |
Antiviral activity against Human herpesvirus 1 strain KOS infected in african green monkey Vero 76 cells assessed as reduction of virus-induced plaque formation after 3 days using crystal violet staining |
CHEMBL1938334 |
| Human herpesvirus 2 |
Inhibition |
= |
66.3 |
% |
Antiherpetic activity against HSV2 at 0.5 mg/ml by MTT assay |
CHEMBL1949540 |
| Human herpesvirus 2 |
Inhibition |
= |
60.6 |
% |
Antiherpetic activity against HSV2 at 0.25 mg/ml by MTT assay |
CHEMBL1949540 |
| Human herpesvirus 3 |
EC50 |
= |
26600.0 |
nM |
Antiviral activity against thymidine kinase-deficient VSV 07-1 infected in HEL cells assessed as reduction of virus plaque formation after 4 days |
CHEMBL2021854 |
| NON-PROTEIN TARGET |
EC50 |
= |
490.0 |
nM |
Antiviral activity against VSV OKA expressing thymidine kinase infected in HEL cells assessed as reduction of virus plaque formation after 4 days |
CHEMBL2021854 |
| HeLa |
CC50 |
= |
541000.0 |
nM |
Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay |
CHEMBL2021854 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HEL cells assessed as minimum compound concentration required to causes microscopically detectable alteration of normal cell morphology |
CHEMBL2021854 |
| Human herpesvirus 1 strain KOS |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days |
CHEMBL2021854 |
| Vesicular stomatitis virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days |
CHEMBL2021854 |
| Vaccinia virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days |
CHEMBL2021854 |
| Human herpesvirus 2 strain G |
EC50 |
= |
400.0 |
nM |
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days |
CHEMBL2021854 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
200.0 |
nM |
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days |
CHEMBL2021854 |
| Human herpesvirus 3 |
EC50 |
= |
2180.0 |
nM |
Antiviral activity against thymidine kinase-positive Varicella-zoster virus YS infected in HEL cells assessed as reduction in virus-induced cytopathicity |
CHEMBL2034851 |
| Human herpesvirus 3 strain Oka vaccine |
EC50 |
= |
2500.0 |
nM |
Antiviral activity against thymidine kinase-positive Varicella-zoster virus OKA infected in HEL cells assessed as reduction in virus-induced cytopathicity |
CHEMBL2034851 |
| Human herpesvirus 3 |
EC50 |
= |
92000.0 |
nM |
Antiviral activity against thymidine kinase-deficient Varicella-zoster virus 07/1 infected in HEL cells assessed as reduction in virus-induced cytopathicity |
CHEMBL2034851 |
| HEL |
MCC |
> |
300000.0 |
nM |
Cytotoxicity against human HEL cells assessed as change in cell morphology by microscopic analysis |
CHEMBL2034851 |
| HEL |
CC50 |
= |
470000.0 |
nM |
Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter |
CHEMBL2034851 |
| Vero |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay |
CHEMBL2034874 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
3000.0 |
nM |
Antiviral activity against Herpes simplex virus type 1 KOS ATCC VR-1493 infected in african green monkey Vero-76 cells assessed as reduction in viral plaque after 3 days by crystal violet staining |
CHEMBL2034874 |
| Human herpesvirus 1 |
IC50 |
= |
2900.0 |
nM |
Antiviral activity against HSV-1 infected in human HFF cells assessed as reduction in cytopathic effect after 3 days by crystal violet staining |
CHEMBL2034823 |
| Human herpesvirus 2 |
IC50 |
= |
2800.0 |
nM |
Antiviral activity against HSV-2 infected in human HFF cells assessed as reduction in cytopathic effect after 3 days by crystal violet staining |
CHEMBL2034823 |
| Human herpesvirus 3 |
IC50 |
= |
1900.0 |
nM |
Antiviral activity against VZV infected in human HFF cells assessed as reduction in cytopathic effect after 7 days by crystal violet staining |
CHEMBL2034823 |
| HFF |
CC50 |
> |
300000.0 |
nM |
Cytotoxicity against human HFF cells after 3 to 8 days by crystal voilet staining |
CHEMBL2034823 |
| Human herpesvirus 3 |
EC50 |
= |
2840.0 |
nM |
Antiviral activity against thymidine kinase positive VZV YS infected in HEL cells by plaque formation assay |
CHEMBL2062419 |
| NON-PROTEIN TARGET |
EC50 |
= |
1640.0 |
nM |
Antiviral activity against thymidine kinase positive VZV OKa infected in HEL cells by plaque formation assay |
CHEMBL2062419 |
| Human herpesvirus 3 |
EC50 |
= |
54000.0 |
nM |
Antiviral activity against thymidine kinase negative VZV 07/01 infected in HEL cells by plaque formation assay |
CHEMBL2062419 |
| Human herpesvirus 3 |
EC50 |
= |
37000.0 |
nM |
Antiviral activity against thymidine kinase negative VZV YS/R infected in HEL cells by plaque formation assay |
CHEMBL2062419 |
| Human herpesvirus 1 |
EC50 |
= |
530.0 |
nM |
Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay |
CHEMBL2062419 |
| Human herpesvirus 2 strain G |
EC50 |
= |
380.0 |
nM |
Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay |
CHEMBL2062419 |
| Human herpesvirus 1 |
EC50 |
>= |
212000.0 |
nM |
Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay |
CHEMBL2062419 |
| Human herpesvirus 5 strain AD169 |
EC50 |
|
|
|
Antiviral activity against HCMV AD169 infected in HEL cells by viral CPE assay |
CHEMBL2062419 |
| Human herpesvirus 5 |
EC50 |
|
|
|
Antiviral activity against HCMV Davis infected in HEL cells by viral CPE assay |
CHEMBL2062419 |
| Felid herpesvirus 1 |
EC50 |
|
|
|
Antiviral activity against Feline herpesvirus infected in CRFK cells by viral CPE assay |
CHEMBL2062419 |
| Vaccinia virus |
EC50 |
> |
1000000.0 |
nM |
Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay |
CHEMBL2062419 |
| HEL |
MCC |
> |
444000.0 |
nM |
Cytotoxicity against HEL cells assessed as effect on cell morphology incubated for 3 days by microscopy |
CHEMBL2062419 |
| HEL |
CC50 |
= |
918000.0 |
nM |
Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay |
CHEMBL2062419 |
| Human herpesvirus 1 |
Inhibition |
|
|
% |
Antiviral activity against HSV-1 infected in african green monkey Vero cells assessed as inhibition of viral replication at 48 uM after 48 hrs by GFP reduction assay |
CHEMBL2069202 |
| Human herpesvirus 1 |
Inhibition |
|
|
% |
Antiviral activity against HSV-1 infected in african green monkey Vero cells assessed as inhibition of viral replication at 48 uM after 48 hrs by plaque reduction assay |
CHEMBL2069202 |
| Human herpesvirus 1 |
Inhibition |
|
|
% |
Antiviral activity against HSV-1 infected in african green monkey Vero cells assessed as inhibition of viral ICP4 gene expression after 48 hrs by RT-PCR analysis |
CHEMBL2069202 |
| Human herpesvirus 1 |
Inhibition |
|
|
% |
Antiviral activity against HSV-1 infected in african green monkey Vero cells assessed as inhibition of GFP gene expression after 48 hrs by RT-PCR analysis |
CHEMBL2069202 |
| Human herpesvirus 1 |
Inhibition |
|
|
% |
Antiviral activity against HSV-1 infected in african green monkey Vero cells assessed as inhibition of viral replication at 50 uM treated 2 hrs after post infection by GFP reduction assay |
CHEMBL2069202 |
| Human herpesvirus 1 |
Inhibition |
|
|
% |
Antiviral activity against HSV-1 infected in african green monkey Vero cells assessed as inhibition of viral replication at 50 uM treated for 24 hrs measured 24 hrs after drug washout by GFP reduction assay |
CHEMBL2069202 |
| Human herpesvirus 1 |
Inhibition |
|
|
% |
Antiviral activity against HSV-1 infected in african green monkey Vero cells assessed as inhibition of viral replication at 50 uM after 48 hrs by GFP reduction assay |
CHEMBL2069202 |
| Solute carrier family 22 member 8 |
Activity |
= |
64.3 |
% |
TP_TRANSPORTER: inhibition of Estrone sulfate uptake (E1S: 0.05 uM, ACV: 1000 uM) in OAT3-expressing S2 cells |
CHEMBL2074052 |
| Solute carrier family 22 member 6 |
Activity |
= |
67.0 |
% |
TP_TRANSPORTER: inhibition of PAH uptake (PAH: 5 uM, ACV: 1000 uM) in OAT1-expressing S2 cells |
CHEMBL2074052 |
| Solute carrier family 22 member 8 |
Activity |
= |
7.66 |
% |
TP_TRANSPORTER: inhibition of Indoxyl sulfate uptake (Indoxyl sulfate: 2 uM, ACV: 1000 uM) in Xenopus laevis oocytes |
CHEMBL2074014 |
| Solute carrier family 22 member 1 |
Activity |
= |
88.4 |
% |
TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, ACV: 1000 uM) in OCT1-expressing S2 cells |
CHEMBL2074052 |
| Solute carrier family 22 member 1 |
Km |
= |
151200.0 |
nM |
TP_TRANSPORTER: uptake in OCT1-expressing S2 cells |
CHEMBL2074052 |
| Solute carrier family 22 member 6 |
Km |
= |
242000.0 |
nM |
TP_TRANSPORTER: uptake in Xenopus laevis oocytes |
CHEMBL2073872 |
| Solute carrier family 22 member 6 |
Km |
= |
342300.0 |
nM |
TP_TRANSPORTER: uptake in OAT1-expressing S2 cells |
CHEMBL2074052 |
| Solute carrier family 22 member 8 |
Activity |
|
|
|
TP_TRANSPORTER: uptake in Xenopus laevis oocytes |
CHEMBL2074134 |
| Solute carrier family 22 member 6 |
Activity |
|
|
|
TP_TRANSPORTER: inhibition of PAH uptake (PAH: 2 uM, ACV: 1000 uM) in Xenopus laevis oocytes |
CHEMBL2073872 |
| Vero |
CC50 |
= |
130.0 |
ug.mL-1 |
Cytotoxicity against african green monkey Vero cells after 2 days by MTT assay |
CHEMBL2086391 |
| Unchecked |
Ratio CC50/EC50 |
= |
61.9 |
|
Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for HSV-1F ATCC 733 |
CHEMBL2086391 |
| Human herpesvirus 1 |
EC50 |
= |
1.6 |
ug.mL-1 |
Antiviral activity against HSV-1F ATCC 733 infected in african green monkey Vero cells after 2 to 3 days by plaque reduction assay |
CHEMBL2086391 |
| Human herpesvirus 2 strain G |
EC50 |
= |
1.8 |
ug.mL-1 |
Antiviral activity against HSV-2G ATCC 734 infected in african green monkey Vero cells after 2 to 3 days by plaque reduction assay |
CHEMBL2086391 |
| Unchecked |
Ratio CC50/EC50 |
= |
81.3 |
|
Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for HSV-1F ATCC 733 by plaque reduction assay |
CHEMBL2086391 |
| Unchecked |
Ratio CC50/EC50 |
= |
72.2 |
|
Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for HSV-2G ATCC 734 by plaque reduction assay |
CHEMBL2086391 |
| Human herpesvirus 1 |
Inhibition |
= |
94.0 |
% |
Antiviral activity against HSV-1F ATCC 733 infected in african green monkey Vero cells assessed as inhibition of virus yield at 20 ug/ml after 3 days by MTT assay |
CHEMBL2086391 |
| Human herpesvirus 1 |
EC50 |
= |
2.1 |
ug.mL-1 |
Antiviral activity against HSV-1F ATCC 733 infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 3 days by MTT assay |
CHEMBL2086391 |
| Human immunodeficiency virus 1 |
GI |
|
|
|
Antiviral activity against HIV1 pseudovirus infected in Jurkat cells coexpressing GFP assessed as viral growth inhibition up to 100 uM incubated for 2 to 8 hrs prior to infection measured after 48 hrs by flow cytofluorimetric analysis |
CHEMBL2146431 |
| Human immunodeficiency virus 1 |
GI |
|
|
|
Antiviral activity against HIV1 pseudovirus infected in Jurkat cells coexpressing GFP assessed as viral growth inhibition incubated for 2 to 8 hrs prior to infection measured after 48 hrs by flow cytofluorimetric analysis |
CHEMBL2146431 |
| Human herpesvirus 1 |
EC50 |
= |
1700.0 |
nM |
Antiviral activity against HSV1 L2 infected in Vero E6 cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs |
CHEMBL2146431 |
| ADMET |
Ratio CC50/EC50 |
> |
1176.0 |
|
Selectivity ratio of CC50 for african green monkey Vero cells to EC50 for HSV1 L2 |
CHEMBL2146431 |
| Human herpesvirus 1 |
EC50 |
= |
530000.0 |
nM |
Antiviral activity against acyclovir-resistant HSV1 L2 infected in Vero E6 cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs |
CHEMBL2146431 |
| ADMET |
Ratio CC50/EC50 |
> |
3.8 |
|
Selectivity ratio of CC50 for african green monkey Vero cells to EC50 for acyclovir-resistant HSV1 L2 |
CHEMBL2146431 |
| Vero |
CC50 |
> |
2000000.0 |
nM |
Cytotoxicity against african green monkey Vero E6 cells after 72 hrs by trypan blue staining |
CHEMBL2146431 |
| Vaccinia virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus infected in HEL assessed as inhibition of virus-induced cytopathicity after 3 days |
CHEMBL2146385 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
400.0 |
nM |
Antiviral activity against HSV1 KOS infected in HEL assessed as inhibition of virus-induced cytopathicity after 3 days |
CHEMBL2146385 |
| Human herpesvirus 2 strain G |
EC50 |
= |
400.0 |
nM |
Antiviral activity against HSV2 G infected in HEL assessed as inhibition of virus-induced cytopathicity after 3 days |
CHEMBL2146385 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
250000.0 |
nM |
Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in HEL assessed as inhibition of virus-induced cytopathicity after 3 days |
CHEMBL2146385 |
| NON-PROTEIN TARGET |
EC50 |
= |
2700.0 |
nM |
Antiviral activity against VZV OKA expressing thymidine kinase infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 3 days |
CHEMBL2146385 |
| Human herpesvirus 3 |
EC50 |
= |
15000.0 |
nM |
Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days |
CHEMBL2146385 |
| HEL |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against HEL assessed as minimum compound concentration causes microscopically detectable alteration of cell morphology after 3 days |
CHEMBL2146385 |
| HEL |
CC50 |
= |
134000.0 |
nM |
Cytotoxicity against HEL after 3 days |
CHEMBL2146385 |
| Herpes simplex virus (type 1 / strain F) |
EC50 |
= |
500.0 |
nM |
Antiviral activity against Herpes simplex virus (type 1 / strain F) infected in Vero cells assessed as reduction of number of viral plaques after 2 days |
CHEMBL2146401 |
| Human herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against HSV1 infected herpes simplex keratitis New zealand rabbit model assessed as reduction in viral DNA level in corneal sample compound administered twice daily as gel 24 hrs post inoculation measured on day 9 post infection by RT-PCR analysis |
CHEMBL2163311 |
| Human herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against HSV1 infected herpes simplex keratitis New zealand rabbit model assessed as reduction in viral DNA level in corneal sample at 0.025% to 0.1% administered twice daily as gel 24 hrs post inoculation measured on day 9 post infection by RT-PCR analysis |
CHEMBL2163311 |
| Human herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against HSV1 infected herpes simplex keratitis New zealand rabbit model assessed as reduction in corneal epithelia involvement score at 0.025% to 0.1% administered twice daily as gel 24 hrs post inoculation measured on day 9 post infection |
CHEMBL2163311 |
| Unchecked |
Ratio CC50/EC50 |
> |
106.95 |
|
Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for HSV2 strain 333 infected in african green monkey Vero cells |
CHEMBL2163311 |
| Unchecked |
Ratio CC50/EC50 |
> |
166.67 |
|
Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for HSV1 strain F ATCC VR733 infected in african green monkey Vero cells |
CHEMBL2163311 |
| NON-PROTEIN TARGET |
Inhibition |
|
|
% |
Antiviral activity against HSV2 strain 333 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect at 3.5 uM after 48 hrs by plaque reduction assay |
CHEMBL2163311 |
| Human herpesvirus 1 |
Inhibition |
|
|
% |
Antiviral activity against HSV1 strain F ATCC VR733 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect at 3.5 uM after 48 hrs by plaque reduction assay |
CHEMBL2163311 |
| NON-PROTEIN TARGET |
EC50 |
= |
1870.0 |
nM |
Antiviral activity against HSV2 strain 333 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect after 48 hrs by plaque reduction assay |
CHEMBL2163311 |
| Human herpesvirus 1 |
EC50 |
= |
1200.0 |
nM |
Antiviral activity against HSV1 strain F ATCC VR733 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect after 48 hrs by plaque reduction assay |
CHEMBL2163311 |
| Vero |
CC50 |
> |
200000.0 |
nM |
Cytotoxicity against african green monkey Vero cells assessed as inhibition of cell viability after 48 hrs by MTT assay |
CHEMBL2163311 |
| Solute carrier organic anion transporter family member 2B1 |
Inhibition |
= |
-15.2 |
% |
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting |
CHEMBL2163248 |
| Solute carrier organic anion transporter family member 1B3 |
Inhibition |
= |
-2.0 |
% |
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting |
CHEMBL2163248 |
| Solute carrier organic anion transporter family member 1B1 |
Inhibition |
= |
2.3 |
% |
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting |
CHEMBL2163248 |
| HEL |
MCC |
> |
250000.0 |
nM |
Toxicity in HEL cells assessed as induction of cell morphology changes |
CHEMBL2203009 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
44000.0 |
nM |
Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL2203009 |
| Vesicular stomatitis virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL2203009 |
| Vaccinia virus |
EC50 |
>= |
250000.0 |
nM |
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL2203009 |
| Human herpesvirus 2 strain G |
EC50 |
= |
140.0 |
nM |
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL2203009 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
140.0 |
nM |
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL2203009 |
| Herpes simplex virus (type 1 / strain F) |
IC50 |
= |
0.2 |
ug.mL-1 |
Antiviral activity against HSV1 F ATCC VR733 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days |
CHEMBL2203092 |
| Human herpesvirus 1 |
EC50 |
= |
22000.0 |
nM |
Antiviral activity against Herpes simplex virus type 1 infected in Vero cells at 0.01 ID50/cells assessed as protection against virus-induced cytopathic effect after 3 days by neutral red dye method |
CHEMBL2203237 |
| Vero |
CC50 |
> |
200000.0 |
nM |
Cytotoxicity against african green monkey Vero cells after 3 days by neutral red dye method |
CHEMBL2203237 |
| Human herpesvirus 1 |
EC50 |
= |
760.0 |
nM |
Antiviral activity against Herpes simplex virus type 1 infected in Vero cells at 0.001 ID50/cells assessed as protection against virus-induced cytopathic effect after 3 days by neutral red dye method |
CHEMBL2203237 |
| Human herpesvirus 1 |
Activity |
= |
100.0 |
% |
Antiviral activity against Human herpesvirus 1 infected African green monkey Vero cells after 66 hr by viral plaque reduction assay |
CHEMBL3045049 |
| Human herpesvirus 1 |
EC50 |
= |
1.5 |
ug.mL-1 |
Antiviral activity against Human herpesvirus 1 infected African green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 3 days by plaque reduction assay |
CHEMBL3046134 |
| Unchecked |
Ratio CC50/EC50 |
= |
850.0 |
|
Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for HSV1 infected in African green monkey Vero cells |
CHEMBL3046134 |
| Vero |
CC50 |
= |
1275.0 |
ug.mL-1 |
Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells assessed as cell viability after 3 days by Alamar blue assay |
CHEMBL3046134 |
| Human parainfluenza virus 3 |
Activity |
|
|
|
Antiviral activity against Human parainfluenza virus 3 infected African green monkey Vero cells assessed as concentration required to cause minimum inhibition of virus-induced cytopathic effect |
CHEMBL3045118 |
| Human parainfluenza virus 3 |
Activity |
|
|
|
Antiviral activity against Human parainfluenza virus 3 infected African green monkey Vero cells assessed as concentration required to cause maximum inhibition of virus-induced cytopathic effect |
CHEMBL3045118 |
| Vero |
MNCC |
|
|
|
Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells assessed as maximum non-toxic concentration |
CHEMBL3045118 |
| Human herpesvirus 1 |
Activity |
< |
0.012 |
ug ml-1 |
Antiviral activity against Human herpesvirus 1 infected bovine MDBK cells assessed as concentration required to cause minimum inhibition of virus-induced cytopathic effect |
CHEMBL3045118 |
| Human herpesvirus 1 |
Activity |
= |
1.6 |
ug ml-1 |
Antiviral activity against Human herpesvirus 1 infected bovine MDBK cells assessed as concentration required to cause maximum inhibition of virus-induced cytopathic effect |
CHEMBL3045118 |
| ADMET |
MNCC |
= |
1.6 |
ug ml-1 |
Cytotoxicity against Bos taurus (bovine) MDBK cells assessed as maximum non-toxic concentration |
CHEMBL3045118 |
| Unchecked |
Ratio CC50/EC50 |
= |
880.0 |
|
Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for Mayaro virus |
CHEMBL3045152 |
| Unchecked |
Ratio CC50/EC50 |
= |
880.0 |
|
Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for Herpes simplex virus 1 |
CHEMBL3045152 |
| Vero |
CC50 |
= |
960000.0 |
nM |
Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 72 hr by MTT assay |
CHEMBL3045152 |
| Human herpesvirus 1 |
Inhibition |
= |
96.0 |
% |
Antiviral activity against Human herpesvirus 1 at 10 uM by end point titration assay |
CHEMBL3045152 |
| Human herpesvirus 1 |
EC50 |
= |
1090.0 |
nM |
Antiviral activity against Human herpesvirus 1 infected in Vero cells after 72 hr by plaque reduction assay |
CHEMBL3045152 |
| MDA-MB-231 |
Activity |
|
|
|
Genotoxicity in Homo sapiens (human) MDA-MB-231 cells assessed as reduction of BP-DNA adduct formation at 100 uM after 24 hr by 32P-postlabeling technique |
CHEMBL3046726 |
| MCF-10A |
Activity |
|
|
|
Genotoxicity in Homo sapiens (human) MCF10A cells assessed as reduction of BP-DNA adduct formation at 100 uM after 24 hr by 32P-postlabeling technique |
CHEMBL3046726 |
| MCF-12A |
Activity |
|
|
|
Genotoxicity in Homo sapiens (human) MCF12A cells assessed as reduction of BP-DNA adduct formation at 100 uM after 24 hr by 32P-postlabeling technique |
CHEMBL3046726 |
| MDA-MB-231 |
Activity |
|
|
|
Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells at 100 uM after 72 hr |
CHEMBL3046726 |
| MCF7 |
Activity |
|
|
|
Cytotoxicity against Homo sapiens (human) MCF7 cells at 100 uM after 72 hr |
CHEMBL3046726 |
| MCF-10A |
Activity |
|
|
|
Cytotoxicity against Homo sapiens (human) MCF10A cells at 100 uM after 72 hr |
CHEMBL3046726 |
| MCF-12A |
Activity |
|
|
|
Cytotoxicity against Homo sapiens (human) MCF12A cells at 100 uM after 72 hr |
CHEMBL3046726 |
| MDA-MB-231 |
Activity |
|
|
|
Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells at 50 uM after 72 hr |
CHEMBL3046726 |
| MCF7 |
Activity |
|
|
|
Cytotoxicity against Homo sapiens (human) MCF7 cells at 50 uM after 72 hr |
CHEMBL3046726 |
| MCF-10A |
Activity |
|
|
|
Cytotoxicity against Homo sapiens (human) MCF10A cells at 50 uM after 72 hr |
CHEMBL3046726 |
| MCF-12A |
Activity |
|
|
|
Cytotoxicity against Homo sapiens (human) MCF12A cells at 50 uM after 72 hr |
CHEMBL3046726 |
| MDA-MB-231 |
Activity |
|
|
|
Cell cycle arrest in Homo sapiens (human) MDA-MB-231 cells assessed as accumulation at G2/M phase at 100 uM after 72 hr by flow cytometry |
CHEMBL3046726 |
| MCF7 |
Activity |
|
|
|
Cell cycle arrest in Homo sapiens (human) MCF7 cells assessed as accumulation at G2/M phase at 100 uM after 72 hr by flow cytometry |
CHEMBL3046726 |
| MCF-12A |
Activity |
|
|
|
Cell cycle arrest in Homo sapiens (human) MCF12A cells assessed as accumulation at G2/M phase at 100 uM after 72 hr by flow cytometry |
CHEMBL3046726 |
| MCF-10A |
Activity |
|
|
|
Cell cycle arrest in Homo sapiens (human) MCF10A cells assessed as accumulation at G2/M phase at 100 uM after 72 hr by flow cytometry |
CHEMBL3046726 |
| MDA-MB-231 |
Activity |
|
|
|
Induction of apoptosis in Homo sapiens (human) MDA-MB-231 cells at 100 uM after 72 hr by flow cytometry |
CHEMBL3046726 |
| MCF7 |
Activity |
|
|
|
Induction of apoptosis in Homo sapiens (human) MCF7 cells at 100 uM after 72 hr by flow cytometry |
CHEMBL3046726 |
| MCF-12A |
Activity |
|
|
|
Induction of apoptosis in Homo sapiens (human) MCF12A cells at 100 uM after 72 hr by flow cytometry |
CHEMBL3046726 |
| MCF-10A |
Activity |
|
|
|
Induction of apoptosis in Homo sapiens (human) MCF10A cells at 100 uM after 72 hr by flow cytometry |
CHEMBL3046726 |
| MDA-MB-231 |
Activity |
|
|
|
Cell cycle arrest in Homo sapiens (human) MDA-MB-231 cells assessed as accumulation at G2/M phase at 50 uM after 72 hr by flow cytometry |
CHEMBL3046726 |
| MCF7 |
Activity |
|
|
|
Cell cycle arrest in Homo sapiens (human) MCF7 cells assessed as accumulation at G2/M phase at 50 uM after 72 hr by flow cytometry |
CHEMBL3046726 |
| MCF-12A |
Activity |
|
|
|
Cell cycle arrest in Homo sapiens (human) MCF12A cells assessed as accumulation at G2/M phase at 50 uM after 72 hr by flow cytometry |
CHEMBL3046726 |
| MCF-10A |
Activity |
|
|
|
Cell cycle arrest in Homo sapiens (human) MCF10A cells assessed as accumulation at G2/M phase at 50 uM after 72 hr by flow cytometry |
CHEMBL3046726 |
| MDA-MB-231 |
Activity |
|
|
|
Induction of apoptosis in Homo sapiens (human) MDA-MB-231 cells at 50 uM after 72 hr by flow cytometry |
CHEMBL3046726 |
| MCF7 |
Activity |
|
|
|
Induction of apoptosis in Homo sapiens (human) MCF7 cells at 50 uM after 72 hr by flow cytometry |
CHEMBL3046726 |
| MCF-12A |
Activity |
|
|
|
Induction of apoptosis in Homo sapiens (human) MCF12A cells at 50 uM after 72 hr by flow cytometry |
CHEMBL3046726 |
| MCF-10A |
Activity |
|
|
|
Induction of apoptosis in Homo sapiens (human) MCF10A cells at 50 uM after 72 hr by flow cytometry |
CHEMBL3046726 |
| MDA-MB-231 |
Activity |
|
|
|
Cell cycle arrest in Homo sapiens (human) MDA-MB-231 cells at 10 uM after 72 hr by flow cytometry |
CHEMBL3046726 |
| MCF7 |
Activity |
|
|
|
Cell cycle arrest in Homo sapiens (human) MCF7 cells at 10 uM after 72 hr by flow cytometry |
CHEMBL3046726 |
| MCF-12A |
Activity |
|
|
|
Cell cycle arrest in Homo sapiens (human) MCF12A cells at 10 uM after 72 hr by flow cytometry |
CHEMBL3046726 |
| MDA-MB-231 |
Activity |
|
|
|
Induction of apoptosis in Homo sapiens (human) MDA-MB-231 cells at 10 uM after 72 hr by flow cytometry |
CHEMBL3046726 |
| MCF7 |
Activity |
|
|
|
Induction of apoptosis in Homo sapiens (human) MCF7 cells at 10 uM after 72 hr by flow cytometry |
CHEMBL3046726 |
| MCF-12A |
Activity |
|
|
|
Induction of apoptosis in Homo sapiens (human) MCF12A cells at 10 uM after 72 hr by flow cytometry |
CHEMBL3046726 |
| MDA-MB-231 |
Activity |
|
|
|
Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells at 10 uM after 72 hr |
CHEMBL3046726 |
| MCF7 |
Activity |
|
|
|
Cytotoxicity against Homo sapiens (human) MCF7 cells at 10 uM after 72 hr |
CHEMBL3046726 |
| MCF-12A |
Activity |
|
|
|
Cytotoxicity against Homo sapiens (human) MCF12A cells at 10 uM after 72 hr |
CHEMBL3046726 |
| Human herpesvirus 1 |
EC50 |
= |
3000.0 |
nM |
Antiviral activity against Human herpesvirus 1 infected African green monkey Vero76 cells assessed as reduction of virus-induced plaque reduction after 3 days by MTT assay |
CHEMBL3046758 |
| HEL |
MCC |
> |
100.0 |
ug.mL-1 |
Cytotoxicity against HEL assessed as minimum concentration required to cause morphological changes |
CHEMBL3045401 |
| HEL |
CC50 |
= |
120.0 |
ug.mL-1 |
Cytotoxicity against HEL |
CHEMBL3045401 |
| Human herpesvirus 3 |
EC50 |
= |
23.0 |
ug.mL-1 |
Antiviral activity against thymidine kinase-deficient Human herpesvirus 3 infected in HEL cells assessed as inhibition of viral plaque formation |
CHEMBL3045401 |
| Human herpesvirus 3 |
EC50 |
= |
0.44 |
ug.mL-1 |
Antiviral activity against thymidine kinase-positive Human herpesvirus 3 infected in HEL cells assessed as inhibition of viral plaque formation |
CHEMBL3045401 |
| Human herpesvirus 1 strain KOS |
MIC |
= |
300.0 |
ug.mL-1 |
Antiviral activity against thymidine kinase-deficient, acylcovir-resistant Human herpesvirus 1 strain KOS infected in HEL cells |
CHEMBL3045159 |
| Vesicular stomatitis virus |
MIC |
> |
500.0 |
ug.mL-1 |
Antiviral activity against Vesicular stomatitis virus infected HEL cells |
CHEMBL3045159 |
| Vaccinia virus |
MIC |
> |
500.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus infected HEL cells |
CHEMBL3045159 |
| Human herpesvirus 2 strain G |
MIC |
= |
20.0 |
ug.mL-1 |
Antiviral activity against Human herpesvirus 2 strain G infected HEL cells |
CHEMBL3045159 |
| Human herpesvirus 1 strain KOS |
MIC |
= |
2.4 |
ug.mL-1 |
Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells |
CHEMBL3045159 |
| HEL |
MCC |
> |
500.0 |
ug.mL-1 |
Cytotoxicity against Homo sapiens (human) HEL cells |
CHEMBL3045159 |
| Human herpesvirus 1 strain KOS |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay |
CHEMBL3045116 |
| Vesicular stomatitis virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay |
CHEMBL3045116 |
| Vaccinia virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay |
CHEMBL3045116 |
| Human herpesvirus 2 strain G |
EC50 |
= |
700.0 |
nM |
Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay |
CHEMBL3045116 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against Homo sapiens (human) HEL cells assessed as change in cellular morphology |
CHEMBL3045116 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
1000.0 |
nM |
Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay |
CHEMBL3045116 |
| Human herpesvirus 1 |
EC50 |
= |
3000.0 |
nM |
Antiviral activity against Human herpesvirus 1 infected African green monkey Vero 76 cells assessed as reduction in plaque number treated after viral infection measured after 3 days by plaque reduction assay |
CHEMBL3046811 |
| Human herpesvirus 3 |
IC50 |
= |
13000.0 |
nM |
Antiviral activity against Varicella zoster virus Ellen infected in human MRC5 cells assessed as inhibition of viral replication by viral reduction plaque assay |
CHEMBL2311537 |
| Human herpesvirus 2 |
EC50 |
= |
58600.0 |
nM |
Antiviral activity against Herpes simplex virus 2 MS infected in Vero cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay |
CHEMBL2331187 |
| Herpes simplex virus (type 1 / strain F) |
EC50 |
= |
1700.0 |
nM |
Antiviral activity against Herpes simplex virus 1 F infected in Vero cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay |
CHEMBL2331187 |
| Vero |
CC50 |
> |
50000.0 |
nM |
Cytotoxicity against african green monkey Vero cells by MTT assay |
CHEMBL2331187 |
| Mus musculus |
Activity |
|
|
|
Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in cytokine IL-2 level in serum at 100 mg/kg qd for 1 month by ELISA |
CHEMBL2331251 |
| Mus musculus |
Activity |
|
|
|
Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in cytokine IFN gamma level in serum at 100 mg/kg qd for 1 month by ELISA |
CHEMBL2331251 |
| Mus musculus |
Activity |
|
|
|
Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in cytokine IL-2 mRNA level in liver at 100 mg/kg qd for 1 month by qPCR analysis |
CHEMBL2331251 |
| Mus musculus |
Activity |
|
|
|
Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in cytokine IFN gamma mRNA level in liver at 100 mg/kg qd for 1 month by qPCR analysis |
CHEMBL2331251 |
| Hepatitis B virus |
IC50 |
> |
1000000.0 |
nM |
Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 6 days by ELISA |
CHEMBL2331251 |
| Hepatitis B virus |
IC50 |
> |
1000000.0 |
nM |
Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 6 days by ELISA |
CHEMBL2331251 |
| ADMET |
CC50 |
= |
630000.0 |
nM |
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in number of viable cells after 3 days by MTT assay |
CHEMBL2331251 |
| Mus musculus |
Activity |
= |
31.2 |
% |
Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in CD3+ population in peripheral blood at 100 mg/kg qd for 1 month by flow cytometry (Rvb = 30.1 +/-2.9%) |
CHEMBL2331251 |
| Mus musculus |
Activity |
= |
18.7 |
% |
Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in CD4+ population in peripheral blood at 100 mg/kg qd for 1 month by flow cytometry (Rvb = 13.6 +/-2.7%) |
CHEMBL2331251 |
| Mus musculus |
Activity |
= |
15.1 |
% |
Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in CD8+ population in peripheral blood at 100 mg/kg qd for 1 month by flow cytometry (Rvb = 14.1 +/-1.4%) |
CHEMBL2331251 |
| Mus musculus |
Activity |
= |
1.2 |
% |
Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in CD4+/CD8+ population in peripheral blood at 100 mg/kg qd for 1 month by flow cytometry (Rvb = 0.9 +/-0.2%) |
CHEMBL2331251 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
5173.5 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
2238.7 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
508.1 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
1299.5 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
259.3 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
1158.2 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
446.7 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
452.8 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HEL cells assessed as effect on cell morphology |
CHEMBL2384920 |
| Vaccinia virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis |
CHEMBL2384920 |
| Human herpesvirus 2 strain G |
EC50 |
= |
80.0 |
nM |
Antiviral activity against Human simplex virus 2 G infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis |
CHEMBL2384920 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
29000.0 |
nM |
Antiviral activity against thymidine kinase-deficient Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis |
CHEMBL2384920 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
80.0 |
nM |
Antiviral activity against Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis |
CHEMBL2384920 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HEL cells |
CHEMBL2417501 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
112000.0 |
nM |
Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL2417501 |
| Vesicular stomatitis virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL2417501 |
| Vaccinia virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL2417501 |
| Human herpesvirus 2 strain G |
EC50 |
= |
200.0 |
nM |
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL2417501 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
400.0 |
nM |
Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL2417501 |
| Human herpesvirus 3 |
EC50 |
= |
143600.0 |
nM |
Antiviral activity against TK-positive Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction of plaque formation |
CHEMBL2417501 |
| NON-PROTEIN TARGET |
EC50 |
= |
26.0 |
nM |
Antiviral activity against TK-positive Varicella-zoster virus OKA infected in human HEL cells assessed as reduction of plaque formation |
CHEMBL2417501 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
112000.0 |
nM |
Antiviral activity against thymidine kinase negative acyclovir positive Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL2417481 |
| Human herpesvirus 3 |
EC50 |
= |
26000.0 |
nM |
Antiviral activity against thymidine kinase negative Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction in the virus plaque formation |
CHEMBL2417481 |
| NON-PROTEIN TARGET |
EC50 |
= |
2100.0 |
nM |
Antiviral activity against thymidine kinase positive Varicella-zoster virus OKA infected in human HEL cells assessed as reduction in virus plaque formation |
CHEMBL2417481 |
| Human herpesvirus 2 strain G |
EC50 |
= |
200.0 |
nM |
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL2417481 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
200.0 |
nM |
Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL2417481 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HEL cells assessed as morphological changes |
CHEMBL2417481 |
| Vesicular stomatitis virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL2417481 |
| Vaccinia virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus Lederle infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL2417481 |
| Human herpesvirus 3 |
Inhibition |
|
|
% |
Antiviral activity against Varicella-zoster virus VR-1367 infected in African green monkey BSC1 cells assessed as inhibition of virus plaque formation |
CHEMBL2434903 |
| Human herpesvirus 5 |
Inhibition |
|
|
% |
Antiviral activity against Cytomegalovirus VR-538 infected in human MRC5 cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL2434903 |
| Human herpesvirus 2 |
Inhibition |
|
|
% |
Antiviral activity against Herpes simplex virus type 2 VR-734 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL2434903 |
| Human adenovirus type 2 |
Inhibition |
|
|
% |
Antiviral activity against Adenovirus 2 VR-1080 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL2434903 |
| Human herpesvirus 1 |
Inhibition |
|
|
% |
Antiviral activity against Herpes simplex virus type 1 VR-260 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL2434903 |
| Human coxsackievirus B4 |
Inhibition |
|
|
% |
Antiviral activity against Coxsackievirus B4 VR-1035 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL2434903 |
| Human echovirus 9 |
Inhibition |
|
|
% |
Antiviral activity against Human echovirus 9 VR-1050 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL2434903 |
| NON-PROTEIN TARGET |
Inhibition |
|
|
% |
Antiviral activity against Poliovirus 1 Sabin VR-1562 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL2434903 |
| Solute carrier organic anion transporter family member 1B3 |
Inhibition |
= |
105.48 |
% |
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM |
CHEMBL3039007 |
| Solute carrier organic anion transporter family member 1B1 |
Inhibition |
= |
103.39 |
% |
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM |
CHEMBL3039007 |
| HEL |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against HEL cells |
CHEMBL3085645 |
| Felid herpesvirus 1 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Feline herpesvirus infected in cat CRFK cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL3085645 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
23000.0 |
nM |
Antiviral activity against acyclovir-resistant thymidine kinase-deficient Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL3085645 |
| Human herpesvirus 2 strain G |
EC50 |
= |
200.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL3085645 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
230.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL3085645 |
| MT4 |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against human MT4 cells assessed as cell viability by propidium iodide staining-based cell counting analysis |
CHEMBL3085645 |
| Human immunodeficiency virus 1 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as p24 production after 3 days by microscopic analysis |
CHEMBL3085645 |
| Homo sapiens |
F |
= |
10.0 |
% |
Oral bioavailability in human |
CHEMBL3085731 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
18000.0 |
nM |
Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL3085731 |
| Human herpesvirus 2 strain G |
EC50 |
= |
500.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL3085731 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
320.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL3085731 |
| No relevant target |
Solubility |
= |
1290.0 |
ug.mL-1 |
Solubility of the compound in deionized water at pH 5.5 after overnight incubation by HPLC analysis |
CHEMBL3085731 |
| NON-PROTEIN TARGET |
Ratio CC50/EC50 |
> |
10.4 |
|
Selectivity index, ratio of CC50 for cytotoxicity to EC50 for HSV2 |
CHEMBL3120115 |
| NON-PROTEIN TARGET |
Ratio CC50/EC50 |
= |
30.3 |
|
Selectivity index, ratio of CC50 for cytotoxicity to EC50 for HSV1 |
CHEMBL3120115 |
| Human herpesvirus 2 |
EC50 |
= |
9600.0 |
nM |
Antiviral activity against HSV2 assessed as inhibition of viral infection |
CHEMBL3120115 |
| Human herpesvirus 1 |
EC50 |
= |
3300.0 |
nM |
Antiviral activity against HSV1 assessed as inhibition of viral infection |
CHEMBL3120115 |
| NON-PROTEIN TARGET |
Hepatotoxicity (moderate) |
= |
18.0 |
|
Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] |
CHEMBL3137667 |
| NON-PROTEIN TARGET |
Hepatotoxicity (moderate) |
= |
50.0 |
% |
Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (acute) |
= |
1.0 |
|
Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source] |
CHEMBL3137667 |
| NON-PROTEIN TARGET |
Hepatotoxicity (acute) |
= |
1.9 |
% |
Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (cytolytic) |
= |
1.0 |
|
Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (choleostasis) |
= |
0.0 |
|
Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (severe hepatitis) |
= |
0.0 |
|
Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (chronic liver disease) |
= |
0.0 |
|
Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (cirrhosis) |
= |
0.0 |
|
Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] |
CHEMBL3137667 |
| NON-PROTEIN TARGET |
Hepatotoxicity (granulomatous hepatitis) |
= |
0.0 |
|
Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (association with vascular disease) |
= |
0.0 |
|
Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (steatosis) |
= |
0.0 |
|
Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (malignant tumour) |
= |
0.0 |
|
Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] |
CHEMBL3137667 |
| NON-PROTEIN TARGET |
Hepatotoxicity (benign tumour) |
= |
0.0 |
|
Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] |
CHEMBL3137667 |
| NON-PROTEIN TARGET |
Hepatotoxicity (animal toxicity known) |
|
|
|
Animal toxicity known. [column 'TOXIC' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (successful reintroduction) |
|
|
|
Presence of at least one case with successful reintroduction. [column 'REINT' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (comment) |
|
|
|
Comments (NB not yet translated). [column 'COMMENTAIRES' in source] |
CHEMBL3137667 |
| NON-PROTEIN TARGET |
Hepatotoxicity (time to onset) |
|
|
|
Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] |
CHEMBL3137667 |
| NON-PROTEIN TARGET |
Hepatotoxicity (mechanism) |
|
|
|
Proposed mechanism(s) of liver damage. [column 'MEC' in source] |
CHEMBL3137667 |
| NON-PROTEIN TARGET |
Potency |
|
2.4 |
nM |
PubChem BioAssay. qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation. (Class of assay: confirmatory) |
CHEMBL1201862 |
| NON-PROTEIN TARGET |
Potency |
|
2.7 |
nM |
PubChem BioAssay. qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Cerebroside-sulfatase |
Potency |
|
23934.1 |
nM |
PubChem BioAssay. qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay. (Class of assay: confirmatory) |
CHEMBL1201862 |
| NON-PROTEIN TARGET |
Potency |
|
211.2 |
nM |
PubChem BioAssay. qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2). (Class of assay: confirmatory) |
CHEMBL1201862 |
| NON-PROTEIN TARGET |
Potency |
|
1.7 |
nM |
PubChem BioAssay. qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Human herpesvirus 3 strain Oka vaccine |
EC50 |
= |
2600.0 |
nM |
Antiviral activity against thymidine kinase-positive Varicella zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation after 5 days |
CHEMBL3259765 |
| Human herpesvirus 3 |
EC50 |
= |
140000.0 |
nM |
Antiviral activity against thymidine kinase-deficient Varicella zoster virus 07-1 infected in HEL cells assessed as reduction in viral plaque formation after 5 days |
CHEMBL3259765 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
200.0 |
nM |
Antiviral activity against thymidine kinase-positive Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathicity after 3 days |
CHEMBL3259765 |
| Human herpesvirus 1 |
EC50 |
= |
50000.0 |
nM |
Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 B-2006 infected in HEL cells assessed as reduction in virus-induced cytopathicity after 3 days |
CHEMBL3259765 |
| Human herpesvirus 2 strain G |
EC50 |
= |
100.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathicity after 3 days |
CHEMBL3259765 |
| HEL |
CC50 |
= |
440000.0 |
nM |
Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 to 5 days by Coulter counting analysis |
CHEMBL3259765 |
| HEL |
MCC |
> |
440000.0 |
nM |
Cytotoxicity against HEL cells assessed as morphological changes after 3 to 5 days by Coulter counting analysis |
CHEMBL3259765 |
| ADMET |
PPB |
|
10.09 |
% |
ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole rat plasma at 37C for >5hrs. Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound. |
CHEMBL3301361 |
| No relevant target |
pKa_A1 |
|
9.26 |
|
ASTRAZENECA: Most acidic pKa value (pKa A1) determined by absorption and potentiometric titration using standard methodology from Sirius Analytical. Experimental range Acids: <= 11. |
CHEMBL3301361 |
| ADMET |
PPB |
|
25.75 |
% |
ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole dog plasma at 37C for >5hrs. Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound. |
CHEMBL3301361 |
| No relevant target |
pKa_B1 |
|
2.2 |
|
ASTRAZENECA: Most basic pKa value (pKa B1) determined by absorption and potentiometric titration using standard methodology from Sirius Analytical. Experimental range Bases: >= 2. |
CHEMBL3301361 |
| No relevant target |
LogD7.4 |
|
-1.42 |
|
ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5 |
CHEMBL3301361 |
| Vesicular stomatitis virus |
ED50 |
= |
1411.0 |
umol/L |
Antiviral activity against vesicular stomatitis virus infected in human WISH cells |
CHEMBL3351685 |
| WISH |
Activity |
= |
3414.0 |
umol/L |
Cytotoxicity against human WISH cells |
CHEMBL3351685 |
| NON-PROTEIN TARGET |
Selectivity Index |
= |
2.4 |
|
Selectivity index, ratio of toxic concentration for human WISH cells to ED50 for vesicular stomatitis virus infected in human WISH cells |
CHEMBL3351685 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against mock-infected African green monkey Vero 76 cells assessed as reduction in proliferation after 48 to 96 hrs by MTT method |
CHEMBL3352401 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
3000.0 |
nM |
Antiviral activity against Human herpesvirus 1 strain KOS ATCC VR- 1493 infected in Vero 76 cells after 3 days by plaque reduction assays |
CHEMBL3352401 |
| MT4 |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay |
CHEMBL3351523 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against mock-infected MDBK cells after 48 to 96 hrs by MTT assay |
CHEMBL3351523 |
| Bovine viral diarrhea virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Bovine viral diarrhea virus infected in MDBK cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3351523 |
| NON-PROTEIN TARGET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay |
CHEMBL3351523 |
| Yellow fever virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3351523 |
| Reovirus sp. |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3351523 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay |
CHEMBL3351523 |
| Human coxsackievirus B5 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay |
CHEMBL3351523 |
| Human poliovirus 1 strain Sabin |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay |
CHEMBL3351523 |
| Respiratory syncytial virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay |
CHEMBL3351523 |
| Vesicular stomatitis virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay |
CHEMBL3351523 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay |
CHEMBL3351523 |
| Human herpesvirus 1 |
EC50 |
= |
1200.0 |
nM |
Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay |
CHEMBL3351523 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method |
CHEMBL3421576 |
| Human herpesvirus 1 |
EC50 |
= |
2800.0 |
nM |
Antiviral activity against HSV1 infected in African green monkey Vero 76 cells after 3 days by plaque reduction assay |
CHEMBL3421576 |
| Plasma |
fCmax |
= |
18.87 |
uM |
Unbound Cmax in human plasma |
CHEMBL3526080 |
| Bile salt export pump |
IC50 |
> |
1000000.0 |
nM |
Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake |
CHEMBL3526080 |
| Cytochrome P450 2J2 |
IC50 |
> |
50000.0 |
nM |
Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method |
CHEMBL3526101 |
| Bile salt export pump |
IC50 |
> |
1000000.0 |
nM |
Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake |
CHEMBL3526080 |
| Solute carrier family 22 member 7 |
FC |
= |
10.0 |
|
Drug transport in human OAT2 expressed in HEK Flp-In cells at 0.06 uM for 10 mins relative to control |
CHEMBL3526025 |
| Solute carrier family 22 member 6 |
FC |
= |
1.7 |
|
Drug transport in human OAT1 expressed in HEK Flp-In cells at 0.06 uM for 10 mins relative to control |
CHEMBL3526025 |
| Solute carrier family 22 member 8 |
FC |
= |
1.7 |
|
Drug transport in human OAT3 expressed in HEK Flp-In cells at 0.06 uM for 10 mins relative to control |
CHEMBL3526025 |
| POU domain, class 2, transcription factor 2 |
Drug transport |
|
|
|
Drug transport in human OCT2 expressed in HEK Flp-In cells at 0.06 uM for 10 mins relative to control |
CHEMBL3526025 |
| ADMET |
Drug transport |
|
|
|
Drug transport in human ENT in HEK cells in presence of 100 uM ENT inhibitor benzythioinosine |
CHEMBL3526025 |
| POU domain, class 2, transcription factor 2 |
Jmax |
= |
561.0 |
pmol/min |
Drug transport in human OAT2 expressed in HEK Flp-In cells assessed as maximal rate of transport measured per mg of protein |
CHEMBL3526025 |
| POU domain, class 2, transcription factor 2 |
Km |
= |
94000.0 |
nM |
Drug transport in human OAT2 expressed in HEK Flp-In cells |
CHEMBL3526025 |
| POU domain, class 2, transcription factor 2 |
Ratio |
= |
6.0 |
uL/min |
Transport efficiency, ratio of maximal rate of transport to Km for drug transport in human OAT2 expressed in HEK Flp-In cells measured per mg of protein |
CHEMBL3526025 |
| Solute carrier family 22 member 6 |
Jmax |
= |
434.0 |
pmol/min |
Drug transport in human OAT1 expressed in HEK Flp-In cells assessed as maximal rate of transport measured per mg of protein |
CHEMBL3526025 |
| Solute carrier family 22 member 6 |
Km |
= |
839000.0 |
nM |
Drug transport in human OAT1 expressed in HEK Flp-In cells |
CHEMBL3526025 |
| Solute carrier family 22 member 6 |
Ratio |
= |
0.5 |
uL/min |
Transport efficiency, ratio of maximal rate of transport to Km for drug transport in human OAT1 expressed in HEK Flp-In cells measured per mg of protein |
CHEMBL3526025 |
| Solute carrier family 22 member 8 |
Jmax |
= |
797.0 |
pmol/min |
Drug transport in human OAT3 expressed in HEK Flp-In cells assessed as maximal rate of transport measured per mg of protein |
CHEMBL3526025 |
| Solute carrier family 22 member 8 |
Km |
= |
772000.0 |
nM |
Drug transport in human OAT3 expressed in HEK Flp-In cells |
CHEMBL3526025 |
| Solute carrier family 22 member 8 |
Ratio |
= |
1.0 |
uL/min |
Transport efficiency, ratio of maximal rate of transport to Km for drug transport in human OAT3 expressed in HEK Flp-In cells measured per mg of protein |
CHEMBL3526025 |
| Mus musculus |
Cmax |
= |
9300.0 |
nM |
Cmax in wild type mouse treated with 25 nmol/g, po of valacyclovir |
CHEMBL3526020 |
| Mus musculus |
AUC |
= |
1129.88 |
ng.hr.mL-1 |
AUC (0 to 180 mins) in PepT1 knockout mouse treated with 25 nmol/g, po of valacyclovir |
CHEMBL3526020 |
| Mus musculus |
AUC |
= |
2781.34 |
ng.hr.mL-1 |
AUC (0 to 180 mins) in wild type mouse treated with 25 nmol/g, po of valacyclovir |
CHEMBL3526020 |
| Mus musculus |
Tmax |
= |
1.167 |
hr |
Tmax in PepT1 knockout mouse treated with 25 nmol/g, po of valacyclovir |
CHEMBL3526020 |
| Mus musculus |
Tmax |
= |
0.4167 |
hr |
Tmax in wild type mouse treated with 25 nmol/g, po of valacyclovir |
CHEMBL3526020 |
| Mus musculus |
Cmax |
= |
2000.0 |
nM |
Cmax in PepT1 knockout mouse treated with 25 nmol/g, po of valacyclovir |
CHEMBL3526020 |
| Jejunum |
Peff |
= |
7.4 |
ucm/s |
Effective permeability of the compound in PepT1 knockout mouse jejunum at 100 uM by HPLC analysis |
CHEMBL3526020 |
| Solute carrier family 15 member 1 |
Peff |
= |
4.0 |
ucm/s |
Effective permeability of the compound assessed as PepT1-mediated drug uptake in wild type mouse jejunum at 100 uM by HPLC analysis |
CHEMBL3526020 |
| Plasma |
Drug metabolism |
|
|
|
Drug level in mouse portal vein plasma treated with valacyclovir at 100 uM by HPLC analysis |
CHEMBL3526020 |
| No relevant target |
Stability |
< |
5.0 |
% |
Chemical stability of the compound |
CHEMBL3526020 |
| Unchecked |
AC50 |
|
14130.0 |
nM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
AC50 |
|
11220.2 |
nM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Ac50 |
|
14.13 |
uM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
AC50 |
|
6309.6 |
nM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
AC50 |
|
707.9 |
nM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Ac50 |
|
11.22 |
uM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Ac50 |
|
0.7079 |
uM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Ac50 |
|
6.31 |
uM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Ac50 |
|
0.631 |
uM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
AC50 |
|
631.0 |
nM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
2000.0 |
nM |
Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL3585293 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
200.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL3585293 |
| Human herpesvirus 3 |
EC50 |
= |
33000.0 |
nM |
Antiviral activity against thymidine kinase-deficient Varicella-zoster virus infected in HEL cells assessed as reduction of virus-induced plaque formation |
CHEMBL3585293 |
| Human herpesvirus 3 |
EC50 |
= |
1500.0 |
nM |
Antiviral activity against Varicella-zoster virus expressing thymidine kinase infected in HEL cells assessed as reduction of virus-induced plaque formation |
CHEMBL3585293 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against HEL cells assessed as alternation of cell morphology by microscopic analysis |
CHEMBL3585293 |
| Vaccinia virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL3585293 |
| Human herpesvirus 2 strain G |
EC50 |
= |
80.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL3585293 |
| NON-PROTEIN TARGET |
EC50 |
> |
1000000.0 |
nM |
Antiviral activity against MERS-CoV EMC/2012 infected in human HuH7 cells assessed as inhibition of virus-induced cytopathic effect after 2 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay |
CHEMBL3596107 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against mock-infected African green monkey Vero118 cells assessed as inhibition of cell survival after 5 days by microscopic analysis |
CHEMBL3596107 |
| ADMET |
CC50 |
> |
1000000.0 |
nM |
Cytotoxicity against mock-infected African green monkey Vero E6 cells assessed as inhibition of cell survival after 3 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay |
CHEMBL3596107 |
| NON-PROTEIN TARGET |
EC50 |
> |
1000000.0 |
nM |
Antiviral activity against SARS-CoV Frankfurt 1 infected in African green monkey Vero E6 cells assessed as inhibition of virus-induced cytopathic effect after 3 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay |
CHEMBL3596107 |
| Vero |
CC50 |
> |
1000000.0 |
nM |
Cytotoxicity against mock-infected African green monkey Vero cells assessed as inhibition of cell survival after 3 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay |
CHEMBL3596107 |
| NON-PROTEIN TARGET |
EC50 |
> |
1000000.0 |
nM |
Antiviral activity against MERS-CoV EMC/2012 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay |
CHEMBL3596107 |
| ADMET |
CC50 |
> |
1000000.0 |
nM |
Cytotoxicity against mock-infected human HuH7 cells assessed as inhibition of cell survival after 2 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay |
CHEMBL3596107 |
| NON-PROTEIN TARGET |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Human coronavirus NL63 infected in African green monkey Vero118 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by microscopic analysis |
CHEMBL3596107 |
| ADMET |
CC50 |
= |
13000.0 |
nM |
Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining |
CHEMBL3616436 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
3000.0 |
nM |
Antiviral activity against Human herpesvirus 1 KOS ATCC VR-1493 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 3 days by crystal violet staining |
CHEMBL3616436 |
| Human herpesvirus 3 strain Oka vaccine |
EC50 |
= |
1820.0 |
nM |
Antiviral activity against thymidine kinase-deficient Varicella zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation |
CHEMBL3621200 |
| Human herpesvirus 3 |
EC50 |
= |
54500.0 |
nM |
Antiviral activity against thymidine kinase-positive Varicella zoster virus 07-1 infected in HEL cells assessed as reduction in viral plaque formation |
CHEMBL3621200 |
| HEL |
MCC |
> |
440000.0 |
nM |
Cytotoxicity against Varicella zoster virus infected HEL cells assessed as alteration of cell morphology incubated for 3 days by microscopy |
CHEMBL3621200 |
| HEL |
CC50 |
> |
440000.0 |
nM |
Cytotoxicity against Varicella zoster virus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method |
CHEMBL3621200 |
| Human herpesvirus 3 |
EC50 |
= |
6400.0 |
nM |
Antiviral activity against Varicella-zoster virus Ellen VR-1367 infected in African green monkey Vero cells after 3 days by MTT assay |
CHEMBL3632602 |
| Human herpesvirus 2 |
EC50 |
= |
1020.0 |
nM |
Antiviral activity against Herpes simplex virus 2 strain MS VR-540 infected in African green monkey Vero cells after 3 days by MTT assay |
CHEMBL3632602 |
| Herpes simplex virus (type 1 / strain F) |
EC50 |
= |
660.0 |
nM |
Antiviral activity against Herpes simplex virus 1 strain F VR-733 infected in African green monkey Vero cells after 3 days by MTT assay |
CHEMBL3632602 |
| Human herpesvirus 5 |
EC50 |
= |
18900.0 |
nM |
Antiviral activity against Human cytomegalovirus Davis VR-807 infected in African green monkey Vero cells after 3 days by MTT assay |
CHEMBL3632602 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human HEL299 cells after 3 days by MTT assay |
CHEMBL3632602 |
| No relevant target |
Solubility |
= |
3920.0 |
ug.mL-1 |
Solubility of compound in double-deionized water after 3 days by LC-MS/MS analysis |
CHEMBL3632602 |
| Human coxsackievirus B5 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against CVB-5 virus Faulkner ATCC VR-185 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay |
CHEMBL3734708 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
3000.0 |
nM |
Antiviral activity against HSV-1 KOS ATCC VR- 1493 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay |
CHEMBL3734708 |
| MT4 |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay |
CHEMBL3734667 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDBK cells assessed as cell viability after 48 to 96 hrs by MTT assay |
CHEMBL3734667 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against BHK cells assessed as cell viability after 48 to 96 hrs by MTT assay |
CHEMBL3734667 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method |
CHEMBL3734667 |
| Bovine viral diarrhea virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against BVDV infected in MDBK cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3734667 |
| Yellow fever virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3734667 |
| NON-PROTEIN TARGET |
EC50 |
|
|
|
Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3734667 |
| Human coxsackievirus B5 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay |
CHEMBL3734667 |
| Human respiratory syncytial virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay |
CHEMBL3734667 |
| Human poliovirus 1 strain Sabin |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay |
CHEMBL3734667 |
| Human immunodeficiency virus 1 |
EC50 |
|
|
|
Antiviral activity against HIV-1 infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay |
CHEMBL3734667 |
| Dengue virus 2 |
EC50 |
|
|
|
Antiviral activity against DENV-2 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3734667 |
| West Nile virus |
EC50 |
|
|
|
Antiviral activity against WNV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3734667 |
| Human herpesvirus 1 |
EC50 |
= |
1200.0 |
nM |
Antiviral activity against HSV1 |
CHEMBL3734667 |
| Vesicular stomatitis virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against VSV |
CHEMBL3734667 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus |
CHEMBL3734667 |
| Dengue virus 2 |
EC50 |
|
|
|
Antiviral activity against DENV-2 New guinea infected in African green monkey Vero cells assessed as reduction in plaque formation administered simultaneously with virus for 1 hr measured after 8 days by crystal violet staining technique |
CHEMBL3758103 |
| Human herpesvirus 1 |
EC50 |
= |
2200.0 |
nM |
Antiviral activity against HHV-1 CDC Atlanta infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 72 hrs by crystal violet staining technique |
CHEMBL3758103 |
| Human herpesvirus 2 |
EC50 |
= |
270.0 |
nM |
Antiviral activity against HHV-2 VR-734-G infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 72 hrs by crystal violet staining technique |
CHEMBL3758103 |
| Dengue virus 2 |
EC50 |
|
|
|
Antiviral activity against DENV-2 New guinea infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 8 days by crystal violet staining technique |
CHEMBL3758103 |
| Human herpesvirus 2 |
FC |
= |
1000.0 |
|
Antiviral activity against HHV-2 VR-734-G infected in African green monkey Vero cells assessed as reduction of viral titer at maximal non-toxic concentration after 72 hrs by crystal violet staining assay relative to control |
CHEMBL3758103 |
| Human herpesvirus 2 |
MNTD |
= |
6.7 |
uM |
Antiviral activity against HHV-2 VR-734-G infected in African green monkey Vero cells assessed as maximal non toxic concentration causing reduction of viral titer after 72 hrs by crystal violet staining assay |
CHEMBL3758103 |
| Dengue virus 2 |
Activity |
|
|
|
Antiviral activity against DENV-2 New guinea infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by crystal violet staining based inverted microscopic analysis relative to control |
CHEMBL3758103 |
| Human herpesvirus 1 |
FC |
= |
10000.0 |
|
Antiviral activity against HHV1 CDC Atlanta infected in African green monkey Vero cells assessed as reduction of viral titer at maximal non-toxic concentration after 48 hrs by crystal violet staining assay relative to control |
CHEMBL3758103 |
| Human herpesvirus 1 |
MNTD |
= |
6.7 |
uM |
Antiviral activity against HHV-1 CDC Atlanta infected in African green monkey Vero cells assessed as maximal non toxic concentration causing reduction of viral titer after 48 hrs by crystal violet staining assay |
CHEMBL3758103 |
| Dengue virus 2 |
MNTD |
|
|
|
Antiviral activity against DENV-2 New guinea infected in African green monkey Vero cells assessed as maximal non toxic concentration causing inhibition of virus-induced cytopathic effect after 3 days by crystal violet staining based inverted microscopic analysis |
CHEMBL3758103 |
| Vero |
IC50 |
> |
1700000.0 |
nM |
Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 72 hrs |
CHEMBL3758103 |
| Vero |
IC50 |
|
|
|
Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 8 days |
CHEMBL3758103 |
| Human herpesvirus 1 |
EC50 |
|
|
|
Antiviral activity against HHV-1 CDC Atlanta infected in African green monkey Vero cells assessed as reduction in plaque formation administered simultaneously with virus for 1 hr measured after 72 hrs by crystal violet staining technique |
CHEMBL3758103 |
| Human herpesvirus 2 |
EC50 |
|
|
|
Antiviral activity against HHV-2 VR-734-G infected in African green monkey Vero cells assessed as reduction in plaque formation administered simultaneously with virus for 1 hr measured after 72 hrs by crystal violet staining technique |
CHEMBL3758103 |
| Human herpesvirus 1 strain KOS |
FC |
= |
4.3 |
|
Antiviral activity against HSV1 KOS ATCC VR1493 infected in African green monkey Vero cells assessed as reduction in EGFP-positive cells at 50 uM treated at 2 hrs post infection measured 24 hrs post infection by flow cytometric analysis relative to control |
CHEMBL3774324 |
| Human herpesvirus 1 strain KOS |
Activity |
= |
33.3 |
PFU/ml |
Antiviral activity against HSV1 KOS ATCC VR1493 infected in African green monkey Vero cells assessed as viral titre at 50 uM treated at 2 hrs post infection measured 48 hrs post infection by flow cytometric analysis relative to control |
CHEMBL3774324 |
| Human herpesvirus 1 strain KOS |
FC |
= |
8.5 |
|
Antiviral activity against HSV1 KOS ATCC VR1493 infected in human iPSC cells assessed as reduction in EGFP-positive cells at 50 uM treated at 2 hrs post infection measured 24 hrs post infection by flow cytometric analysis relative to control |
CHEMBL3774324 |
| Human herpesvirus 1 strain KOS |
Activity |
|
|
|
Antiviral activity against HSV1 KOS ATCC VR1493 infected in human iPSC cells assessed as viral DNA replication at 50 uM measured 24 hrs post infection by FISH analysis |
CHEMBL3774324 |
| Human herpesvirus 1 strain KOS |
FC |
= |
2300.0 |
|
Antiviral activity against HSV1 KOS ATCC VR1493 infected in human iPSC cells assessed as reduction in viral DNA copy at 50 uM measured 24 hrs post infection by RT-qPCR analysis relative to control |
CHEMBL3774324 |
| Human herpesvirus 1 strain KOS |
Activity |
|
|
|
Antiviral activity against HSV1 KOS ATCC VR1493 infected in human iPSC cells assessed as reduction in expression of ICP4 gene at 50 uM measured 24 hrs post infection by RT-qPCR analysis |
CHEMBL3774324 |
| Human herpesvirus 1 strain KOS |
Activity |
|
|
|
Antiviral activity against HSV1 KOS ATCC VR1493 infected in human iPSC cells assessed as reduction in expression of DNA polymerase gene at 50 uM measured 24 hrs post infection by RT-qPCR analysis |
CHEMBL3774324 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
70.0 |
nM |
Antiviral activity against HSV1 KOS ATCC VR1493 infected in African green monkey Vero cells assessed as reduction in EGFP-positive cells treated at 2 hrs post infection measured 24 hrs post infection by flow cytometric analysis |
CHEMBL3774324 |
| ADMET |
Activity |
|
|
|
Cytotoxicity against human iPSC cells assessed as cell viability at 0.1 to 50 uM after 24 to 48 hrs by live/dead fixable viability dye-based flow cytometric analysis |
CHEMBL3774324 |
| Human herpesvirus 3 |
FC |
= |
1.8 |
|
Antiviral activity against VZV infected in human ARPE19 cells at 50 uM treated at 2 hrs post infection measured 48 hrs post infection by luciferase assay relative to control |
CHEMBL3774324 |
| ADMET |
Activity |
|
|
|
Cytotoxicity against human ARPE19 cells assessed as cell viability at 0.1 to 50 uM after 24 to 48 hrs by live/dead fixable viability dye-based flow cytometric analysis |
CHEMBL3774324 |
| Human herpesvirus 1 strain KOS |
Activity |
|
|
|
Antiviral activity against HSV1 KOS ATCC VR1493 infected in human iPSC cells assessed as reduction in expression of ICP4 at 50 uM measured 24 hrs post infection by western blot analysis |
CHEMBL3774324 |
| ADMET |
CC50 |
|
|
|
Cytotoxicity against mock-infected BHK21 cells assessed as reduction in cell viability after 72 hrs by MTT assay |
CHEMBL3808296 |
| NON-PROTEIN TARGET |
EC50 |
|
|
|
Antiviral activity against Yellow fever virus 17D infected in BHK21 cells assessed as inhibition of virus induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3808296 |
| NON-PROTEIN TARGET |
EC50 |
|
|
|
Antiviral activity against Reovirus type-1 3651 infected in BHK21 cells assessed as inhibition of virus induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3808296 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against mock-infected african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay |
CHEMBL3808296 |
| Human coxsackievirus B2 |
EC50 |
|
|
|
Antiviral activity against CVB-2 infected in Vero 76 cells after 3 days by crystal violet staining based plaque reduction assay |
CHEMBL3808296 |
| Human poliovirus 1 strain Sabin |
EC50 |
|
|
|
Antiviral activity against Human poliovirus 1 strain Sabin infected in Vero 76 cells after 2 days by crystal violet staining based plaque reduction assay |
CHEMBL3808296 |
| Respiratory syncytial virus |
EC50 |
|
|
|
Antiviral activity against Respiratory syncytial virus A2 infected in Vero 76 cells after 5 days by crystal violet staining based plaque reduction assay |
CHEMBL3808296 |
| Vesicular stomatitis virus |
EC50 |
|
|
|
Antiviral activity against Vesicular stomatitis virus Indiana infected in Vero 76 cells after 2 days by crystal violet staining based plaque reduction assay |
CHEMBL3808296 |
| Vaccinia virus |
EC50 |
= |
1500.0 |
nM |
Antiviral activity against Vaccinia virus Elstree infected in Vero 76 cells after 3 days by crystal violet staining based plaque reduction assay |
CHEMBL3808296 |
| Human herpesvirus 3 |
EC50 |
= |
27000.0 |
nM |
Antiviral activity against TK-deficient Varicella-zoster virus infected in HEL cells |
CHEMBL3826905 |
| CDGSH iron-sulfur domain-containing protein 1 |
IC50 |
|
|
|
Displacement of [3H]rosiglitazone from recombinant human C-terminal His-tagged MitoNEET cytosolic domain (32 to 108 residues) expressed in Escherichia coli BL21 by scintillation proximity assay |
CHEMBL3862005 |
| CDGSH iron-sulfur domain-containing protein 1 |
Ki |
|
|
|
Displacement of [3H]rosiglitazone from recombinant human C-terminal His-tagged MitoNEET cytosolic domain (32 to 108 residues) expressed in Escherichia coli BL21 by Cheng-Prusoff analysis |
CHEMBL3862005 |
| NON-PROTEIN TARGET |
EC50 |
= |
1900.0 |
nM |
Antiviral activity against thymidine Kinase expressing Varicella-Zoster virus OKA infected in HEL cells assessed as inhibition of virus plaque formation |
CHEMBL3877247 |
| NON-PROTEIN TARGET |
EC50 |
= |
26000.0 |
nM |
Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in HEL cells assessed as inhibition of virus plaque formation |
CHEMBL3877247 |
| NON-PROTEIN TARGET |
EC50 |
|
|
|
Antiviral activity against thymidine kinase deficient Varicella-Zoster virus YS-R infected in HEL cells assessed as inhibition of virus plaque formation |
CHEMBL3877247 |
| NON-PROTEIN TARGET |
CC50 |
= |
191000.0 |
nM |
Cytotoxicity against HEL cells assessed as growth inhibition after 3 days by coulter counter method |
CHEMBL3877247 |
| NON-PROTEIN TARGET |
EC50 |
= |
80.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation |
CHEMBL3877247 |
| NON-PROTEIN TARGET |
EC50 |
= |
112000.0 |
nM |
Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation |
CHEMBL3877247 |
| NON-PROTEIN TARGET |
EC50 |
= |
200.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation |
CHEMBL3877247 |
| NON-PROTEIN TARGET |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against HEL cells assessed as alteration of cell morphology after 3 days by microscopic method |
CHEMBL3877247 |
| Schistosoma mansoni |
ALT |
= |
50.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALB |
= |
41300.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALP |
= |
356.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
AST |
= |
78.17 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BUN |
= |
141.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CO2 |
= |
31330000.0 |
nM |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHLORIDE |
= |
98.5 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHOL |
= |
765.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CK |
= |
248.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CREAT |
= |
2.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
GLUC |
= |
1440.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LDH |
= |
107.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LIPASE |
= |
9.83 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PHOS |
= |
128.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
POTASSIUM |
= |
6.75 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
SODIUM |
= |
142.0 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BILI |
= |
1.8 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PROT |
= |
59800.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
URATE |
= |
14.2 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASO |
= |
0.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOS |
= |
37.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYM |
= |
12359.33 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONO |
= |
122.67 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTSG |
= |
847.67 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASOLE |
= |
0.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOSLE |
= |
0.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBC |
= |
5750000.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HCT |
= |
36.08 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HGB |
= |
140700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
WBC |
= |
13370.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYMLE |
= |
92.5 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCH |
= |
24.47 |
pg |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCHC |
= |
389800.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCV |
= |
62.78 |
fL |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONOLE |
= |
1.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTLE |
= |
6.17 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBCNUC |
= |
0.17 |
/100WBC |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PLAT |
= |
1202170.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALT |
= |
49.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALB |
= |
40700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALP |
= |
300.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
AST |
= |
83.5 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BUN |
= |
160.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CO2 |
= |
29670000.0 |
nM |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHLORIDE |
= |
100.5 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHOL |
= |
743.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CK |
= |
489.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CREAT |
= |
3.5 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
GLUC |
= |
1510.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LDH |
= |
133.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LIPASE |
= |
11.17 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PHOS |
= |
108.8 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
POTASSIUM |
= |
5.5 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
SODIUM |
= |
145.7 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BILI |
= |
2.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PROT |
= |
60500.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
URATE |
= |
6.8 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASO |
= |
0.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOS |
= |
0.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYM |
= |
8681.17 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONO |
= |
79.83 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTSG |
= |
689.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASOLE |
= |
0.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOSLE |
= |
0.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBC |
= |
5490000.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HCT |
= |
33.55 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HGB |
= |
131000.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
WBC |
= |
9450.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYMLE |
= |
92.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCH |
= |
23.92 |
pg |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCHC |
= |
390700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCV |
= |
61.22 |
fL |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONOLE |
= |
0.67 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTLE |
= |
7.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBCNUC |
= |
0.17 |
/100WBC |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PLAT |
= |
1001170.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALT |
= |
50.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALB |
= |
43000.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALP |
= |
334.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
AST |
= |
88.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BUN |
= |
173.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CO2 |
= |
25670000.0 |
nM |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHLORIDE |
= |
101.0 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHOL |
= |
700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CK |
= |
328.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CREAT |
= |
3.4 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
GLUC |
= |
1830.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LDH |
= |
177.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LIPASE |
= |
10.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PHOS |
= |
126.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
POTASSIUM |
= |
5.7 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
SODIUM |
= |
144.1 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BILI |
= |
1.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PROT |
= |
61700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
URATE |
= |
22.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASO |
= |
0.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOS |
= |
0.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYM |
= |
14421.67 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONO |
= |
118.67 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTSG |
= |
559.67 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASOLE |
= |
0.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOSLE |
= |
0.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBC |
= |
5800000.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HCT |
= |
35.43 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HGB |
= |
139700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
WBC |
= |
15100.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYMLE |
= |
95.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCH |
= |
24.1 |
pg |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCHC |
= |
394000.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCV |
= |
61.1 |
fL |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONOLE |
= |
0.67 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTLE |
= |
4.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBCNUC |
= |
0.0 |
/100WBC |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PLAT |
= |
1133330.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALT |
= |
54.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALB |
= |
41000.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALP |
= |
310.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
AST |
= |
89.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BUN |
= |
140.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CO2 |
= |
31000000.0 |
nM |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHLORIDE |
= |
100.33 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHOL |
= |
713.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CK |
= |
331.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CREAT |
= |
3.5 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
GLUC |
= |
1496.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LDH |
= |
119.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LIPASE |
= |
11.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PHOS |
= |
119.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
POTASSIUM |
= |
6.3 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
SODIUM |
= |
145.23 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BILI |
= |
1.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PROT |
= |
58700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
URATE |
= |
9.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASO |
= |
0.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOS |
= |
23.33 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYM |
= |
6827.33 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONO |
= |
23.33 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTSG |
= |
459.33 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASOLE |
= |
0.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOSLE |
= |
0.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBC |
= |
5770000.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HCT |
= |
36.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HGB |
= |
139300.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
WBC |
= |
7330.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYMLE |
= |
92.67 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCH |
= |
24.17 |
pg |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCHC |
= |
387000.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCV |
= |
62.47 |
fL |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONOLE |
= |
0.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTLE |
= |
6.67 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBCNUC |
= |
0.0 |
/100WBC |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PLAT |
= |
980670.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALT |
= |
47.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALB |
= |
40700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALP |
= |
321.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
AST |
= |
79.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BUN |
= |
126.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CO2 |
= |
28330000.0 |
nM |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHLORIDE |
= |
100.0 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHOL |
= |
673.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CK |
= |
458.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CREAT |
= |
2.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
GLUC |
= |
1540.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LDH |
= |
123.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LIPASE |
= |
9.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PHOS |
= |
113.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
POTASSIUM |
= |
5.85 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
SODIUM |
= |
142.43 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BILI |
= |
1.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PROT |
= |
57700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
URATE |
= |
9.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASO |
= |
0.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOS |
= |
28.33 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYM |
= |
6898.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONO |
= |
45.67 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTSG |
= |
428.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASOLE |
= |
0.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOSLE |
= |
0.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBC |
= |
5270000.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HCT |
= |
32.97 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HGB |
= |
128000.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
WBC |
= |
7400.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYMLE |
= |
93.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCH |
= |
24.37 |
pg |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCHC |
= |
388700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCV |
= |
62.67 |
fL |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONOLE |
= |
0.67 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTLE |
= |
6.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBCNUC |
= |
0.0 |
/100WBC |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PLAT |
= |
1125670.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALT |
= |
46.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALB |
= |
41700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALP |
= |
320.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
AST |
= |
74.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BUN |
= |
156.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CO2 |
= |
29330000.0 |
nM |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHLORIDE |
= |
101.0 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHOL |
= |
576.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CK |
= |
253.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CREAT |
= |
4.4 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
GLUC |
= |
1556.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LDH |
= |
135.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LIPASE |
= |
12.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PHOS |
= |
99.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
POTASSIUM |
= |
5.65 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
SODIUM |
= |
145.17 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BILI |
= |
1.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PROT |
= |
58300.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
URATE |
= |
8.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASO |
= |
0.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOS |
= |
32.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYM |
= |
9269.33 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONO |
= |
115.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTSG |
= |
383.67 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASOLE |
= |
0.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOSLE |
= |
0.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBC |
= |
5830000.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HCT |
= |
35.13 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HGB |
= |
139000.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
WBC |
= |
9800.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYMLE |
= |
94.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCH |
= |
23.83 |
pg |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCHC |
= |
396000.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCV |
= |
60.17 |
fL |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONOLE |
= |
1.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTLE |
= |
4.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBCNUC |
= |
0.33 |
/100WBC |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PLAT |
= |
783000.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against virus infected HEL cells assessed as alteration in cell morphology by microscopic method |
CHEMBL3994569 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
250000.0 |
nM |
Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL3994569 |
| Human herpesvirus 2 strain G |
EC50 |
= |
400.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL3994569 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
200.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL3994569 |
| HEL |
CC50 |
= |
440000.0 |
nM |
Cytotoxicity against HEL cells infected with Varicella-Zoster virus assessed as growth inhibition |
CHEMBL3994569 |
| HEL |
MCC |
> |
440000.0 |
nM |
Cytotoxicity against HEL cells infected with Varicella-Zoster virus assessed as alteration in cell morphology by microscopic method |
CHEMBL3994569 |
| Human herpesvirus 3 |
EC50 |
= |
50300.0 |
nM |
Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in HEL cells assessed as reduction in virus plaque formation |
CHEMBL3994569 |
| Human herpesvirus 3 strain Oka vaccine |
EC50 |
= |
800.0 |
nM |
Antiviral activity against thymidine kinase expressing Varicella-Zoster virus OKA infected in HEL cells assessed as reduction in virus plaque formation |
CHEMBL3994569 |
| Herpes simplex virus (type 1 / strain F) |
IC50 |
= |
410.0 |
nM |
Antiviral activity against Herpes simplex virus-1 F VR 733 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL3994572 |
| Vero |
TC50 |
> |
100.0 |
umol/L |
Cytotoxicity against African green monkey Vero cells assessed as growth inhibition after 48 hrs |
CHEMBL3994572 |
| Unchecked |
Selectivity Index |
> |
244.0 |
|
Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Herpes simplex virus-1 F VR 733 infected in African green monkey Vero cells |
CHEMBL3994572 |
| Rattus norvegicus |
F |
< |
20.0 |
% |
Oral bioavailability in rat at 25 mg/kg by HPLC analysis |
CHEMBL3997766 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HEL cells assessed as alteration of normal cell morphology by microscopic analysis |
CHEMBL4000146 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
200.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis |
CHEMBL4000146 |
| Human herpesvirus 2 |
EC50 |
= |
100.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis |
CHEMBL4000146 |
| Vaccinia virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis |
CHEMBL4000146 |
| Vesicular stomatitis virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis |
CHEMBL4000146 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
10000.0 |
nM |
Antiviral activity against acyclovir-resistant TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis |
CHEMBL4000146 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
1240.0 |
nM |
Antiviral activity against Human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis |
CHEMBL4000146 |
| Human herpesvirus 5 |
EC50 |
= |
510.0 |
nM |
Antiviral activity against Human cytomegalovirus strain Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis |
CHEMBL4000146 |
| Human herpesvirus 3 strain Oka vaccine |
EC50 |
= |
1690.0 |
nM |
Antiviral activity against TK positive Varicella-zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis |
CHEMBL4000146 |
| Human herpesvirus 3 |
EC50 |
= |
49300.0 |
nM |
Antiviral activity against TK negative Varicella-zoster virus 07-1 infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis |
CHEMBL4000146 |
| Vero |
CC50 |
> |
1000000.0 |
nM |
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay |
CHEMBL4000243 |
| Human herpesvirus 1 |
EC50 |
= |
3000.0 |
nM |
Antiviral activity against HSV-1 infected in African green monkey Vero cells by plaque reduction assay |
CHEMBL4000243 |
| Bile salt export pump |
IC50 |
> |
135000.0 |
nM |
Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-taurocholate by topcount based membrane vesicle transport assay |
CHEMBL4011581 |
| Bile salt export pump |
IC50 |
> |
1000000.0 |
nM |
Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method |
CHEMBL4017441 |
| Vero C1008 |
MCC |
> |
444000.0 |
nM |
Cytotoxicity against African green monkey Vero E6 cells measured after 3 days by trypan blue assay |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC50 |
= |
1730.0 |
nM |
Antiviral activity against HSV1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Unchecked |
Selectivity Index |
> |
256.0 |
|
Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for HSV-1 L2 infected in African green monkey Vero E6 cells |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC50 |
> |
444000.0 |
nM |
Antiviral activity against acyclovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Unchecked |
Selectivity Index |
> |
1.0 |
|
Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for acyclovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC50 |
= |
27800.0 |
nM |
Antiviral activity against HSV-1 L2/Rp-ACV/2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Unchecked |
Selectivity Index |
= |
16.0 |
|
Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for HSV-1 L2/Rp-ACV/2 infected in African green monkey Vero E6 cells |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC50 |
= |
3500.0 |
nM |
Antiviral activity against foscarnet-resistant HSV-1 F+ infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Unchecked |
Selectivity Index |
> |
128.0 |
|
Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for HSV-1 F+ infected in African green monkey Vero E6 cells |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC50 |
> |
444000.0 |
nM |
Antiviral activity against acyclovir and foscarnet-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Unchecked |
Selectivity Index |
> |
1.0 |
|
Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for acyclovir and foscarnet-resistant HSV-1 L2 infected in African green monkey Vero E6 cells |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC50 |
= |
17300.0 |
nM |
Antiviral activity against acyclovir and cidofovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Unchecked |
Selectivity Index |
> |
26.0 |
|
Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for acyclovir and cidofovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC95 |
= |
6900.0 |
nM |
Antiviral activity against HSV1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC95 |
> |
444000.0 |
nM |
Antiviral activity against acyclovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC95 |
= |
111000.0 |
nM |
Antiviral activity against HSV-1 L2/Rp-ACV/2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC95 |
= |
13900.0 |
nM |
Antiviral activity against foscarnet-resistant HSV-1 F+ infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC95 |
> |
444000.0 |
nM |
Antiviral activity against acyclovir and foscarnet-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC95 |
= |
138800.0 |
nM |
Antiviral activity against acyclovir and cidofovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
400.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4017507 |
| Human herpesvirus 2 strain G |
EC50 |
= |
400.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4017507 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
60000.0 |
nM |
Antiviral activity against ACV-resistant thymidine kinase deficient Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4017507 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HEL cells assessed as alteration to cell morphology by microscopic analysis |
CHEMBL4017507 |
| Human herpesvirus 5 |
EC50 |
|
|
|
Antiviral activity against human cytomegalovirus AD-169 infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4017507 |
| Human herpesvirus 5 |
EC50 |
|
|
|
Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4017507 |
| Human herpesvirus 3 strain Oka vaccine |
EC50 |
= |
1880.0 |
nM |
Antiviral activity against Varicella-Zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4017507 |
| Human herpesvirus 3 |
EC50 |
= |
73000.0 |
nM |
Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4017507 |
| HEL |
CC50 |
= |
787000.0 |
nM |
Cytotoxicity against human HEL cells assessed as cell growth inhibition by cell counting method |
CHEMBL4017507 |
| Bile salt export pump |
IC50 |
> |
133000.0 |
nM |
Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay |
CHEMBL4028801 |
| Canalicular multispecific organic anion transporter 1 |
IC50 |
> |
133000.0 |
nM |
Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay |
CHEMBL4028801 |
| Canalicular multispecific organic anion transporter 2 |
IC50 |
> |
133000.0 |
nM |
Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay |
CHEMBL4028801 |
| Multidrug resistance-associated protein 4 |
IC50 |
> |
133000.0 |
nM |
Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay |
CHEMBL4028801 |
| Homo sapiens |
DILI_severity_class |
= |
5.0 |
|
Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index |
CHEMBL4028802 |
| Homo sapiens |
DILI_Concern |
|
|
|
Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status |
CHEMBL4028802 |
| Human herpesvirus 5 strain AD169 |
EC50 |
|
|
|
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4038313 |
| Human herpesvirus 5 |
EC50 |
|
|
|
Antiviral activity against HCMV Davis strain infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4038313 |
| Human herpesvirus 3 strain Oka vaccine |
EC50 |
= |
3020.0 |
nM |
Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka strain assessed as inhibition of plaque formation |
CHEMBL4038313 |
| Human herpesvirus 3 |
EC50 |
= |
20700.0 |
nM |
Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in HEL cells assessed as inhibition of plaque formation |
CHEMBL4038313 |
| HEL |
MCC |
> |
444000.0 |
nM |
Cytotoxic activity against HEL cells assessed as alteration of cell morphology after 3 days by microscopic method |
CHEMBL4038313 |
| HEL |
CC50 |
> |
444000.0 |
nM |
Cytotoxic activity against HEL cells assessed as reduction in cell proliferation after 3 days by coulter counting method |
CHEMBL4038313 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
400.0 |
nM |
Antiviral activity against wild type Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4043131 |
| Human herpesvirus 2 strain G |
EC50 |
= |
180.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4043131 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
54000.0 |
nM |
Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4043131 |
| Human herpesvirus 3 |
EC50 |
= |
1500.0 |
nM |
Antiviral activity against wild type thymidine kinase expressing Varicella-Zoster virus Oka infected in HEL cells assessed as inhibition of virus-induced plaque formation |
CHEMBL4043131 |
| Human herpesvirus 3 |
EC50 |
= |
38900.0 |
nM |
Antiviral activity against wild type thymidine kinase-deficient Varicella-Zoster virus 07-1 infected in HEL cells assessed as inhibition of virus-induced plaque formation |
CHEMBL4043131 |
| Human herpesvirus 5 strain AD169 |
EC50 |
|
|
|
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4043131 |
| Human herpesvirus 5 |
EC50 |
|
|
|
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4043131 |
| Vaccinia virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus Lederle infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4043131 |
| HEL |
MCC |
> |
440000.0 |
nM |
Cytotoxicity against HEL cells assessed as alteration of cell morphology by microscopic analysis |
CHEMBL4043131 |
| HEL |
CC50 |
> |
440000.0 |
nM |
Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 days by coulter counter method |
CHEMBL4043131 |
| Human herpesvirus 1 |
Activity |
= |
89.6 |
% |
Anti-viral activity against Herpes simplex virus-1 harboring EGFP infected in iPSC-derived neurons assessed as viable cells at 10 mM treated 2 hrs post infection measured after 72 hrs by Alexa fluor 488 staining based flow cytometric analysis (Rvb = 17.8%) |
CHEMBL4043249 |
| Human herpesvirus 1 |
Activity |
= |
7.92 |
% |
Anti-viral activity against Herpes simplex virus-1 harboring EGFP infected in iPSC-derived neurons assessed as early apoptotic cells at 10 mM treated 2 hrs post infection measured after 72 hrs by Alexa fluor 488 staining based flow cytometric analysis (Rvb = 13.2%) |
CHEMBL4043249 |
| Human herpesvirus 1 |
Activity |
= |
1.36 |
% |
Anti-viral activity against Herpes simplex virus-1 harboring EGFP infected in iPSC-derived neurons assessed as late apoptotic cells at 10 mM treated 2 hrs post infection measured after 72 hrs by Alexa fluor 488 staining based flow cytometric analysis (Rvb = 65.7%) |
CHEMBL4043249 |
| Human herpesvirus 1 |
Activity |
= |
1.13 |
% |
Anti-viral activity against Herpes simplex virus-1 harboring EGFP infected in iPSC-derived neurons assessed as necrotic cells at 10 mM treated 2 hrs post infection measured after 72 hrs by Alexa fluor 488 staining based flow cytometric analysis (Rvb = 3.33%) |
CHEMBL4043249 |
| Human herpesvirus 1 |
Activity |
= |
92.6 |
% |
Anti-viral activity against Herpes simplex virus-1 harboring EGFP infected in iPSC-derived neurons assessed as viable cells at 50 mM treated 2 hrs post infection measured after 72 hrs by Alexa fluor 488 staining based flow cytometric analysis (Rvb = 17.8%) |
CHEMBL4043249 |
| Human herpesvirus 1 |
Activity |
= |
6.22 |
% |
Anti-viral activity against Herpes simplex virus-1 harboring EGFP infected in iPSC-derived neurons assessed as early apoptotic cells at 50 mM treated 2 hrs post infection measured after 72 hrs by Alexa fluor 488 staining based flow cytometric analysis (Rvb = 13.2%) |
CHEMBL4043249 |
| Human herpesvirus 1 |
Activity |
= |
0.44 |
% |
Anti-viral activity against Herpes simplex virus-1 harboring EGFP infected in iPSC-derived neurons assessed as late apoptotic cells at 50 mM treated 2 hrs post infection measured after 72 hrs by Alexa fluor 488 staining based flow cytometric analysis (Rvb = 65.7%) |
CHEMBL4043249 |
| Human herpesvirus 1 |
Activity |
= |
0.76 |
% |
Anti-viral activity against Herpes simplex virus-1 harboring EGFP infected in iPSC-derived neurons assessed as necrotic cells at 50 mM treated 2 hrs post infection measured after 72 hrs by Alexa fluor 488 staining based flow cytometric analysis (Rvb = 3.33%) |
CHEMBL4043249 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
800.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL4118253 |
| Human herpesvirus 2 strain G |
EC50 |
= |
400.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL4118253 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
126000.0 |
nM |
Antiviral activity against acyclovir-resistant thymidine kinase deficient Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL4118253 |
| Vaccinia virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL4118253 |
| Human herpesvirus 3 |
EC50 |
= |
3550.0 |
nM |
Antiviral activity against thymidine kinase expressing Varicella-Zoster virus infected in HEL cells assessed as reduction in virus plaque formation |
CHEMBL4118253 |
| Human herpesvirus 3 |
EC50 |
= |
14870.0 |
nM |
Antiviral activity against thymidine kinase deficient Varicella-Zoster virus infected in HEL cells assessed as reduction in virus plaque formation |
CHEMBL4118253 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against HEL cells assessed as alteration of cell morphology by microscopic analysis |
CHEMBL4118253 |
| Vero 76 |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay |
CHEMBL4130485 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
1800.0 |
nM |
Antiviral activity against Human herpesvirus 1 KOS ATCC VR 1493 infected in African green monkey Vero 76 cells assessed as protection against virus-induced cytopathic effect after 3 days by crystal violet staining-based plaque reduction assay |
CHEMBL4130485 |
| Herpes simplex virus (type 1 / strain F) |
IC50 |
= |
150.0 |
nM |
Antiviral activity against HSV1/F infected in African green monkey Vero cells assessed as inhibition of plaque formation after 24 hrs by crystal violet staining-based assay |
CHEMBL4130537 |
| Vero |
CC50 |
> |
200000.0 |
nM |
Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability after 24 hrs by CellTiter-Glo luminescent assay |
CHEMBL4130537 |
| Unchecked |
Ratio CC50/IC50 |
> |
1333.0 |
|
Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for HSV1/F |
CHEMBL4130537 |
| Human herpesvirus 3 strain Oka vaccine |
EC50 |
= |
2350.0 |
nM |
Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka infected in human HEL cells assessed as reduction in plaque formation after 5 days |
CHEMBL4152322 |
| Human herpesvirus 3 |
EC50 |
= |
133300.0 |
nM |
Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in human HEL cells assessed as reduction in plaque formation after 5 days |
CHEMBL4152322 |
| HEL |
CC50 |
> |
440000.0 |
nM |
Cytostatic activity against human HEL cells after 3 days by coulter counter method |
CHEMBL4152322 |
| Unchecked |
Ratio CC50/IC50 |
|
|
|
Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for HSV-2 infected in African green monkey Vero cells |
CHEMBL4190298 |
| Unchecked |
Ratio CC50/IC50 |
|
|
|
Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for HSV-1 infected in African green monkey Vero cells |
CHEMBL4190298 |
| Human herpesvirus 2 |
IC50 |
= |
0.0031100000000000004 |
nM |
Antiviral activity against HSV-2 infected in African green monkey Vero cells assessed as inhibition of virus plaque formation after 72 hrs by Giemsa staining based assay |
CHEMBL4190298 |
| Human herpesvirus 1 |
IC50 |
= |
0.00475 |
nM |
Antiviral activity against HSV-1 infected in African green monkey Vero cells assessed as inhibition of virus plaque formation after 72 hrs by Giemsa staining based assay |
CHEMBL4190298 |
| Vero |
CC50 |
|
|
|
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 3 days by MTT assay |
CHEMBL4190298 |
| Human herpesvirus 5 |
EC50 |
|
|
|
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral cytopathic effect |
CHEMBL4196014 |
| Human herpesvirus 5 strain AD169 |
EC50 |
|
|
|
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral cytopathic effect |
CHEMBL4196014 |
| Human herpesvirus 3 strain Oka vaccine |
EC50 |
= |
2930.0 |
nM |
Antiviral activity against Varicella zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation |
CHEMBL4196014 |
| Human herpesvirus 3 |
EC50 |
= |
54400.0 |
nM |
Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in HEL cells assessed as reduction in viral plaque formation |
CHEMBL4196014 |
| HEL |
MCC |
> |
440000.0 |
nM |
Cytotoxicity against HEL cells assessed as alteration of cell morphology by microscopic method |
CHEMBL4196014 |
| HEL |
CC50 |
> |
440000.0 |
nM |
Cytostatic activity against HEL cells after 3 days by Coulter counting method |
CHEMBL4196014 |
| Unchecked |
Ratio CC50/EC50 |
> |
150.0 |
|
Selectivity index, ratio of CC50 for HEL cells to EC50 for Varicella zoster virus Oka infected in HEL cells |
CHEMBL4196014 |
| Unchecked |
Ratio CC50/EC50 |
> |
8.0 |
|
Selectivity index, ratio of CC50 for HEL cells to EC50 for thymidine kinase deficient Varicella zoster virus 07/1 infected in HEL cells |
CHEMBL4196014 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
1200.0 |
nM |
Antiviral activity against Human simplex virus 1 KOS infected in HEL cells assessed as reduction in viral cytopathic effect |
CHEMBL4196014 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
94000.0 |
nM |
Antiviral activity against thymidine kinase deficient acyclovir-resistant Human simplex virus 1 KOS infected in HEL cells assessed as reduction in viral cytopathic effect |
CHEMBL4196014 |
| Human herpesvirus 2 strain G |
EC50 |
= |
700.0 |
nM |
Antiviral activity against Human simplex virus 2 G infected in HEL cells assessed as reduction in viral cytopathic effect |
CHEMBL4196014 |
| Vaccinia virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction in viral cytopathic effect |
CHEMBL4196014 |
| Vero |
TC50 |
> |
100.0 |
uM |
Cytotoxicity against African green monkey Vero cells measured after 48 hrs |
CHEMBL4196144 |
| Herpes simplex virus (type 1 / strain F) |
IC50 |
= |
410.0 |
nM |
Antiviral activity against HSV1 F VR 733 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4196144 |
| Unchecked |
Selectivity Index |
> |
243.9 |
|
Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for HSV1 strain F VR 733 infected in African green monkey Vero cells |
CHEMBL4196144 |
| Human herpesvirus 1 strain KOS |
Inhibition |
|
|
% |
Antiviral activity against Herpes simplex virus 1 KOS infected in African green monkey Vero cells assessed as inhibition of plaque formation at 5 ug treated 1 hr prior to viral infection followed by compound washout and subsequent compound addition measured after 72 hrs by Giemsa staining based assay |
CHEMBL4196157 |
| Herpes simplex virus (type 1 / strain F) |
Activity |
= |
0.1 |
% |
Antiviral activity against Herpes simplex virus-1 strain F infected in African green monkey Vero cells assessed as late protein gb level at 50 ug/ml after 48 hrs by immunostaining based luminescent microscopic method (Rvb = 95.6%) |
CHEMBL4219185 |
| Human herpesvirus 3 strain Oka vaccine |
EC50 |
= |
3370.0 |
nM |
Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka infected in HEL cells assessed as inhibition of plaque formation measured after 5 days post infection |
CHEMBL4229353 |
| Human herpesvirus 3 |
EC50 |
= |
14120.0 |
nM |
Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in HEL cells assessed as inhibition of plaque formation measured after 5 days post infection |
CHEMBL4229353 |
| Human herpesvirus 5 strain AD169 |
EC50 |
|
|
|
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of plaque formation measured after 6 to 7 days post infection |
CHEMBL4229353 |
| Human herpesvirus 5 |
EC50 |
|
|
|
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of plaque formation measured after 6 to 7 days post infection |
CHEMBL4229353 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
300.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection |
CHEMBL4229353 |
| Human herpesvirus 1 strain KOS |
EC50 |
> |
88000.0 |
nM |
Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection |
CHEMBL4229353 |
| Human herpesvirus 2 strain G |
EC50 |
= |
290.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection |
CHEMBL4229353 |
| HEL |
CC50 |
> |
444000.0 |
nM |
Cytostatic activity against HEL cells after 3 days by Coulter counting method |
CHEMBL4229353 |
| HEL |
MCC |
> |
444000.0 |
nM |
Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days by microscopic analysis |
CHEMBL4229353 |
| Human herpesvirus 3 strain Oka vaccine |
EC50 |
= |
5310.0 |
nM |
Antiviral activity against TK-positive VZV Oka infected in HEL cells assessed as reduction in plaque formation after 5 days |
CHEMBL4251608 |
| Human herpesvirus 5 |
EC50 |
|
|
|
Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction in virus-induced cytopathic effect after 6 to 7 days |
CHEMBL4251608 |
| Human herpesvirus 5 strain AD169 |
EC50 |
|
|
|
Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction in virus-induced cytopathic effect after 6 to 7 days |
CHEMBL4251608 |
| Human herpesvirus 3 |
EC50 |
= |
53510.0 |
nM |
Antiviral activity against TK-defecient VZV 07-1 infected in HEL cells assessed as reduction in plaque formation after 5 days |
CHEMBL4251608 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
380.0 |
nM |
Antiviral activity against HSV1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathic effect after 2 to 3 days |
CHEMBL4251608 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
88810.0 |
nM |
Antiviral activity against acyclovir-resistant HSV1 KOS harboring TK- mutant infected in HEL cells assessed as reduction in virus-induced cytopathic effect after 2 to 3 days |
CHEMBL4251608 |
| Human herpesvirus 2 strain G |
EC50 |
= |
290.0 |
nM |
Antiviral activity against HSV2 strain G infected in HEL cells assessed as reduction in virus-induced cytopathic effect after 2 to 3 days |
CHEMBL4251608 |
| HEL |
CC50 |
> |
444000.0 |
nM |
Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method |
CHEMBL4251608 |
| HEL |
MCC |
> |
444000.0 |
nM |
Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days by microscopic method |
CHEMBL4251608 |
| No relevant target |
permeability |
= |
0.0 |
ucm/s |
Permeability of the compound by PAMPA |
CHEMBL4251652 |
| No relevant target |
permeability |
= |
0.1 |
ucm/s |
Permeability of the compound at 500 uM after 8 hrs by PAMPA |
CHEMBL4251652 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
470.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection |
CHEMBL4251741 |
| Human herpesvirus 1 strain KOS |
EC50 |
> |
88800.0 |
nM |
Antiviral activity against ACV-resistant thymidine kinase deficient Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection |
CHEMBL4251741 |
| Human herpesvirus 2 strain G |
EC50 |
= |
340.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection |
CHEMBL4251741 |
| Human herpesvirus 3 strain Oka vaccine |
EC50 |
= |
2840.0 |
nM |
Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka assessed as inhibition of plaque formation measured after 5 days post-infection |
CHEMBL4251741 |
| Human herpesvirus 3 |
EC50 |
= |
54800.0 |
nM |
Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 assessed as inhibition of plaque formation measured after 5 days post-infection |
CHEMBL4251741 |
| Human herpesvirus 5 strain AD169 |
EC50 |
|
|
|
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 6 to 7 days post-infection |
CHEMBL4251741 |
| Human herpesvirus 5 |
EC50 |
|
|
|
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 6 to 7 days post-infection |
CHEMBL4251741 |
| HEL |
MCC |
> |
88800.0 |
nM |
Cytotoxicity against HEL cells assessed as morphological changes after 3 days by microscopic analysis |
CHEMBL4251741 |
| HEL |
CC50 |
> |
444000.0 |
nM |
Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method |
CHEMBL4251741 |
| Herpes simplex virus (type 1 / strain F) |
IC50 |
= |
1290.0 |
nM |
Antiviral activity against acyclovir-resistant HSV1 KOS infected in African green monkey Vero cells assessed as inhibition of viral replication after 48 hrs by naphthol blue-black staining-based assay |
CHEMBL4265906 |
| Unchecked |
Ratio CC50/IC50 |
> |
1500.0 |
|
Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for HSV1 KOS |
CHEMBL4265906 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days by microscopic method |
CHEMBL4265975 |
| Herpes simplex virus (type 1 / strain F) |
EC50 |
= |
600.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method |
CHEMBL4265975 |
| Human herpesvirus 2 strain G |
EC50 |
= |
600.0 |
nM |
Antiviral activity against Human herpesvirus 2 strain G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method |
CHEMBL4265975 |
| Herpes simplex virus (type 1 / strain F) |
EC50 |
= |
2000.0 |
nM |
Antiviral activity against acyclovir-resistant TK-defecient Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method |
CHEMBL4265975 |
| Vaccinia virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method |
CHEMBL4265975 |
| Human herpesvirus 5 |
EC50 |
|
|
|
Antiviral activity against Human cytomegalovirus Davis strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL4270599 |
| Human herpesvirus 5 strain AD169 |
EC50 |
|
|
|
Antiviral activity against Human cytomegalovirus AD169 strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL4270599 |
| Human herpesvirus 3 |
EC50 |
= |
36740.0 |
nM |
Antiviral activity against thymidine kinase-deficient Varicella Zoster virus 07-1 strain infected in HELF cells assessed as inhibition of virus-induced plaque formation |
CHEMBL4270599 |
| Human herpesvirus 3 strain Oka vaccine |
EC50 |
= |
1260.0 |
nM |
Antiviral activity against thymidine kinase-deficient Varicella Zoster virus Oka strain infected in HELF cells assessed as inhibition of virus-induced plaque formation |
CHEMBL4270599 |
| Unchecked |
CC50 |
> |
440000.0 |
nM |
Cytotoxicity against HELF cells after by Coulter counter method |
CHEMBL4270599 |
| Unchecked |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against HELF cells assessed as alteration of cell morphology by microscopic analysis |
CHEMBL4270599 |
| Vaccinia virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus Lederle infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL4270599 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
10000.0 |
nM |
Antiviral activity against thymidine kinase-deficient acyclovir-resistant Human herpesvirus 1 KOS strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL4270599 |
| Human herpesvirus 2 strain G |
EC50 |
= |
200.0 |
nM |
Antiviral activity against Human herpesvirus 2 G strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL4270599 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
200.0 |
nM |
Antiviral activity against Human herpesvirus 1 KOS strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL4270599 |
| SARS-CoV-2 |
Inhibition index |
= |
0.1444 |
|
Inhibition of cell viability relative to arbidol control (inhibition index > 1 indicates higher activity) measured by fluorescence (OD590nm) in Vero E6 cells infected with SARS-CoV-2 (strain BavPat1) at MOI 0.002 after 72hrs |
CHEMBL4303097 |
| SARS-CoV-2 |
Inhibition |
= |
8.75 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging |
CHEMBL4303101 |
| SARS-CoV-2 |
Hit score |
= |
0.1075 |
|
Antiviral activity against SARS-CoV-2 (USA-WA1/2020 strain) measured by imaging in HRCE cells at MOI 0.4 after 96 hrs (reported as hit score from 0-1 for on-disease vs off-disease activity: scores >0.6 considered hits) |
CHEMBL4303122 |
| Human herpesvirus 1 |
Activity |
= |
100.0 |
% |
Antiviral activity against Herpes simplex virus 1 at 20 ug/10'5 |
CHEMBL4342407 |
| Human herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against Herpes simplex virus 1 at 50 ug/10'5 |
CHEMBL4342407 |
| Purine nucleoside phosphorylase |
Ki |
= |
91000.0 |
nM |
Inhibition of human PNP |
CHEMBL4368864 |
| Human herpesvirus 1 |
EC50 |
= |
900.0 |
nM |
Antiviral activity against herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis |
CHEMBL4368930 |
| Human herpesvirus 2 |
EC50 |
= |
900.0 |
nM |
Antiviral activity against herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis |
CHEMBL4368930 |
| Human herpesvirus 1 |
EC50 |
= |
100000.0 |
nM |
Antiviral activity against thymidine kinase deficient and aciclovir resistant herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis |
CHEMBL4368930 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against HEL cells assessed as effect on cell morphology at 0.32 to 200 uM by microscopic analysis |
CHEMBL4368930 |
| Human herpesvirus 3 |
EC50 |
= |
5000.0 |
nM |
Antiviral activity against Varicella-zoster virus Oka harboring thymidine kinase infected in HEL cells assessed as reduction in virus plaque formation |
CHEMBL4368930 |
| Human herpesvirus 3 |
EC50 |
= |
59200.0 |
nM |
Antiviral activity against thymidine kinase deficient Varicella-zoster virus 07-1 infected in HEL cells assessed as reduction in virus plaque formation |
CHEMBL4368930 |
| Human herpesvirus 5 |
EC50 |
|
|
|
Antiviral activity against Human cytomegalovirus AD169 assessed as reduction in virus-induced cytopathogenicity by microscopic analysis |
CHEMBL4368930 |
| Human herpesvirus 5 |
EC50 |
|
|
|
Antiviral activity against Human cytomegalovirus Davis assessed as reduction in virus-induced cytopathogenicity by microscopic analysis |
CHEMBL4368930 |
| No relevant target |
Peff |
= |
0.0 |
10'-6 cm/s |
Effective permeability of compound by PAMPA |
CHEMBL4373684 |
| No relevant target |
Peff |
= |
0.6 |
10'-6 cm/s |
Effective permeability of compound incubated for 8 hrs by PAMPA |
CHEMBL4373684 |
| No relevant target |
Fa |
= |
13.36 |
% |
Fraction absorbed of the compound by PAMPA |
CHEMBL4373684 |
| Vero |
CC50 |
> |
2000000.0 |
nM |
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by SRB assay |
CHEMBL4390653 |
| Human herpesvirus 1 |
IC50 |
= |
1380.0 |
nM |
Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in African green monkey Vero cells assessed as inhibition of viral replication after 48 hrs by naphthol blue-black staining-based plaque reduction assay |
CHEMBL4390653 |
| Unchecked |
Ratio CC50/IC50 |
> |
1449.0 |
|
Selectivity index, ratio of Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by SRB assay to Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in African green monkey Vero cells assessed as inhibition of viral replication after 48 hrs by naphthol blue-black staining-based plaque reduction assay |
CHEMBL4390653 |
| Human herpesvirus 1 |
IC50 |
|
|
|
Antiviral activity against acyclovir-resistant Herpes simplex virus 1 29-R infected in African green monkey Vero cells assessed as inhibition of viral replication after 48 hrs by naphthol blue-black staining-based plaque reduction assay |
CHEMBL4390653 |
| Human herpesvirus 2 |
IC50 |
= |
3230.0 |
nM |
Antiviral activity against Herpes simplex virus 2-333 infected in African green monkey Vero cells assessed as inhibition of viral replication after 48 hrs by naphthol blue-black staining-based plaque reduction assay |
CHEMBL4390653 |
| Unchecked |
Ratio CC50/IC50 |
> |
619.0 |
|
Selectivity index, ratio of Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by SRB assay to Antiviral activity against Herpes simplex virus 2-333 infected in African green monkey Vero cells assessed as inhibition of viral replication after 48 hrs by naphthol blue-black staining-based plaque reduction assay |
CHEMBL4390653 |
| Hepatitis A virus |
IC50 |
= |
35.6 |
ug.mL-1 |
Antiviral activity against Hepatitis A virus infected in rhesus monkey FRhK4 cells assessed as reduction in virus-induced cytopathic effect incubated for 72 hrs by MTT assay |
CHEMBL4390665 |
| Unchecked |
CC50 |
> |
1000.0 |
ug.mL-1 |
Cytotoxicity against rhesus monkey FRhK4 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay |
CHEMBL4390665 |
| Hepatitis A virus |
IC50 |
= |
33.5 |
ug.mL-1 |
Antiviral activity against Hepatitis A virus infected in rhesus monkey FRhK4 cells assessed as inhibition in viral adsorption using cells pre-incubated with compound for 24 hrs before viral infection for 1 hr by MTT assay |
CHEMBL4390665 |
| Hepatitis A virus |
IC50 |
= |
30.6 |
ug.mL-1 |
Antiviral activity against Hepatitis A virus infected in rhesus monkey FRhK4 cells assessed as inhibition in viral replication using cells pre-infected with virus before compound exposure for 72 hrs by MTT assay |
CHEMBL4390665 |
| ADMET |
Ratio CC50/IC50 |
= |
80.0 |
|
Therapeutic index, ratio of CC50 of rhesus monkey FRhK cells to IC50 of antiviral activity against Hepatitis A virus infected in rhesus monkey FRhK4 cells |
CHEMBL4390665 |
| ADMET |
Ratio CC50/IC50 |
= |
85.0 |
|
Therapeutic index, ratio of CC50 of rhesus monkey FRhK cells to IC50 of antiviral activity against Hepatitis A virus infected in rhesus monkey FRhK4 cells assessed as inhibition in viral adsorption using cells pre-incubated with compound for 24 hrs before viral infection for 1 hr by MTT assay |
CHEMBL4390665 |
| ADMET |
Ratio CC50/IC50 |
= |
93.0 |
|
Therapeutic index, ratio of CC50 of rhesus monkey FRhK cells to IC50 for antiviral activity against Hepatitis A virus infected in rhesus monkey FRhK4 cells assessed as inhibition in viral replication using cells pre-infected with virus before compound exposure for 72 hrs by MTT assay |
CHEMBL4390665 |
| Human adenovirus type 2 |
EC50 |
= |
5800.0 |
nM |
Antiviral activity against Human adenovirus 2 infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis |
CHEMBL4406859 |
| Vaccinia virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis |
CHEMBL4406859 |
| Human herpesvirus 1 |
EC50 |
= |
17000.0 |
nM |
Antiviral activity against Herpes simplex virus 1 TK-KOS-ACV infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis |
CHEMBL4406859 |
| Human herpesvirus 2 |
EC50 |
= |
2000.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis |
CHEMBL4406859 |
| Human herpesvirus 1 |
EC50 |
= |
900.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis |
CHEMBL4406859 |
| Unchecked |
CC50 |
> |
440000.0 |
nM |
Cytotoxicity against human HELF cells assessed as reduction in cell viability incubated for 3 days by coulter counter method |
CHEMBL4406859 |
| Unchecked |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HELF cells assessed as minimum cytotoxic concentration by observing alteration in cell morphology incubated for 3 days by microscopic analysis |
CHEMBL4406859 |
| Human herpesvirus 3 |
EC50 |
= |
96000.0 |
nM |
Antiviral activity against thymidine kinase positive Varicella zoster virus infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by Giemsa staining based microscopic analysis |
CHEMBL4406859 |
| Human herpesvirus 3 |
EC50 |
= |
1560.0 |
nM |
Antiviral activity against thymidine kinase deficient Varicella zoster virus infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by Giemsa staining based microscopic analysis |
CHEMBL4406859 |
| Cytochrome P450 3A4 |
FC |
= |
1.0 |
|
Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NADPH measured after 24 hrs in absence of compound, CYP3A4 and NADPH by cell titer-glo luminescence assay relative to BSO alone |
CHEMBL4477225 |
| Cytochrome P450 2D6 |
FC |
= |
1.0 |
|
Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NADPH measured after 24 hrs in absence of compound, CYP3A4 and NADPH by cell titer-glo luminescence assay relative to BSO alone |
CHEMBL4477225 |
| Cytochrome P450 2C9 |
FC |
= |
1.0 |
|
Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NADPH measured after 24 hrs in absence of compound, CYP3A4 and NADPH by cell titer-glo luminescence assay relative to BSO alone |
CHEMBL4477225 |
| Replicase polyprotein 1ab |
Inhibition |
= |
6.729 |
% |
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate |
CHEMBL4495564 |
| SARS-CoV-2 |
Inhibition |
= |
0.04 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| Candida albicans |
Inhibition |
= |
4.6 |
% |
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630 |
CHEMBL4513141 |
| Filobasidiella neoformans |
Inhibition |
= |
-1.27 |
% |
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570) |
CHEMBL4513141 |
| Escherichia coli |
Inhibition |
= |
4.79 |
% |
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600) |
CHEMBL4513141 |
| Klebsiella pneumoniae |
Inhibition |
= |
6.29 |
% |
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600) |
CHEMBL4513141 |
| Pseudomonas aeruginosa |
Inhibition |
= |
9.14 |
% |
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600) |
CHEMBL4513141 |
| Acinetobacter baumannii |
Inhibition |
= |
6.13 |
% |
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600 |
CHEMBL4513141 |
| Staphylococcus aureus subsp. aureus |
Inhibition |
= |
-22.02 |
% |
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600) |
CHEMBL4513141 |
| Candida albicans |
MIC |
> |
20000.0 |
nM |
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630 |
CHEMBL4513161 |
| Filobasidiella neoformans |
MIC |
> |
20000.0 |
nM |
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570) |
CHEMBL4513161 |
| Escherichia coli |
MIC |
> |
20000.0 |
nM |
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600) |
CHEMBL4513161 |
| Klebsiella pneumoniae |
MIC |
> |
20000.0 |
nM |
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600) |
CHEMBL4513161 |
| Pseudomonas aeruginosa |
MIC |
> |
20000.0 |
nM |
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600) |
CHEMBL4513161 |
| Acinetobacter baumannii |
MIC |
> |
20000.0 |
nM |
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600 |
CHEMBL4513161 |
| Pseudomonas aeruginosa |
MIC |
> |
20000.0 |
nM |
Antibacterial activity against Pseudomonas aeruginosa PAO397 [PAO1 d(mexAB-oprM) d(mexCD-oprJ) d(mexEF-oprN) d(mexJKL) d(mexXY) d(opmH)] (CO-ADD:GN_211); MIC in CAMBH media using NBS plates, by OD(600) |
CHEMBL4513161 |
| Staphylococcus aureus subsp. aureus |
MIC |
> |
20000.0 |
nM |
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600) |
CHEMBL4513161 |
| Erythrocyte |
HC10 |
> |
20.0 |
uM |
Haemolysis of human Red Blood Cells (CO-ADD:HA_150); HC10, by OD(450) |
CHEMBL4513161 |
| HEK293 |
CC50 |
> |
20000.0 |
nM |
Cytotoxicity against HEK293 cells (CO-ADD:MA_007); CC50 by cell viability assay in DMEM (10% FBS) media using TC plates, by Resazurin F(560/590) |
CHEMBL4513161 |
| Human herpesvirus 2 |
IC50 |
= |
31000.0 |
nM |
Antiviral activity against Herpes simplex virus 2 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect after 24 hrs by crystal violet staining based assay |
CHEMBL4602665 |
| Human herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against ACV-sensitive Herpes simplex virus 1 KOS infected in male Balb/c mouse assessed as reduction in ulcerated lesion at 50 mg/g applied topically as cream formulation 5 times a day at 3 hrs interval for 10 days measured on day 2 post infection |
CHEMBL4610063 |
| Human herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against ACV-sensitive Herpes simplex virus 1 KOS infected in male Balb/c mouse assessed as reduction in ulcerated lesion at 50 mg/g applied topically as cream formulation 5 times a day at 3 hrs interval for 10 days measured on day 7 post infection |
CHEMBL4610063 |
| Human herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against ACV-resistant Herpes simplex virus 1 AR-29 infected in female Balb/c mouse assessed as reduction in skin lesion at 50 mg/g applied topically as cream formulation 5 times a day at 3 hrs interval for 10 days |
CHEMBL4610063 |
| Human herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against ACV-resistant Herpes simplex virus 1 AR-29 infected in female Balb/c mouse assessed as reduction in zosteriform lesion at 50 mg/g applied topically as cream formulation 5 times a day at 3 hrs interval for 10 days measured on day 7 post infection |
CHEMBL4610063 |
| Human herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against ACV-resistant Herpes simplex virus 1 AR-29 infected in male Balb/c mouse assessed as reduction in ulcerated lesion at 50 mg/g applied topically as cream formulation 5 times a day at 3 hrs interval for 10 days measured on day 5 post infection |
CHEMBL4610063 |
| Human herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against ACV-resistant Herpes simplex virus 1 AR-29 infected in male Balb/c mouse assessed as reduction in zosteriform lesion at 50 mg/g applied topically as cream formulation 5 times a day at 3 hrs interval for 10 days measured on day 5 post infection |
CHEMBL4610063 |
| Human herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against ACV-sensitive Herpes simplex virus 1 KOS infected in female Balb/c mouse assessed as reduction in ulcerated lesion at 50 mg/g applied topically as cream formulation 5 times a day at 3 hrs interval for 10 days measured on day 3 to day 5 post infection |
CHEMBL4610063 |
| Cytomegalovirus |
EC50 |
|
|
|
Antiviral activity against Cytomegalovirus AD169 infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days |
CHEMBL4619792 |
| Cytomegalovirus |
EC50 |
|
|
|
Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days |
CHEMBL4619792 |
| Human herpesvirus 3 |
EC50 |
= |
7060.0 |
nM |
Antiviral activity against thymidine kinase positive Varicella zoster virus OKA infected in human HEL cells assessed as reduction in plaque formation measured after 5 days |
CHEMBL4619792 |
| Human herpesvirus 3 |
EC50 |
= |
42700.0 |
nM |
Antiviral activity against thymidine kinase deficient Varicella zoster virus 07-1 infected in human HEL cells assessed as reduction in plaque formation measured after 5 days |
CHEMBL4619792 |
| HEL |
MCC |
> |
444000.0 |
nM |
Cytotoxicity against human HEL cells assessed as minimum cytotoxic concentration for change in cellular morphology incubated for 3 days by microscopic analysis |
CHEMBL4619792 |
| HEL |
CC50 |
> |
444000.0 |
nM |
Cytotoxicity against human HEL cells assessed as reduction in cell proliferation incubated for 3 days by Coulter counter method |
CHEMBL4619792 |
| No relevant target |
LogP |
>= |
1.0 |
|
Lipophilicity, log P of the compound |
CHEMBL4622856 |
| Unchecked |
Ratio CC50/EC50 |
= |
916.0 |
|
Selectivity index, ratio of CC50 for cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay to EC50 for antiviral activity against Herpes simplex virus 1 infected in African green monkey vero cells assessed as reduction in plaque formation treated 1 hr post viral infection |
CHEMBL4627304 |
| Human herpesvirus 1 |
EC50 |
= |
1200.0 |
ug.mL-1 |
Antiviral activity against Herpes simplex virus 1 infected in African green monkey vero cells assessed as reduction in plaque formation treated 1 hr post viral infection by plaque reduction assay |
CHEMBL4627304 |
| Unchecked |
Ratio CC50/EC50 |
= |
86.0 |
|
Selectivity index, ratio of CC50 for cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay to EC50 for antiviral activity against Herpes simplex virus 1 infected in African green monkey Vero cells assessed as reduction in plaque formation pretreated with compound for 1 hr followed by viral infection at 0.01 PFU/cells for 1 hr by plaque reduction assay |
CHEMBL4627304 |
| Human herpesvirus 1 |
EC50 |
= |
12800.0 |
ug.mL-1 |
Antiviral activity against Herpes simplex virus 1 infected in African green monkey Vero cells assessed as reduction in plaque formation pretreated with compound for 1 hr followed by viral infection at 0.01 PFU/cells for 1 hr by plaque reduction assay |
CHEMBL4627304 |
| Vero |
CC50 |
= |
1100000.0 |
ug.mL-1 |
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay |
CHEMBL4627304 |
| SARS-CoV-2 |
Inhibition |
= |
0.04 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| SARS-CoV-2 |
IC50 |
> |
20000.0 |
nM |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4651402 |
| SARS-CoV-2 |
IC50 |
< |
19952.62 |
nM |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4651402 |
| Unchecked |
Ratio CC50/EC50 |
= |
19.0 |
|
Selectivity index, ratio of CC50 for human HEL cells to EC50 for antiviral activity against thymidine kinase deficient Varicella zoster virus 07-1 infected in human HEL cells |
CHEMBL4673379 |
| Unchecked |
Ratio CC50/EC50 |
= |
265.0 |
|
Selectivity index, ratio of CC50 for human HEL cells to EC50 for antiviral activity against thymidine kinase positive Varicella zoster virus OKA infected in human HEL cells |
CHEMBL4673379 |
| HEL |
CC50 |
= |
424000.0 |
nM |
Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis |
CHEMBL4673379 |
| HEL |
MCC |
> |
440000.0 |
nM |
Cytotoxicity against human HEL cells assessed as alteration in cell morphology incubated for 3 days by microscopic analysis |
CHEMBL4673379 |
| Unchecked |
EC50 |
|
|
|
Antiviral activity against Human cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus plaque formation measured on 6 to 7 post-viral infection |
CHEMBL4673379 |
| Unchecked |
EC50 |
|
|
|
Antiviral activity against Human cytomegalovirus AD169 infected in human HEL cells assessed as reduction in virus plaque formation measured on day 6 to 7 post-viral infection |
CHEMBL4673379 |
| Human herpesvirus 3 |
EC50 |
= |
22150.0 |
nM |
Antiviral activity against thymidine kinase deficient Varicella zoster virus 07-1 infected in human HEL cells assessed as reduction in virus plaque formation measured on day 5 post-viral infection |
CHEMBL4673379 |
| Human herpesvirus 3 |
EC50 |
= |
1600.0 |
nM |
Antiviral activity against thymidine kinase positive Varicella zoster virus OKA infected in human HEL cells assessed as reduction in virus plaque formation measured on day 5 post-viral infection |
CHEMBL4673379 |
| Human herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against recombinant EGFP/RFP expressing Herpes simplex virus 1 KOS infected in iPSC-neurons assessed as decrease in proportion of fluorescent cells compound added 2 hr post infection incubated for 48 hrs by flow cytometry analysis |
CHEMBL4699512 |
| Human herpesvirus 1 |
IC50 |
= |
27400.0 |
nM |
Antiviral activity against Herpes simplex virus 1 infected in neuronal progenitor cells assessed as decrease in fluorescent cells |
CHEMBL4699512 |
| ADMET |
Drugabsorption |
= |
2.98 |
% |
Drug absorption of the compound incubated for 8 hrs by PAMPA-TGI assay |
CHEMBL4706524 |
| ADMET |
permeability |
= |
0.08 |
10^-6 cm/s |
Permeability of the compound incubated for 8 hrs by PAMPA-TGI assay |
CHEMBL4706524 |
| ADMET |
permeability |
= |
0.06 |
10^-6 cm/s |
Permeability of the compound by PAMPA-TGI assay |
CHEMBL4706524 |
| Unchecked |
EC50 |
= |
990.0 |
nM |
Inhibition of HSV2 replication in HFF cells incubated for 7 days |
CHEMBL4715800 |
| HFF |
CC50 |
> |
300000.0 |
nM |
Cytotoxicity in HFF cells incubated for 7 days by CellTiter-Glo assay |
CHEMBL4715800 |
| Unchecked |
Ratio CC50/EC50 |
> |
300.0 |
|
Selectivity index, ratio of CC50 for HFF to EC50 for inhibition of HSV2 replication in HFF cells |
CHEMBL4715800 |
| Unchecked |
EC50 |
|
|
|
Antiviral activity against HCMV AD169 infected in human HFF cells assessed as reduction in virus-induced cytopathic effect incubated for 14 days by cell-titer glo assay |
CHEMBL4732039 |
| Unchecked |
EC90 |
|
|
|
Antiviral activity against HCMV AD169 infected in human HFF cells assessed as reduction in virus-induced cytopathic effect incubated for 14 days by cell-titer glo assay |
CHEMBL4732039 |
| HFF |
CC50 |
|
|
|
Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 14 days by cell titer glo assay |
CHEMBL4732039 |
| Human herpesvirus 3 |
EC50 |
= |
4170.0 |
nM |
Antiviral activity against VZV infected in human HFF cells assessed as reduction in virus-induced cytopathic effect incubated for 14 days by cell-titer glo assay |
CHEMBL4732039 |
| Human herpesvirus 3 |
EC90 |
= |
30.23 |
uM |
Antiviral activity against VZV infected in human HFF cells assessed as reduction in virus-induced cytopathic effect incubated for 14 days by cell-titer glo assay |
CHEMBL4732039 |
| Unchecked |
Ratio CC50/EC50 |
> |
36.0 |
|
Selectivity index, ratio of CC50 of human HFF cells to EC50 of antiviral activity against VZV |
CHEMBL4732039 |
| Human herpesvirus 3 |
EC50 |
= |
490.0 |
nM |
Antiviral activity against thymidine kinase positive Varicella zoster virus OKA infected in human HEL cells assessed as reduction in virus-induced cytopathogenic effect measured after 3 days coulter counter method |
CHEMBL4732054 |
| Human herpesvirus 3 |
EC50 |
= |
23220.0 |
nM |
Antiviral activity against thymidine kinase deficient Varicella zoster virus 07-1 infected in human HEL cells assessed as reduction in virus-induced cytopathogenic effect measured after 3 days coulter counter method |
CHEMBL4732054 |
| HEL |
MCC |
> |
440000.0 |
nM |
Cytotoxicity against human HEL cells assessed as concentration required to cause visible alteration in cell morphology incubated for 3 days by coulter counter method |
CHEMBL4732054 |
| HEL |
CC50 |
> |
300000.0 |
nM |
Cytotoxicity against human HEL cells assessed as reduction in cell growth incubated for 3 days by coulter counter method |
CHEMBL4732054 |
| A549 |
CC20 |
= |
196.08 |
uM |
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay |
CHEMBL4831514 |
| A549 |
CC50 |
= |
1555600.0 |
nM |
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay |
CHEMBL4831514 |
| Enterovirus E |
EC50 |
= |
222.0 |
|
Antiviral activity against Enterovirus E LCR-4 infected in A549 cells assessed as reduction in virus titer preincubated for 24 hrs followed by viral infection and measured after 72 hrs by microscopic analysis |
CHEMBL4831514 |
| ADMET |
Selectivity Index |
= |
7.0 |
|
Selectivity index, ratio of CC50 for cytotoxicity against human A549 cells to EC50 for antiviral activity against Enterovirus E LCR-4 infected in A549 cells |
CHEMBL4831514 |
| Vesicular stomatitis virus |
Activity |
|
|
|
Antiviral activity against Vesicular stomatitis virus Indiana infected in A549 cells assessed as inhibition of viral adsorption at early stage of replication treated for 1 hr during viral infection followed by replacement with fresh medium and measured after 48 hrs by MTT assay |
CHEMBL4831514 |
| Human herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against Human herpesvirus-1 MacIntyre infected in A549 cells assessed as inhibition of viral adsorption at early stage of replication treated for 1 hr during viral infection followed by replacement with fresh medium and measured after 48 hrs by MTT assay |
CHEMBL4831514 |
| Enterovirus E |
Activity |
|
|
|
Antiviral activity against Enterovirus E LCR-4 infected in A549 cells assessed as inhibition of viral adsorption at early stage of replication treated for 1 hr during viral infection followed by replacement with fresh medium and measured after 72 hrs by MTT assay |
CHEMBL4831514 |
| Human adenovirus type 5 |
Activity |
|
|
|
Antiviral activity against Human adenovirus 5 Adenoid 75 infected in A549 cells assessed as inhibition of viral adsorption at early stage of replication treated for 1 hr during viral infection followed by replacement with fresh medium and measured after 72 hrs by MTT assay |
CHEMBL4831514 |
| Human herpesvirus 1 |
EC50 |
= |
111100.0 |
nM |
Antiviral activity against Human herpesvirus 1 MacIntyre infected in A549 cells assessed as reduction in virus titer treated 1 hr post viral infection followed by replacement with fresh medium with compounds and measured after 48 hrs by MTT assay |
CHEMBL4831514 |
| ADMET |
Selectivity Index |
= |
14.0 |
|
Selectivity index, ratio of CC50 for cytotoxicity against human A549 cells to EC50 for antiviral activity against Human herpesvirus 1 MacIntyre infected in A549 cells assessed as reduction in virus titer treated 1 hr post viral infection followed by replacement with fresh medium with compounds and measured after 72 hrs by MTT assay |
CHEMBL4831514 |
| Human herpesvirus 3 |
EC50 |
= |
12000.0 |
nM |
Antiviral activity against thymidine kinase positive Varicella zoster virus |
CHEMBL4842312 |
| Human herpesvirus 3 |
EC50 |
= |
56000.0 |
nM |
Antiviral activity against thymidine kinase deficient Varicella zoster virus |
CHEMBL4842312 |
| HEL |
CC50 |
> |
300000.0 |
nM |
Cytotoxicity against human HEL cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method |
CHEMBL4842312 |
| ADMET |
Ratio CC50/EC50 |
> |
1.5 |
|
Selectivity index, ratio of CC50 for human HEL cells to EC50 for antiviral activity against thymidine kinase deficient Varicella zoster virus |
CHEMBL4842312 |
| Human herpesvirus 3 |
EC50 |
= |
9.0 |
nM |
Antiviral activity against Varicella zoster virus assessed as inhibition of viral replication |
CHEMBL4842312 |
| Human herpesvirus 1 |
EC50 |
= |
3600.0 |
nM |
Antiviral activity against HSV-1 infected in African green monkey Vero cells assessed as inhibition of viral replication incubated for 3 days by MTT assay |
CHEMBL5038622 |
| Vero |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 3 days by MTT assay |
CHEMBL5038622 |
| ADMET |
Ratio |
> |
27.9 |
|
Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for HSV-1 infected in African green monkey Vero cells |
CHEMBL5038622 |
| Human herpesvirus 2 |
EC50 |
= |
4600.0 |
nM |
Antiviral activity against HSV-2 infected in African green monkey Vero cells assessed as inhibition of viral replication incubated for 3 days by MTT assay |
CHEMBL5038622 |
| ADMET |
Ratio |
> |
21.9 |
|
Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for HSV-2 infected in African green monkey Vero cells |
CHEMBL5038622 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against HEL cells assessed as alteration of cell morphology by microscopic analysis |
CHEMBL5108006 |
| Human herpesvirus 1 |
EC50 |
= |
800.0 |
nM |
Antiviral activity against HSV-1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis |
CHEMBL5108006 |
| Human herpesvirus 2 |
EC50 |
= |
400.0 |
nM |
Antiviral activity against HSV-2 G strain infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis |
CHEMBL5108006 |
| Human herpesvirus 1 |
EC50 |
= |
126000.0 |
nM |
Antiviral activity against thymidine kinase deficient mutant Acyclovir resistant HSV-1 KOS strain infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis |
CHEMBL5108006 |
| Human herpesvirus 5 |
EC50 |
|
|
|
Antiviral activity against Human cytomegalovirus AD-169 infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis |
CHEMBL5108006 |
| Human herpesvirus 5 |
EC50 |
|
|
|
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis |
CHEMBL5108006 |
| Human herpesvirus 3 |
EC50 |
= |
700.0 |
nM |
Antiviral activity against Varicella zoster-virus OKA strain harboring thymidine kinase infected in HEL cells assessed as reduction in plaque formation by microscopic analysis |
CHEMBL5108006 |
| Human herpesvirus 3 |
EC50 |
= |
14740.0 |
nM |
Antiviral activity against thymidine kinase deficient Varicella zoster-virus O7-1 strain infected in HEL cells assessed as reduction in plaque formation by microscopic analysis |
CHEMBL5108006 |
| Vaccinia virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis |
CHEMBL5108006 |
| Human adenovirus type 2 |
EC50 |
|
|
|
Antiviral activity against Human adenovirus 2 infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis |
CHEMBL5108006 |
| Human herpesvirus 1 |
ED50 |
= |
0.5 |
mg.kg-1 |
Antiviral activity against HSV-1 infected in po dosed BALB/c mouse administered twice on infection day and three times daily from day 1 to 4 post infection |
CHEMBL5108063 |
| Human herpesvirus 2 |
ED50 |
= |
0.5 |
mg.kg-1 |
Antiviral activity against HSV-2 infected in po dosed BALB/c mouse administered twice on infection day and three times daily from day 1 to 4 post infection |
CHEMBL5108063 |
| ADMET |
T1/2 |
= |
1.0 |
hr |
Elimination half life in rat |
CHEMBL5108063 |
| ADMET |
T1/2 |
= |
1.3 |
hr |
Elimination half life in monkey |
CHEMBL5108063 |
| ADMET |
T1/2 |
= |
2.7 |
hr |
Elimination half life in human |
CHEMBL5108063 |
| ADMET |
F |
= |
65.0 |
% |
Oral bioavailability in rat |
CHEMBL5108063 |
| ADMET |
F |
= |
83.0 |
% |
Oral bioavailability in dog |
CHEMBL5108063 |
| ADMET |
F |
= |
63.0 |
% |
Oral bioavailability in monkey |
CHEMBL5108063 |
| ADMET |
F |
= |
54.0 |
% |
Oral bioavailability in human at 350 mg administered as 1 hr intravenous infusion once a week and measured upto 24 hrs |
CHEMBL5108063 |
| Human herpesvirus 5 |
EC50 |
= |
2270.0 |
nM |
Antiviral activity against HCMV AD-169 infected in HEL cells assessed as reduction in virus plaque formation |
CHEMBL5120909 |
| Human herpesvirus 5 |
EC50 |
= |
2080.0 |
nM |
Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction in virus plaque formation |
CHEMBL5120909 |
| Human herpesvirus 3 |
EC50 |
= |
7100.0 |
nM |
Antiviral activity against VZV TK+ infected in HEL cells assessed as reduction in virus plaque formation |
CHEMBL5120909 |
| Human herpesvirus 3 |
EC50 |
= |
275830.0 |
nM |
Antiviral activity against VZV TK- infected in HEL cells assessed as reduction in virus plaque formation |
CHEMBL5120909 |
| HEL |
MCC |
> |
444030.0 |
nM |
Cytotoxicity against human HEL cells assessed as change in cell morphology measured after 3 days by coulter counting method |
CHEMBL5120909 |
| HEL |
CC50 |
> |
444030.0 |
nM |
Cytotoxicity against human HEL cells assessed as reduction in cell growth measured after 3 days by coulter counting method |
CHEMBL5120909 |
| Human herpesvirus 5 |
EC50 |
|
|
|
Antiviral activity against HCMV AD-169 infected in HFF cells assessed as reduction in viral replication measured after 14 days |
CHEMBL5120909 |
| Human herpesvirus 5 |
EC90 |
|
|
|
Antiviral activity against HCMV AD-169 infected in HFF cells assessed as reduction in viral replication measured after 14 days |
CHEMBL5120909 |
| HFF |
CC50 |
|
|
|
Cytotoxicity against human HFF cells infected with HCMV AD-169 virus assessed as reduction in cell viability by cell titer-glo assay |
CHEMBL5120909 |
| ADMET |
Ratio CC50/EC50 |
|
|
|
Selectivity index, ratio of CC50 for cytotoxicity against human HFF cells infected with HCMV AD-169 virus assessed as reduction in cell viability by cell titer-glo assay to EC50 for antiviral activity against HCMV AD-169 infected in HFF cells assessed as inhibition of virus-induced cytopathic effect measured after 14 days |
CHEMBL5120909 |
| Human herpesvirus 3 |
EC50 |
= |
4170.0 |
nM |
Antiviral activity against VZV Ellen infected in HFF cells assessed as reduction in viral replication measured after 14 days |
CHEMBL5120909 |
| Human herpesvirus 3 |
EC90 |
= |
30.23 |
uM |
Antiviral activity against VZV Ellen infected in HFF cells assessed as reduction in viral replication measured after 14 days |
CHEMBL5120909 |
| HFF |
CC50 |
> |
150000.0 |
nM |
Cytotoxicity against human HFF cells infected with VZV Ellen virus assessed as reduction in cell viability by cell titer-glo assay |
CHEMBL5120909 |
| ADMET |
Ratio CC50/EC50 |
> |
36.0 |
|
Selectivity index, ratio of CC50 for cytotoxicity against human HFF cells infected with VZV Ellen virus assessed as reduction in cell viability by cell titer-glo assay to EC50 for antiviral activity against VZV Ellen infected in HFF cells assessed as inhibition of virus-induced cytopathic effect measured after 14 days |
CHEMBL5120909 |
| Human herpesvirus 3 |
EC50 |
= |
700.0 |
nM |
Antiviral activity against VZV strain Oka bearing wild type thymidine kinase assessed as reduction in virus induced cytopathogenicity |
CHEMBL5126541 |
| Human herpesvirus 2 |
log(activity) |
= |
2.9 |
|
Antiviral activity against HSV-2 infected in African green monkey Vero cells assessed as inhibition of viral replication by measuring log suppression of virus-induced cytopathic effect at 5 uM incubated for 1 hr followed by washing with PBS and subsequent treatment with compound for 24 hrs by plaque assay |
CHEMBL5137030 |
| Human herpesvirus 2 |
log(activity) |
= |
1.79 |
|
Antiviral activity against HSV-2 infected in African green monkey Vero cells assessed as inhibition of viral replication by measuring log suppression of virus-induced cytopathic effect at 1 uM incubated for 1 hr followed by washing with PBS and subsequent treatment with compound for 24 hrs by plaque assay |
CHEMBL5137030 |
| Human herpesvirus 1 |
log(activity) |
= |
3.36 |
|
Antiviral activity against HSV-1 infected in African green monkey Vero cells assessed as inhibition of viral replication by measuring log suppression of virus-induced cytopathic effect at 5 uM incubated for 1 hr followed by washing with PBS and subsequent treatment with compound for 24 hrs by plaque assay |
CHEMBL5137030 |
| Human herpesvirus 1 |
log(activity) |
= |
2.42 |
|
Antiviral activity against HSV-1 infected in African green monkey Vero cells assessed as inhibition of viral replication by measuring log suppression of virus-induced cytopathic effect at 1 uM incubated for 1 hr followed by washing with PBS and subsequent treatment with compound for 24 hrs by plaque assay |
CHEMBL5137030 |
| Human herpesvirus 1 |
EC50 |
= |
160.0 |
nM |
Antiviral activity against HSV-1 infected in African green monkey Vero cells assessed as inhibition of viral replication incubated for 1 hr followed by washing with PBS and subsequent treatment with compound for 24 hrs by plaque reduction assay |
CHEMBL5137030 |
| Human herpesvirus 2 |
EC50 |
= |
1440.0 |
nM |
Antiviral activity against HSV-2 infected in African green monkey Vero cells assessed as inhibition of viral replication incubated for 1 hr followed by washing with PBS and subsequent treatment with compound for 24 hrs by plaque reduction assay |
CHEMBL5137030 |
| Vero |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 24 hrs by MTS assay |
CHEMBL5137030 |
| ADMET |
Ratio CC50/EC50 |
> |
69.0 |
|
Selectivity index, ratio of CC50 for cytotoxicity against African green monkey Vero cells to EC50 for antiviral activity against HSV-2 infected in African green monkey Vero cells |
CHEMBL5137030 |
| Vero C1008 |
CC100 |
|
|
|
Cytotoxicity against African green monkey Vero E6 cells measured after 72 hrs by MTT assay |
CHEMBL5137096 |
| BHK-21 |
CC100 |
|
|
|
Cytotoxicity against golden hamster BHK-21 cells measured after 6 days by MTT assay |
CHEMBL5137096 |
| Zika virus |
EC |
|
|
|
Antiviral activity against ZIKV infected in African green monkey Vero E6 cells assessed as inhibition of virus induced cytopathic effect measured after 72 hrs by crystal violet staining based inverted microscopic analysis |
CHEMBL5137096 |
| Zika virus |
EC |
|
|
|
Antiviral activity against ZIKV infected in African green monkey Vero E6 cells assessed as inhibition of plaque formation by measuring reduction in PFU per well incubated for 72 hrs by crystal violet staining based assay |
CHEMBL5137096 |
| Dengue virus 2 |
EC |
|
|
|
Antiviral activity against DENV2 infected in African green monkey Vero E6 cells assessed as inhibition of virus induced cytopathic effect measured after 72 hrs by crystal violet staining based inverted microscopic analysis |
CHEMBL5137096 |
| Dengue virus 2 |
EC |
|
|
|
Antiviral activity against DENV2 infected in hamster BHK-21 cells assessed as inhibition of plaque formation by measuring reduction in PFU per well incubated for 6 days by crystal violet staining based assay |
CHEMBL5137096 |
| Human herpesvirus 1 |
FC |
= |
100.0 |
|
Antiviral activity against HHV-1 29R strain infected in African green monkey Vero E6 cells assessed as reduction factor at 3.1 to 25 ug/ml measured after 72 hrs by crystal violet staining based inverted microscopic analysis |
CHEMBL5137096 |
| Human herpesvirus 1 |
EC |
= |
1.5 |
ug ml-1 |
Antiviral activity against HHV-1 29R strain infected in African green monkey Vero E6 cells assessed as concentration required for higher viral reduction factor measured after 72 hrs by crystal violet staining based inverted microscopic analysis |
CHEMBL5137096 |
| Chikungunya virus |
FC |
|
|
|
Antiviral activity against CHIKV infected in African green monkey Vero E6 cells assessed as reduction factor at 3.1 to 25 ug/ml measured after 72 hrs by crystal violet staining based inverted microscopic analysis |
CHEMBL5137096 |
| Chikungunya virus |
EC |
|
|
|
Antiviral activity against CHIKV infected in African green monkey Vero E6 cells assessed as concentration required for higher viral reduction factor measured after 72 hrs by crystal violet staining based inverted microscopic analysis |
CHEMBL5137096 |
